var title_f37_54_38752="Ipratropium: Patient drug information";
var content_f37_54_38752=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"12\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ipratropium: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12804655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12804656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/62/13284?source=see_link\">",
"       Ipratropium (nasal): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/51/39732?source=see_link\">",
"       Ipratropium (oral inhalation): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10768 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-562547D45F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_54_38752=[""].join("\n");
var outline_f37_54_38752=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/62/13284?source=related_link\">",
"      Ipratropium (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/51/39732?source=related_link\">",
"      Ipratropium (oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_54_38753="Fiberoptic nasotracheal intubation";
var content_f37_54_38753=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F56432&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F56432&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fiberoptic nasotracheal intubation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 275px; height: 635px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    After nasal application of a topical vasoconstrictor (eg, phenylephrine spray), the endotracheal tube is first inserted until the tip reaches the supraglottic area. Then the fiberoptic bronchoscope is inserted through the tube until the airway landmarks are visualized.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: King BR, Hagberg CA. Management of the difficult airway. In: Textbook of Pediatric Emergency Medicine Procedures, 2nd edition, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_54_38753=[""].join("\n");
var outline_f37_54_38753=null;
var title_f37_54_38754="Patient information: Epilepsy in children (The Basics)";
var content_f37_54_38754=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16569\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/57/39824\">",
"         EEG (electroencephalogram)",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?18/0/18434\">",
"         Patient information: EEG (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?42/40/43650\">",
"         Patient information: Epilepsy in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?11/20/11586\">",
"         Patient information: Febrile seizures (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?6/21/6483\">",
"         Patient information: Reducing the costs of medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?27/56/28546\">",
"         Patient information: Seizures (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?0/26/419\">",
"         Patient information: Seizures in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Epilepsy in children (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/epilepsy-in-children-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H10147912\">",
"      <span class=\"h1\">",
"       What is epilepsy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Epilepsy is a condition that causes people to have repeated seizures. Seizures are caused by abnormal electrical activity in the brain. Seizures can make people pass out, or move or behave strangely. Epilepsy can start at any age.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10147927\">",
"      <span class=\"h1\">",
"       What are the symptoms of a seizure?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are different kinds of seizures. Each causes a different set of symptoms. Most seizures last only a few seconds or minutes.",
"     </p>",
"     <p>",
"      Children who have &ldquo;tonic clonic&rdquo; or &ldquo;grand mal&rdquo; seizures often pass out, get stiff, and then have jerking movements. Other types of seizures cause less dramatic symptoms. For instance, some children have shaking movements in just 1 arm or in a part of their face. Other children suddenly stop responding and stare for a few seconds.",
"     </p>",
"     <p>",
"      Sometimes, people can tell that they are about to have a seizure. They have a certain feeling or smell a certain smell. This feeling or smell is called an &ldquo;aura.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10147942\">",
"      <span class=\"h1\">",
"       If my child has seizures, will he or she need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The doctor will do tests to learn more about the seizures and to check whether they are caused by epilepsy. (Not all seizures are caused by epilepsy.) Your child will probably have an:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        EEG &ndash; An EEG measures electrical activity in the brain (",
"        <a class=\"graphic graphic_figure graphicRef55691 \" href=\"mobipreview.htm?38/57/39824\">",
"         figure 1",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        MRI or CT scan &ndash; These tests create pictures of the brain.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10147957\">",
"      <span class=\"h1\">",
"       How is epilepsy treated in children?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Epilepsy in children is usually treated with anti-seizure medicines. These medicines can&rsquo;t cure epilepsy, but they can help prevent seizures. There are different anti-seizure medicines. The right one for your child will depend on the type of seizures he or she has, and on other factors.",
"     </p>",
"     <p>",
"      Anti-seizure medicines usually work well to prevent seizures. But if they don&rsquo;t control your child&rsquo;s epilepsy, your doctor might talk with you about other possible treatments. These can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A special diet that your child can follow",
"       </li>",
"       <li>",
"        Brain surgery",
"       </li>",
"       <li>",
"        A device called a &ldquo;vagus nerve stimulator&rdquo; that goes in the chest to help control seizures",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10147972\">",
"      <span class=\"h1\">",
"       What should I know about anti-seizure medicines?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You should know that:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        These medicines can cause side effects. They can make your child feel tired or dizzy, or cause other problems. Let your doctor know about any side effects your child has. Your doctor can work with you to find the best medicine and dose for your child. You should also let your doctor know right away if your child gets a new rash. This can be a serious side effect.",
"       </li>",
"       <li>",
"        Anti-seizure medicines can affect other medicines your child takes. Also, other medicines can keep anti-seizure medicines from working well. Let your doctor know if your child starts any other new medicines.",
"       </li>",
"       <li>",
"        Your child might need regular blood tests to check the amount of anti-seizure medicine in his or her body.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10147987\">",
"      <span class=\"h1\">",
"       Will my child need anti-seizure medicines for the rest of his or her life?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably not. Most children outgrow their epilepsy and stop having seizures when they are teens or young adults. But don&rsquo;t ever stop your child&rsquo;s anti-seizure medicine without talking to your doctor.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10148002\">",
"      <span class=\"h1\">",
"       How can I keep my child from having more seizures?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To help keep your child from having more seizures, you can make sure that he or she:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Takes his or her anti-seizure medicines exactly as directed &ndash; Stopping or changing your child&rsquo;s medicines raises his or her chances of having a seizure. If your child has any problems with the medicines, talk with your doctor. You should also let him or her know if you can&rsquo;t afford the medicines. There are often ways to solve these problems.",
"       </li>",
"       <li>",
"        Gets enough sleep &ndash; Not getting enough sleep raises your child&rsquo;s chances of having a seizure.",
"       </li>",
"       <li>",
"        Eats a healthy diet",
"       </li>",
"       <li>",
"        Does not drink alcohol or use drugs",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10148017\">",
"      <span class=\"h1\">",
"       Can my teen drive if he or she has epilepsy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Each state and country has its own rules. To be allowed to drive, your teen will probably need to be seizure-free for a certain amount of time. He or she might also need the doctor&rsquo;s permission.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10148032\">",
"      <span class=\"h1\">",
"       When should I call the doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your child&rsquo;s doctor will make a plan with you telling you when to call him or her. In general, call the doctor or nurse if your child has more seizures than usual or if the seizures last longer than usual.",
"     </p>",
"     <p>",
"      Some seizures are a medical emergency.",
"      <strong>",
"       If your child has a seizure that lasts longer than 5 minutes, or if he or she has repeated seizures over a few minutes, call 9-1-1",
"      </strong>",
"      .",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10148047\">",
"      <span class=\"h1\">",
"       What else should I do if my child has epilepsy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You should:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have your child wear a medical bracelet.",
"       </li>",
"       <li>",
"        Ask your child&rsquo;s doctor what to do if your child has a seizure.",
"       </li>",
"       <li>",
"        Talk to your child&rsquo;s school about his or her epilepsy. Tell them which symptoms to watch for and how to treat them. Also, let them know if your child needs to avoid any activities.",
"       </li>",
"       <li>",
"        Have your child talk to a counselor if he or she feels sad or worried.",
"       </li>",
"       <li>",
"        Talk with your teen about how to stay safe.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10148062\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/56/28546?source=see_link\">",
"       Patient information: Seizures (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/40/43650?source=see_link\">",
"       Patient information: Epilepsy in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/20/11586?source=see_link\">",
"       Patient information: Febrile seizures (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/0/18434?source=see_link\">",
"       Patient information: EEG (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=see_link\">",
"       Patient information: Reducing the costs of medicines (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/26/419?source=see_link\">",
"       Patient information: Seizures in children (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?37/54/38754?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16569 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-4FABCF92AE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_54_38754=[""].join("\n");
var outline_f37_54_38754=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10147912\">",
"      What is epilepsy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10147927\">",
"      What are the symptoms of a seizure?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10147942\">",
"      If my child has seizures, will he or she need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10147957\">",
"      How is epilepsy treated in children?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10147972\">",
"      What should I know about anti-seizure medicines?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10147987\">",
"      Will my child need anti-seizure medicines for the rest of his or her life?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10148002\">",
"      How can I keep my child from having more seizures?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10148017\">",
"      Can my teen drive if he or she has epilepsy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10148032\">",
"      When should I call the doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10148047\">",
"      What else should I do if my child has epilepsy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10148062\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16569\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/57/39824\">",
"      EEG (electroencephalogram)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/0/18434?source=related_link\">",
"      Patient information: EEG (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/40/43650?source=related_link\">",
"      Patient information: Epilepsy in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/20/11586?source=related_link\">",
"      Patient information: Febrile seizures (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/56/28546?source=related_link\">",
"      Patient information: Seizures (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/26/419?source=related_link\">",
"      Patient information: Seizures in children (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_54_38755="C1 inhibitor concentrate (human): Patient drug information";
var content_f37_54_38755=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   C1 inhibitor concentrate (human): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/57/23444?source=see_link\">",
"     see \"C1 inhibitor concentrate (human): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/49/11028?source=see_link\">",
"     see \"C1 inhibitor concentrate (human): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6759053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Berinert&reg;;",
"     </li>",
"     <li>",
"      Cinryze&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13261898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Berinert&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692100",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat swelling of the face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3761922",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to avoid swelling of the face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to C1 inhibitor or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3761923",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep an EpiPen&reg; with you at all times.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697239",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had blood clots, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698276",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698358",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Stuffy nose.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699335",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature or in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12114 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.21-37D25D05A2-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_54_38755=[""].join("\n");
var outline_f37_54_38755=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6759053\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13261898\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023870\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023869\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023873\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023874\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023876\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023872\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023877\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023878\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?22/57/23444?source=related_link\">",
"      C1 inhibitor concentrate (human): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/49/11028?source=related_link\">",
"      C1 inhibitor concentrate (human): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_54_38756="Sinoatrial nodal pause, arrest, and exit block";
var content_f37_54_38756=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sinoatrial nodal pause, arrest, and exit block",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/54/38756/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/54/38756/contributors\">",
"     Alan Cheng, MD, FACC, FAHA, FHRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/54/38756/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/54/38756/contributors\">",
"     Brian Olshansky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/54/38756/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/54/38756/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/54/38756/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H691132746\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sinoatrial (SA) node represents the integrated activity of pacemaker cells, sometimes called P cells, in a compact region at the junction of the high right atrium and the superior vena cava. Perinodal cells, sometimes called transitional or (T) cells, transmit the electrical impulse from the SA node to the right atrium. Each of these cell types has distinct expression profiles of ion channels and gap junctions.",
"   </p>",
"   <p>",
"    Given the architecture of the SA node, SA nodal dysfunction typically results from either abnormalities in impulse generation by the P cells or abnormalities in conduction across the T cells. SA nodal dysfunction is more commonly an acquired condition, but in some patients it can be inherited, with gene mutations having been described in some forms of inherited SA nodal dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38756/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients with SA nodal dysfunction may be asymptomatic or highly symptomatic as in cases of sick sinus syndrome.",
"   </p>",
"   <p>",
"    Sinoatrial nodal pauses, arrest, and exit block will be discussed here. Additional details regarding the anatomy and electrophysiology of the SA node, as well as a discussion of the sick sinus syndrome, are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/29/6614?source=see_link\">",
"     \"Anatomy and electrophysiology of the sinoatrial node\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/31/22008?source=see_link\">",
"     \"Manifestations and causes of the sick sinus syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1083436\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sinus pause, arrest, and exit block may arise from ischemic, inflammatory, or infiltrative or fibrotic disease of the SA node, excessive vagal tone, digitalis, and some antiarrhythmic and other drugs. The causes of sinus node dysfunction are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/31/22008?source=see_link&amp;anchor=H4#H4\">",
"     \"Manifestations and causes of the sick sinus syndrome\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H526693838\">",
"    <span class=\"h1\">",
"     TYPES OF SA NODAL DYSFUNCTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Sinus pause or arrest",
"    </span>",
"    &nbsp;&mdash;&nbsp;A sinus pause or arrest is defined as the transient absence of sinus P waves on the ECG that may last from 2 seconds to several minutes (",
"    <a class=\"graphic graphic_waveform graphicRef75018 \" href=\"mobipreview.htm?3/17/3352\">",
"     waveform 1",
"    </a>",
"    ). This abnormality is an alteration in discharge by the SA pacemaker; as a result, the duration of the pause has no arithmetical relationship to the basic sinus rate (ie, the cycle length of the pause is not a multiple of the basic sinus cycle length as would occur with 2:1 or 3:1 SA nodal block). The pause or arrest often allows escape beats or rhythms to occur, but lower pacemakers may be sluggish or even absent in the sick sinus syndrome.",
"   </p>",
"   <p>",
"    A pause that is 2 seconds and perhaps somewhat longer does not necessarily indicate disease, since it can occur in the normal heart [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38756/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Longer episodes of sinus arrest can produce symptoms of dizziness, presyncope, syncope, and, rarely, death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     SA nodal exit block",
"    </span>",
"    &nbsp;&mdash;&nbsp;SA nodal exit block occurs as a result of interference with the delivery of impulses from the SA node to its neighboring atrial tissue. This results in the absence of a P wave on the surface ECG since the P wave is the only manifestation of SA nodal activity. Following the convention for atrioventricular (AV) nodal block, SA nodal exit block can be classified as first, second, or third degree. This problem is most easily conceptualized as having three components:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A relatively constant input &ndash; The input is from the SA nodal pacemaker, which is not seen on the surface ECG. The behavior of the SA nodal pacemaker is, as noted above, inferred from the P waves of atrial activation. The rate or cycle length of the input can be presumed from portions on the ECG where normal P-P cycles are observed.",
"     </li>",
"     <li>",
"      An area across which block occurs &ndash; Exit block is thought to involve the perinodal T cells. The type of exit block in the perinodal tissues must be inferred from the output or response, that is, from the P waves.",
"     </li>",
"     <li>",
"      An output &ndash; The P wave abnormalities reflect the type of exit block which is present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    First degree SA nodal exit block reflects a slowing of impulse exit but there is still 1:1 conduction. This abnormality cannot be recognized on the ECG recorded from the body surface.",
"   </p>",
"   <p>",
"    Second degree SA nodal exit block has two types.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type I (Wenckebach type) is characterized by progressively decreasing P-P intervals prior to a pause caused by a dropped P wave; the pause has a duration that is less than two P-P cycles (",
"      <a class=\"graphic graphic_waveform graphicRef68081 \" href=\"mobipreview.htm?16/0/16389\">",
"       waveform 2",
"      </a>",
"      ). The mechanisms of Wenckebach conduction are considered elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/42/18087?source=see_link\">",
"       \"Second degree atrioventricular block: Mobitz type I (Wenckebach block)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In type II exit block, the P-P output is an integer multiple of the presumed sinus pacemaker input (eg, 2:1, 3:1, 4:1). Therefore the P-P cycle length surrounding the pause is a multiple of the normal P-P interval (",
"      <a class=\"graphic graphic_waveform graphicRef54936 \" href=\"mobipreview.htm?12/56/13189\">",
"       waveform 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Third degree SA nodal exit block prevents sinus node pacemaker impulses from reaching the right atrium. This disorder cannot be distinguished from sinus arrest because the P-wave recorded on the surface ECG is not a direct measure of sinus node activity, only of atrial depolarization (which will be absent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H526693845\">",
"    <span class=\"h2\">",
"     Variants of SA nodal dysfunction",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H526693852\">",
"    <span class=\"h3\">",
"     Sinus arrhythmia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sinus arrhythmia is a term that describes small changes in the sinus cycle length. The formal definition of sinus arrhythmia is a variation in the P-P interval by 0.12 sec (120 msec) or more in the presence of normal P waves and the usual PR interval (",
"    <a class=\"graphic graphic_waveform graphicRef73688 \" href=\"mobipreview.htm?20/37/21080\">",
"     waveform 4",
"    </a>",
"    ), or a difference of 10 percent or greater between the longest and shortest P-P intervals. Sinus arrhythmia is more common in the young and also in those exposed to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    , while it is less frequently seen in older patients and those with diabetes. Typically, the P wave morphology remains relatively constant, but small variations in the PR interval may be seen. There are two predominant types of sinus arrhythmia, one occurring as a result of normal respiration and another in the presence of digoxin toxicity. Sinus arrhythmia (except when due to digoxin toxicity) is not considered abnormal and rarely causes symptoms; therefore, no treatment is typically recommended. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/2/2086?source=see_link&amp;anchor=H8#H8\">",
"     \"Normal sinus rhythm and sinus arrhythmia\", section on 'Sinus arrhythmia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H526693860\">",
"    <span class=\"h3\">",
"     Wandering atrial pacemaker",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wandering atrial pacemaker refers to a change in the dominant pacemaker focus from the sinus node. A wandering atrial pacemaker is present when there are three or more ectopic foci within the atrial myocardium that serve as the dominant pacemaker (",
"    <a class=\"graphic graphic_waveform graphicRef54943 \" href=\"mobipreview.htm?9/37/9815\">",
"     waveform 5",
"    </a>",
"    ). Because the location of the pacemaker changes, the PR interval can vary as well depending on its proximity to the AV node. Wandering pacemaker is not considered abnormal and can often be seen in young, healthy individuals (eg, athletes). Rarely is this symptomatic; therefore, no treatment is typically indicated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/40/34438?source=see_link&amp;anchor=H4#H4\">",
"     \"ECG tutorial: Atrial and atrioventricular nodal (supraventricular) arrhythmias\", section on 'Wandering atrial pacemaker'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1083616\">",
"    <span class=\"h1\">",
"     ELECTROPHYSIOLOGIC AND ELECTROCARDIOGRAPHIC FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mass of the crescent-shaped SA node is too small to create an electrical signal that can be routinely recorded on the surface ECG. As a result, we generally infer SA nodal activity from the ECG appearance of the response to that activity (ie, P waves). Although signal-averaged electrocardiograms focusing on the P wave can identify sinus nodal dysfunction, this is not a commonly used clinical tool due in large measure to problems in registration, particularly during a sinus arrhythmia, and because many of the conduction events are transient and are missed by this technique [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38756/abstract/4\">",
"     4",
"    </a>",
"    ]. Hence, common signs of SA nodal dysfunction on the surface ECG include marked sinus bradycardia that is disproportionate to an individual's metabolic or conditioned state and periods of absent P waves. In order to more clearly delineate the mechanism underlying periods of SA nodal dysfunction, electrophysiology studies are needed but are not commonly performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1083623\">",
"    <span class=\"h2\">",
"     Electrophysiologic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;SA nodal activity can be recorded using an intracardiac electrode catheter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38756/abstract/5-10\">",
"     5-10",
"    </a>",
"    ]. The following observations were noted in a study of 38 patients with severe symptomatic sick sinus syndrome in whom intracardiac SA nodal electrograms could be recorded [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38756/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      9 had complete SA block, unidirectional in 7 and bidirectional in 2",
"     </li>",
"     <li>",
"      13 had normal 1:1 sinoatrial conduction",
"     </li>",
"     <li>",
"      9 had second degree sinoatrial exit block",
"     </li>",
"     <li>",
"      7 patients had no recordable sinus nodal electrogram, which could result from technical failure or from SA nodal quiescence",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Electrophysiologic techniques utilizing both pacing at different rates and extra stimuli can be used to assess several characteristics of SA nodal function, including postpacing escape times, SA nodal recovery time, SA nodal conduction time, SA nodal refractoriness, and the assessment of the \"intrinsic\" heart rate and other parameters following pharmacologic and autonomic intervention. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/51/22328?source=see_link&amp;anchor=H4#H4\">",
"     \"Invasive cardiac electrophysiology studies: Bradyarrhythmias\", section on 'Sinus node dysfunction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sinus node dysfunction, as in the sick sinus syndrome, can coexist with atrioventricular node conduction disturbances. This has been termed binodal disease. Electrophysiologic studies suggest that individuals with binodal disease also commonly have intra-atrial conduction disturbances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38756/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/21/17749?source=see_link\">",
"     \"ECG tutorial: Atrioventricular block\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1083507\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy is the same as for sinus bradycardia or the sick sinus syndrome. Asymptomatic patients with SA nodal pauses, arrest, or exit block often do not require treatment. Patients with symptoms are often treated by discontinuing possible offending drugs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    with a permanent pacemaker. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/50/3878?source=see_link&amp;anchor=H14#H14\">",
"     \"Sinus bradycardia\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/44/37576?source=see_link\">",
"     \"Treatment of the sick sinus syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1083284\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A sinus pause or arrest is the transient absence of sinus P waves on the electrocardiogram (ECG) that may last from two seconds to several minutes. This abnormality is an alteration in discharge by the SA pacemaker; as a result, the duration of the pause has no arithmetical relationship to the basic sinus rate. The pause or arrest often allows escape beats or rhythms to occur. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Sinus pause or arrest'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SA nodal exit block occurs as a result of interference with the delivery of impulses from the SA node to its neighboring atrial tissue. This results in the absence of a P wave on the surface ECG since the P wave is the only manifestation of SA nodal activity. Following the convention for atrioventricular (AV) nodal block, SA nodal exit block can be classified as first, second, or third degree. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'SA nodal exit block'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other variations of SA nodal dysfunction which are generally non-pathologic include sinus arrhythmia and wandering atrial pacemaker. (See",
"      <a class=\"local\" href=\"#H526693845\">",
"       'Variants of SA nodal dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Asymptomatic patients with SA nodal pauses, arrest, or exit block often do not require treatment. Patients with symptoms are often treated by discontinuing possible offending drugs",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      with a permanent pacemaker. (See",
"      <a class=\"local\" href=\"#H1083507\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38756/abstract/1\">",
"      Park DS, Fishman GI. The cardiac conduction system. Circulation 2011; 123:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38756/abstract/2\">",
"      Hilgard J, Ezri MD, Denes P. Significance of ventricular pauses of three seconds or more detected on twenty-four-hour Holter recordings. Am J Cardiol 1985; 55:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38756/abstract/3\">",
"      Brodsky M, Wu D, Denes P, et al. Arrhythmias documented by 24 hour continuous electrocardiographic monitoring in 50 male medical students without apparent heart disease. Am J Cardiol 1977; 39:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38756/abstract/4\">",
"      Yamada T, Fukunami M, Shimonagata T, et al. Identification of sinus node dysfunction by use of P-wave signal-averaged electrocardiograms in paroxysmal atrial fibrillation: a prospective study. Am Heart J 2001; 142:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38756/abstract/5\">",
"      Hombach V, Gil-Sanchez D, Zanker R, et al. An approach to direct detection of sinus nodal activity in man. J Electrocardiol 1979; 12:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38756/abstract/6\">",
"      Hariman RJ, Krongrad E, Boxer RA, et al. Method for recording electrical activity of the sinoatrial node and automatic atrial foci during cardiac catheterization in human subjects. Am J Cardiol 1980; 45:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38756/abstract/7\">",
"      Reiffel JA, Gang E, Gliklich J, et al. The human sinus node electrogram: a transvenous catheter technique and a comparison of directly measured and indirectly estimated sinoatrial conduction time in adults. Circulation 1980; 62:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38756/abstract/8\">",
"      Asseman P, Berzin B, Desry D, et al. Persistent sinus nodal electrograms during abnormally prolonged postpacing atrial pauses in sick sinus syndrome in humans: sinoatrial block vs overdrive suppression. Circulation 1983; 68:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38756/abstract/9\">",
"      Gomes JA, Hariman RI, Chowdry IA. New application of direct sinus node recordings in man: assessment of sinus node recovery time. Circulation 1984; 70:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38756/abstract/10\">",
"      Wu DL, Yeh SJ, Lin FC, et al. Sinus automaticity and sinoatrial conduction in severe symptomatic sick sinus syndrome. J Am Coll Cardiol 1992; 19:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38756/abstract/11\">",
"      Sakai Y, Imai S, Sato Y, et al. Clinical and electrophysiological characteristics of binodal disease. Circ J 2006; 70:1580.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 894 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-D40D2B0C78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_54_38756=[""].join("\n");
var outline_f37_54_38756=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1083284\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H691132746\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1083436\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H526693838\">",
"      TYPES OF SA NODAL DYSFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Sinus pause or arrest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SA nodal exit block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H526693845\">",
"      Variants of SA nodal dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H526693852\">",
"      - Sinus arrhythmia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H526693860\">",
"      - Wandering atrial pacemaker",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1083616\">",
"      ELECTROPHYSIOLOGIC AND ELECTROCARDIOGRAPHIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1083623\">",
"      Electrophysiologic features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1083507\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1083284\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/894\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/894|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?3/17/3352\" title=\"waveform 1\">",
"      Sinus pause tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?16/0/16389\" title=\"waveform 2\">",
"      ECG type I sinoatrial block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?12/56/13189\" title=\"waveform 3\">",
"      ECG type II sinoatrial block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?20/37/21080\" title=\"waveform 4\">",
"      Sinus arrhythmia tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?9/37/9815\" title=\"waveform 5\">",
"      Wandering atrial pacer tutorial",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/29/6614?source=related_link\">",
"      Anatomy and electrophysiology of the sinoatrial node",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/40/34438?source=related_link\">",
"      ECG tutorial: Atrial and atrioventricular nodal (supraventricular) arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/21/17749?source=related_link\">",
"      ECG tutorial: Atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/51/22328?source=related_link\">",
"      Invasive cardiac electrophysiology studies: Bradyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/31/22008?source=related_link\">",
"      Manifestations and causes of the sick sinus syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/2/2086?source=related_link\">",
"      Normal sinus rhythm and sinus arrhythmia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/42/18087?source=related_link\">",
"      Second degree atrioventricular block: Mobitz type I (Wenckebach block)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/50/3878?source=related_link\">",
"      Sinus bradycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/44/37576?source=related_link\">",
"      Treatment of the sick sinus syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_54_38757="Typical atrial flutter";
var content_f37_54_38757=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74395&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74395&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 601px\">",
"   <div class=\"ttl\">",
"    Typical atrial flutter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 581px; height: 314px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electrocardiogram in type I counterclockwise typical atrial flutter. The biphasic flutter (F) waves are prominently negative (lead II) in counterclockwise typical flutter. The patient is on a beta-blocker which explains the 4:1 conduction pattern.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_54_38757=[""].join("\n");
var outline_f37_54_38757=null;
var title_f37_54_38758="Diagnosis of diabetes mellitus";
var content_f37_54_38758=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis of diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/54/38758/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/54/38758/contributors\">",
"     David K McCulloch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/54/38758/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/54/38758/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/54/38758/contributors\">",
"     Joseph I Wolfsdorf, MB, BCh",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/54/38758/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/54/38758/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/54/38758/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term diabetes mellitus describes several diseases of abnormal carbohydrate metabolism that are characterized by hyperglycemia. It is associated with a relative or absolute impairment in insulin secretion, along with varying degrees of peripheral resistance to the action of insulin. Every few years, the diabetes community reevaluates the current recommendations for the classification, diagnosis, and screening of diabetes, reflecting new information from research and clinical practice.",
"   </p>",
"   <p>",
"    The American Diabetes Association (ADA) issued diagnostic criteria for diabetes mellitus in 1997, with follow-up in 2003 and 2010 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38758/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The diagnosis is based on one of four abnormalities: hemoglobin A1C (A1C), fasting plasma glucose (FPG), random elevated glucose with symptoms, or abnormal oral glucose tolerance test (OGTT) (",
"    <a class=\"graphic graphic_table graphicRef61853 \" href=\"mobipreview.htm?28/3/28731\">",
"     table 1",
"    </a>",
"    ). Patients with impaired fasting glucose (IFG)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    impaired glucose tolerance (IGT) are referred to as having increased risk for diabetes (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Diagnostic criteria'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Recommendations for routine screening for diabetes are provided elsewhere. The etiologic classification of diabetes mellitus is also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/16/2312?source=see_link\">",
"     \"Screening for diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/33/14874?source=see_link\">",
"     \"Classification of diabetes mellitus and genetic diabetic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 1997 ADA Expert Committee introduced the terms type 1 and type 2 diabetes, and recommended against terms like insulin-dependent, non-insulin-dependent, juvenile-onset, maturity-onset, and adult-onset diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38758/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition to type 1 and type 2 diabetes, \"specific types\" of diabetes are identified: gestational diabetes, and diabetes secondary to recognized genetic defects, diseases of the exocrine pancreas, other endocrinopathies, or to drugs. This change was an attempt to classify diabetes according to etiologic differences rather than descriptions based upon age at onset or type of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of diabetes mellitus is easily established when a patient presents with classic symptoms of hyperglycemia (thirst, polyuria, weight loss, blurry vision) and has a random blood glucose value of 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (11.1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    or higher, and confirmed on another occasion.",
"   </p>",
"   <p>",
"    Other diagnostic criteria have been developed based upon the observed association between glucose levels and the risk for developing retinopathy. Fasting plasma glucose values &ge;126",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (7.0",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    two-hour post oral glucose challenge values of &ge;200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (11.1",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    and A1C values &ge;6.5 percent are associated with an increased prevalence of retinopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38758/abstract/3\">",
"     3",
"    </a>",
"    ]. The diagnosis of diabetes in an asymptomatic individual can be established with any of the above criteria, as described below. An abnormal result should be confirmed by repeat measurement with the same test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     WHO criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2006 WHO criteria define diabetes as a fasting glucose &ge;126",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (7.0",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    or a two-hour post glucose challenge value &ge;200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (11.1",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    Impaired glucose tolerance (IGT) is defined as a fasting glucose &lt;126 (7.0",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    and a two-hour glucose &ge;140",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (7.8",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    but &lt;200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (11.05",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38758/abstract/4\">",
"     4",
"    </a>",
"    ]. Impaired fasting glucose (IFG) is defined as a fasting glucose of 110 to 125",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (6.1 to 6.9",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    In 2011, the WHO concluded that an A1C value of &ge;6.5 percent (48",
"    <span class=\"nowrap\">",
"     mmol/mol)",
"    </span>",
"    can be used as a diagnostic test for diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38758/abstract/5\">",
"     5",
"    </a>",
"    ]. A value of &lt;6.5 percent does not exclude diabetes diagnosed using glucose levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     ADA criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2003, the ADA recommended the use of fasting glucose levels (no caloric intake for at least eight hours) or 75 g glucose tolerance test for diagnosing diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38758/abstract/2\">",
"     2",
"    </a>",
"    ]. In 2009, an International Expert Committee recommended using a hemoglobin A1C (A1C) value of &ge;6.5 percent (&ge;48",
"    <span class=\"nowrap\">",
"     mmol/mol)",
"    </span>",
"    to diagnose diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38758/abstract/6\">",
"     6",
"    </a>",
"    ], and the ADA affirmed the decision (",
"    <a class=\"graphic graphic_table graphicRef61853 \" href=\"mobipreview.htm?28/3/28731\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38758/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Hemoglobin A1C'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The shift from using the FPG to using A1C to diagnose diabetes may decrease the proportion of patients identified as having diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38758/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. As an example, in a study of 6890 adults without a history of diabetes participating in the National Health and Nutrition Examination Survey (1999 to 2006), the prevalence of diabetes using A1C versus fasting glucose criteria was 2.3 versus 3.6 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38758/abstract/7\">",
"     7",
"    </a>",
"    ]. Overall, the A1C and FPG criteria resulted in the same classification for 98 percent of the population studied.",
"   </p>",
"   <p>",
"    The following definitions are from ADA reports (",
"    <a class=\"graphic graphic_table graphicRef61853 \" href=\"mobipreview.htm?28/3/28731\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef82479 \" href=\"mobipreview.htm?1/61/2011\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38758/abstract/2,3,9,10\">",
"     2,3,9,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normal &mdash; Fasting plasma glucose (FPG) &lt;100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.6",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      Two-hour glucose during OGTT &lt;140",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (7.8",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      Categories of increased risk for diabetes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Impaired fasting glucose (IFG) &mdash; Fasting plasma glucose between 100 and 125",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.6 to 6.9",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      Impaired glucose tolerance (IGT) &mdash; Two-hour plasma glucose value during a 75 g oral glucose tolerance test between 140 and 199",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (7.8 to 11.0",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      A1C &mdash; Persons with 5.7 to 6.4 percent (6.0 to 6.4 percent in the International Expert Committee report [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/54/38758/abstract/6\">",
"       6",
"      </a>",
"      ]) are at highest risk, although there is a continuum of increasing risk across the entire spectrum of A1C levels less than 6.5 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diabetes mellitus &mdash; FPG at or above 126",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (7.0",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      A1C &ge;6.5 percent (48",
"      <span class=\"nowrap\">",
"       mmol/mol),",
"      </span>",
"      a two-hour value in an OGTT (2-h PG) at or above 200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (11.1",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      or a random (or \"casual\") plasma glucose concentration &ge;200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (11.1",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in the presence of symptoms (",
"      <a class=\"graphic graphic_table graphicRef61853 \" href=\"mobipreview.htm?28/3/28731\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the absence of unequivocal symptomatic hyperglycemia, the diagnosis of diabetes must be confirmed on a subsequent day by repeat measurement, repeating the same test for confirmation. However, if two different tests (eg, FPG and A1C) are available and are concordant for the diagnosis of diabetes, additional testing is not needed. If two different tests are discordant, the test that is diagnostic of diabetes should be repeated to confirm the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38758/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of confirming the diagnosis by repeat measurement on a subsequent day, especially when the diagnosis is based upon glucose measurements, is illustrated by a report from the National Health and Nutrition Examination Survey (NHANES) III Second Examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38758/abstract/11\">",
"     11",
"    </a>",
"    ]. The prevalence of diabetes based upon either fasting glucose or two-hour post OGTT glucose significantly decreased when the diagnosis was contingent upon having two abnormal measurements rather than a single abnormal measurement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     EDEG criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The European Diabetes Epidemiology Group (EDEG) issued a position statement in 2006 recommending that the original cut-off point for IFG (110",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or 6.1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    be retained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38758/abstract/12\">",
"     12",
"    </a>",
"    ]. They also recommend that the term \"non-diabetic hyperglycemia\" be used in preference to \"impaired fasting glucose.\" These recommendations were based on recognition that the risk for diabetes is a continuous variable with fasting glucose levels, with no clear threshold for risk of diabetes or cardiovascular disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     HEMOGLOBIN A1C",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been long-standing interest in the use of hemoglobin A1C (A1C) values for screening and identification of impaired glucose tolerance and diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38758/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. In the 1999 to 2004 National Health and Nutrition Examination Survey (NHANES) population, an A1C of 5.8 percent had the highest sensitivity (86 percent) and specificity (92 percent) for diagnosing diabetes compared with the fasting glucose criteria (fasting plasma glucose &gt;126",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [7",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38758/abstract/15\">",
"     15",
"    </a>",
"    ]. Similar results were noted in a systematic review of studies assessing the accuracy of A1C in the detection of type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38758/abstract/16\">",
"     16",
"    </a>",
"    ]. A1C and FPG were found to be similarly effective in diagnosing diabetes. Using an A1C cut-off point of &gt;6.1 percent to diagnose diabetes, sensitivity ranged from 78 to 81 percent and specificity 79 to 84 percent, when compared with diabetes diagnosed with FPG.",
"   </p>",
"   <p>",
"    A1C values also correlate with the prevalence of retinopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38758/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. As an example, in the 2005 to 2006 NHANES, 1066 individuals &ge;40 years had retinal fundus photography and measurements of A1C and fasting plasma glucose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38758/abstract/19\">",
"     19",
"    </a>",
"    ]. The prevalence of retinopathy increased above an A1C of 5.5 percent and a FPG of 104",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.8",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    A1C was more accurate than FPG in identifying cases of retinopathy.",
"   </p>",
"   <p>",
"    A1C values were not previously recommended to diagnose diabetes because of variation in A1C assays. However, the National Glycohemoglobin Standardization Program (NGSP) has standardized more than 99 percent of the assays used in the United States to the DCCT standard. A strict quality control program has improved precision and accuracy of assays in the US and many international assays. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11993?source=see_link&amp;anchor=H4#H4\">",
"     \"Estimation of blood glucose control in diabetes mellitus\", section on 'Assay'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An International Expert Committee issued a consensus report in June 2009, recommending that an A1C level &ge;6.5 percent be used to diagnose diabetes, and the ADA affirmed this decision [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38758/abstract/3,6\">",
"     3,6",
"    </a>",
"    ]. The diagnosis should be confirmed with a repeat A1C. In making the recommendation, the report noted several technical advantages of the A1C assay over glucose testing, increased patient convenience (since there is no special preparation or timing required for the A1C test), and the correlation of A1C levels with retinopathy. The report also noted that if an A1C test is either unavailable or uninterpretable, for example owing to rapid red cell turnover with anemia, the previous diagnostic methods and criteria, using glucose testing, should be used. The A1C assay and potential sources of error are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11993?source=see_link&amp;anchor=H3#H3\">",
"     \"Estimation of blood glucose control in diabetes mellitus\", section on 'Hemoglobin A1C'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     A1C, FPG, AND OGTT AS PREDICTORS OF DIABETES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the natural history of IFG and IGT is variable, approximately 25 percent of subjects with either will progress to diabetes over three to five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38758/abstract/10\">",
"     10",
"    </a>",
"    ]. Subjects with additional diabetes risk factors, including obesity and family history, are more likely to develop diabetes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/30/29162?source=see_link&amp;anchor=H3#H3\">",
"     \"Prediction and prevention of type 2 diabetes mellitus\", section on 'Impaired glucose tolerance'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/30/29162?source=see_link&amp;anchor=H4#H4\">",
"     \"Prediction and prevention of type 2 diabetes mellitus\", section on 'Impaired fasting glucose'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A1C values may also be used to predict the incidence of type 2 diabetes. As an example, in a prospective cohort study of 26,563 women followed for 10 years, baseline A1C level was an independent predictor of type 2 diabetes, even at levels considered to be within the normal range [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38758/abstract/20\">",
"     20",
"    </a>",
"    ]. In those individuals with baseline A1C in the highest quintile (A1C &gt;5.22), the adjusted relative risk of diabetes was 8.2, 95% CI 6.0-11.1. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/30/29162?source=see_link&amp;anchor=H6#H6\">",
"     \"Prediction and prevention of type 2 diabetes mellitus\", section on 'Hemoglobin A1C'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A1C criteria for identifying patients with impaired glucose regulation were derived using data from the National Health and Nutrition Survey, 2005 to 2006 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38758/abstract/3\">",
"     3",
"    </a>",
"    ]. Compared with other cut points, an A1C cut point of 5.7 percent had the best sensitivity (39 percent) and specificity (91 percent) for identifying cases of IFG (FPG &ge;100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [5.6",
"    <span class=\"nowrap\">",
"     mmol/L]).",
"    </span>",
"   </p>",
"   <p>",
"    Although most of the high risk groups have been defined categorically (eg, IFG or IGT), the risk for developing diabetes follows a continuum across the entire spectrum of subdiabetic glycemic values. Higher fasting or 2-h OGTT glucose values or higher A1C values convey higher risk than lower values.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     A1C, FPG, AND OGTT AS PREDICTORS OF CARDIOVASCULAR RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is strong, consistent evidence that the relationship between blood glucose levels and cardiovascular risk extends into the nondiabetic range. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7578?source=see_link&amp;anchor=H18#H18\">",
"     \"Glycemic control and vascular complications in type 2 diabetes mellitus\", section on 'Prediabetes and cardiovascular risk'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following observations have been made in different reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Data from the Atherosclerosis Risk in Communities (ARIC) study showed a relationship between A1C level and coronary heart disease in non-diabetic individuals [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/54/38758/abstract/21\">",
"       21",
"      </a>",
"      ]. The relative risk of a cardiovascular event was 1.38 (95% CI 1.22-1.56) for every 1 percentage point increase in hemoglobin A1C for subjects without diabetes whose A1C was 5.5 percent or greater.",
"     </li>",
"     <li>",
"      Several studies have shown that, compared with impaired fasting glucose, impaired glucose tolerance is a better predictor of cardiovascular disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/54/38758/abstract/22,23\">",
"       22,23",
"      </a>",
"      ] and mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/54/38758/abstract/24,25\">",
"       24,25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a 10-year prospective study of almost 6800 non-diabetic subjects, each one standard deviation increase in two-hour glucose increased the hazard ratio for both coronary events (1.17, 95% CI 1.05-1.30) and cardiovascular mortality (1.22, 95% CI 1.09-1.37) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/54/38758/abstract/26\">",
"       26",
"      </a>",
"      ]. The respective values for a one standard deviation increase in fasting glucose were lower (1.05 and 1.13). These observations suggest that postprandial (OGTT) hyperglycemia is more strongly associated with cardiovascular risk and mortality than FPG.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, the old criteria for impaired fasting glucose, compared with the new criteria, were more predictive of impaired glucose tolerance, CHD, and risk of the metabolic syndrome as defined by NCEP criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38758/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. As an example, in the Framingham Heart Study, the risk of developing CHD over a four-year period was greater in women with IFG based upon the 1997 compared to the 2003 criteria (odds ratios 2.2 [95% CI 1.1-4.4] and 1.7 [95% CI 1.0-3.0], respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38758/abstract/29\">",
"     29",
"    </a>",
"    ]. In contrast, men were not at increased risk of developing CHD by either IFG definition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/43/692?source=see_link\">",
"       \"Patient information: Type 1 diabetes (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/44/33475?source=see_link\">",
"       \"Patient information: Type 2 diabetes (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/14/227?source=see_link\">",
"       \"Patient information: Hemoglobin A1C tests (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/26/36259?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/22/9572?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to ADA criteria, the diagnostic thresholds for categories of increased risk for diabetes and for the diagnosis of diabetes mellitus are as follows (",
"    <a class=\"graphic graphic_table graphicRef61853 \" href=\"mobipreview.htm?28/3/28731\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef82479 \" href=\"mobipreview.htm?1/61/2011\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38758/abstract/2,3,9,10\">",
"     2,3,9,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normal &mdash; Fasting plasma glucose (FPG) &lt;100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.6",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Categories of increased risk for diabetes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Impaired fasting glucose (IFG) &mdash; FPG &ge;100 to 125",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.6 to 6.9",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Impaired glucose tolerance (IGT) &mdash; 2-h PG (75 g OGTT) &ge;140 to 199",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (7.8 to 11.0",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      A1C &mdash; 5.7 to 6.4 percent (the International Expert Committee recommended 6.0 to 6.4 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/54/38758/abstract/6\">",
"       6",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diabetes mellitus &mdash; A1C &ge;6.5 percent (48",
"      <span class=\"nowrap\">",
"       mmol/mol),",
"      </span>",
"      FPG &ge;126",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (7.0",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      2-h PG &ge;200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (11.1",
"      <span class=\"nowrap\">",
"       mmol/L);",
"      </span>",
"      random PG &gt;200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (11.1",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in the presence of symptoms (",
"      <a class=\"graphic graphic_table graphicRef61853 \" href=\"mobipreview.htm?28/3/28731\">",
"       table 1",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      In the absence of unequivocal symptomatic hyperglycemia, the diagnosis of diabetes must be confirmed on a subsequent day by repeat measurement, repeating the same test for confirmation.",
"     </li>",
"     <li>",
"      A1C, FPG, and 2-h PG are used to diagnose lesser degrees of impaired glucose regulation. There is currently no consensus on using one in preference to the other. While the 2-h PG is a more sensitive test in most populations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/54/38758/abstract/30\">",
"       30",
"      </a>",
"      ], A1C and FPG are more convenient.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38758/abstract/1\">",
"      Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38758/abstract/2\">",
"      Genuth S, Alberti KG, Bennett P, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26:3160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38758/abstract/3\">",
"      American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33 Suppl 1:S62.",
"     </a>",
"    </li>",
"    <li>",
"     file://whqlibdoc.who.int/publications/2006/9241594934_eng.pdf (Accessed on December 22, 2011).",
"    </li>",
"    <li>",
"     file://www.who.int/diabetes/publications/report-hba1c_2011.pdf (Accessed on June 07, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38758/abstract/6\">",
"      International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009; 32:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38758/abstract/7\">",
"      Carson AP, Reynolds K, Fonseca VA, Muntner P. Comparison of A1C and fasting glucose criteria to diagnose diabetes among U.S. adults. Diabetes Care 2010; 33:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38758/abstract/8\">",
"      Cowie CC, Rust KF, Byrd-Holt DD, et al. Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988-2006. Diabetes Care 2010; 33:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38758/abstract/9\">",
"      American Diabetes Association. Standards of medical care in diabetes--2013. Diabetes Care 2013; 36 Suppl 1:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38758/abstract/10\">",
"      Nathan DM, Davidson MB, DeFronzo RA, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007; 30:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38758/abstract/11\">",
"      Selvin E, Crainiceanu CM, Brancati FL, Coresh J. Short-term variability in measures of glycemia and implications for the classification of diabetes. Arch Intern Med 2007; 167:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38758/abstract/12\">",
"      Forouhi NG, Balkau B, Borch-Johnsen K, et al. The threshold for diagnosing impaired fasting glucose: a position statement by the European Diabetes Epidemiology Group. Diabetologia 2006; 49:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38758/abstract/13\">",
"      Peters AL, Davidson MB, Schriger DL, Hasselblad V. A clinical approach for the diagnosis of diabetes mellitus: an analysis using glycosylated hemoglobin levels. Meta-analysis Research Group on the Diagnosis of Diabetes Using Glycated Hemoglobin Levels. JAMA 1996; 276:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38758/abstract/14\">",
"      Rohlfing CL, Little RR, Wiedmeyer HM, et al. Use of GHb (HbA1c) in screening for undiagnosed diabetes in the U.S. population. Diabetes Care 2000; 23:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38758/abstract/15\">",
"      Buell C, Kermah D, Davidson MB. Utility of A1C for diabetes screening in the 1999 2004 NHANES population. Diabetes Care 2007; 30:2233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38758/abstract/16\">",
"      Bennett CM, Guo M, Dharmage SC. HbA(1c) as a screening tool for detection of Type 2 diabetes: a systematic review. Diabet Med 2007; 24:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38758/abstract/17\">",
"      Miyazaki M, Kubo M, Kiyohara Y, et al. Comparison of diagnostic methods for diabetes mellitus based on prevalence of retinopathy in a Japanese population: the Hisayama Study. Diabetologia 2004; 47:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38758/abstract/18\">",
"      Massin P, Lange C, Tichet J, et al. Hemoglobin A1c and fasting plasma glucose levels as predictors of retinopathy at 10 years: the French DESIR study. Arch Ophthalmol 2011; 129:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38758/abstract/19\">",
"      Cheng YJ, Gregg EW, Geiss LS, et al. Association of A1C and fasting plasma glucose levels with diabetic retinopathy prevalence in the U.S. population: Implications for diabetes diagnostic thresholds. Diabetes Care 2009; 32:2027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38758/abstract/20\">",
"      Pradhan AD, Rifai N, Buring JE, Ridker PM. Hemoglobin A1c predicts diabetes but not cardiovascular disease in nondiabetic women. Am J Med 2007; 120:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38758/abstract/21\">",
"      Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010; 362:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38758/abstract/22\">",
"      Tominaga M, Eguchi H, Manaka H, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999; 22:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38758/abstract/23\">",
"      Meigs JB, Nathan DM, D'Agostino RB Sr, et al. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 2002; 25:1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38758/abstract/24\">",
"      Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999; 354:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38758/abstract/25\">",
"      DECODE Study Group, the European Diabetes Epidemiology Group.. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38758/abstract/26\">",
"      Qiao Q, Py&ouml;r&auml;l&auml; K, Py&ouml;r&auml;l&auml; M, et al. Two-hour glucose is a better risk predictor for incident coronary heart disease and cardiovascular mortality than fasting glucose. Eur Heart J 2002; 23:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38758/abstract/27\">",
"      Kim SH, Chunawala L, Linde R, Reaven GM. Comparison of the 1997 and 2003 American Diabetes Association classification of impaired fasting glucose: impact on prevalence of impaired fasting glucose, coronary heart disease risk factors, and coronary heart disease in a community-based medical practice. J Am Coll Cardiol 2006; 48:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38758/abstract/28\">",
"      Phillips LS, Weintraub WS, Ziemer DC, et al. All pre-diabetes is not the same: metabolic and vascular risks of impaired fasting glucose at 100 versus 110 mg/dl: the Screening for Impaired Glucose Tolerance study 1 (SIGT 1). Diabetes Care 2006; 29:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38758/abstract/29\">",
"      Levitzky YS, Pencina MJ, D'Agostino RB, et al. Impact of impaired fasting glucose on cardiovascular disease: the Framingham Heart Study. J Am Coll Cardiol 2008; 51:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38758/abstract/30\">",
"      Woerle HJ, Pimenta WP, Meyer C, et al. Diagnostic and therapeutic implications of relationships between fasting, 2-hour postchallenge plasma glucose and hemoglobin a1c values. Arch Intern Med 2004; 164:1627.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1812 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-D795AC79FE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_54_38758=[""].join("\n");
var outline_f37_54_38758=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSTIC CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      WHO criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ADA criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EDEG criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      HEMOGLOBIN A1C",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      A1C, FPG, AND OGTT AS PREDICTORS OF DIABETES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      A1C, FPG, AND OGTT AS PREDICTORS OF CARDIOVASCULAR RISK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1812\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1812|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/3/28731\" title=\"table 1\">",
"      ADA criteria for diagnosis diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/61/2011\" title=\"table 2\">",
"      Categories of increased risk for diabetes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/33/14874?source=related_link\">",
"      Classification of diabetes mellitus and genetic diabetic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11993?source=related_link\">",
"      Estimation of blood glucose control in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7578?source=related_link\">",
"      Glycemic control and vascular complications in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/26/36259?source=related_link\">",
"      Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/22/9572?source=related_link\">",
"      Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/14/227?source=related_link\">",
"      Patient information: Hemoglobin A1C tests (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/43/692?source=related_link\">",
"      Patient information: Type 1 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/44/33475?source=related_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/30/29162?source=related_link\">",
"      Prediction and prevention of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/16/2312?source=related_link\">",
"      Screening for diabetes mellitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_54_38759="M mode mitral valve motion";
var content_f37_54_38759=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67656&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67656&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 548px\">",
"   <div class=\"ttl\">",
"    M-mode echocardiogram of the normal mitral valve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 528px; height: 322px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFCAhADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5Ur2r/hnLxd5e/wDtDQsdcefMTj/v1XitfpOqIswyexJ9hwD/AF/Ok3YmTsfIcv7OHjGOMv8AbtCbAyAJ5cn6ZjpY/wBm/wAYSIjDUNCAddwzNMMfX91xX15GIJEDxGN485DLgg4p7JkgnApXZHMz5CH7NvjAgn+0vD+PX7RL6Z/55Uh/Zu8YAAnUNBAPT9/Nz/5Cr69ZTsw2CaieFSrFAd4HY8n0H60uYOdnyK37OHi8Af8AEx0A/S4l/wDjVI37OXi4cDUNBJ9BPL/8ar67Me5QVbb65FR7CXIRSfpRzMXOz5Ib9nLxcq7m1HQQPeeb/wCNUxv2dvFqttOoaFnGc/aJcf8AouvrgpwCw69CR+lIUB5wM+tHMw55HyJJ+z54sQZN/ohHtNL/APG6af2fvFYHN9og/wC28v8A8br6yuowu1lUAHjAFQyR7Mhx1HT3/pTuLnZ8oN8AvFSg/wCm6LwM/wCul/8AjdYXiz4U654Y0O41W/utNktodu4QSOWO5goxlAOp9a+xpIF2gL3/ABrzb4+W2z4Ua02AMNBx/wBtkouxqbvY+SLG2e8vLe1hx5k8ixpk8ZY4Gfzr1rT/ANn3xdd2NvctdaPbGaMP5M80gdMj7rARkZHoCa8w8NHHiPSv+vuL/wBDFfoayDORGdmOTzx1/wAf0ok2tjV3Pkc/s7eLQ203+h5PH+um/wDjVSJ+zj4udto1LQA3obiXJP8A36r6c8QeINC0Czkuda1G0t0jXP7xwXP0A5zXFeC/iz4f8TeIJtOt/OsictbPd/ILgf7J7H2qOdiuzxSf9nfxbDE0j6hoeFIBxPKTycf88ql/4Zv8XgndqWgLj1nm/wDjVfVV/M/2UNIuyMuu4/xElgAMfr+FXFlt5LllOFcA5Q/3fWnzMLnyh/wzN4x37f7T8PZJx/x8Tf8AxqnP+zJ4zVSf7S8PHHYXE3/xqvrlJsEF23HsPfp1/CrKyKy85XIyQaOdhc+Mpf2cfGEbANf6Fz0xPL/8bqqPgB4o+0GD+0dCEgG4gzy8D/v3X2HqzW9vavNM7LFu5IB49+KxrmztxdLeYBfyyin/AGT0FHMxczPmFP2cPFz/AHdR0D/wIl/+NVyUnwt1lOftullS21T5kgDYklQkZTpmFj9GX1IH23ZFPswZWYg5zlvyx+v4GvO7zw5a6rrPhUXvmpbz3mor+7OCzGRnjU/gZDQpMG3Y8Th/Zy8XSWUV0dS0BIpApG64l43DjOIquf8ADMXjLHGqeHenH+kT8/8AkGvqTQEiuvC9lDcEtCIUzu9hSeI/Fmh+F9Le51bUraCONeFMgZj6AKOaTm0Vc+M/H3wZ8Q+B9Le+1a80qaFIjKRbSyMcCSOPHzRgZzKp+gPsD5lX0z8ZPHkXjnwBql1ZaddWdjDGIoZrhcfaVM9sSy/QqOPevmari29wR7jdfszeN7eNna70N1U4OyeU49/9XUa/s3eL2CEaloHzkgDzpjjHPOIq+u/FPifTfDGmzah4guYbawjO0TSHJYn+FVH3j16ehrx3Xv2hvCln9pi0O0v9VuwdsKrH5cczeuckgf8AAc1HO+hN3c8s/wCGZvGO0kan4eOOuJ5+P/IVMb9mrxgAn/Ez8PnfwuJ5ueM/88q9Z+DHjLW/Gdyt5LZ3UMNpO4vi90xTkZVdpOOhHGB0Ne03ZRlilkJaMdF/u/XHT/69HO1uF2fHsX7NPjKVpFXUNA3RjJBuJfTP/PKpV/Zj8asFI1DQACM8zzD/ANpV9g+XCx81HwuCpCjCknof5D8aalwsijCrtXIDdiKOdgmz48P7M/jbBIvNDOOmJ5ef/IdKf2ZvGgiSRr/QArAk5nm+XHr+6r67cs2Y1cfgD07daDdwPLNapLBNJAq74vMG5QQMZXqOCMevFHOwuz48vf2cvF1nZz3MmoaEyQxNMwSaYkqoJOP3WOgpulfs6+LNS0yC+g1PQFimiWZVeeYMAwyAf3WM19ceL/LHhbV9nBeylVmBxgmNhx+dGhRQt4b02N1U4tYsjtjYMUudjTPjnXfgV4g0NbNtQ1jQE+13C20eJpj8zdCf3XA961n/AGavGCyPGdS8P7l7efN830/dc19cXtlBfWrRXsMJtIiJC0wBRSvO7ngY4rl/GXxT8J+C3EWr6rDLdKA/2S1/eykEZB44546kCjna6hc+bz+zT4xUZbUdAHb/AF83/wAariPiZ8NNY+Hf9m/21d6dcfb/ADfK+xyO+PL253bkX++MYz0NfUHgP44eH/HHiS10a20y7sLu5ZxE1w6lGVVJxxzuOMY9cda89/bMiMY8Hn5cN9t+77GH/wCtThNt2KPmilwSCewpKcNu3vu/nWoAFyM5A9M96McZyPpXX6x8O9e0Xw3ba7qQ0+GzubWG8hjN9EZ5IpcBGEW7eQc+nGD6GuQycDnj0oAQDP09aXacA8ckjrStwFJwePXPc/lSY4OMcDJ5oAUJlSQy8DJoCEg8gYOME4OaQNipIgOC23aOTnPT04NAERHAPY0Ec9Qak2MXbK44J+Y4/wAn+tNWNmV2UZCDLewyBn8yKAGkY7ipbO3e7u4LaLHmTOsa59ScCoyCByK1vCYA1+1kbBEQebkAjKIzDg+60AUbSxlu7xraEoZArtknAIRSx/RTVWul+HZV/HGlLMN6zTGNxjOQ6lT/ADrN8R6bJo+u39hKjIYJmQA/3c8fpigDNx6c0Y4zSjIU8HB4z/SgYDDOSO+OKAEIxnpx70Y/xoGSQByTwBSg8Y6j0oASkpT3x0qSJTJKFRgmMkFmxjGT+f8AWgCKilpKACvv34s/2qnga8tPD1jNc6nqBWwt/JQt5fmkK0jEA7FVScseAfSvgKv03hRimCNoXoM9Pr+dTIiW55H8DtH1bw3Pr3hnU9KubGzt5xd6fI5M0QjkHzRiXADFWGcdfmPpXrBhJTgKCCQfem3F7aW0m2WZA542r8zHrxgc1Gb6ZwTb6bdyDGAzgRg/nSu2Q2hzxBo9xAZc4PHf6UxoVO7KdD37f/Xpjzan5w3R6fBF6yzEtj2AGP1pPtcMXyNqMJ6FVRMt7d+aLiCWGMIRtXjHJGRTViR8kAY6DaSKiku4mBNudRf0MUHH/oJqkyyXE6t5evDP8LNsX8QRRq9hNmoLYH+FuPUmvPPEPxP8LaD4xj0DUbx42Cv9pnJbbbOFBVT67s9ulHiLQ7rU52NvpursD8pZ9XEOR3IANcppPw7s11fVrm48MJqtwyqha+1ETYcjPX1xt560lG4Jo9cvmWOzaaEyMIz85ZiAoBGW/AHP4VK0KuM7yy5/vZ57isrTbvV3T/TdEuY2QY2RXSOGwOO/t3rS8+UICdPvISSxZVUEZPJJx159O9Owrkb2xK8Nn5f1rzn9oGLb8INeOSfltz06f6RHxXod5dxoUBkntskD97bEqTn1rhv2iV2/B3xCDwf9H4/7eI6Brc+NdDjkl1rT44ZDFK9xGqSAZ2ksMH8K+zB8NNdviU1nx7rk27grbqkYx+XvXxx4Y/5GXSf+vuL/ANDFfaHxF1i8Txr4Y8PDXZfD+kahHcTT38RRJJGQDESu4KqTnPTnIH1JJNmzVzD074I+HUvWmujdandK7HffzGQYB6lRjn611niv4d6Fr+kRWl7aojQj9xLbjy3hYDgqR07cV03hdI20W28vVxrG0On247CZgGIGSmFJHQkd1NXnOxnyCFA6EUnJk2R4bf8AhL4h6RpJS28XSy2ttInlxywCRyCwxk45xVwaR8RL6+eE+MLdpYgVEiWYU7u46civX5rV5drQzMjEfd6q31H0p/ltBCNwUSsMB8cnjjH4/pS07Cs+55pZeDfiBtRB48ZRg7iLVSc8Y6jp0ofwh8T11TafH6+QyEBvsq5GOnGPpXqVkywscndkAA5PI/8A1VbuIop1BjLITjLKeo9KTt2Q7PuePN4S+JMsoguvHpDZyQtmuCM/SqWqfBnU72RrnVPGmsTXjH/WRERxrjp8or3CMPyJMH0wD/WkuY1khdXBK09OiCx4PF4N+IGlrHaaT43H2RcqBcQKXUD3x+dd7deEW1DwRp+lTancw6nbslyt/CcOlyAdzr/sks3HvXVrZo0uXQ8cH1q9HEidF4wMZPFLTsFjxw/CG7ng8rUfGeuzwBQPKhdY8D04FXtB+B/hK2uEur1bzVriIja19cFx65wOPwr1R442ZvMyNw6dOPenW0UcMQWL7uT3zTvbYdjxP9qa1itPhaiwokUaSJEsajAGXQ8f98V8bV9q/tYx7vhI7gD5L6H9d1fFVXHYpH2jbfAzQU1Z5NXvtW1iBDiKzupsRRk8knbgnnn8ea7jQvh94X0Ka3fStEsLSaAgRz+VulGeuGPOeT1rlPjrd2Nn8Q/AEGvalPp+g3A1H7Y0d5JbK+2JDHuZGB4crjnqcd63fgrqOq3fhCNtcN5cobmcWN1dg+bNbB8RM+eSxGeTgkAfWo1S0Ish/wBmOgfFcxxKq2viSzZnQAAC5tiPm46ZjL5+grc8U6bc63Z2ltblIjFeWt0/H3kinSRkGOuQpH41T+KWkarqvh2C+8MhY/EWlT/abDzQMFsFXQ54IZGYYry228LfF7xIguPEXii30NNzQG2tUG4ow2s3yDGdpOMnqByKLN6oV1se2LqOnGI77yxULlSDcqNpBwR16g4rPPiLRobmWNNa01ZIyN6/aEBX1zk8HkfnXma/s3eEPKP2rUdekduW/wBIQck8k/J1J5/Coz+zf4MRgzya1IF4Yi5X5j6n5Ov0qeW/Uo7e4+Jvgy0uf33ivSPJUHeiyFnyvXBH+TXmtrqs+j6zpXxDgW4MHiu8+xahHIMpBbmQrDKuPu4CIecjkiumX9n34foRjT7tmXGRJevg/liu11zw5Bqfha88PLF9lsZrU2abP+WSkYUqO+BijS1rgWfFxeHRp5PNfbLJb2zRk/IA86KePX5iM15RFo3j3VNE0PQ9F8RDRrqG0e+vJmbe7pLO4t1BA4Coh4HTirGifDLxiniLS77xP4v/ALVs9OlBjtgWCyRAbgW6ZYSCM4Ofu9elejeFosTSTcb1sbOAH2VC/wDOQ0mknZpC3PMl+C3iTWJ44vFfj7UtR04ZD20BZDJ6ckkdh1Brd0D4DeBNLeKa8sbnUp0b/WXszMrHsCq4Xge1epxKyBWRgoHGB61aXeYdswDEkjjofamny/DoNI8++IvhzRIvD/8AbFhp1va6hpDx39vPBEqPiE7ygx2Khhj3rx/9tKJEHg1oTmJ/thU5zkYgwfyxX0vqVjaXlnLaygtHKChj4wwx09s5x+NfFfx+0rxdoUegaR4nukvdIsPtEGkXRA8yWICIkv3OA0ajP901Ubt3Y1o7HkFP3nyyoOBkZGTyeef1P50ynY47fnWpR7F48+JOh+I/hto2iWk2rw32n6VZ2LW8mnWpglkh2738/cZlGM4AwDgZAya82sdJZobG81Wb7Lpl1IwEgG+R1UjeVUckD1PGc1r+EvCV/fWE+tNp1xcWtjLDILf7Mx+2Jvw6oRwSAMkeh/P0fWdB12PSvCGpaVoksU9tb3UUthpy73tnm3+WSrg8HOWyDjv1WgCO1+Fvhh4LaVbvULxJVV4jFIqearDIPKceuM8Aflo23wv8HvJJHImpLswS4mDD6YxnPsPUfSu50DFj4V046ksdvJFYwpcpNtj8pwvICjoBjAHoOK1BqmlQWa3B1CyitAobz/NBXAGNwxwcbu3Xt0NAHAx/Cvwq8hgksbtDzgyXTMUYcEYHU+uOhGPpbT4TeFFicf2dNJJ82FNxKMe33uvfGOa6R/EejQuANa008FVC3SEEEdfQcf5wM1HH4x8LmGJ5dd00wEggeYCeTngZ9R/PnNAHKap8IvDN1aMYYptObI+eGYuO/BLFgRyPTjB71werfBrUoLpk0vUrS5gOMNKGiZh6EdPT8a940PXNL10N/Zl5HP1B2Ny2CfmCnnnd+vTir1xEiwOpjETKNvU4K/j+g9+1AHznJ8GPEHlKftmnNO/JTziAPXcxGAcc4+vpU5+HU/hrwtres38sU00Ns8UPkSblTfhCzcA5wxHtn2r6CRImQsyqUQjJJzs9R7Yx6fwmvPvjxqMdh4JubWVg09/KkSZ6YU7iw79Bt9+fegD538O3JsvEGnXAzmG4RztPo2a9j+PPhGN7SPxJpyjzIwEvMHlhkKj579h07Z7jHiO1dwO1kUYDnGcE556cfSvp74eX9t4y8AC11CP7RJGn2K9BJAOPuHI4OVwflzjjmgD5az7UvOAT0PGc11fxC8IXvhDWvslxFI9q677acj5ZE5547jByP0wa5hoiv3kZRjIJPX05xz0NACQRGeZIo9is5ABkkVVB92OAB9aYfw6dqeEcL8ynYxxkg4yOv4jP61e0vSbvVNUgsrFDLcTH+IFQO7Ek9gOSaAM0DP8AOtzSPCWvatj7DpV06lQ4dl8tSp6Hc2Bivd/Bnwl0rRZTNqcq6hdKRgSqAkZwf4OeQfXPf056TwiJ5LXxWW3TCHxHeWqeYxGxVSL5R/dxknAAwaAPlbW9KvNE1SfTtTi8m8gIEibg2MgEcgkdCKoV2vxlXb8SNXBVFOIThDlf9SnT2riqACv0gk0y5uLlmuZ3li/h8yTCZ55CIBkEerV+b9fp4OGycn+tJ7kSVynBZ/Z0xbmC3yT80FuIzj65NP8A7Ojl4nurqTscy7c/984q8yfLuGGyOvrQAwbJIJBx/nNSSkU00uyVVY20JXgBpRvP/jxNWPKEWRFsUD+6AD69qs/MqhQOBx9aYUDMGXoeoHGf89KaYiucnI9fWo5EDIeT68c/lUxThuM+mD2oC56ZJ9KLFWM+dMuvy7TwTuFYXhhZDa3l4/P229ln2rghQD5YHuMRg/jW9q8zWunXVwXKpHGScDpx1/Oq1jbtb6fbW8xDPHEqSHHBbHzH8TmkQyxGgyQqgH2FIygrg9DVqEfJ1DHpk88elMMR81cuSP4Qw4/SgLEAHHOfTnvXmP7RqKPg54iI64tz/wCTEVepyRle2F7V5h+0epX4M+I8jH/Hucen+kRU7dgS1Pi/w26R+ItKeRgqLdxFmboBvHJr7v1zV/BWo262muahoN7ESHWG6Mcq59cNkZ5r8/x1r1bRPFPg/wAHam7aLYPrtpeiAzrqVqha1VSSyxkn5mIOOwGByaU0+hs79D6w07xF4St4o7LT9Z0aCKIbUgimRFQeigcCpx4q8OSE48RabkfMf9IXj9a8u8JWejTXqXGqyeEJNF1aN9RtoJbRYLiGMnKjnjjnJz1zjiuR8f8Aj7wVqstrpGkeD7DWZlmYwi3AgAKsVGSo+bdjIA4wR3qFq9/w/wCCZts+hLfxl4WiO0+INLDAYOJ1xT/+Ez8KtEoTXtPbjjEoOOK+Y/C/iCw8QzHTPEfw+jNvDPuifTYBGbZQpBSTOMjqeSDk/SvovwZF4cu/Dlhc6Fp+nrY3EZkgDWqBmQNtLcjP5+oos09X+H/BHdstL4r8NDzGXXrI7WyT5nGPyq0vi3w3JHtXWbI/LuOxunv0rnfifrdp4Y8KzXUOj6dPPO/2eNXiSNY9ytl2bb91QP5DvWV8D/Eek6n4Wjs7jU9I1PUbdGkKxWwWRI84wQVGQCQAR7Umrdf6+8NTsYvGugMT/wATiDIxwVb8+lI3jvw4k3l/2tGxIzxFJgcf7taWtWX2+xhFrdDTgJo5WmjiTcyKwJj5HAPQ0nibVbrS9DvNQ03T476S3UyfZk+UyKOoXAOWxnA7nAzTt5i1MkeO9AkYbdS65H+ok/8Aiaki8beHipUXzkA/8+0pz/47Vb4c/EK28a6Zd3Npa3VnLaTGGW0uFCyLwCGIHY8/ka80+IfxtsbfXDp1pq97p1nFDITdWUazyTS7toXaSAig7jnqQO3GVYq3Q9K1Hx7oVtbNNNdziBULPI1tIqRgd2OOlYqfGfwFGCB4jhwO3lsf6V4H488d/Enxp4KtnaF08PTZheW0GPth3bfmGSQMj7tc7pHwa8X6tHI01pBp5iiUxrcMF8z24zg/XFUoNrsGh7V8d/H/AIR8VfCbWrLR9atrq/RoJkhQHLATICeR2DV8jV7H4p+FK+CfAur6hquswSam8UYhtY8AOpniDEZOWx7CvHKuG1rlRP1KkZHZ944HBBHJ9xWNrWq2GjwNdald21paIdzzTyLGE+pJ61d1uK5nsLmOwnW3u2QiKSVDIqN2bGf0zXgGv/BLXPE2u22oeK/FL6m0J2nchAReoCJ90AntWbVyWz2nwz4o0XxPpT6loV5HdWaSNEzAEfMO2D+fvTdF1mHXw09rBOlgDiK4ddnnEMwJUEZ25HXvmo/BHhbSfDdmkOmWy5EflvLsw0nqDx9OnFbskUexVgZNkShVCgfKRzjHb0xStoArxkiQh23OMDPRfb9KqiOcOAsjujYZVwAI/YHGfzrD8Sa7q+iyWT2uitqlkId9xJBMBMrDjiMj5hjnG79ayNF+JNjrBja20/XLeHOwzS6edu7HTKk8jp0xQ0+wuZHZHcHy+OeSc8sKoQTytJJnDQ5AVup75/lVO58VM00cVno2qXxfKmUW4jRT05MjKf0q1bT3Lzos+mC2hwSWadWbHH8IH9aVhpkpJyTJ8khXgEZHByf0FZPhMbYbqYKHVjByucEC2hH+P6/Wt6aIRq20gA9efboff39qx/BYR9NDx7QHZeSRg7VVCMf8BpPoO5vRSqQqHgKeMnnPpVjAxGpTaCOrckH9ear/AMebdduBnnkkc8+3SrRwE8xzwBu6dKOoyN0jaRRsIIYMCo4yCP8AP/16+Y/22QFXwWBgf8fp4/7YV9PghVV2c4xt+Y4ByeOP0r5h/bcwD4MCqAoF5jn2t6uG4kfLteyfCbwDZXtlpfiC9le4aSRilrgKqlWYAsec8qDjI59R18br6F8A+ItP8N/CjSr29lt1dRLhCcSv+/fATsT9enXpWxR3HiTWINH0mfULuQqtsrbSpwXYbhsHQZwQO46/7VeD+LvipreuzzNZTf2baONpt48MzHn5t5Gc8+o6/Wsfx3421HxdcQm4CW9lCT5NtG3AJxlm9WxgZ9vrXMgbogQsY6qSXwfXOM/h6fjQBNc311dMXuJ5ZHbOdzMTgjnr2P8ASkWRGj5k2hCAFdmO5SR2x2wPTt6UyC2eV0RAS8jBU4yGOattYyN5obKGNASshAZAODu4+Xnj64B6igCp8j7vKbylP8LHg8nH1P6fSpZLeYQhwgjCnB29iTjk9qlFgwuhHNLExIySG4yVzgkdcY5xznitHSvDV3eSywtI1uVjM4SRCC6DAyQOh+YDB9aAKGnahdWE7T2FxPaSxLlWhcqwPQ/QZOcV1lt8SvF1va+RBq1zckkMJX/ekHHIwevH5c+ua5uC323B82JcM20iTAXgHC4HTPGDj9DWidP1PS4RNBFdCMqZeDh8EBTggZ6MckZGDnNAGs3xL8U/adyaxIGj3HeBlWBHBZcdR6gY5rB8Q6xrXiSdf7Y1EXDRhnAeZAgPAO0A7c8Dpz+GKdYQI9uC9xc6ekisJJQp8t8jgYBB5GRnGCaZF5STQ/2ckqRxqN0puMK7D5gwZlUqeBx/LrQBnX9qbWZIJoFglVfm3HOexJPQ8g9OnvXZfB/xUnhrxdBFJOI9LvnEF1821V7LJk9gSTj6/Ss5vD1x/Zi6jJHdi2kUg+acs20cA4X7uV45Pp1FVLewa+82GFTugyTO7lDsI2glSDkDGOOwoA+rNb8P2Gt2zWWqafBPbE7irD+I/wASkchsdSK8k8XfA4b57jwzfoIyd0VpcgnbknIWT04H3h+NdD8N/iA8drY6b4ouIWlaSW1hucgtG0YGRKSQAp4CsPXnGa9OCxXNsksJimg27o3VsqVGOR9OPpjPegD5W0v4U+KdTvVt/wCzJLbk7555F8pBng5GSR1zivZ/h38OLTwfZT3E00d7qcqkfaFjKhEH8K5HfjJz+lejeUoMKSj5D6j5ixIw3pxxxivPvjF4lvvDehQ2ujxynVLlg2YUEggAIIYjnBIxj8/agCx418caN4Wsy91ci6ug4X7HBLiQgkjPPQcHn2FeKj4p6vbQ61/ZENtZwahqc2obmG50aQLlRz/sDtXBX13c6jcSXF3LPPM5zmTkkk5xmnR2M11cOqbp5N2wDI3MR145OAM89BQAviDVrvW9Wn1DUJBJcyhVZgMDCqFH6KBWdU94nl3LrnJGM+uccg+/r71BQAV+n0JCOM8FyOMda/MGv1BQKCrA7xnjPr7VLIkPRWVxkDaTgD0pWAyn3evGR2qnrOs6dodkbrWLuGytlIXzJm2gk9h3J9hXmfif4z6ZbW7nw5Zy6gVTf9quc28Cju3zYZwBkkKM1JCPWCctg8HPTrmql3eQWoDXlxBaqc8yShP5mvBdZ1n4ia7rNmukai2p6FJGJpjotuYlI3APF5jDIJUnBOP0rmLn4Z+KI11K61i0sLexkt1gN1qeoGUxMrxnzsZPLbOV9XIp8rHfsfRMvi/w6hYSeINMzu2nF0hx6dOnSprbxFot7OsVprWn3ErnCqlyhbPsM149ovw51K90K5j0u78IPFPDHbtcW0TPgpsYHgYJyCf+B0ar8H9YufDWn6Yo0OSa0DMbuLfDLLIQoVsgcDg592pJN9f6+8m7PXPFSyPYwWkY3m9uo7dhwcIW+c/gAa0pItzyNgHcc4zzmvl27+HvjrRddsofD1xfR3VvbyXReG+83c3CggMe5bbjrW3pPxF+KPhCJW8aeGLi/wBODhHuHgKupx/eXIP/AOumovoUtT6HhUpIwIxn0qUgNwQD+FcV4d+Jnh/WLKO5mdtNVm2Brkjyy2TxvHAJweGxXbRmOSNZI3WSNlyrIcg/j0oTQIY4UZJHJ615f+0igHwU8SHkFfs459ftMVep5ONvGM85rzH9pb/kifiT/t2x7f6TFR1Bbnw3p0cs2oWsduFaZ5VVA3QsSMZ/GvctD+Ck91BNbTWd/Z6u4ESfa0V7WPK4kkLqegydnXkZOOK8X8MAHxJpIPQ3cP8A6GK++vEjzr4dv5dFmjOotAZLVnbMLSn7oPbDHA9ORTk7bFSPkbxz4K1Axp4ntnudT8GRhYoLjfmWKJfkCMh5XBBGRxznNTeDPCVp4i8aw/8ACB6vPp1xDGLiOW4t2YLJgFljOP4c4+Y59M19IeDPh3/Y99qep6vqsuovqqMk9iyBbVdx3EBOnHSjU/hnp0mjw6Tot9eaJYxCTC2RALmRtxLHrx0HtSvpYm+h4n4t+EOqSzofDviE6pq7BhqaNPh5HyHLDBwQA6cE+lVfAer+I/hVqdtrPiqzxpmoCS2+xbsSRoCGLRqPlUBsDHGfzI9Q8K/C3VvCes3cGnaoZ9C1K1ljupJWxcQzYYo6H67M1ylt4N1v4mR6oniWa9stbjhQoJ4ituJlfy2aP22ISfUzE9qVr7gm0U/i78Rr7xT4Z07w5p8dlc6pq7IZBYuZA8PDJgEDY7t1XkgIM9a4nw/4O+J3g3URfaPpt1aXUsJgV0ZCWDclQM/ewucdeK9Q+FfhCz8J+KvEWoaXaJ4j+z2oez8kYkhlEhSSHnow5/Ba9mvrye/8L6dq1t4f1CS+huI7mDT5sJLG3KFmHsjufyp6JW3GndXR8saxpPxa8d3VxFqKahcPYHY8JdYljbGcYyATj0rLki+KPw+kW4k/tiyiUgk7zJER7gEjHHevsXSfFWj6lqC2MEepW1/IXYQ3NjJE2F6sxK4APYk81sXFssyNDKqSxsCDHINw20Wh2HqfCfi34p694jjJEkemyzW6QXhs8x/bArEqz47r0H1NP8GfCzWPFenrcWjFZ5TuRHQgBAQGYk8Z5BA7jNfQGi/AjT9H+IX9rB4bjSFkllS0kXJXco2r6EBt36V7DdiDS7KWaK0IiQDEFpDudugwqjr/AIU/djsK9z5MtvgP42g1hbNdRig02E747zzjsyRztQcg5z+VW7a5+L3g+w1KBIXvLeOTyxLMBK/yfLmME5Ix7V9R6LqWn65aedptz5saNiRHQo8TYB2up5Vsc4PrXkfjHw14x8ZfEqYxXUugaZo2fsN0gyblm5346HGCMVLSl0B3R88eKvFl3r1jqb+JNNU67MqBbogx+XErphQnTkq+SfWuAr6v+MPw+sfDnwq8R38jm9v0hto47uX/AFmGuYy+fq388V8oVcbdC47H6I+EV13xBDp+u6vc/wBmwFPMOn2TiSO4OBiQuecYxhRW34i1/SPDtg2o61qEVnaqTzMcE4/ujqfwrgNf1eHxFrdr4Vg1G50y1WRY51tomikaSNmO2FsYZOBkjsoPSsD4n/DmHxB42l1HVfE1sLGGCNkt55QHtwcLnBPRjzwM1jb5GTl2PQvC/wAS/C3iQyrYaksXljcFukMJdT/EgbG4VvSarp9lfWemzShbu+kZYIhyeI2cse4XEbc/hXnHg34f6FrNrputGJodTsJ2WGUfMrIjYG5WHQ4J/Gtbx1ZaXN4gspbFJotft7iO4ivYfnWNyyx+VKBkiN1JHTAyTRYLs6m68TaHYeIbXQbnUYItXuo/NitmbDOvP4djgZ5rRUWxzE+zzV+do1YAj3x1/TmuK8efD/S9fnku5tME2o3Dx775ZdkkIQgBl+ig8fT3rldD+Gtnp+vrdi18T3LxP5n2x7pVMp68jdk8/wA6LMOZp7HrvkSSIhZ2UFtwA7fXtUqWxG5pHy+RtIHOPSnfNNDj5gSoJ3r0Pv61KChBDHbIT1x3xQWVLgpZ2V1N5gGyMszHkKMcnH51yHgq5vdR+H0FzpbqszwyzWzyfcZ9zbSwPb7v+FdjeWgnt7qJ5CvmoynGOcjGf1Fc58JUW3+G/hyOMmSAWMZUnnIIz/UUMS1ZyvhXXPiOl59m8TeE7K4heQKtzZXAjwGOSTk8qoB9849a9caBYo2OTjqABxXhPxruvH9hrwuPBtpFbW7AF7uKXfI6hcfOp+WOMHp3JFWPhn4r1jStQhtfGXiZL83SAtC9rIDA55GJCAu3HXrSenTQpSWzPaJtoiJlXI7D8etfL/7bed3gwkYz9t7/APXDmvb9dGqapplzqGn61HPbbC1tYWkanz3BztMmck8Y4xXzh+1X4ttPFMPhYw2l1Y3dq94s9tcgB0z5G08djg1UNwTVz5+q9HBcG0jlRZJIAcnglVbJGPTnjrg8/nRrd08Xw05DPNcR6Ycn5DvHBPOzOPvd2x9a2KMuG3lnOUXdjGduMAEgfzI/OtKxstQzGPsQMQAdzInGDkBmznA7dMVuWlzpwsESa6sV8uDYGEJM7Puzk54BAbbkdQo5znGfNc2ht5IxcXNxckEKzL/qgpycDdySBjJNAFy50eCW3T+z5WiuYxKJ4iqttI4AG0knGce2BjJqjdQyRxxvFMYgwBjcsylP4TGByR/EcY49Tmrtlp9xsS5d53iUSy+T5pGNvsSMLnn1x1AAydhiup2FhHY+H4IbmODa7cf6UxBIfJPzAc88g5HpQByiQSzCRJplPluI5NkbMWI4DAYwensT365rYhD6fareRbL60IXzzdwF4iScgNtPJBz8n410Eb3OjXFsuoaXDcTSW4kn+0zDzZkDf6uMqTgEbSM4bIzW8uk3lnBeQLew2ck7rePbSkuIYu6Z5yWO09Oi4oA5KO+02e9vbiR5B5ix4SOTaI2HBAfgFDyAwJPIFWmszNZLDPf60LqBmMs6gMq5GFBUHep+77H8Oez0nQbeeyN68ENxbxM6hJmWMykqSGweFAI2jr978aTw1pUEfieyOoaneW9ncKyxxlmMynHKsVY9TjJz2PTJoA5DQ/DrNJJLpcshVDs3XMcscUgwcEqOc5PAHAJ9qTWr65tJJ49S0lIkiBSQbpAshI6EYx756HoM17W2k3tvdW93Z6gI7oXaOst5L9ogEWD8oXG5XGMn5R9a09UXRZrm9M8iSavdI5VpEVkIC88nlBnoT3YUAfNusLapYTXdtqd/OzqV8ry28vO31zjgkcjOcc9TU1lLcaldWdvLpQS0y8YhWRlErMOBvIznPU56ZAOTiupuFiaO5VdMFkFSSKWESKxaPYTuUN7gscZ4A4Hbo/Er6fI2peH9CvY4rWCMoss0gYSl2DL5b8AFGOcjnFAHkzadewaf/bIEckSsWdWYMshLAbdoHGM/ePU+tdB4V8dv4d1aIx6lc3VhFEN0E4ba3UbdnIVhkZxwdoPFX9cW3huLG+0e9nj8uCQTxtIsiQyjDF9oGFXJB6Y4Oa0ta+x6npnlPqMMl8GN00VvuV5R1EwYnHIO0MT1wCcUAXrr4qeIdS0ln0qx02KSbJRftOZiucZUHvnp/wDrx56bP+zNQi1XxHBci2kkKlzd+c2cZwQOcnI446GtnVYbS61GS88OXn2W/DGJWD+XtyPvSP8A3u2M844zWrodtrOrQXi3mqWF7etHILe0tWXzmZRwAFGSDvI56bsjHWgDyyezjdZpTL9n3p5iRrbuFxlsKrE5CkEc85Lgc03T4CLW9kW5dfJkbEZGwhsYRtgyQST2GAQOfTtbnQ4YJVbX9didJVEcySRsJbVQuEDDbjjc3I6leOxqk1rp66/4ijlECrK3lJbxpl2I2tlMKNqZGc8dB6cgHn97FLDdOlx/ruC3zbuSM8n155qCreqWstlfy29xC0MseA0bZyDgetVKACv0K8Y+MItGils9E2S6hb/NdEI0kVgm3JeVUBJwOdvHYkgYz+etfZvhW+igvrm3ufC+oQfvmaK+humufO3McyuVXKFjlvmx1pNXM5uxa0rw9deJbiLVba8udYvJiTHrV7vjtoo23Z8iMDG4EKAVyGGcsMkV2ei/DPRbHUV1fU4RrGtbsm5njCoj92SIHauePU1x1rN4dj0aOG21fX9JQkx2kYv7lOc4AKsCFBJ4GOnSskw65BdtbDxFr7ukCSvcCW4ESNnmNmZMdB97B/DpU++vht9//AM9Ez34ueFDZUDHA6fhWL4tAm0K9U2d3eqQA9rZsglmXdygLEAZHBOQcZxzXl7Xd/FK89v4w1uGOPIEF06sruOPvshXYT0Of8Kl1Dxb4q0+xeY3lujHBja7ETxH5iOWVV69Oo9elK7W/wCH/BSG5dDuvh7pa6Xo08TLskkuWkdPmJj4ARDuVSdqhRnHQDk9a6ZsHAGM56+teX6d4+1wmcanBpEXlEBciUbxjsybxng+3uc1BY/HXwodabTdUM1rIh2tcxK00APpnaGH/fNPmvuio66I9G02Ey+IdTuGGYxFDArA8g/M7D8mjNajtGkLOH8oJ1zwv415LovjXUtT8NM/grTpdY1jUbq4lNw6tFa2oMhCl5GHzEKF+RcnGOlacPw71DX0EnxG1ubVlIwNPsWa2tF46sFIZ+e5NGrE30JPF3hfwhrls1zFqFppVxKSgu7GSMCZlP3WTo/f3GSO9YHw8sfE/g7xbcafdR3Oq+G71DKlxbW7Rx275OMRvjbx1C5HIPrXqGheHNH8OweRoemWlhH0/wBHiCMfqcZP61yXxNgludU0SKO9fT0Bk8zUICfNt97IibAGXJZj33gYyVPUOW3f8P8AMLW1Oua/l3hYtMvZF/ib5F2/m3TrmvP/ANpnP/ClfEmTni25/wC3mKvTbaM29pHBJJJO0ahDNJje5HVjgAZPsBXmX7S7g/BPxGpK7ttuf/JmKhIpHw/oTpHrenvNII41uIyzk42jcMmvvTwdpCeHPDVppr3/ANtsbdWaKeXkCDcWQE9PlU9favg7w7Gk3iDTIpVDxvdRKykZBBcZBr6q+KXj++0axXQ/Cvh+7mt7L/Qrua+tHMJQBVQIQfmDYPPcfU0p+SHJ2PZLyyt9a0jAl3ISlzbyxvgbhyjZHY5/EGsGXxTpOka3c6dqT3X9rvFHLKY7aWRJzt6RYU9O4FfOT/EXxDoN5omka1JFqdvp9sGtYdPlKpOHAZPMIGWCqFwAOMeua9d1LxF401z4e2fiDw09npuoW7T/AG+zuUJOQcKoyOGxjg4yaizva35A+53mn+JLK7u0tLmG50+ecn7JHexGL7UgGTtz/Fw3yH5sAHHNbgUsFAAOeMA9q+frKbxRpVqg8X6beeILLUUF1PB0uLe4UKTNCAMgKrRjC8/I5wO/v3h69tNX021vtPningYfK8ZyPoe4I7j1o1TswTuLY6daadeSy21nHFNcys0skQxuYgEsf++VqLRYNSN3qp1Igqt872Ljk+QwHH8xzUt7q9jYRx3GoSGGBkeQ7/l2LGpZy38vqR615t8MvjLpOs6TfjX7qK21GzSe5fgRxvAG+TaSeW5UY9TQ2r6gj1/e7A5YkdOe34+lNBUZBGc182Xf7Tk09vPHp+gwwSgZiaeVnB56bQBkke/FJoPjnxL4xh1LV7+/tfDstpbi3sLp7N1hLSuEIMh+UZJXJOcDntTUm+gXPpNxlSRwT2PauPtBejxRqE98lxNqfkTJZImUtIogQY42fo0r4DsRnAbHbmHw1qTeHfA9vfavr03iSG4nQW1zbwbmcSEKAAOuDvJPYA+lY914U1fxL4v1PxRJfz2ElkktnoVs+QiEKUM7r3DNvI9iD7U0rv8AqwNnd2qpY2s81xHFDMU8+7kiXq+35mJ/iwB+QqrZSG4toYZL2Ke/eDzvMiGPMjJ4bb1A5ArylfiYfBvhbWtC8USxR+INDsooYZXkMrX8rpwwUjlcnqePWqnwK+I1jquk2j+Ir6Ia/H5tmJWcBmhH73L9gueAf9mpcu47G7+0Ir2fwV8SQSrK7StblWCkhQLiL7zdBntnrXxNX2d+0DqD3Hwy8VJEZriyurW0vorjbiKNTdQKkanuWG9z+FfGNaQ2Gj9JL/QLC/1ezu2VZLzTkeCL5smJWXkeuSM8+9JB4ftbu8j1S802yN5GoRTIBIYlU/Lhv19q+RzonjXwz41N5psWow31vcZV2Rz5pzjLZ4ZW/XP0r6z+H+q6vrHhmG91yMRXUm5WiNuYGBBx93c2fY96yvJPUyTTN+PzECK20rznaMcVm3Or6Jaa7FYXFxbw6reJujj4DyqpA4PoCfzqxGLy3v7qea8W6s5HXybYRANFnCkbgeVB5ORnrzXkHxO8M3V94+XxNoF9Bd6lpQiMll5yq8cSMM5QNnYctnIHBpu72G3bc9h06+F47PaBZbHlFmz95hwdo7r2z657c1DPqjWuoLa/Yb54VT/XRRb1P4A7s/hXnes/Gzw14d8VRaDfRyWkKR5WVFykSn/VAqOQCoDewdcjrV2P4ueAZdUeIeJbBJ1QbpjG4Q+uHIwfzqbl2fQ6O98UXKyRrY+HtTeNjhprnZbIO38bA+/Sr631611FI1tCLF4S8skc+90cZwAMfMCBjIrzbWfjp4C02UqL2XVZQMFrS3Lgf8COAePSsG1/aN8Panqqaa9leafYy4SPUJgriNjkAunZfUjPFK/qHK2j3eO4ju7eOe3dTDKiPFKh3bweQR7dPyqDSNOh0fT4rW1Lm1t40hiiJ/1UargAevQE/WvNfAmu21k32O51SzgthKbc2Pnb3EpclWtgMl4pA2R6c9hXeavdmW4Ww07UY47qF4ppI1w7iLcMgr1KkZGexx71SuT5lq40/wDtSO3kjnltriGTzBJGNnmnawwQQfl+YnHTNQXPhHS5tWsb/UMXN7bxtH5kyjMxYYJbAweM8VwPiTxl4u0/xjFa6LoEr6FG0Uck1wvJLsAzK2fRuAfrXq91LDBbvLdfu4ovnLyEBUHUnPoB3oTd7DVmUzplhbWC2EVvFBap8qLEu3YfY9j718j/ALWnhtdE1jw9dm7ku5ryGVJJJcF28vywCT3OGA/CvpfQ/iHomtaw9jo5ubqMK7PdLCUhjCDJ3M+Bg4xmvDP22liLeDZopBIJheOGByMHyCMHpjmqg7sfLrc+Xq7zwpo2jahplg19rcsM7tIJoEK5iiG47hkjkkZx06njFcHXoXhcaFb6DYXzXtnLq8DuZNOuov3TrlxksBndyp+gx7HUol1nwxodg4a01d78KEMSxSREuM4IIUnaefU59abp0d06XUkVvbQiSRZBavFwFL5VYu4HTIzyN1amk2uk6lf3F7ELC2l+99ne6YRS4H3WDDJU5BOOevY1vQT2+t6XcvpVvbJp9vGVjMQBuHmADMi7l+ZMZVQO+PfAA2zu7z+20uNGi0yeGIJK0iShYgrlYxGQxwrYBY46c546zajp/wBmZtRXVbubUZ5nutP06U7kuRuP7xGzwyrk4PXj8e08M+Cp73UXvPEdrbzSpcNHcWobaDIQHGSMYGBz79Dya7bwv4dS+si+raXBYQWytFZWkMh861Gza4MgP8RBIA6evagDyLwxoqWmrMuoWN1f39raPP5LR+YD5gO1+OX+8M4yRgkZrVi8NavrsJjtdL0/SrC3hjjnkuHLPvJLF0ZuQMbeeBgnGMmvRNcaz8J+GVtzezaxc6WBepFesZpCjMFyxAyducKTnoOuKg8OaTqV9pdtMBa3cepElzITD9lJJY4XOXJwFJzzjPfNAHM2fh65sbWK11TUjcXE92nkyWqJD+6yAzfIfnCng5PAc59tC38KvpVjcXkV5ZzQPMkcc9hKLaQIJRvAIOMnhcDtxXplvaWlxLHcm1eR5I/nDgjyivCgKSdrEMenUHqah0/RvsaXAnkOS+xLhVCysu4t8wAwOeOnTr04AMXxBp2gCUPqFhbyQMmQttp4ldn3ZA3ICRggDBx1781SGt6F4ps77TrYwpfbVRbDUneDcSQOQCOB6DkD0wMdTqS3l1BdWy2twIWcktFKBI6jqFPbnt6HGa5/Qvhxp9lqN5eXzT373UWwJqQ80Wx3cc/xEDuewoA4jxB4Y8O6hoV1Na7IJbWzlE9tHC6vvCEhhkcgEe47ccVt3cUElh4m0rSLWB7VXVbKSLC7nAGVfnKyBvYE5B5xxs6rpF7YfDXWLJktVuGsrkkwKfLGUJDKOxH4CtPQvDI0Kaaa0eC5laZ2lu3GZJRjgFs4OD3PTFAHMxWNqjabcy6WkVzcgIjQ2x22/wAjtuZDwCSDn8OQW546+g0rStcSxl06YWcXmJLcpD82+QlRjP8AC4bd2I2jHSvXdS0SW4FyYLW1khlRgwaPG4tgZyoyRjqD6joRzy2reHLvVdWsra0WSx+xS7l1HAXJADfKg6oQCmW7jHvQBwmveFTY+Jle2u9FsdMHkiS4mbZJKNo5VQPuk54wMnrmtrU9L0WXxI8D3l3bzeZBPD9kmjY3LDdkowU7QMHIONw6ivTDo9q2t3d5c21u1zuRY5hEu5kA6HjHJz2z061Rbw7YTeIBqd/9qlnlcQwQ+YQsJG7O3PGSOh4H50AeT674bvYby5tr2+jvC0sk8t95iRCKNxiIRgHnhXyM4yo55rP8GXd4L3XfDl9pNoNXuNSUysMsVjeBY2ZSDjgMGIOfv47GvV9U0sXGpxjUpTb26QH93EmUlCupVz/vDPy88dznmtpOjWVtqfxBtY9Ktp4l1pEWEAL8rWsTY3dVAODgEAc9McAHyR8RrV7PxpqUEty11IhTdO2394TGpyAvAHPA7DArmq7346GL/hamuLbxtHEhhjCMu3G2CNf6de/WuCoAK+3rbXtTuJ9OsNN0zUL7U5IdzzpPk2TkDl3k+UnHJwOCQCO1fENfd+gao2keN9Itb9DHZXkMlnDIw24mYIyqB2UrEQPcjPJqZJdTOprZGrYeGvGCQRq3ieLTrYDLCKxgmmLf3jJsVf8Ax2tmDw5fC2SG/wDFOr3SgfNgRwM+f9qNQR+BrpWG6MAggeo5+lLKNqLu5A65/nS07L8/zIS7nL23w98MQ2phbSYJ42k8xluWafc3Xcd5PNXh4a0OMFF0bTQq4wBbp179qi8Uz6pZm2bS7jTbO0G97m6vuVQAfKFGRkk/1q7ol39s0i0uzPHcmaMnzoojGjnkZCnkCqU5bXKS6if2Vpp6abZEDn/ULx+lU9UtLFdNvpYLW2huIomCSiAApIVIUg49WFP8UarJo2mveQ6dfanKrBFtbJcuxOeeeAOOtea6x8TNcEtvY3/w416JZ5V+VXVzIoOcDtnIFHNN7Xf3ktxW9kdjBf2fgLTETVhaafo/BF2ZsEzOAWXy8ZLF9x47H2rtVwCMFiu3jbzXheq+PtNfx5p2r+LvCfiHT7eztJUt2ubXzUjlZ1/ebVyAcAgHqM1p+KPiloiX8ctzoHiK+s4kA5geKIkk5Pln75xjrxSs76p/cx80bbnpV74htopTb2qy6ldcg21kA5Uj+8cgJ26nPPSq3/E6vhFK1tpdiE+ZGkJun+oI2gHHfmsDwV8UvB2vTC0067TTrkAH7Jdx/Zz6YXPBr0EBY0ByoUDt6VMZL+tCmnbyMNbDUdytLr05H8UcdtEqkf8AfOfXvXBftL/8kU8RkAc/Zv8A0oir1hyCpBIGDk4Ga8n/AGj9z/AvxG8kTRv/AKPlCwO3/SYh1Hr1qkJLU+JvDP8AyMmk/wDX3F/6GK/RqIbguSdoGRntzxX5y+GOfEuk/wDX3D/6GK/RpQNxIBVCODn/AD6GlIuRUTw3pCam+piwt/7RYKDcNGC4CjaoB7YAxxVxrSPz1kAcSIGI28A54OR3PvVyFVPRgB1zSsCoGcDjnjpU7kpLoZ15ZW1yY/Ph3yRNvic/ejYjG4HsccVwfji98a+Gre81Lw/bw6lHIEf7JHEP3ZWQgnHXLo6lj6xn1r0oqud3J7deK4X4geILTwVo2qeILeRi/wButEvEA37xlA6L6P5RJz/u09OoHj+peK7j4zePLHRdChu7bSJbaGPUg/ASFXMk30y3lp7lRXtvin4Y+FfEukW1hfackAhCRwTW4CSxonQAjtjOfrWf8PvFPgHVtbu/+ESks01a8Xz5ljtTFLKBgknjkDP516UmHVXAHIpRklsNK/xHI+Evh94b8K23kaJpFugL7nllUO5PTOTXQXNpHNbtb3VvDJbvwY2UFD+FaB54B6elQuWV40xuVicnpt4/XmnzNj5UiC0iht4BFaxLFCq4WKNcADJ6Dtyf1plyZFR/JVZWBAAY4GMjPP0yatlNgyueMEen+elVJGHlu3YjIGPWlcLW0PMPib8OtF8aBW1WFo7tARDdxfK2OwJ7j2NeReKP2epYbhG8M6nhCihlueGLEgHBHbBJ+vFfSWrxyPAiRD967DoTx7/zqcwRtK2UZvlXqeOP/wBf6Vam0K3Y8T+Ieg6v4b/Zu8QWHiLVn1K9V7dYyx4hiFxCEQfguT9a+R6+2P2mLC2uPhBqtxIsjSWrQvCSxADGaNCcd+GYc+pr4nojsUj6z8CfGHxd4h8Rpp9xp/8AaCNDNJHawqsZnIXgO+OAMHkDrxXqvhX4hWT6ZMfGD6boN7ESDZteiRvLAPJBGQevHPT8K3NJ8CaBphjWHSrFooo9qu0YeSQE7iGJ6jcFI+ladz4T8P3d0tzc6Lp8kynIZoFOfrxzWfs0tv8AMhXvqcPrHxGbS545NH8I61qdlNCszXUMXl4TBKDBGSMAnr36c183ePfiDff8JcuueGbD/hHpxKzFY5TI9yzHlpQcDn+6B3r7Uh0qCCVpIR5YBLKqEgAnrx0r5h+PAOqfFODRrV4bbTbS0V7g7AqySkliWPdipAA6k03FWsyXe+pwF5oml6j/AGpJ4k1iYeNLmcXE1sNOlkjPmgOCXUcZD5HIAHGK768/ZlkksIHtNUga4lQOyvEyBSR0HJ6e9O160l8O/F7xVqE9l49axu3tJ7P/AIRt2EdyFj+ZpW7gNkBe25ugxX07YzC+0m3u0jmtxcRLLsnTa6ZGdrDsRnkVo7w6afP/AIH6iiubZnzh4d/ZttreJm1XU185efLgjyoOf7zdeK7my+CPg+ztVDW9zcykFSzzkbuPbgV6fPGY5SFBLOAeAAD6n604x78yckoc7QeoHpU87Gonj1l8NNR8O69b/wBg/ZLu1jLrbXd4zebYhtx2gDh1yxIz0yR0rwb+z/Gnw61+y8Uazb3lx9td1uBI5LTpkh1J5wSM4+ua+wvGOqzaV4L1XVLTm6t7cvEWGQTwN2O/rVm+0bTdTivYr62juIpm/eCWMMD8uFOD3Hr7VLs90FmnozxT4a/tBWd7cSJ4os7XSrVvmjltkeQNJyTkHkcD0OSa9Oi+I2i6nr+n2FjqGneVPEZJxczeVMgIyoEbDB3DvmsOT4ReG7xo5kjmtokC7oEkOAwOcg/UD9azNS+Cekap4imv3aC2gaQSrbJHuDDGOc9AetLk7SKUu6PSLrU/DGj3sNnc3+n2Vzcg+XC0qKX3eq++a+cP2zp7Ka38ErptzbT20QvY1Fu4ZUx5A28dK9M1X4F6Bc6dcpaQwfb5FAVpI8rkMD164xXhX7SXhO78Kaf4Zj1CSNprie9YJAf3QUCDBUdic4P+6KqN73vctNdjw2voj4O2ekyeBLRJLWC41mXzJYPtapJkGYxlYwW6AAttOOS3XcM/O9fS/wANV+2/CHRNLhs4YtRuhO1ncvH5m90ndj0B2EKCATjkj3zoMvXfhHxB9turN9E0WXRztUSwBIpWXswPQP3wByOMc1f8O3Gq6xpkkMVnLa6zaNFZ3drMAkSg8GWNWGcgjJP3eCQBjAt+FJPEsuswPqH9rY2BJYLuOIxSZU7QHHK8465znt37az0mCK8WZNPTT5pgzzb5Vkkdh0VnPUDtjjII9qAM630m7Xw0yXyumrSwGSWS0byY5A6n5Qf7y5JLEHkDB61Z03w1LZXlveRanf3oMQhEbymRY5AoBlQN0GAAwHc/XO9/Zr+YwW8cwMFjWFETbEPcnnkDHp19sTwadb2he5t4G81ywLMQSwPUZ/hAPYYHP40AURpaRz3lxbWn2meeaNJQ7hMxYGeCME5yenRsHNXYdMWEO5igieRAjYG6NFGQAqevJHH+FaMCNtc70X+63Cj8fTB6/wBK0IQq4EqM2OMqefr7GgDMsrOC2iFvCvlKMv8AMWO0kc43HgDpjjH41OY13jzvLQpkJvA+Qnrzj0wD9D+FtIj0ZWEhAK49T6dieBVZhxteNWGMMCBj6DseR/KgBl3LNDbkIkLz8Y3kgfeAOR7AnnnkfhUzxuE3MCFboAuS2cZxgdM9OvXv3jd9xLbWVG2ovy7s56dT/P8AkKSyvLW7aYWUkdyU4kEbgkdcBu4P19/Q5AMrxOj/APCK60XiiINjcNyxwf3R+vv+Y9a2ZogJWiDRht5B2rjIBPQY/XNZ/jAFfCusBRmRrO4CkDrmJhgfpnp/U7Usa/bJN43AuSrfjyP0P+eQAY8MDrNOZyCkmFjb7jIvfnHrgj8aRGiIEaSGRUUrK6HMkZAzjpyTnd+FayIpdQw3ITjthux/D6e/4RiFVLvEiRvKRljwzHgDPr6UAZ5hVJSYl2AQkk7Ad5HQlj19P8arXUCzq/JjJVQqK4Gcc4J9zgH+taoCuMNlYe+/5QOuc/QZ4+lNtYwsipIw8xj8xbjnHOc8Dv0oAwvshk0mJLiBbSYdIYX+4AeMHuOPy6kmsvwyHPiHx3iP5v8AhIEDMrbsZtIc8eg59PTjt1V7NiRgqPvjUn5fvHJIxt/Dsa5Tw8bhte+IG0IH/wCEgXYBJliRaRY47D7nPr9OAD5P/aEBHxf1/PP+o/8ASeOvOq9F/aFJPxh8Q7jlgYFPTqIIxXnVABX2vqVpZ6xpz6ZBfvqmoQLGRJE2yG0cMCreaTndlccY6DI6V8UV9l+HL3XdP1670PXdKW1ubOMSrLboRFcRBtqmAA8jGAASAu7acDqmZVOh6J8OvEk93LPoWvz+Zr9guWn8po1vIunmICByMgMMDn2IruG/ebSucA9x1ryLxDFvuYbqG8a11mzuFWOa2TiBnXHl45DklhuB+XGR2zWv4d+IMsGpQ6T4xiS2uZmb7LfRDEU6BtoaRckwktwN3B7VDVtehMXfTqdlruhadri241WziuhbyiSDdkGNx0YEdGHardvAYII4XklkZBxJK4LnHqQMd8dKuBRjkfQ5zxTJAu0NwQOckZGO9CfQdyJsIjdAxwSB6VgTSCfxpbw/OxsrF7hQD95pHKYx64Tv61n/ABK8T6z4UsbXUNF8PTazACz3ixPtMMQGdw6nv6EcHpTPh94p0nxveXmuaMzbEt4raWGQAMj5L4YDPIzjPT0pso7SJUe3EYUBcY2t8wHsadjdvUHOOPm5xTdjSIAWeIhgfkwCfb6GuR8X+Jhoev6VayR6tKt8HATT4kkZSrKNzIVLFfnHIPGOlJX6E2TLuveCPDviJSmt6FY3gBIDvGFdfcMuD+tee3Nxd/CbxbpSXOo3d94H1Z/syx3TmRtNmOCuGPJQ8/r6c+xcRu2GX5uMg15/8etNiv8A4Yavvjkka3Ec0QRjlm3hcDHqrsPxqt9GNe6tD0F2UKSGypHUcj615d+0uhX4G+Jt2P8Al2xtP/TzFXVfDHUJtV+Hfhy+uyoup7GNnI7kDH9K5P8AaZZ2+CHiMMBgC2IOOv8ApMVJDtqfEXhfnxLpH/X3D/6GK/Rp0YGJkYFWOOfocn+n41+cvhb/AJGbSP8Ar8h/9DFfo4Z4SsaM2S7mMcYDNzwPyP5UTLY+33J8g27QMjBq7G6yZj+bI7kYB78Gs2wvLa9WZ7NtwhkaJuMfOOtW7VmlVvvqFJw3rj2/A1AhZQ0ZXYoZcgEZ5A9a4P4o6PYL8LPE1pcSkLLbT3BkKb3eQAyDAHUgKF9lX2rvLq5topo7cnE83zIuOo+teLftF+J7vw/J4ebS71Le6Q3FxGjpuE5BjiKEdvklkPPGAR3p36g0J8E/EukC5021ufFLa3rOp2sIhtfsKobFki3yxs6qOp3AZ/u17hbXME7zLbzLL5TmOTac+W46qfcVl+HJLDUNHsdR06O0ZLqFJllhgVAwYDJHGR3q/p2mWunPeNaJsa8na5mJOd0jdT7fSm3fVMaRcXBQEjk0MARzSkgfXpTWbbnJJ+gpDI2XBbb8vyk+3p/n61AeVBYgt3GP8+1c94Z8d6J4k1O7s9InkkmgBfeyEJcIrmNniY8Oob5SR3relY5BBXcSAPQ0r3QmZ8qOJirAMqtu3Hr70Q+YLgou4hl3DPYVKsTFx85Y5PJHT1/wpd6pMdnJU4OOKBHk37RkcK/CLXkaRvM/dTIjZPP2mFScnpjd096+Kq+5v2lPm+C/iAkgHFsfXINzF3r4ZrSGw0fqkc4JHXtSemeQeKVs46Z+lM3YdvYdOOaTYDNxaVfmATkEHrurzKTwzba3ovim9u4klS61NrjAyHxb7IwuRz/yzfj1Ir0pyo3zIMnbk4HJx/n8a5T4fae48E2+8sPtzT3TcDd++ldxn0IVh+VK5DVzR8GRuPDGmL57TzQwrFK5JXc6fKxA6YyprdP7yM7SeTwc1yvw1t5IPDZt5LgzSQXt3G7FiWH7+QgEnvgr+ddJJsigESAxjOBxgev09alDWqIpEkYbUOzPy+tePfHj4lax4KudN03wvZwXOoyJJezBk3hLaJWMmRnjoTnnhW74r2pQG+bLgNwfm4FeYeN/h1p+peKNZ8UaxrGpWtuNLWxCae2xlgG9pQ+VbcGyOAB0PBotcNjtdC1uw1/w3Y6vFGHtL6BLhOjYDDO3juDwR6itGFGcK7fKkmAqglTjHU+nPb6Vyfwu8NReD/Cw0Wz1N9S06Gd5LKRwu+OB8OEYjhiGLnPoeg6V2anef3u4nkDA6UILLoNljRRhUCjOBxTlK+VyhY4HTj8val8uOQMX3NzyD7e1O3rHl2bbHgAA0mNIfGFUBR8hHAGecV8rftvlseClbBx9tOR0OfIr6q+Vxldp9+vFfKf7cMu668HRhgdqXbfmYf8AD9KqO4z5cr3n4ZfFJPC/gbTtLGlNcyIZP3kspC/NKzccdOeeex9yPBq7fwqdOfRIxI19NdpP88MQRVjUhsNnBLA4wRgYPfkVqM9gufjdeGGJBolsjcja8rKzMMENxyFyPYcdTTLf4seIr6S8uY7SyZXC+W/lAxwqdx25LY+YY5PpnpyfPzbWS3LiHS9aaV2LiN5FG/sADsBIzxnrxXQ2M0Vtgy+FBPLIyCIXALFzsySPlyRyR1H6mgDYk+Jfi95iq6nZkIgYrHCny/NjDcHIJIz7c9xWnZ+PvGs9uTE0zxgEZitUdgcAg/KvTH9Mc5rIe21S8ci20vTdPhKglokCr0Bz65Gev5VLaC50y6lI166F6oYeVZ7j827uAOR0z25oA6iD4q+JWtmE1pbw3Qfy2d1bHBxuxkcDnnvnjoauR/ETxd50e2OzSJsYIiwDkZ4J9sYHvWXp0+t6j5dnZ5MkjqVjjiVGfPPUr93qTx69asaqDpU32TxE9zDtj3pHDKkpB6DAEYGDyc8Y9aAFi+I3i+W5jVGjKkZQG1U9hjt0BOM+449eg8PfFW8MpTxDp67WT5XtVIYngEncemMdCeD7c8RcXVvNKJVuGsmhQhpIGZy33sZ5znjrwOnpxHrPiy6v/KOpRxOYQwBWMsH5OWK+vBzwOp4oA9N8S/EWLSbq22wE2TxtLKPMVpPunaNueM989gfw5PSPiU9nqMs0ejWVtZlt8622I5Djd8x5AOASefT8uQhv9OkmimXS7CdS2yN2keNgAw/gVuWJxj3x6itBp9NvJSbHTJLdJMKTbzltxIXIJIOSOB3zhecYoA6TxF8StVurXUGs44YtOltJgVuRhwNjDcCDg4Jx3HrzXomo+OtGSTV4VulN9ayeXLAHG7GR91m4bqDjjr9K+fdZtbX+ytTMryQQrZTjZvDj/VHGOB3GPoPrW5rX9mRag39mot0TMQJJImUN/eYYbOM4/PtigDtLL4m6rNcyW1tpkVwwfy+GwxBbAbA4I4596pyfEXxLZ3LR3mljAODGyMMNwBk87jkcH36muPsIrlNTt7rSYpYriJjJEtsTJtIP3+f4vY/3jzir82r6mb1ZJkulnjDDiSTY4A5AXjbnIz0HseaANj/hOfG11NGYbXysDcRHa5DMOnLHoR29SOawdU8TeMMOsurvbeW2VihMUZwMHnj29+3TNB1yG7SRL7TdQkuNrqUMhEYI5HGCcE8nGenesO8nult5saRb2oBK7hHl1XPck9fu9/5cgGxpOueMdZnWytNTuZ2ddqypIq8D7pU7QQORyMZ9O1ZsOj6wvijxWuteIlsEhvIDdMtyZGeR4Bk9fmGG64OMHrjBpW+qwwiVw1+JOMyLcY4xj5duPX9O+apWy/2n4p8SC20wXskrWMmZS7lQIMk9ec8nqOg4HYA8w+IIiHjDUfs95NexbkIuJjl3+ReTXO1v+O7WSy8V31vNCYJE2boyMYyinp+NYFABX6SeJ/C+m+LLSG01aGYmFvNguIJWikgb1V1IIOccdOB6V+bdfqLGcAEgZwckfhUt2ImeJ+IdP8SeAR/aUjSa94et4h5X2aALcWjAEB3UcyDBPz5yC24gkZqGXWNP1Lw9f3NvPaawj2X2zV7hQWQnZiG1QdjztI5O0noTXuqYYkrjb047/WuA8WfCjQdduzf2Xm6NqZYO09jhUlI/56R/dfp7H3o0exlbucXp0+reENG0aK11O9jub6SKN4ZD50XnSv5hRUYERqke4YTb8zL2GK3LT4j69ZaZfXGv+H47gWM3kzCwcpN91HLLE2cgB1P3hxT/ABB4M8UTajY37XGk6o1kzGJWD2zDcp3HJ3DcWKtk/wBwDjJNU5vCXi/UXvhJaaVaR3klw87SXjSswkgjiC/Ko4Cxgn1IHSkop9B3ZmJ+0l4YkvorTT9H1u6kkbYipGgdmPQBQ3JJrzyHxHY6B8RrHxJ4Yt7nRdPvJ5P7TgkkQh4d4H+pGdp+8eTyQdtex23wmiedppdQh0+Fnhl8nSLNYCrRszblkYswJaRiSMHAA4wBW/4X8GaNH4Ei0i70mJYruAG8jcZd3PzEs/UsCevWmkl10+Q7t7I6+wube9tIp7KZJraRQ8ciHKup5BBqSIJ8xQDOcGvJrPwn418C2q23gG/stV0YMzrp2rcSRk9Qki4479ueuaup4z8fRCNbj4eytITiTyLxdq89sjnipUZDdj047I1J4VepxXlfx9nvNS0nTfB2jYbUfEFwsLrjJjt1O55COwHy8+2K1nuviFrE09vb6bo+iWe8hLu6la5kYA8ERDAB6HBJ9K0vCngmLRdau9bv9Qm1XXLmIQvdzIE2pnO1VBOATjuegAwBihKz1FobeiaXb6JolppdjCY7eyhWCIE5yqjHWvOv2mAV+BniMLt24ts9f+fmLivVH+QEt057V5X+02WHwR8SLtBQi2+bPOftMXamnd3Gtz4f8M/8jHpWDg/a4uf+Biv0IkjEl/bTXBIW3JZU6qHxjd9Rlhn3Nfnt4a/5GLSv+vqL/wBDFfokFWRyWPXBCk5GO1Ey2R+F7+bUrOWW4sjZESNGwDA+YVYjzF7bWGCD1Oa3bVJGtkabIfuFwAfryaz4phA6RzHZvby48jq2CQPyBP4VrQMrIpRsqPlNQuw0N8stPl4ozGF+WQHkc9PpXiPxT8M3Xjv4sWdtZx+bY6FYCe7BI5nYl0h57uFQH0DZr1OBNWvrOHUZ1NpqtiblRZLJ+4mPzLGX7kbdrfia4n4baPqq6X4o1We+W71LWbxb+CRF2pKiZMYAP3QyqAM5wpXriqV0xS10LH7O91ct4BfTr2J4JtKupLYRyAhljYLKgOfaTH4CvSrqEXNrLCZJYxIpBeM4YA+hxxXmHgfVrG0+IviGKCW5kj1bT4Na/e5Yk/MPlHb5DGuPVD616nH5k1pujCxTOmVWRc7WI74689alK5SY1NuPLQkmMAEnPAxxk965/wCIeqXGi+Ctd1Szj3yWdnJKuGxghSc59uvvWheadqsul38EWqx297PCqRXUdsP3DYwWC5+bnJHpxVV9EursaRcahfg6hZDEskKYiuAw2urISeGHPseRTsJnkWh6T4t8M2nw9n/svTn0zT/Ls5WsmlNwLe5Ch/MjYc/MUc4+6y9MZx7UsUcKLGgX9yNqgdR+frXn3hzxnqer/F7xP4ftYLOSxsDETK5IeNFUiQADq3mOB6ADvxXos1srM6jrJgnJ7D3/AAo36B0KAtPM1Brl5JMBAgjDZTqTnHrz19KGSPzXjCkDJZgTjt2NTiJYVZSoJxwAOfxp8cQM8Rde2GOe/wDnFIDzD9pKyS3+CHiDy9wUfZjjOcD7RGB+HJr4Yr7y/adjRfgj4jwdrA2xA9f9Ji4r4NrSOwz9UZArDa2Dnt60xowd2WPPTHapSM/WmFGMgO449KTEYvim5n07w5qlxabDPBayPDuXI3heAfXnFVvBcM0XhDQlVy7fY4icED7ygk+/Wr/ivy10C8eZwqxp5nPOdvzY/HbUWiS6e8S6ZbTl7ixtoBLFgqUVkwm4dshDx7VL0ZPU85+JOu6j4b+Gfja+0G6YahZ6iQkywiRoVkeIuQOnypKeT0xXmnjPWNb8GaZrtr4eu/EemlYPtkP2y8j1GC8tTIIpJU3bnibLhvvD39voXR4LW51LxXZ3CJPDNeqskTjcpVrSEEEHjBwePeud074UeEtI0nX7Sys5FTVrZ7SaSa5d2EZz8qkk7FB5/DnNNRi9ydUjzXwl458S6l8avCularpN3pNm+kPGIWu/NW7iZNyzHaNufl7ZI5Ga9A+PiXFz8PJrG2J825lU7C331jHmbeOedoHHrWp4f8N+HdTu/DPiW3tT9ssNO+y2com3KseCuD2YjnB962NXtrXVtc06zuHUzwJNcgDkAFPKP/o0VK5VsN3aH+CVe68IaFJOF8z7HAWXb0IQA4/KtshkRjExOB3Pp9ax/Dc622ixRXDYMc8lsC52gjzWVQM+2MCtuAJl2BGc8j0/zxQtikN3EgruyW5GeKVWPyK8fBwc+hocJu27fnPzDj/PrUp4y3fHpQtQGQxlCc7RyTha+Rv22Hc+IfDEboQVtZm3cYJLjgfTH619eKX/AIgMdiDXx1+2c/meK9GxjEMUkHXk4Eb8/wDfwflVR0YWPnSvaPhpot7qHhawOlwRwb5GNxLHEXllIkKrknjGGK49A394GvF6+3P2cYYpPg74cd4i7xm4KnPAzcS+nPp/nroUcnB4a8RSSTeRpuqLFK+0tJJBCSo7FgCSOMYBBHHXFLaeDtfDSPqF3Lp1sGCgzSs6MxO1TgZycj8ivdSa91jtpZSpvoLZmAOGVmJ+vIHtRcWkgmtFtr/yA7MRC6b2l6EgBufl9R9D6UAeEnwZqdyJZxLcm1hdhvaMFFIB3Pl29iTweuDnFWtI0WKyuppIdYWG8sojJJJAyRtGoGW2sqHOd3fgdD1r2jQrOW206SPULibUiXY77hQGAIAZeOq+388VnX3hq1vr+1gSCx+ziA/6MqtH8pIyQUIAGSeD/jQB5npqz69q3k23ia4ljfeI3GE8wggEArg9fXoPWuouPhWZ9s6XC/ae7XDGZT1zxhcZyTwaXV/h9d2gP/CK2Fnp9yJAFuotQlDKh6gqy4XOOg6cdKzLfwp8RY5ndtZlc7hiV7rKtxgDH6Yx3oAtp8PbS3V7jV5LO3sExGqmFl+Y8EHJyM57Y61QMPw7+2rBZpFcSEKwRpJlAxj72SPXp14xV5fhx4luXkbUNShPnkSOr3TsSe38ODjjHvVa4+HXiKzUtYX1k/HLRuVYj0Hy4zn+I+g98gGFeaToEN4RZvpht3UiOO3tZZAcZ6/3uAf09ebfh3R/Dk+nRtqX9nbzn5UjlVl65XaVA7eoHI65XNmb4b+K7xFafURuXjc8x4XBBHA4GOD9faq1t8MNYEiC31CGQr90FyS3qcg/7R/76PPTABqeKPA/h9vDurpDDOk0lnctFlseUwjYnPzfdPatlvhvokd7NBugacOzJGS5ODnCgFue1cf4j8CeJn0K/lvJZLyZbOZGZpW8zPlNgYH8v6Vr3OieJ7KK5kn0rT7qNJC7ShCZjjphj1IAwcdgMDg0AO1DwjY22sNY2NxqnnMBujt2GwcAZO4j/OePSDTvA08plnN9MsXmiPc746dQcEgKQexP51zMMGqz3bzrZXbSxyN5uBI2Af4WweB0GOvA962YfFsPkPZ39hp8Mx+aRSJIgxA6so7g8+nqRQB2Nr4U8P2enBtQWO4YYBMty2Gzjj73fj8653XtJ8IXengR32m6bKXB3hwXJJHUOSOue3euc1XVormVnt00W3JwZF2NIQVz82W4HYYP445rIluWuHVIJLR7hMkxWembiu05Hzbc469j26c0AdDd+GtD0xJfKtZ9avpsiGADakeOfM3Af7OfTI4HWsHRbzStO1Px7dy/abWVbrT1ghidTMmLZiyhmGMDHGcfdGa0xo/inxDbKt//AG0UySgldYE4zgn1Iz7Yx09crw58OLrU/G/i+D+1EtTarYNJ5iGUsJIGIUZAIxgjkHr3xyAeE/FTUItV8e6pe28MkEcpixHIcspESA/qDXJ12fxg0mTQ/iJqmnTzefLCsG6Ty1jyTBG33V4HXHFcZQAV+osTeYmNvy9Pb3Ffl1X6iRgQIiRxMF6HHb396mREiVAEG0cAdOaVSSeQMeoobBUlsEDnmgHC8c8etQZjZGClQcDdxknvSRLkAr9wdOOT70x7ZJXjkuEV3jbcncKcEcf4/wAqs4xnGPamh9CNVBOduCp4P+FIgG5l4+npUgOemOppoX5sjOT29aFqK4iRoiqFA46UAfNkDHvUVtbmCMB5pLhsk75MZ6+2Bx0/CpgOSQTz60tw2DHTt9KQtztHJzz7Uozk5PFJuG/AByepwf50IBTgk9TivLf2ncH4G+JTjtbf+lMVeoqCOwry/wDaez/wo7xLjpi2/wDSmKmtxrc+GfDQz4j0oet3F/6GK/RP7AIkBC4A5+Xnn1/rX52+GOfEuk/9fcP/AKGK/SFIifvv/DjrwKcjVkqRhpAXOQOmR/nFVL7V1tLzS7aOGS6OoTeTEsSjEahcvIzdNoGKhhluZLiOysLdlt0hLrdM3ygg7VjOeS3UnjpjmtiziESr5YUZAAVeFUeijsKn1AdNCLhY1l3BEdZOGwcqcj8Kq6VZraT3TxFRDcSr5SIOI1WNUC+2Ch/OuZ1rxBongLT9c1HUNS8w/bFnkgkk3PH5irhFXqR8rMAPem/CW0vIfCSX2r3DG41Sd9U2b87BO25UP4MOB3outkBkePL228KfE3wVe29grSao82nXEq9oyyFQB2w7bvoDXpzqrxSxSMyqwK7lOCMjBwa8x+Pe208P6VrUjAf2RqdvdEfxSKW2ug9Dgg/gap6D8QrqbWNc0rQrC9127hv55/NUAWyxMcJEJCcZDMpOMjAbFGtxqyPW408qFUBchQBljk4HFVJ7+KO6FvISGMTTMSPlVVwCSfxrivE3xS0Pwvrc2j6jLeXOohFZo7K3MwhZh8qtyOSeQPTrirGi6/a6/olzZTRa87SQuJHvLE23mKy7SFJGMDJOM8YppN9BNo87+EunXEPjo+KrnEcfiO81KGIN99k3JNET7Yil/T1r3MpvkAHO3gnNeTwWk/htfh/ph+0TzWuoBriSTjZGyvbIOe/zLwOu0mvW8IkuC3J4x05/z/nmk3Z6gvIikTcG5Jk6DA5HrmqFxHqccDpYrbyzu+YmmJVIF2jG7GS2SG6f3vatC6lW2gd8M7qCVUDLMeg4HuRmnRNMlnG96Io5ymZAhyFIGTg96BnlX7S0IX4LeJ3y2f8ARcA8/wDLzF3r4Tr7v/aMuob/APZ81u8tZDLbzx2kkb4xvU3MODjtnr+NfCFXDYD9U+9NZeDyfSor66hsbSe6uXEcESl3c5wAOp4qjNd3N2rJaRPFDImFu2xgE4wVXOTwcjik2thHO+IdU/tjT9UttGcS29vbTrNcA5AmwVEY/wBoE5PpjHeuis9Ihs9X1TUTIzS34iDggAKI1IGPzNZFxp9pofh230u2aP8A0u6SNmYfNM7uDIxx1Y8n2ropUZgDI+/jPlgYyc8H6VOzEjC0FPJ8W+KVOSJJLacEjuYVT/2nUfjvWLDSPCms3V1gxQJ5ckaDJdnAwmPfcAfYn0qsuoyW/wAUJLFyTJc6Sk2wEY+SaQAgeuH/APHe/aP4pWl7qPhGaz0y2he7u5o4owxHJJO4nI44zzzQJ7HmnwZ8darqnh+Tw7pGk6dFNZltsz3JRbVXLEExkZfDHACnB4yRmvRPBWnTWXiKaG6leSWCzA8yU5kklkcSTFvTlosAcAcc15V4x8ISfC/VfD3iPQVjup2ufKnilYBMEZ256AZ7/wAq9a8B6fcwXOo6hqbIdTnRZLlozlQ7Mz7Bzj5U8scdgKm1nYlO5U0iym8SaPbbpDHLYa69zPvBbd5Mz4QenG38jXfQAbjgjBGQMY71yHgG2l0u11xr+QJDJrFzLEcgfIxUDOPfNdXDMjwJLCVdWXKupyCvXIP401ZaFIlZW8wFT+fQVHdTLZW5lKs6mRQQMsfmYDgd+TT1aRiFHbqxHWpJY1kUBugYN+IOR/KqGl2KtvqENxK0Sbi6jcyldpHp1r4v/aile71KK8dWTzdZ1CIK3byobKPg+ny19sSBt3HSvib9pCNhofhu5Z94u9T1acNnO47rdWPsNyNj2xQnqgW9jwqvuf8AZmV3+DOgKGBJ8/y0ZcAn7TNnnuOR+p7Gvhivur9mclPgt4cZ1Xyx9pOTnkfaZf8AA/5zWhR6XbrdNKzXTR7SBtWJSCx6ZOe3p+fei4KxoWWBpJJCQTEpZmPQDPpxgE46e9Tb/MY5wpHLcYIJ9fr757fg6KTLDLMyMMqSOo68Y9iOg7j8ACQjzGYOH2jjduHcfdx6j/69VrjULC11G1sry9s4b66Ba3tpJ1WWbaDuKoTl8D0B461dV8hlIKsBkZ7joSK8b8V+EL+b436b4ia2urjTitokU8N2kcVu0chLGVG+ZuPuBepP1FAHrxRsKEYHacZyOMcdO+Of/r1JHGixdcgfLw3T2J/yaUt93yzuUkYO4n+vPFOUKqbUZDgZzjAx/wDqNACOuQSDtYqVGG6k9Of89qqTLIIiloEQuNxfcQR74xxwf1q9IoIBAOcZ2kkEmuc1TxTFZeNNJ8ONZuX1GGSVLk3CKqlFZioQne3CnLAbRlecnFAF6RL0XEri8tY7RUwAUOUIOcs2e2Dn6H3o0hJNrSC8trpQ7FhAg+fnAGc+x9M/nWkIVYeUQCBwysCQc89T9fft+JZWsVqojgjEQwDtQYGenPHPQc0AZ+vyzWmiXt3AoS4itpZQe6sEJGV5B6Dg96vSL+8wSFBdh9eCQP8APtVDxQgbwzq5bLZtJwCCT1Rv8/p2zWrKVW4be6gEDGcZ/wA/4/kAVfJTLSbOODkDk8diKPIheNWeKNs8glQcn8utUbLXtCvtWn0yw1rTbnVYSVltIruOSaPYcMGjBLDB4ORwaW41TSIIZLie+s0gS4+yF2mXAnzt8rr97PG3r7UASSWMDIGW3gV/9lAPpzileKONsJGsZAySq/L69B+H5fWofE+v6V4bslvPEN9a2NmZFh824YKrOQSFHcnAJx6An1xR1HxDounaMdYvdTtYNIkZXjvFkXy9rEBCrDIIOOv8qAL+/MhheNiqgHf25GTlj1PB/D6iuF8MDHxW+IzxHcDFo8vY7/3Mo/UAD88da6XQvEOkeJLW5n8P6naahHC3lyNbt5gViMgflj8qwvC6Kvxa+Iu3fhrbSMjqR+6mGKAPkz9pMg/GrxERwP8ARuPT/Roq8yr039pQ5+NfiM8f8u3T/r2irzKgArqv+FieNcY/4TDxH6f8hOf/AOKrla/QXW/Dfwz8O2a3evaB4U0+3eQQrJc2MCKXKkgZK9cK35GkxNnxGPiF40wB/wAJf4iwOg/tOb/4qnf8LG8b/wDQ4+JP/BpP/wDFV9yaN4Q+Hes6fFe6R4c8J31rIPlmt7CB0J6HkL7dKu/8K68FeaR/wiHh3OztpkJ7+m2lcnmPg3/hY3jfp/wmPiT/AMGk/wD8VR/wsTxrnP8AwmHiPOMZ/tOf/wCKr7sh+H/gx9Qmibwd4bVFjVlP9nQFiSTnI2/SsrxL8I/DepC8Ww0LQLDzLby45E06MGN8SfNgAD+Jc8Z+Xg5wQ0w50fFH/CxPGuMf8Jh4jx/2E5//AIqj/hYvjb/ocfEn/g0n/wDiq+zrX4NaCgYTaVoUyYlwTpsasSxdlyQONpcAYx8qgHPFSL8IPD8Yt2j0Dw6zwyI5D2CkSjByrcdMnj170xc6Pi3/AIWL42/6HHxJ/wCDSf8A+Ko/4WL42/6HHxJ/4NJ//iq+5dO+FXhaAStdeG/DsjtOZgBpkRUKeqYK8AdsVH4j+GPhW+sry1sPC3h60lPkskyWEKsAHy38PHAx05zQPmXY+Hv+Fi+Nv+hx8R/+DSf/AOKo/wCFi+Nv+hx8R/8Agzn/APiq+zF+Dfh4a09xLomimxaXJgFpGo8vycYHy5BMpZs54G0dhUKfBzSI7G1CaF4ekmjhh377RAHkVlZ8nbyCQ34Nt6ACjcOZHxz/AMLE8a/9Dh4j/wDBnP8A/FVV1Txp4p1axlstV8S63e2cuPMt7m/lkjfBBGVZiDggH6ivtq1+FXhq2k1afV/D2geRcSB4jDZxfuF38IoK4HbJ6846cVz/AO0X4M8MaT8HfEV7pXhvQ7K7i+z7J7awiikTNxGDtZVBGQSPoaQKSPjnwt/yM2kf9fkP/oYr9KgpeJcFR2+v+ea/MvS7lrPU7S6RVZoJklCscAlWBwfyr7o8W/G3wdomk+dpl/FrGoS4MFpanduY8DccYUevf2qZuxTPQNZ1iy0PTlvNQnjgs0ZEd5OOWYKMepyR+FcIfiXqWv6pd23w50m1122t0MT3M0xgSO5HOCT1Xb6d68us/h147+KuqJq3xCvZdK007THZKMMVx/DHn5c+rc19E+HNA0rw5o1vp2kWcdpaW6ghV7sB95j3Pualx094FLXQ8V0v4Ia/4h8XLrvxF1e1uhK4luLa33HdjhUzgDaBxx2r1fQv+Jjp889pbRpuukKxkbUMMM+E2joP3aAjoMkVJr3iC8k0eNPCdoNX1G7LxQyJkW0eAQXeTptBGMA5J6VZ8Ay2j6VdW2nM01lp8/8AZ8cjdX8mJI269fnVx+FNtbWsCWtzkvjNp2oeKPAGu6ZawSWs9nsumeWPdHcIAzbY2HU5HOQMcetcL8L9Q+IGm+FNHvvDnhqyk8LJEN1ikqrc3RIO+YE9ctz/ACFfQWq2Meo6Xd2VwXSO4ieFmQ/MAwIJHoea8v8ACOtXOhfCfR47G0lutchM2n2mnsdpuJIiw2k9iERjnIpO1rC2ZxGoXPjfw94kh8c30K21nqroNTsYbPz3soUI2hu5ZumRzz7V23jfx6niDwWkHgyW+/tHVNyxyNbtGbWKMqZ3k3Y27UJGeckgCuDj+KOo6X8OvF13rSrZa3PPIYnRg4juXICQKMnlEBZvSvLvCfxM8VXsOoRap4g+1RSQfZVsZVAluPNbaVjIXtu3HkdKNGr2/Eevc+ofFFle/wDCC6ReajcSi6sPsNzclgC/mJNCzscdSqrIMdyTXciPddlmQfeymfYYz9etch8Sbq8k+GF/d2EMk0r2oaQAYZUOCzFeeRg5HbJ9K2LPxLpc1rYPd39rbXcshh8lnAbzQ7Rsir1Pzqy/hSvYDoF/1gzjHqTSF0LqWXGAQGbjHHP0oLZO0kkg8j3rzD4o+MNOvYrXw1o1zPqmq3F7GlzZaY4afyFOZQT0GVBUnPem3bYq5j/tF+JtD1P4OeKtO0vUILm7h+zl4oTnYFubfJ9MfOvPfPHevh6vtH4x+GbHw5+zz4kFtYwWt3cfZnnKKNwH2qLbGT3CLtXjj5c18XVcdhH6oSxpNGySoroeCrDim7otpiBX5cKVB+7noMU2K5WSSVArjy2C5I4bPceo7fgarWcUsE1zPeSh5JpMKEGFRM4Ue555PvUti0Oe8XJGmr+GUeVYgb5RFERlpXAJOT6BQx9/w56tkG75AoP3W9hj/wDVXkereLX1j41aHoyWjJHpskrBpCMPIYmBcEdscD6n0r1n5kiKhWBBySxz3JJqb32ErHHa5YzL8SNBvmwfNgez3AY2/LI7c++F49jWxqVjJeeKtGuP3qw2aSyMAx2u7AKMjPUYP51LrjGRbGVVzLbXHmHALbRsZScD/eq/YP5jSTiRzDNteJGUqQpUdjznOaelxdTG8eaCniHwzc2rRnz4f39ucAkyryvH1rM+EZmk8FiW+VEklnkLgMDnopORxkkHp3rtZcMuGJGe3t3qGzt7eys0tbONI4YhgRrwFFDYWs7mfqNpZ3EBidIwkjDy+QNxB8zjvn5Sc+2aZoGnz21tcR+bIts5xEhYs0QAAIDHk5wevIrmNatdVuviho11HHINF0+283aDhftMkhhOQOuI2JFd3JhTI8SsZHxkZxk0ahbqSIDHCqIvyqMenHtT93zEYP41Qg1Ozl1JrCK7ge+jj3yQB9zIM4yRnjn1q8xK7iRuGOAKV0UUtavEsdLu7q5AEEMTvK2eihSePevjn9o+0ksvAHw0inwZ9uovKw5Du0kJLZ7gk5z6GvpjxP4v0d9C1eC01C1uniWW2mRZM+U21vvfTBHPGetfN/7TlubfwN8L1aUzFrW6feTn7wgbH4Zx+FOO4lufPdfc/wCzSw/4Ut4e2sqlRc5weSftE3GDx+P8u/wxX3L+zTGD8FtBIIWR/tCq3TpcSn8unP4VqUesxbVc5G4ZXnPA47D1/wD10uWUZ3fKOwyRkeuOn9cGqJheOMkyDCkKMKRnv/nOOue/LNRuotLtZbyeZvJRMuQM9TxtHc59M8c0AaoZzJhwnldu2OfT6V5D8SJ01XxTeabqP2l0t4IjZxxBymW5eRguPQrz0BByO/odjcNdSTuI5oLZAR5twdrSEck7D0AHIPSoNHu4byWf7KxkMu+UuMtgbtowe4wMge5xQB5J4V8ear4dto7SOSO+twfLS0u2YTR8gbdx6Dk4B9BivWfDPjew1jbbzhtOvSSvlTOMsQAOGxgnJAx1B7VjeKoPD39vIPEVtHPMlnJMjSJxJ5ZDEBu/4+p9q4/U9PsoLWG/8PJYXekFDNeWKMZJI95X5xz2BBPptHHXIB7ZPfQ2yFrmRIV3EAN/ER6Acn6DmuDil8G6p8QjriTvB4gtlazLNMUjdQrDcU+620OwB/2u9edaFPq89nBpdjJNaW11IXi1N1CxwwgZwhHJz8ueT1A61QTWVjMS29vZXNvbiSRbfZlkHPLg8EN972HegD6PjnVIzJztCl9znjAGetedfCz4s2Pj+/exj0i402T7KbyAyTJIksIfyzypyrBiPlI6ZNYPh/VLi2uoJra3XTbC+Qw4ikaSAPIGCuyn7hDYyCenPT7tf9nXwF/wj8+panfai19eabPc6FBFDGFjSNJg5JIALksSfm6Dj0oA9c8TgP4a1fKgH7HNnOOP3bd+9ee6tpHxOXx5olzPrtnqfhcXcJu7XTIRZSL8wwzBmZmjB2lgJDlQw246+ieI8PoWqfuX/wCPSYFj/uH/AA/lV1HjMaLvjZmUcAjH3R07Y7/jQB5F4HuDpHj6y0TQ9Qs/E3h27ju7uNkgQXGiMSH2SyL1WQuV2sA+cdAvOtc6Hb23x40+7gt51W60ue6uVRz5DXEbJFFLtPy+YI3dQfT8c+kbllAKqTtfaMtk+vNRTMyMFO7ac42jLDGP1oA4r4wSQW+j2d1FrI0fWLdpZ9Oufsf2hWcRsrw7SNpMiNsCE7i2NoJGK1dMvtQvPAFrfanp/wBj1ObSvNuLSKMr5MphJMYU8qf9k5I6HpW/GTEqIZVTjjaAQRjPH50wspYOW2887kG0dvy4/wA8UAeOeFfA+pa14a8AznVtS0C2sNFRZ5dOmMN3cyMQRFIGXAjj25G7dkucADk9X4NhFt8TPGcDTzXPlado6NPO6mSXCXHzuVAG4+wAz2rspAHidSC5B5C9frj2/L61xuhX0Nl8T/iBc3LJHBFp2lPJ5nRVEdwTmgD5P/aaIb43+JCBgf6Ngen+jRV5dXc/G7VG1v4o65qRheFLpopIkdcERmFPL4902n8a4agAr74+N/h7V/EGieGhoFrPczWGuW19KtrPFDMkUaybmRpCF3DIxnuRxwa+B6/UCM5woHXpgdD6/pSZMjhfgh4d1rw14WnstahW2Vr64mt4GZJJlhdsp5sifK0nLZI46V6CABcZ43Fefzpx+8vJ/wAaaSTNlcEY9ffmoM3qQoVGpXJMLK3lJmXPDjLfKPp/Wmanqun6ZbfaNTvbaztydokuZVjUn0yaIxEdWuQEbzDDHvJPGAWxgevWuESG38UfGK/a+jim07wvaJbRRSqGVrq5Xe7ehxGFGO2TTeokj0eN1kVJEYMjAEMpyCPXNSDpyOBXD/CjUWuPCJsDhrjRbubSXXPQQyFE/wDIew1a1DxBrVuLn7HoU1y8U8sYUAjzIwmUkUnggtwR+VCu9h2Ouxk5/l2qsUjNzOFVt5VAzZ6jnH9fzp1jNJNZ273MZjneJWkTBwrEDI59KcpJupgZMgBPk/u9efx/pTKsSZxtzzk8UowffFIRuBB7/hS55oC3Qq6o0i2TmGWOKT5cNJjavzDOc15v+0+MfA3xP/27f+lUVej6mzLYyGO3W4IK/u89fmH/AOv8K84/af5+Bnif/t25/wC3qKmEVqfBmnWzXmoWtshCvNKsYJ7FiB/WvtP4M/BzT/B2NS1dE1DXCf3TMuY7df8AZB/i9z0r448K/wDIz6P/ANfkP/oYr9IdWuZrCznuoLZ7qRFAEKEAuWYL1PAHIJPoDQ5W2KkrnMePvHen+ErYK6vdazcIwsLKFd7zyjgDA5xnr9CK1fCMGsjRILvxJO8uqXVtE89uiAR27hBuVR7nOc/SvL7hfDnwtjtfE1hpupeIfEeuR4tjgvuLYZyP7gZm3Y96xL3w18YNc0a5Ou+JLfSrWV/O+zeeI3CueQzj7qqKz5W9V9+y+VwTXU9b1P4h6LYazN4fs/MvNejiUpYQJkl2AwhxwuM5JPAGab8C7WW1+Gmlpc4N0Zbg3DA5zJ5zhiD3GR19K8gsvEPhfwZar4Z0i8hFxLbzNf8AiRRl2wCcI3ViW+T8K9n8D6xpeheD/Dtlq+p2VpeXFok6wyyiM4k+bAB9N2PwqOZLVsqKb2R2RVyIkMp3pgvgAb+CPwGefwr5U+LXijXLO61zwppQmgivtXa9W+GQ0ELH58Achd2WLccZ9a+sevSvMtUmGn33i/WNY8PLc3NtGvkrEm7z7MEdT0LZRmx6AVpZNaq4m2fO/gHwX4P1XUrU+JNeubRXuXlgtLkhUmtlIBdnPeRumO1X/i/D4O1jxFp8fgPTdQudZj228pt0YQoiBo1PTk7gp3dCO/NfSXhTwfo0Wl2E09pFeyfZkEctxECRHuMijHqC1dTbWFtZiMWdrBDtUR/IgGEGSFHtnt71V3tf8CbGD4ssCnw91iwgAkK6VNAisfvYhK9ffpmvKtQ+D9l4iuLnWIJLu3v9QW2urO9hkwltIyFnOzuNw3Z65k9q9v1NFOm3f2hQ0HkSBlx1Xacj8qj0fjQtPYjDfZozj0+UUloU1dnhF1onxh8R2q+Gryez0vTIx9mn1GI/POi4+fI5O4fTpzXoHg3wboXwx0tBp1healqM24S3ccIkmlwMkE/wrx0rurq2N0I1MksSxusuYzgkg9D7e1MhH2A3k13LFBag5RSQqRqO5PqScn6UtIr3dP68xJO+up5d+1NZRzfBzXpzJKrW5tmVFYhTm4jHI7/eP5V8I19f/tKfFTwxqPgTWvC2l3hvtQuDCDJAMxRlJ0YqW9cIenrXyBThJSWhVrH6U6hNd6cEt9MC3Os3S7EMoKxKRkvKwH3VyScDkkgV84fGDx/4gsLlPCWja7JILdWOp6pE4LXEj5/dhh90KDjA5Hetn4x/EnXob/UvDxJtWntkaZbWcZt8qN0ZcdGOeT2XOOcY4/4U+HE04pLBo0PiPxJIyGKy8wrDaxDkyyN05BAAPOazUeZ6oycrbFnwNHeB9S1bSY0WXStBu2W4jlaR3mEL7Tg9CGbjHqa6K1/tTT/h5o2raRqWqQ3Wv3C6XLY6lcNcpcwzARhxuwQ6liyleoB6ivVvhhoenQ6Td2VwrxaizTQ3Nu4AeMN95Af4lPVT2H41o+F/hP4Q8NazHqemWEjX8EYjgkubmSfyExjCB2IXjjjpT5Yy3HFs7W7jimj2ltjnO2RRypx978MU+2cywI5RkJH3W6iuI8XfFPwh4T1iTR9b1GSC/SJJDFHaySAK3TlVI7frXWaNqdvqemWl7aM8lvcRLLGxRl3Iwypweehp37oq+poCojEpZifvE8Uu9VcA43kZAHcU7bkhhwfp2pD3OU8U3t4b7T9Eso/LudSWZ0ue1u8Sh1cj+L5tv5j1rmvENx4/uJIdD0y3jtp5HYXOt4GwweqL/DIQR9MV6TceWrrK7Kgjz87DoD157dKa3kzWqzCZDFgP5mRgjg5J/Cno9yHfoc54G8K2fhXTymmRs73BEtxczndNOx6lj/IUninxt4d0gRWOp33ktdiWPdEd3klVJbcR91vQdSSBivD/AIk/E7ULq5+16DqU+maXG/k2qhGMt/gktIDjCrvARR1IYt6V5j4Ril17xTeat4qntNOt4pjd3s+/y3Ur82yMDnzCQPujNS7vXZBzJKyNzVPFVzrWzTLewez09nk8pASJ5kaRGbz/AHO3AHUbq1P2vLY2Phr4a2TEFra1uIWx6qlsD+oNdpB4d0XVk0+SxiaHVn2XUe20e3T7IpAlI8zlzhuvUkA461zn7b4OzwSxBDML0lSc4/49+KuKsxUz5Zr7O+AWkXN58HNAddZ1CzgkjuQUg8sBSLmX7pIyD1JP5V8Y19V/B3XtT0n4OaNLH4k0TS7BXuYgblC7oVkkkZSB/EAd2P7rA47jQ1PoHSkkt7NoXluJmBwHmYMecHnPX/8AVU1xLDaQNdXslrDEg+a4lZURTwByeBknpnHSvLILnVdYuJ7OH4gQy3K2SXzw2NiqbYJApR0Y9A2V5yT8wzjgL4d8V9Xv7DXb3Rdf8Sand2p00sIBdF1kn804VwvHQZ544FAHvvibxs+sTXuiaGqrCgc3t3ISTFGCd23HYheD0+bArsfh1bwJ4a8+3UrDdysYkJLFIwSirnn+7nvyT1rz63utO1bUp9F0bRzZafeEAyKCjTJyzMcdEABA3E8/mfXLG3isLKG1tIvKiij2xoo2jA6Y/D9aALvlRNGCyBl24bcuc9uhHtz9a4T4geEBdadG/huytLe8iPKxKIHlQ8kAjHcDr1BPNd1E5bazhxg7ct94cHn/AD6UB8hWRgo6Zx/ntQB4t4esdZ8V36aZrSz21rasfMPktGxUHAVj3Pbpn5ia9Ru/Cmiy20ltNpdr5LnJSKJV59jXL+BrzUp/it8R7W61C6m0+yewS0tnJEUAaJmbYOmc9x17+3oe4llZFxkg4yPz+vagDx7xP4NTw5qVtNZSFtFuX8iTcAzRFhgdOT1OD2IHoK6BfDBsrJ1tfFGo/alw1nLJcHYBxtDjPzAnjJOefSu01uytNU0m4tr6KNoZAPmb7u4dGB68HBBrzNfhrqTWLSvrS/bVjCRID8gIP8TD69v6ZoAur46eHTr3RvF1sljqi27RiRiDHMWU4PHY8DPTn8K9Gt5VktoREN4SNA2GySCueex4rxyPxBBLLaaH47sUZogsEy3cavgk4DoxOdp4z7Z5GDjWfR/DUMI1HTNbvtOiTETy2kjqu0EYRx2ABwOn86APT0DlQfKPXIyCcjGc/jTJ5IYI8ySRxjkncQD04B/SvKJtX8JWS/8AEx8SXF7F5hcGW4lLYJ6AAgAZHX+XeVNU+H+rXQhtpUErFt8tzuOBjJ3bmweDjn07cZAO11PWrKxjmlub60gEeHZvMztz9OvAJxWPb/EPw1t2x6iLkpxthhaRmYjjoMdB7dq599V8AaPGS7WE7Lhvltkdgdv0HPI9D1rE1v4h2WnNE3hGLzHdRuMsQhWMZyQqqOuO59qAOruviA00ZfSvD2r3hIDbQgjwOM5Pb/PTtwbyalL4q8Zav4ijjtBDY6ZMLHdvik3JMsRfPB2nJI6bhx0qmnxc8QTWoSNLNiso3HZ/qxu/u9umQe2OtYesaprXie+8T6kJvsSyaKQEs23faZLVJSpIPIOWH60AeJfE03b+NtQk1Bna5lWGVy7Fj88SMBk+gIFctWz4svEv9YFyl1LdtJa23mSysWYyCCMOCTzw4YfhxxWNQAV+n8QDKBuAbOBxX5gV+nqA+gPHAIzn/JqWTIso5MZb7zDAIHrSJh5WHOMd+/PanRsvQd+RS/8ALf8A4Cf51K3MmUWmW31G6Mkp8qO2WQgk/IATk+n/AOquT+CVrMvgOHVL1GS+1u5m1WYNnI81yUH02BKl+KWpf2foF7BDIovtV8jS7ZAPnLzP5ZI9cKxbH+ya7OCCG2tooII0jt4lVI0UcKo4UD8hTY76HmlnbjT/AIz6zpLtJFY+ILCLVVSJtg8yI+XIhx3bKEkckLjOM16bbw+TEkanIXgYAGB2GBxXnPxpim0uy0jxhYRk3Xh+7WWbb1e0f5Jlx34wfbGak+JXiOe40zSdD8K3StrPiUhLaaM5+z2pGZLj6Beh9TQx2uXvDPxEs9d8ZX2hxWkkcCLI1lelwUvPKYLNtHUbXyPfFdqmftMuQm3C4x179a8w8e6LaeDPDnhrV9Dt2ij8MXUe8R/ee1kOybcT1BzuPuM16bCVNxIybCrKhUrySOefpRawExxkDvQpBzgg/jRjo2ORyOx9KDhfu8A+1O4X0MzXnKWMjS7o7cY3Mn3idy4xyMd8159+066t8DfFAUqcG3Bx2/0qKuq+IPim18OaWFYTXOqXDqlpYWih7i4fOcKvpgHLHgCvKvi/beJG+BHjPVPF9xsvL9rV4dNjOYrCIXMWIwf4nPVm9aOo0fHujRzTavYxWsnl3Dzosb5xtYsMH8DX2d4b+GviSW8tLv4ieKW1ex0/diw85hE4yfmlOAH45we3Bxivjjwy4j8SaU7HCrdxEn23ivu34veOtI8P+CGubqaRbq+gYWMCgF2dkbYzIT9zOM59cUTklui2c94h8enUpNS8PeFZl023gtCLPV2O2Eyx482JT2IjPB9RXhmpeIrbxL4n0y+udL1PxNqXkGO600SOsRkQBY2yM5BADMAAMk1z/hPwb4l+IWuW9rAlx5MzmWW4nUrFGG+YuO3OSQB1r6Nt/hVceEdNsdJ8G6wdKubxlN/qmwvPOBxtUdEUdRjrSVO25F77HmFv8LdVsLvS9Y8Y6Tb2OkX19GJ4YJcNaCSXaIyvYbSPp3r3PVLrwho2q+JrPxS+nLp1rp1pEEvSrNIgWYkLu5Zj7ZOfequs+FbvTvAU+n/2leay/wDpLvPeSFpLieSMpFGFPH3ioGehwa6PSfAvh3WrDTNU8Q+H9NvNWNpBHNJcxLKyuiAFcnPQ7hTb1utAsiD4Ef2kfg34Z+3NIbwwkhrgkt5XmsUz3/1e3H4V1XiDR4dVlt/tBnCKGT91IRwxUnI6EYXGfQn1rVTZEEijj2qF+VUGAAMce3WvG/itaa4/xO0pdNsr3VbG80mZTYR6zLYoZI5FzIdh7K4Hod3tStpZGl77nsyxxrtKIo2jC4HQegpwOQDyKzPDOmQ6PoNjYW0LQRwxKoiaZpih6kb25bknk1p5BJHcUgG4WSIhhvUgqQR17GvL18L+KND1LWdS0zUbfWLS+nWVNJuQQkaK6bdjE43BF2+hIU+teojrUEHMIZnWRGJKFV4Ck5H6YoVuoHjWp/tAaFY6ZeLPaXcfiC2BQ6bJGynzQ2GTdjAxzz7V5lJ4f+Inxq1l9XulfSdDlxGkUsrLAqKcj5P4znndjrX0FrHhXwVZXj6zqmlaRFdyTGU3Vwg+aUjOST34z0968u8V/GDwncaha3aa5rMy2DbTY6dmCO7cFSHZ8htg5AHsSalOMX3/AK8he91Mf4o/CPw/4G+BniC5gja81dBbE3k3VCbiNSEHYEEivk6vo/4seNPFXi74XX19Y6Y1j4NlmEMoZvOkZlmRlLO2WwWKgY4yuK+cK1TbV2gVuh9TeAfBd54o1sTvDJpWi36MJgrZaWPflkRiS20lAC55PPrX0zouk6XomnJY6PaQWdrHgCOFQOfU9yfc1NbwWlksENvAEWNPKQ45Vcj5cnnH+FUvFmuw+HtMF5Lbz3Tl1SO3gTc8jE9B9OvPpUXtsRGNtySCNkvo/wC0nSSdpHa2dEK4GD8p564/lWoQCrcgepHasO31DTtTvQ0fly3+ny+TLGHIa3Z0GQR34ZR6c1uOwUDgkEgVKLR49r3gy517406i41jxBpNqdFtmEumTmDznEsq7WfaQduM7evzZ6Yr16JTb28ce6SXYgG9uWbAxk+prnPFev3WjpZSWVvHcIbkfalJ2lLUcSSg+qsycfWt+AyyEszqUBIwtNu72En0uWAB19fWvL9X+MvhnT7i7VrbWXs7Od7W6vYrCRre3lVipVpMYzkZ+hFelkSZG04weQeAa8RF54h8DDxL4Y0nwxqesX+q3099pV4iI9oBNjPnsSNuxs8Y5GOmc0NJ/8D/gkyZ6X478Q2fh7wVea/LaG/tohHIIVYAyBnUAjIxxuzj2rwfxN8QdW+JWkJoelaVPo1iHM+ozJcBhJAgyyZAAC9M888Dua9I+OMdpY/DOzfXgXnjngUpbD78uDuCDjA4Yj6CvCfEAvLLSorDRdJ1Kwt9QY26R3Eo868AY/MVCghBkZXoSUHQEUrEylZ2RhWdvca1qmlx2El1d6/qcssbS5ziMt+7dBxs+UcegGRivpTwJ8GNH8O6rHqV0/wDaF1FhlMq8CUDl/c5ziqfwW+FUHhpLbWtfVrnxFIuQz/8ALBcYUADjIHHTjtXsRG7rk4P0qr2CML6szNY08ahYPHMfLYHKSKeV5H+GPcda+af24WLL4JLDDf6aD9f9H6V9Mx6jZah5kFsftCLvR2QHarLgFSfX/Cvl/wDbSmFxpvw+nV0kEsV3JvQEK2RbnIB5wc55oi7s1SsfL9eqfD7wD4x1jR9NvrGASeHpZXmXzbuNYixJgfKE8E4IJI5UfgfK6+of2efGtw3hzRvC76GstpGZh9s3kglpHcblxjqSvXofUgVoMwPD3w78TaY13DqGoPcX88K2drBbXKSlrdMFQzZ4jBwNvH3enQjq9J+EGrmOK7kOm2l1Hho/PQSGP+8OQRnGCGHPQ16P4j8QR+Fp4ZBpUlxaMFD3UGB5ZJAGeOBnP/6iKpWPxHtZtUtRdRzWWmXCNChuLUlXcdC0gPyjJHGPTpQB1Phu2/s65ltI9LnibCn7ezB/PcrkkMfmABBABrqVmPlgErkKenILdf8AP1rAhuJTqG5tQkNszMoiACrnkkPkE+wIwMeuCa0L3UltIy628txLyVVOCfr6D3PrQBpoy4IYqDncqk5yMA88fy/LNPUsdrySYRj1zg9MgHHX/wDVXDSeJvEbL5ljotjDGcoFvL4JIjf3WQZ+Y9QBWcfiI1rZiDxlpD2N+5wiqcRykHA2knI/hHU8n8KAO4tNPsLXU9S1CyhtxqWoiI3ciH5pvLG1CwyegOOPzrQM7BQWG0kg5JyMn8P8/qPDtI8UtdXN1DYWuk6VMvzC+DtDGkO7ndIWP3sqMDuc16rp1q8EcF2dblmh8rO2SVHgx652hv8Ax7HH1oA276CK9tZYblBLBKMFSflYdev5f56Q2sVvp9vDbwRiKPGFjXgKOvb/AOt/j5ZqHjPWZdk2ha5ot7tlwsVuB5kqkcEh2H3TkcYxjr1q/cSeLL7S5Tqms2GmtJhPs8cfzAfUEkZ4GPyoAwvif420Ca4uLV9KTUZLHcr3LZRUwNzqD/EQFPBPXjvXF+FtD1rXfDIutDsdYtJXys9rKTGsoPZc8OuCOenPavYbP4f6BFpZgvraK5aeExyzytyxI5wOi8dO4z9CZrK80LwL4cXTTq11NFZK0pe5na5lO4/L1z+AAA/OgDxW38GatevJ5Om3siw/LIZZViAIJyCce3Y+hrWf4V6pcMXWGCzK5Yu9xuIX1Ax6YyO5rcv/AImS3ypDpdreW8hLRqsluSGcjIYsM/LjPGO35TJdeMPEmnIbPUbS204ycX+1opJxnk9PXpgDPFAHNH4ZX1gsj6pOsy4UCOCGRt25cbc5Hv8A4V2/h74faJBp4e9s/PeVM5ZnXcuOPlB479TkZ5p9rF4qjkhsIdYiaJWbzbg2jOQf4SzMeT0AI/GmTQ+JreV4tQ8UQWkSHKyG2UOw2noP6UAXG+G3hmS5lRLFbckBG24xg8gkdc/0J68GuN1TRLBLqO00G5vdJ1S2bIiuG2B933GRwOjfd4z1wRg5q5ca3caFqbWkni+2m1F4QwW9tlCHC/dyuSDye1Szav8A2lDo+tSm2uJ4HWAxNJLtycNgKUJyNuQc9Rg0AfLnxdgurb4harBqEdvHdxiFJVt0VUDCFAcBQB9cAc5rjq6z4rXUV98QtauoFZY5pQ4DZBGUXrnnP1rk6ACv0+QAjGeo79vavzBr9OrZmkO2RWTBK/XHQj2PWpZMiyEBXgkkdfr9a5/x9r114X8I6prdtbLeXFpCpjtzkb2Lhccc9+3WukU7SikY7AgcUz5ZZcMocDsR6Hj8qkzPBPBHjK31rxNouo/EaLVYtVlm2abFLYGGws5G+VcMeXkOcBm6Z4xXtWsLd3l3a22mXgt2hk33RGCRGUfbxjqXC8egqt4u0geIdK1bTpkidZbX9w275kmHKMPQhtpBrL8CeLtO1D4bw+J7t0tkEMk+on/nnMmRLkdRyOB6ECjQN0aWhWWqtY3Np4lnt7zz35AQbDCY1UoRjnLbs56/jTvD/hDw94buZJ9H0yK1nkQRGUMzsIx0RSxJVR/dGBXNeFLPxb4l0iLWNb8Q3Wjfbf39tp+n28P7iFuUDs6sWbbgnoATUXiLV/EPgDULG/1bUm1rwlLIILyaa3RLixLcLIWQAMmeDkcU9egeR32sada6xpF3pl9GJLS7haGRD0KsMV5h4D+ImkeHfDH9neN9Yt7HWNHdtNnWfIeXyydjhQMkFCpH41va34h13U/E/wDwjvgpLYCBFm1DWLtTLDbBxuSONQRvkKkNjOACPWoL/wCFWh69qq3vjCS516+ijCiWcrCmCTkBIgvHA+8TQthrQ5XVf2grG6l+xeA9C1LXr9jtU+UUQHtwOSPyqHT9L+MfjSXzNa1eLwjprciK0Qed9OPm4HcmvX9G0XSfDloINH0+1sbcAKfIjAJ54yep69/WtfAzzninpcHLseSw/CHw3ocEuqahPqmq6oMBr67uZGk5YA4CsOucVm/tAeHLDQfgr4sOmG7ihkW1UwSXMksYIuovmUOTg/SvXtacRabK7zm3A25kC7sfMO3v0/GvOv2nf+SH+Jxxj/Rsf+BUVLS4RbPgy1eSO6heAsJldShXqGB4x71758MPBuu/F/xO2ueM7u7l0+zIWaVxtaUrjEKDjaMdSPfua8S8K/8AI0aP/wBfkP8A6GK/RLxDq+keCfDd3qd4YrWxg3PtjUAyyMWbaAOrMc1TaXqaNX0NawsraxtYLa0hjghhjWONI+AqqMAD2AFStc26X0VnI3+kyIZFXqdo6msbSU1h9HFzez2q3kqiXAhI+zg7TsIz820bxnvxWvo+l2unwRrblpNqkLLK5eQqTnljzgnnHSs9bgkgvN1rmd4w9sgMsuF3OSBkEDuai0GCG0RoLEo1uXlmYhskGR/MGPUHexrW7EAcVzdlqs0WprbG2iADNbSJF1SQBHRB6/uXLf8AASB2pjsdITjGQcGs+40fT5dcttYktlbU4IXt4p8nKxsQWX06qOtXYfN+bzdmdx27c/dzxn3qtaXkV/G8lnKsiRyvCxHHzKSrD6ggii4WLanIBI7Zz71Dd3SWlpLcTfcRGkPbgAk/oK5nRfGml614s1TRdPuhLcabtWQJjazEfMM98dOO9dTPHHcQPDMAySKUZc9QRgj8s0kM8o8Kn4lappuk+KG1nTJYtQMVw+iG3CxxW0hB+WX729VOeeDjFZfiP4lP4V8Z3+j6pfG00K9tplsL1o9xtZlLISfUeYHwOwVa0Lf4b+KLbTbfw6PF0cfgy1lG2OK323phV94iMwOByAMgdK7jWfCuiazbTw6np9vfIZPN2TruCNkk4xgjJZjj1JpJK+pN2fKRsviL8V4YpdW1Epo0Y8uG7kURw3DocBVQY3Oxz+tet/CH4GW2m20moePre11DUXHlxWhAaK3TtwOC38vrXpsnhTR1vtNv5YyqaW7zWkBfZBbu/wB59o6nk4z0zxWP44+JPh/wrq0elaze3Fu9zCW3wIG2ZyASexyOB7iqvbYVr6yMD9o3SrXS/gT4pSyiMEO2zjSFW/dxqtzEAEXovU59a+Ea+v8A4oeKL7xT+z94iuINNurLQLeG1ghm1Bibm6cXMAD+mMBsk9Sa+QKqLutSttj9Q9QuRCsLMsas0iq+852qc+nU8cD1rPhj1KbWJ7iebbpahfs8HlgPu2/MzE+/QCs3RFk/tK61/WQ9t50XyLK5CQxByIwRnaG2kE47sfUV1UIWSLesxkSQBlbj9MCs73J3PO/HmoS6Kmv31jawwyz6TLLFd527p40ZgvueM/hXR+D/ABNF4j8JadqsqpD9qhRmJcBRIeCo9wwIx9K1Nf0ez1rSbmwvIkkSdCuSOhx1r5K8M2114f1S90UXsMNrd37WV7LJIyrDPFIV81Rn5VdS2DjhyOcDFDX2hNtH0Zo+raf4l17VmshG62TnTLhJPmEg+fcijpg4DE98Y7VFrni5vA3hCOfUbDU702sps41tk8x5Qv3ZG9ARjk/1rO8G+F5fCvwwtm8O2bXGpy+VqDRyEq0zEJuU7jkEx7gATwTWhY6/4h1vxXaw6Zo8cHh9Cw1C4vUO5iMqY0A6uGHJ5GKEmGzKem/EfUIZID4m8M3un2stu91LcofMigjBO0N3yQOa9EtWgvLSKeA5imRZIyOPlIBH0rM1DTJp1nEU80cJABjbDh8Z+XByNp6EcfWuZm1e9u/BVpDY7dP1u/lGnQoMkRMCd7AdwqBm/ACi1hXfU4Px9baz4z8VWlvperXK2keqNDFCEAijCROruGxy2Vk/77AHOa6nw18NNL0DxNHewy3F7qQhTddXrmZlTPzFQejHaB+JNdh4a8KWmhyQx2yk20Fssah2LFpCxLvz3PHP1roUt40kLYy7dz7dP507XBQ1uyQsAdzEAEcc9qytHuY9XVNUs55TbSKUiU5C4D/MdvQk44PpVXx1PNDoZitAnnXMiW+WONiMwDt+Az+OK2bCNI7OGOBAsCoBGAc/Ljijdl9bFTWJTp2iXk8FuJY4kLmGP5SVH3sY74yR718h/tVanDe6b4Otkn3TWz3ytAQA0CEwhFOP90/ka+ynRJVeOXayngr7H1r4o/a10KPRvGdk8Ujy/akeQu7AngINpAHGP1zVLV3Fszwmvuv9mvWI7L4K+GIZUCrtumMsjhF/4+peAT1PPSvhSvpXTvDS6t+yfFcafpct9rXlMkXkxmWUJ/aOWCqMnGAxOB/Dk9Kso+pbTxBbXbT+Qu9In279wwfpTF16VoDIdMuEw5Xa7qDgdG69CeB3+lcD4E8LyeFNBlhupdPjdbuS5D6da/ZIZIzGFQSJk7jwT1xuIGTtrs7WS3vIJJIJo5fLbZL5Uofy3GQQfQj3oAtabrt1dLIZ9IntWSQpteVCW5IDAA5wcenf61bOqHei+RtBGW3Mcj6YBzWG+8eWklw0U7klG2K2NpyTk8Y9Dx69+bdtFcRJ++nW4G3BYjGCCecD2oA2I77e5XyyuM53HGB609LsOuURicZC9z7CqMKeYvmAow3blIH3RgY+vIqYhW5bhc8bz/j74H1oAlS8drdpDbSrKASIiRkkds5xTzdBUy6bTtB+8MZ7gHvTSPkViCB/tHGOc81UOd7Z3Eu4JywUqvHtyOuPrQBdjuhIgYIy5zgMCD+VHnzBxuji2nGSJCSfoNvNQJuIaQ5C4JIB9On6f57VK2G+6wGMdxx/nn8qAJ0lDJuwR7Y5H1pGlwMhCw7Y71CiKgULgAg4HpUjnCqAehAGM4+hoAUXAK5CtyOMjg0ediMMy4YnG0HPNV4t0NozXWwlQzFlJHy/59Ko2E6ukUaTC4kYeaDI5jcIzfLleWHpzjke9AE9zq0kEzqNPuZI0j3+YhXDNz8g5yTwPbkc1d+1DaG2kAjJzwR+BqsY9zo4EmFYkAnHPPYd/wCn45hlt5hlkuCmXUuOCuBjIAx0wCPxPtQBj+KPG0XhuztbzUNPuWtZJjDLLEQwhOcKT7MSBn356GgeO9PkitZ7YCW1uo/NhkV8lgG2kFACwbOQBjk9xWlfWFtqcUlreW1vPah0YxygsCVwwzn0IGPTis7w74atNAdmtMQi4LM8UUSRK7k/fKgdQDj0x7mgD4p/aYma4+NviOV4ZYC4tj5cuNy/6NF1wSP1ry+vUP2mcD43eIwM4H2Ydc9LaKvL6ACv08CiRdhJG8YJHGK/MOv0+jjYqAGQZXkkH6UmTIsogEYjdt2PUYzQeLgHOPlpoYrIy5GBgmnkjdkA56VmZFQbf7XdyE+aAAEt8x+b09PevOtb+ENtf3mpRw67qVn4f1K7F/e6TCqCKSUYJIbqoJAJA749BXpSCMztcBGEhUR5J6jOallBaGRUPJUgHPtVXDYII1jjjCqqgKFGOw9B7VHqNjb6jZTWd7Ek1rOpjlidQVdSMEEHtUkZJztH1J7nFP3HI479u1LYGYvg7wtpfhDQ00rRYnS1WRpT5r73ZmPJLHk8YH0ArVRcXMzFRgqvPXOM9vaps1GI8SvIvDMApyM8DOP50XAftXBJHU5+v+cU8E9en160zqTkcHikZiOABk9M0JgZ/iOSRNGuTbxrLNtBVWUsAcjkjqcdcd8V51+0pu/4UN4iEj75NtrufZs3n7TDk7e30r0jUreK60+WGdWMLAM2GwTg5/pXk/7TOrRSfCHXLVo3WSeO3kjOflIFzET9aZS00PijRrpbHWLG7dSywTxykDqQrA/0r7J8C2l78Wxa+JPF8fkaFYTBbDSoySJ5Rj99Mf4uCBxgdenf430J4Y9b097rH2dbiMyZ6bdwz+lfoz4KOnx6NZw6HbzR6U1sk1tIynDI2SBz7EY9vpRI06nQgcjjOeMetVbG9N5dO1vJbyWMe6Ilcl/OViDz0wB+teceN/HUl54otvA3hRnl1e6lEd9coMrawEZfB/vYJ57HHeus8O6TbeDPC66dZzJN9ljwizyhfNlOWG5ieCzEnn1qLjNq43afNd3q/ablZWTdHnKxhRj5B7nk+9c/4LuRH4n8X6ZvLpaXkc3mOuCWlj3ke+BgZ9AK8E8VeOfEsMNnqz+MnKTebHqNjYW4f7L5cjHK8/cOVj3HGevStzxh41s9N8X2WqanfSx2muabbyyLYcrCDNnLnu3kblJ9e3NCYmz6O89EUF2VUGBuZuOTgfnx+def/FbXYPAvgXUDpqf8TC7Mptot2C8jsC7Z7Y3k1W+H3ijw7460SxsodSa9msym6GTMcsphZSsjLnpuUGvJvjpql5478S6HougyG6W1nNstxEuFkuX5bb7Ku3NCdwb0MvR7GL4fz2/izwvqF1qk8NrFe6hDND5cM1rM20mN8nJDcHjg817p8OPiv4f8ZRWcVvMsGpzhle1JAKsqruIz/DknB9qva1YRL4Gm0Wzt7VLuKx8pbeaEfvFUchR6Fhke9fPvjzwFp/gjRfDHiHRIb6K7vL0Mv7zKxxH5o1JHQ7f1OO1O2mm4XsfU2v6xa6Hot/q125FpZwtNJj+IAZwvqTwB7mquhK82mafdPMdkltGWGeCxUHcT68gV4J8cIfGtpol8up63aW3hrUr6OOz08QlpVHytHGxH3QNhz15Q+taw+KXhrRr2bw54pTUkWxEdmZFXMR+zvhJAQc5fqRj+Gk21uFzpNV8SeJ/GWu6joHgyC1ttE+ygtrtzGzAlsg+UMgNyMZ5xjNT+Bvg1oPh25g1HVpJdc1pRlrq7Ysm/1VD+XOa6zw5rFld+ErC98M2clxp0kKG1iQBAF3bdvPQjBJ+lb97cfYrSe4ZGkSIbtqjlsdh7mqTS2C2tzzb9pxAnwH8SqqhVH2UAAYH/AB8xdBXwLX238bvsifs6+JTY3kt7FJdKTO5J3v8AbU3AeykFR/u18SVUXdDP0X1TxRo8Ot6bodz9ov5J7eS7IhTeojiXcC6+u4EADnI5rpLfVIZZrWCYpb3cil0t2cFtuPTr0I/lXjHiq2m0HUTf+H7xrLUra2i01JZbdZYbUnafKTOBJM5GT2X5iTxzm+DPGWjeG/EEdo9/LrWv3MoN7cwuu0KSA3mzuQW28naMKCOuOayd0ZpnuFzeWtrr86zr5DfZxIX3n98N2MAeoJA655rxz4p+D9Lt/GWn2tjNe2l1rsnlviFGgldn3AseCPmUA4yfnU/XrviFrj6vaSrplmtzFptxFLcRHl7q3bo0JU8AsNuT0xn3rN+IGvQzWVvdyW87JpV1p+oWlw74dkkkBJzjpnKtnptGc5ov2B2Z7CkG3CjAjA27R6emKbNjB2ndgglc81GJCA6KQDkgYPU+mfWo4byGXfIqnCMUyTnmndDJ4hKULtyW7En1rnU8PyjxVBqkdy7W8IlZISAQHfg8+mOw9BWq15JvMbIdo+8AecVbD+WhCqFHRQTR0DTclkKAoGZQR83PB47j/PehBtbmUkMxwM/p/n0qq7yOIi5GA45xz7VzfxB8Rnw54YvdQRJJLlQkNqA2N00jBEHuAzAn2BoDm6nGS+LLHWvjJcWt2txNa6f/AMS20jTIikmJ/fs56ZXgD/d9a9aWfMkMUskKygbiiHJP0Hp7183+AIHsDfTzXLSafp0Dsl3k+bPMZSZAAeQSWdefXuBXe6hqEES6hea4Tpupajaw28F3BdZLRlshY1HK9ee5wSewpXtqSpHeeLL+zje0sNSWeBL2RVt71R8kdwDmNSRypyBjPB6V8wfte3MWpWfgvUhEIbyb7bFdRZyYpY/IVk/A5x7HPeveLrTdbg01Wa5ebTGhdZreUtcfJhQHQsFYPjcw7cV4B+1dai20vwczMpuJ5Lya4VW3BJTFaBgDk+mfbNVHctas+d6+yv2eZ7m6+Fmg23mWkVnaxzOwkUO8hNzMW68IoUKAeuSSeAA3xrX3H+zdGr/Bfw8dinatwScHr9qlGDjrx/TvitSj0O4t2Fs4hjJaN/MEe0IkrjO3cew3AHI7j8+evNLnuXtlgXUtBEEyzTwWiwyR3DCRTuLDBJyBuJx8pIwc108N3bSXklnG8T3UcYldQ4LBGPysyg8A8/0zVvGFJ2kjcQfy7fgKAOW8W6s+iaI18izSTRzxzQQFyrSkurNGR6bC4APA46nAHU6TeW2rWFve2Evm2tzCs0Dj5SUYAqcdQcHvXk3xFt7nxB4stdMtJtZltNHCzXR0+INmWdjkPI33QkXO0ZJ3cA9u8+HJEfhyxihK+XEgQKoGCcnOPbJxj1HagDp0B+VWXtyBnJPbrViMKcAKFJGeDkHvx7VFkJgMmAPm2gjt2/x/pUsT5JDDDjhun5/yNAAwwOAA4+8fbmoVzI2SXBCnP93P8+3T61PLvIOQTg5APAI71EMqgWRmzjJOcEH09hz7/wCIA5mPJiAycY3cde/+e9JAsnlqWbzGY8HG0Y9xk8+9MVkSN/PUBUDOT3PqQPSp4ShjSSPDbhuBHORjjFADlGeAcnHQ9fpThnaeVMnfjn270iKCVIxtPI9we/505eRlBgemMH/61ACHBTgkgcZAHWo9kUJeRkQSPwzYwW9Bn8aWTiQbCVcjA9MY64+tRyylYZWRGlbadqBQGbt1bAoAa0ipJHwrFjsBUckgZxx+P5UyW1gKtGqgZw2FbaSOTnj1PfvzSyLcvNF5XkRRiTD7lJYx7STj0O7GM9gapWUHk3l2rWrRIojC3rsrSXO7JIbHIwSAAfw4oAtRSxzSSeUpDpIUY8qCcZx78Y56eh9Jdg3K+cjAwVxz/jXM6drcFx43vrL7QY44o/IiiY4WVly7sg7EA4P0FdPAVUbclmyec9u3SgD4J/aZ3f8AC7vEe8AN/o2QOg/0aKvL69T/AGnv+S5eJen/AC7dsf8ALtFXllABX6eIcYYfKQO56mvzDr9OduDuHcY6+5qZEyJA7F/lwMnoOM1KpDAMzEhiM8cVAjDOeRgkU9QVBx8wySAP6UiLD4QVYcgrztA5wKnTaVKrgqBgimnPlYOBkY5601EVocKc55znr0/+tSEKg3hGx8wHDVMByahRCgA3E5HQfrinq25mUYwODQDH9KQ53DHTvzUUgXZtPXpxT1DYBJG/jPp70hD8ZIqGVCWJJOMcYHSphyaQgcexoTsCKtwWFtMpX+BjwPavCP2mbWab4X3FzCCY4liab5uAGkiA4/3sV71coTby8nlWP04rxr9p6Bk+EerSxNIEYW3mKIyyn97FjkcL+PU1aKW58Y+H3ji17TZJwDClzEzgjPyhhnjvX3t8SfGEfgHwx9qigcSSlbSytkQFAVPTA6ZQnHX7o47V8D6HMLbWtPnZN4iuI3K5+9hgcV9WWB17xp44gu9ZsntdPgT7TbW10MMIZNsZm4z84VDhOuXB6ClJMtsn0BrH4R6BqGv+Jb0XPiXXjl/KBKp84MkWezjcc9BnFeceJfFmq/EzxPe6H4dglZNSvxcw/azs+RE2orY42gdDk81J41g1T4seJ7l9B0W5DQFGCpIAFWQHa2Dx+8Kl89hXVa54Ik1jwLY+G/Dd7ZJ4l0OX7Bcb1KGeRcyMEcDqGY8egyam3Viuec+B5dY8LX154ilgjutDs7lbLXLa1RSqx7tvluCMMDg4IyM9SM1o6boltrfhuO71KaSHw9Y3k1iJipea1SRVkgkIGcrtXY3XG7jJr0yLw7Y6NoKXlz4iicXxXT9QFrGrwpJJG4KyeoMrElhyDg1zvwPOjT3/AIi0uNLq40HUtNSKTKld8krrCPLXHA3u65PT1wKLp6guxzsWgXHhy9i8R+G21fR7K/VINOurnYwZpVKuGKnIXLLtbGeOnFek/CfwpF4Us7TxRqjy3F3bCUXse12MSPGpRo0xksTyT1+fHFQ/ENB4RtLUapYY8EXRa9sobdjI9peBA0ZZugXcq4GcfO3pXsOj+K7bUtIjOli31HWRbxTT2Uciq+SF3An7oIz60rpWXcLHmHjX4lQ+NorbTfBUl9mOUNeXMlvsEKsMBck5B6k/QiuBvtU+IL6ZJq/jhZY9D1UL5DTRAmKZAzxbYl5QkrtyfUZ7V9D3mpeFdTl1Dw8t7a2t+wEV1DAu2SNuDgsBjIyO/eq/j6zh125t9JvleSwv4nEDKcqLuMiSMhh935Ufk8dBTTiwsz5u1/4qDx5qugx+KQtpo9k8UgEQ3/aJ8xq7SdgpXzcY6A96wU8R6rB4s1HxGPDbahod9dSXJhubVmjdXL4XdggdQfXKjFdRZ/BrXzfMostJ1OCx82Fbd5SgxiXbubA5Ekh+XOThO1e4+FfEnhXw14OstPu9Sght9OB06aeVfkeeKNXfBGQcg5Hr26U21HcNzkPDnxF0fQ7LSro2moaW1ypig0eLBtYp7hzIjuThlyrKw7KDjrXHaxf3eqa7qSWPjF1i8P2oleIytP8AbrpSzyCIcbwGYKMZ4UVq/FS7074g+I5PDvhm383Xd0YtrtMLbErnczv7Rlccegry/WfCHiVNUj8H+HdPkur7QkaWS4hG0mU8zOrnGV5RQOvyihR5ttQuzW8c/FJpfh3qvgX+yHtbMW9qIHmf9/5nmRzSO4zjDNvI9AV9TXhNek6z8PtStfBOp6xNqMbDTXj+32rRsGimZkRUDH72FcknoCMcnp5tVRVik7n1B8fviEde8QPoOmyJcw6bcF0ayJZZCy45J43LhuR0LcZxXO+HPhpquq6fZT3EEgivYmuDsIXMfO0yucAAkA4GTjk4rp9B0rQ9B8RWlh51heanNLGbqEvthiheJsFSODkOwyT1C+or1S38YeDdH1W1ibxDZbr/APdwQlS6RxZ2IikcIc9j1rLnSMdz5k8AXuv+FfGp/suVpr4n7LbyTPmNS54R+23OPbOOle7/ABIvjqeg6fPZQRbEtjDdW8SlleCc5SSM90zEWHowWuY+L9homl3N7qdtHANPfYJI1Lb5d24SPFjgFcZxkEEV1mp6fO/guzm1BxLNaxPY2U8DBUuLd48xb0HHGIj16kgdaNL6Du2tTjfEeq/ErwZodrqWn+JrHU9GkjBhbb5g28LliV5PA985qG18dfF2+jkg0Pw9Z2xkctJItqZMEnPUkjk5NQeA/iX4S0Rp49Vg1m30e6UrLYyxpc2nXlhg7lOfarnij4kQw+HYtF8FambLTJNzm7vLpBMyHJEcYUkqMd2wccUKy3QXOm0sfF2WFGOpyG5STZJ/osXlrnqNvXjIr0XS9V8R3CxfaNOtZtTsj5Op2kE4QhiAUkjJ4KsOcH1I6g1842HxP8Q2+lQ6YnjHS7PT0XaHjEnnLz/fKZP16mu98J3OtatpdnqfhjUkGrIyJ57Sb0lDMQ0cp67G2h0JA7jgkilddENM9qtdR1S4N6NR0GS2t4ZFECCeOR5+eXODhR0xz6+leffHnXLGzOj214wxFL/aUkOMs3lhhGAOcguW/BGPasPUJ/iMb+OHxJPFNEkkSyxaWxGyNyfmdVBLHK5GP7gB4JrK8XTR6rrmgtpOjSSyQMIvL1LKTSmNgBuHUId2zP8A00c9qqzE3fRHQ6fAfDXw6tr/AFe8s7fWL1RcssisUMgKsM7VJ4VQuB1LH1riLrUIbfTIdNtLOa1uGklvTqc6k5aQn544j90AEqmSMdQO9db4tuZbbxTHPr80dwNMtxHbWlou/wDflSdxHA5kA64wAfSszVNS0DW9AWOdLg615RZNqnYXByWkJx0yRjp6ZpEvU4zwt4vvfBmvJcTX99caVE5Nxbl93nR7eSqkkcfe7fpWb+01rGla3YeGrvRZxJDJd6hI6L91WP2fkH3xn65qaLTdKuo7mO7jZtR8mSaF4nDpt2kFHUHHQg8cjHQ1578QFlt/Dfh2yZLdYYZLpozGCDhvKyD7ZGR/vGnFWasXBtvU4OvuP9m5yvwX8Ok9B9pCnOP+XiUnPI+n4/iPhyvuX9m1S3wX8OfdUH7QoZzwD9pl/wAf0rY1PT4fLEnIHmEDJ4z7E8c//X/ClU8vndwVwpPB/L61E0mRIygGMEgHpgntz/noKhkuI7RbiWWUhlBlK7t21Quchu3Q5/D3yAS6faxwae+1BIZHaWRWwQ7M2705yCB34HtWFoF1JY+M9U0oRWywTbLtAJMOodTnA74dGyR6j1roLFjNYQeWWw0KlscE5H8//rfjyHjqC4i8ZeDNZtIpBHbXclvdlRhmilG1VbttDlSf0z0oA9FTgkLwpPBxzznr+Yp/3R0LHOeT/X8f0qJmwxC9MjkHBPX/AOtSbsp8zZb0HH6/560ASSkkfKgwSp+b68j8v6UySMNJEVfARssMH5xg4H54P5fjJI+DgMhAHI74I6/59/wjTd5YVvmY9ATgnrgfp/OgDF1RNS/tyxezLNbpCxnB4Gdy7V+pGSf933rchU7AM52nAO0jr/8ArA/zxWQuBE1sIfIIfexyHIGMY/DPX2qa1YBPLaQtIDnB5wD0/r/nFAFocJn15PHWnZAxkcnsKaCWBO75lyCopkjhJl3HIVcng5+vp/8AroAeOccjOO9IR85Y9ByCOPqKbuBn5DA7RjB9T6UsYY7mZgATxjt+dADbiZbe3aWV/kjGWwuc/QCqmr3SW+nTTkHaEJUCMsxJ6ADucnpV2TPKocE55xjH+eahnhV2g+TcA4cc5xgEg5oA8nn0G/0HV9M1rWdXMNp5ixeTFEAtq7IwL7v9tsbiehxzgYr1W1MZt4dkgcOoKyA5DA9G/WqesadHqWl3FhIqkzIRuHGGxkEehBAI/PtmoPCV3JeeHrOe4T/SRHsuFHXzFyG/Hv8AjQB8P/tNjHxw8SDBXAtuD1H+ixV5dXqX7ToI+OHiMNjIFrnHT/j1iry2gAr9OVJLAEHGBkjk5/zj86/Mavc1/aa8aAqTp+gNtGObeb8/9b17UmmS1c+x8ZXOSc9u1WI5FKDDFh1yOhr41H7T/jQEH+zPDuR/07zf/Haaf2nfGhA/4lvh/j0gm/8AjtTysXKfZwZdwBXdjoeOM/8A66agJYL9w4/h5x7fy/SvjVv2oPGrddN8Pf8AgPN/8dpv/DT3jPj/AIlvh7jp/o83H/kWjlYcp9n8RthVBwvc89aeT0I6Z7d6+MB+1F41BJ/s3w9zwf3E/wD8epR+1H42AwNN8O4/695v/jtFmHKfZ5wTuUgkcDn9KXk7T09RXxcP2ovGoOf7M8O59fs83/x2kP7UHjQ9dN8PH6wT8f8AkalysXIz7QO1QpweTxj1NNeRcZBzgjpzmvjMftR+Ns5Om+HT9beb/wCO0n/DUXjX/oGeHf8AwHm/+O01FjUD7MZiynk5AI+XpXh37UF3br8MNRt2Dm4dYNu2cIAPNQ5ZCct0OMA469BmvIh+0/40HTTPDv8A4Dzf/Ha5Xxz8Z/EPjPQZdJ1Wx0ZIJAqmSC3YSABw4wzOccjt2ppMOU4HQkil1vT47kgQPcRrIScfKWGee3FfS/iD4m6haR6pJDOLXV7i6i1FbZ0yA8ZdJLXf0wqJbv7kkd6+XIX8uVH2q21gdrdD7Gu48W/E3V/FV3Bc6pY6UJIEeOIQwMgQOhU/xcnndk5OQPpRKNynfoe4+FIrMRQWviTWB4cXSSIRLGzRyarZHKCQ99oZhtb0BrSfw9cXnxL+32119ntb2MXMF0lyDGrtCPMnjx97CApn3r5n8UeNdY8TBP7VkidkjjhRlTBWNAQqDn7oyT7966XTPjH4i0/wvNocVrpbwSwyW5uJIpDMsb5+VWDgADOBgfnUcjJ5WfQvw5fQfDsdtp0drZzrrd6rQWsk6syW/mOBMcnBGFVgRyd1aviu78P+HfFWgpp8kFlGZJLTVLVMeYsLEOoKjkKGJfPUcetfJV54+1G60uKzNnp8TwMrQXUaSCaHasSgK2/AH7pTjHVm9al8RfEbV9fltp76CyW8g2AXUSyLI4VSuGO/BBGAeM/KOnOXyy2uNKx9O614t07XPH3iHw/eraal4XWzS1uvs8mVSNd7ZA6B4zvJI/hA9K4zwaPFHg3+yr7wRo/2+HWrZ7e3lvgYwGSRpOScfeRWIJ68Y6V4TY+NdQsdEt9Lt7ayWCOR5JZAjiS5DFMpIwYZXCbcDHDN3Oa6U/GvxU2s/bW+wm1EH2ePTSj/AGWJfLMY2LvyCEZhnd3o5XsGp6p8TbX4q+KZHtI/C8dtayv5om0raRNuAHzyA84rJ0Gy8ceBdS0xfHN5rGneFo5C5NuRcKzjohK527jgc9ia5Xw3+0L4z8P6TbabZx6VJZ2yeXEk0DsVXsMhwTjtnmrWoftIeL9QtpYbnTfDzLLH5bZtZGzzkHBkIyMelJRv8SHqeieCPDPih7XVNLufGkFu2r2ZutOtTKHlkjYq6XJPUfdCE/Wuf8H+Eb3wt4n1ew8baPdX/hp4nlhyjSQXNxG37iT5c8sAR/wPnrXlOtfErVdXvZr26sdOS+adJYriESo1vGoUCCMCTAi+X7uCeTz0rZ1b45+MNS8OW+jl7K2jhkWRbi3iZZjtJIUksRgZHbsKOVrZCs+pvQ2mrado+tyadaXGi6jYagktxBDy0MEz4CeuQ6qv+7iu1+Fula/d6j/a3ju9u10ezK3cE3meWWmMpcq5HO0Mp3Z6cV4/ffF3X77XYtVurXS3nW38iRPJcRzkLtWSQB/mdcAg9ARnFP1r4x+I9U0Cz0cQabZ2dsjIBbRODIGUq+/c7ZznJ96bjfoFmb/xT03xcdI1HU5LG/s9AvR9tmEvyqc3OQMdwWnjYfh6V4vXqXiv44eK/FPg678N6vHpslndbPMmWFhN8kiuMHfjqoHTp+deW1UVoNKx61ca0umaHdWejzj+27pFhKWzB1jQpH5ivuHDAowBBOBnHBBrn4Hv7bT76b+0vs8UsypIDCHLSoAy5Y524wOnGOnpXK3eqT3I2lUjXHKpkBjxycnrwKdZ6oLW0khWwspHcEGaRWLgEYwPmx+lLlM1Fnc6frWr6vqEx1u9aSHUWjSQRYZbgY2MoxwjbGbnAr1vwL8UrWXwhpOl6tAEntUjgWdiNs1quMS4HAkhIjJB5IUkZ7fNem6xdafcQywFCIpVmWNh8m9ehx61oQ+K7yPTksjb2ckC7Dh4ycshbDdeuHZTjgjHGQCFyByvU+yfEnwu8HeILOSe3gh06+mjMzeRkqSSfm8vrwRg4A71xVt4S+Huk2czix1nxLLDiF5LaBlgBPAG7aF4x6nFfO1t491m0REtJFhSF1ktwryH7M4/ijJcleOCM7SOoNddrn7QPj7VY0jTULewjClWWzh2+YT/ABFmJIP0IHtQufr/AF+AvZntunaF4LnWC21XwHrtpBMoTzHt5JEUZ7Fev5dKL3Srn4Y6i934aVBp9zJuVEBVMHACuOpAwP174r5pb4keJZLoXVxqE810GV1lkuJSVZehA347dMY9q7e6/aL8V3toba/0nw5dRnBPnWsh5HfHmYBzzwOtLlk9H/X4Iag1qj2zw/F4k8XeJ4/ErNd21thrBFt5ApCAhg5yMcb26j+ED1rT8fW8HhW4v9fmfN/cMtrpW87yr7i8krexLucdgoHGRXgun/tH+KtOtWtrPRvDcUDHd5a282AcYyB5vH+T61jeMPjl4o8VWlnb31rpMEVqxdRbxSDcSB97dIc4xQoNDcND07Vb7TDpdiv2qWbVr2UXF0N+7BGQoZz12KMn3LfhS8R35fSLc6dp88w+1b7qUA+RIi/cjZ/7ufmOCa8Yi8fapHPDN9m09pIlKLuhOCD1yM4JI4ye1alx8WvENxafZpItP8njKiN8HHYjdgj0z07Yo5GTyM6WbxPp8OvRmeNrJkcs6xITGxHIVepGCMdcDIPauV+KF0t3HprwqEhV5UC4/iCQhj9CRwO1c3f+Irm+XFxBakqcoVQjy/8AdAOP0qvqWsXOoWdrbThPKtmdo8Zz820EEkn+4Kai07lxjbcza+5/2aMH4NeGwCqsftGCeuftUvrkev8Anr8MV9n/ALPN5ex/B7QVs9KuJSklwvmy3CxxODJM2Rkn5Qyop4HJJ5C1oWeraZcvcxSNPazW5FxLCqyOMyBDjePRW6jPYisfxnci6XT9AhdPP1W6Tz9uQ0dosi+YxwOAx2xjPUy46jAs2trqk6NJq2pRW9wsLpJHaRlY4HY53hnB3bV2jJ4ySeuKwtOsNIvdb0/V7G+up9yhIZlneZb2IONjNKxJOwh3CA7c5bH3SQD0OArGm1WUYwMZ3fT/APVWB8Q7e9uvCd+mljfeKU2qHCDlsMMnj7pLDPAIrcgyIRkKpB3NweV9R2/+vSapYx6jp1xZSlWjuIjEFboCcj60AGnXJutPtpG3bmQbhgAhsYIH5YFWonDOecsfugc8DHbrj9ea+R/tHxRkuv7J0XxLNLbWn2hZLqbZDEoiwHO5l3Ny3Bxkjacc1W8E3nxM8W+Jk0qy8T6rFc2srfamupWWOMxugOV5DP8ANnaeOB6mgD6P8X/EXSNAuJdOtpZNV1zaQlnZxmYq5B2rJt4X7rE98KfasPw54y8ReJ9LFtq/hPUNH8/bAbuWURCVywARFHzAEZJbtgj0q18O4NHu4JrnwyF/smCWZZNRaJUN/cZO4jbjKAnqMZK4yec9J4T0TUdKtiur6rJqdyMlXaFYVQFiTtRfTgZ6naPXkA3ngKaaLa0KpIibIjgEAqMD+Q6/rUGkXIv9PgvF3RiVeU/unJBzx7D0/wAbyfJsbhRnBJPA59a8703xxDoqalp+p2V4JLK5kji2xqPt8rOW8q3BI3lVYM3pk+hwAelIxZzkEBTgc5yOuaeAADgcdOO9cx4Z8a6L4i82O1nktr1P9baXkZhlT0yp/wA9fSuhM8KOFeSKNmO4ZIGf/r8fpQArqHmQBjuT5uO3bn26/wCejlBVcHPBB5P51UutW0+zb/Sr+1jyMhXlUMe/A7mrSSB/mHHcZBGaAHk/OB2z3WoJZv8ATIIwRtw7nPUgYHA/GmXtwYLSSdpYraKI7nkmOAqA/MfbjOKzdJcyXF3dyNJvcIyxygL5Cc7Ux24G455+b6UAa4OSpJGTnIA4/CuV0C1XS/FurQWpZ7a9Bu5CxJWObIXaD2yuDg59sdK6RZOgYgqvIJOARzgjjp0qpcSLHqFgioc3EjZZMgZ8tjk46nC9TyOnpQB8M/tPZ/4Xl4lycn/RufX/AEWKvLK9S/abJPxw8SFuTi2zxj/l1i7V5bQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFe4fDPxdq0fg6z0S18ZJoljErrIRYqotVMpcyPMSGYnccKnOSo45NeH19N/s56J4Y1zwxGl54c0865Ekojvb+F5kuDvPOw4TaoZQecnaQMdaAMS78daRp0F7aWWv+JPHeraikYkjnUpZMFwVDKcysVHYYB79SK9v+Dtjqd7o1trWvGezkkaU22k/MsVvyF37WyzuRkFmJxkhQB16LTdLttLvLA6fpdp/aUyFry/gto7dQqg5JIGfmbAVM5CjJPBrfSWUBluJFMqsSMderYJB6f/AFvrQBdhRWUMuWCNkDuDge3uORUqqqqm0BW4256Z/wAahQhZFZmIHXLAZHf/ADmnjKx7VClRxt6DJ+lAHlXjTwVf6v4gv4NL07TIIrpQw1G53SOshw/lmJsoV3xKxJB6rxnmo/Cfw11u1n1LT/Euux3nhlnYR2Vui27XOSSTJ5YXYhZnOwE5yMkDIPqrKueuRjJ3YPHXOOnY0sShnJJZQO/Gfz9TQA+zsbfT7OG1srSG2trdRHHBEgCIozwqjAA/z61MyrJuV/mU9MHqPx/H86SclF+XBKjIHTH+f6VVttQgudQvrOBmM9kyJMSpXBZNwAboePQnnAoA0EX5wX2g+36VmG2tjqjSXEMbSRzB7VmjBZGdMMQex9e+M9ukPiHX9O8M6TLqmtTtBZxlIiVieQszMFVVRAWJJIGAPepdN1aHXrLTtR0aWOawu4xcRyujKzIegAOMHkZzz1FAGX41svDFxowuvEyRmwtcHzFZxsGdvVOSOfoKraH4S8ISxxXOmWFs4kjBU73Lbe2VLZHXr7+/OZ8UfE174U0WC5sfDcmvWkbSS3TmRFW1jA5blSMnnp6d68Q1P4rS37XQjPiLQ7qbbIbSxhtke3XAZV83arlWDAgMPTHIJoA+mYPDejRSrJBpNmkgZXVvJXKsDkH8CT09aq6jrGk6PFLLqfiK1gSIeW8cskK+WSMjAALbsAkDp7d6+arn4t3eoaj/AGfodj4p1WSOFdynWHjJC8uxSBc4z3LE81o6R4EvrpLO7i+FE00jRnzPturvDFIznvGS0mFHHLYx2yaAPYD408MeIJtM03TLn+2JWdJS8mRFArHAklZgULHICpyxJHC9V6zSLyybUbyxSaP7YR9ok2BsOu4oXyeuGUqBnPyjsRXjfijRvHnhb4d31/pUWj6Zb2XmXP8AYukwE7BwrSLN97O1nc42tjIzzx0nwtvtJm8UTW2h67p+tWsGjQeU1nbiFYg00jFCoJ5G5cg/MuRuyTyAerNuDfMRkZ2nOP1riPiy/wBj8H3OoG41OKPT3W5ZtNlEU2PunYWBHRj1Fdo5wXYkA/d45xj/AD/+qoL61+2wzQSghGAA/iKkc5GQeRgHv2oA/Ov4kx3kfjXUjqVveW1zIY5TFeytJOqvGrL5jNyXKlSenJ6DpXM16H+0DZy2Hxg8RW893LeSK8TGaUAM26FGwcAdM46DpXnlABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV9m/ASC4k+DXhw28pT/X+Y2eifaZPl9hyT6n3r4yr7Q+BF1a2HwJ0O71SaOzsYzcF7qZjGij7RJwW+pHfHUUAesSXsEUdr5jsDMwRFY5MjZUdMc4yOegHJPFZuqX0Gh3umNdbhBdSPCZgmVRwuVDNn5STwBz6V5r4j+KEE19NpPhOzF5rDQ7YNUuHSG0VWJ5VnP7xWIIUAAMehwKw/GvxVvtG87T7waNPIFQyT6czTxWF2GEse9GUZzgqfmPQ9MEUAfQT3sFsYoZ5iGkcRjggBmJxn0yeKktrmK8iimtZkltpApSVGJDKc4KsOv8An1FfPn9sar9iv7q6M/jMxZS4m03UI4Y7WFwS0JjTiUqhyzkBQdgGfmzZ0XxNBZ2sk9j4m0xYX1B7Wyim1CRlkSPCLF5agpgttxLjOwFguTQB70TmUbw20jJYpjH+fTFPhlgW4Nu7obgDzPLA+YoSwBx74/Q/h414l8ZeIG0KC61nULPwFavI0Uv2sNPqO5BuIiAUJgqUO7sSB358t1Hxx4Pt7pJtLvfGl1drc/aX1E3oVWZkAdMnBIYfeACEnIBAxQB9fSo+1t/3cEEbevUdOuKa8oVOBjYeOv8Aj+dfKGj+N9A1zVNr6vJp2/LfaruM2rzwj5vJ89ZiyODhVLswIwTyzZ9O8KeL7nw1vtvGXiAX1qi4bU5MSQK5VpEKShRvUoCoBAO9cYO4YAPSvEVpeXOnwnTdSXSry2dbmO5ktvPRMZDbkJXKlGdT8wIznPFcn/Y+teKZLS9PjDULSC1iFsjQWiIl7cR/euXTkbScbU6ALnPNKuu2mqQyz+JtXstJ0a5iSWLTpJxDcrECW3zPnKF1HKDopIJzT4PiBJcaSmsaN4b1C/8ADBdgl/bOoZlRirMLc4JUN0weQCeMYIBPPpHiw2A03WH0PxNZzyYmW5jktWZAN3O0MpPTt1xWr4V8NadpOjyaZBoVtYwSsPNhMzXYkwu3lnGWwABgjgDisjwv8VPC+vX0FlbyXlrd3UrCOG7tzGQw7Z6A49676No9vmNIv97OQBj6+nTvmgDj/wCytWt/EYuNG0jw3ZWDuiSzMrC7uIkBwnyLhQCOOT24BrrYIpiiSXDKjhTvVGLjdj+9gE/kKheC3mlhnWPzJEUMkg5XaT0HbqOQOvGauLJ9wkkZ6DcOOen+f8KAK/lPHKrm5mVd4CgAYB2lcHjnruOfQdMckdrbxsVjhiiUk8IoA5OW/AkAmpfNJuFRdpHQEP8AM2OuF/ujPWufn16Oz1cadqN1FHPcrJPZr5qqZY0HzA9gRg89CPSgDebLFCu7buJHy8evFLLtkQsAqjbn16DP8sVwWjfE/R9R8pkEyWzcecqsVQhtrJ8yguQ7IpCBvvDkjmuytb6LUbNZrKWR4pFO3ja2c5zhuh9iO1AHwx+0wQfjb4jKlSp+zEFemPs0VeYV6j+03j/heHiXHrb5+v2aLNeXUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXZeDNdsNCEF3dx3kt1AzSwmK6MY6FfLIxlQQzHcpJzgccmuNrvfDd7p+haDZ3j/ZNTuZvNma0yYZLfadgDyqd5Rg24INoJ5J45AM7VdRm1vxVqWsiKO1llm+1yR6cH8u2JYfOCM4UMRnB64A9ren65FeRx6c9lFYwtcPNbTwMzSWkbjDKMfPJxyNzdRx1wekuNe8MwtZXFteazPczS/8TJ4YhbxSQEOZVMakKHdyuFGVVQoJOSB2E+oaL59gtp4e0hNNtla5XUYLE/aNUHyKzxQruMRVPmwzAjO7g8UASeFvCPje00yzuJdE0+O3P7+a4WVLa6dcsd+8HzVZlJ+UgZHDAYrf1HTbXT7LU5/G/gyS6s5sxz6xp86JfCINtjMsKlcsG+9IuVYgHmn6PrN3c6Hfazpdrqmg3LXgkuLm6B+wRRCQEyNFuLK+3JJKgNg8k7Qb2o+NtRW2eXxj8OI9V01ioSXTCssSRzKACwIJy5JxnaMMF5OaAMXwr4k+HnheV76HVPGWu/asOxlt3eHC5GxlbAY9AeuCBXoN18VPCUM8mna3YappDgDcl7pn7sZBbBCbudo3Zx9DkVxY13T9U1nfpnhbV7udClxCmmamImhAA2xvY5UAgD5htPOSCc5q0fFPhiWyhtZfAtjoV087GSDWLG3wPusJT5mwuGO7oScqe2MgHp2nW2i+Kray1O3t9PvNIvI/3AuLBTwA2SodQwB9CAOOO1ZekeD7Oy1iw1iwsLHSbciS1n0tJFkg+8WimQKSomyMcYwHPPGD5hr9jpupW/m6TpPhW6d4vLJttJusxqF+8xt2dflGflHH3e2K5u00Xw94c8ZMmpafJpqWcEVz8uqvIYpOJF/dlQ6uVOUDDaTgE8mgD6DksPAniO5mnvLHQ9SljDTtcTQAthMZLtgZI4znnGc5FdR4du7K70KwvNFVF06VAbdY4/LTy88FEwDt9OmRz9fGfCvxn8N+L9WitNb8PC0aLzbkz3ixypbYzhwCv32HoOMd+TXqraxptw8dtHf2y6ncQv8AZYwVEvlggEANhsgsMg4x07GgC3rV/p2n6fc6jq6pHaWMLSTzSR7hGmfYEn6DJzjiuS0/4z+Br+aS3i1oFgjSYktJlUqoOSCU5468VwfxLgu9X/svSNJsbeJ3eSxur+UJHb3EZXcfLBYPJ5eA/wAoY8HkduNn+FthoOqaQw1c3Qnk8q8CyQIp8pSZEQO6mbey42Y4UndzwAD3rV/ip4U0Oxs7jWtUjtku4hNb20cMjSGPPD4C5GRgjIHfk445DU/2gfDiXsVpbWGqTQyAeVc+XtWQdeI8FyCdg6DIfPHWvANe0nVPDOt32pano2kT2sDI7W8sqPEGYkLHgMNyjBBQE7cf7OQWFp4o8159UsY9RRFkuAlxcxtKzGNmDEhvNJ2uSM8N8h5GCQD1bRb+78VbPGnieXWJXRmtIdN06eO1iyzoixAmQMFBkRnYgAEgEnbg4UniZrSTXLTxQk2r22nXTSWNjeJEJGl3RmOJ8HLxh35CFt2Tng1yDaT4sttIGkxy27298kYn03TpDdTwEHc+6FMkbtqO2PlJCqTwcdB4Z8F6jrktxb69Z6rp95IiSy6hqEBLwRiQsxVAC4mYRKFTGEQSHnrQB33ha51+HULq/i1HUtUkubNpDo1/b7ZLW4C48xIhkCIMQQsXzBQOCa3bO/01n/tPw/4jEniKZ8SabeXrR2kE6kGfEbgFQcEDI43cdRjC0T4cWFrFdHQtdutRuWjEsmnvcAERyNmKRXjyY5Dt/wBYPRhwCQIFvPHPhvXLYzIPE2izxybPt1mweFsDb5p2ZZUBGXXIYHPcAAHz/wDG5tQf4o64+sy20uoO0TzNakmIEwodqk9QBgZ9uK4Wu0+MmpT6v8SNYvruXTZZpfJy2mljb4EKKNm7B4AAOe+a4ugAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK2vDd+1lfq8V6thIYZY1ucPiMsrDJCgnJBK5A43Z6jIxaKAOx+16Zr9xeXWqa7c2kyIn2YaiJL15GwSQ0qqCqAk9ATz7Vnpq6G8e5W7u4nmCC4cPteT5ctgIANocDqc424HWueooA7/AMIeNY9FmFvqoOoae82X8pnEsYUYEkbN/FjACsNu0YIGTSP4uTTdce70rW9Zu4gkz25uAqCGZnJ5i+aNkYAZXA++f7vPA0UAeu6n8RbzUdEttRuNU8Of2jFuaTTjYzyG43HADI0fkrtGT8rDOcHNQ+GfifpFgE/tLw04IQJ5mm6lPbk8YLlCWQtwOQBxgV5RRQB7nc+MvCetWFtBpuuahodzDEVlfxBbDUIpyQQNpjRmDj++QD6VS03X/CiCeztfFutWNw1sYHv7+B7qES954CuJULbcAFQQHNeM0UAe0f2l4eiu2v3+JVxqvmWIhaDUbG5MvDbhETtIxy4GHG0uDkgGr1r8R/DGn+JZm08NN4cS34tdQiMk9xcY3qxkC7tquFUbn+6Dxzz4TRQB7xffEHQI721k0rUzapaqq2kqJJJOjFSJDJI8WUjCsyxpGGy20uQBU2qfEDwb532DwwtlptkkCW8N5eWBlm80lt88smxpGC/K6gAEv94bRgeA0UAe53XjnwNoeqfatGuPE+sGdpHuLa5uiLPeRgSbGAZzkAkMMc47CsG++I80ljbOs+mq2/7RHFElxJJbyI++NXV9sKrk9Y1JwOoJJPlVFAHrfg34nTweKn1PVtVezheH97DaWaIkuGP7slBkfKThwMgnPHOZtd8dw3GpwSWeq6W/kTSlrmRbxXuo9w2bzgtu25UEEcZBxnB8eooA9xk8U+ELDVYL2w8Q6i5+2tM8lmJrSdrZwuYZDtIJV/mB5BVXB5YZ3tP+LUeka3eXl147n8QRLItvBFLaSpFLARjzWjMYCyI2GwCNwBGQTXzhRQB1fxR1S31vxzqOoWeqSatBOISLyW2Fu8pESA5jAABBBHHXGe9cpRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The position of the beam relative to the long axis precordial plane anatomy is shown in panel A; a diagram of the M-mode pattern of the mitral valve echo is seen in panel B. During diastole the movement of the anterior leaflet (AL) of the valve has an M-shape pattern, while the posterior mitral valve leaflet (PML) moves in the opposite direction (panels C and D). The initial opening, the D-point, reaches a peak at the E point; this represents maximal opening of the valve associated with rapid filling after which there is temporary equilization of pressure and the valve leaflets move back to or near their closed position at the F-point. The speed with which the leaflets close from E to F is known as the E to F slope. The A wave is the peak opening during atrial contraction after which the valve closes (C-point). If the PR interval is prolonged and atrial contraction delayed, the leaflets may \"float\" back to an opened position (GH in panel D). During systole the segment between C and D represents the coapted leaflets and their migration from posterior to anterior with the descent of the base and the torsion of the longitudinal myocardial segments (panels E and F). Panel E is from a patient with cardiomyopathy; the reduced E to F slope and B notch in diastole indicate elevated left ventricular filling pressure and diastolic dysfunction. Panel F is recorded from a normal individual.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_54_38759=[""].join("\n");
var outline_f37_54_38759=null;
var title_f37_54_38760="Arthropod-borne encephalitides";
var content_f37_54_38760=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Arthropod-borne encephalitides",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/54/38760/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/54/38760/contributors\">",
"     Lyle R Petersen, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/54/38760/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/54/38760/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/54/38760/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/54/38760/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/54/38760/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthropod-borne encephalitis viruses represent a significant public health problem throughout most of the world. These viruses, which belong to the families Flaviviridae, Togaviridae, Bunyaviridae, and Reoviridae, are usually highly adapted to particular reservoir hosts and are spread from animal to animal via the bite of an infected arthropod, usually a specific mosquito or tick species (",
"    <a class=\"graphic graphic_table graphicRef77283 \" href=\"mobipreview.htm?15/61/16349\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This topic will review the major characteristics of most of the arthropod-borne viral encephalitides. General issues related to viral encephalitis, including clinical manifestations, cerebrospinal fluid findings, distinction from postinfectious encephalitis and meningitis, and an approach to the patients with suspected central nervous system infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/3/38968?source=see_link\">",
"     \"Viral encephalitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TRANSMISSION CYCLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mosquito or tick becomes infected when feeding on the blood of the viremic animal. The virus then replicates in the mosquito or tick tissues, ultimately infecting the salivary glands. The mosquito or tick transmits the virus to a new host when it injects infective salivary fluid while taking a blood meal.",
"   </p>",
"   <p>",
"    The natural animal hosts of these viruses usually remain unaffected and viral circulation generally remains undetected until one of the following occurs:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Humans encroach on the natural enzootic focus",
"     </li>",
"     <li>",
"      Environmental or other conditions that favor substantial amplification in the primary vector-host cycle cause a sufficient number of vectors to become infected so that the human risk is substantially increased",
"     </li>",
"     <li>",
"      The virus escapes the primary cycle via a secondary vector or vertebrate host, thereby bringing infected, human-biting vectors in close proximity to human habitation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although infected humans may become ill, they usually do not develop sufficient viremia to infect feeding vectors. As a result, humans do not usually contribute to the transmission cycle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GEOGRAPHIC DISTRIBUTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the mosquito-borne encephalitis viruses, the greatest public health threat in North America are posed by the West Nile, St. Louis encephalitis, and La Crosse encephalitis viruses (",
"    <a class=\"graphic graphic_table graphicRef77283 \" href=\"mobipreview.htm?15/61/16349\">",
"     table 1",
"    </a>",
"    ). Venezuelan equine encephalitis virus is of concern in Central and South America, while Japanese encephalitis virus affects persons living or traveling to parts of Asia. Dengue is a rare cause of encephalitis throughout the tropical world. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16088?source=see_link\">",
"     \"Epidemiology and pathogenesis of West Nile virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38023?source=see_link\">",
"     \"St. Louis encephalitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among the tick-borne viruses that cause encephalitis, tick-borne encephalitis virus has the greatest public health impact worldwide and is of concern to residents of or visitors to northern parts of Eastern Europe and Asia. Powassan virus is a rare, tick-borne cause of encephalitis in the north central and northeastern parts of the United States, eastern Canada, and Russia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CROSS-REACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The close antigenic relationships among the flaviviruses may cause a problem with diagnosis. Individuals who have been recently vaccinated with yellow fever, tick borne encephalitis virus, or Japanese encephalitis vaccines or who have been recently infected with a related flavivirus may have a positive serologic test to one or more flaviviruses not causing the current illness. The plaque reduction neutralization test (PRNT), which is the most specific test for the arthropod-borne flaviviruses, may identify serologic cross-reactions among the flaviviruses. However, some degree of cross-reaction in neutralizing antibody may still cause ambiguous results. Cross reactivities of the bunyaviruses and togaviruses causing encephalitis is not as extensive (",
"    <a class=\"graphic graphic_table graphicRef77283 \" href=\"mobipreview.htm?15/61/16349\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     WEST NILE, ST. LOUIS, AND DENGUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;These three causes of arthropod-borne encephalitis are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      West Nile virus encephalitis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16088?source=see_link\">",
"       \"Epidemiology and pathogenesis of West Nile virus infection\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      St. Louis encephalitis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38023?source=see_link\">",
"       \"St. Louis encephalitis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Dengue virus infection (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/34/18985?source=see_link\">",
"       \"Clinical presentation and diagnosis of dengue virus infections\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EASTERN EQUINE ENCEPHALITIS VIRUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eastern equine encephalitis (EEE) virus (family Togaviridae, genus Alphavirus) is widely distributed throughout North, Central, and South America and the Caribbean. Four genetic lineages exist: Subtype I in North America and the Caribbean, and subtypes II to IV in South and Central America [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/1\">",
"     1",
"    </a>",
"    ]. While subtype I is associated with severe clinical disease, subtypes II to IV are not clearly associated with human disease.",
"   </p>",
"   <p>",
"    In North America, wild birds and Culiseta melanura, a mosquito that is found in swamp areas that support cedar, red maple and loblolly bay trees, maintain the virus. The ecology of South American EEE strains is not well described. Laboratory-acquired infections have occurred, and EEE virus is a potential agent of bioterrorism through the aerosol route.",
"   </p>",
"   <p>",
"    Although infections can occur throughout the year, peak incidence is in August and September. In the United States, human infections are usually sporadic and small outbreaks occur each summer, mostly along the Atlantic and Gulf coasts. From 1964 to 2010, 270 cases of EEE were reported, with the largest number of cases identified in Florida, Georgia, Massachusetts, and New Jersey. In 2005, 21 cases were reported, which included an outbreak of 11 cases (with four fatalities) in New Hampshire and Massachusetts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/2\">",
"     2",
"    </a>",
"    ]. This was the first outbreak in New Hampshire recorded during 41 years of surveillance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/2\">",
"     2",
"    </a>",
"    ]. All 11 patients had resided in a wooded area located within a half mile of a swamp or cranberry bog.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incubation period usually exceeds one week after the mosquito bite. The illness often begins with a prodrome lasting several days, with fever, headache, nausea and vomiting being common. Approximately two percent of infected adults and six percent of infected children develop encephalitis.",
"   </p>",
"   <p>",
"    Once neurologic symptoms begin, the clinical condition deteriorates rapidly, with approximately 90 percent becoming comatose or stuporous. Seizures, and focal neurologic signs, including cranial nerve palsies, develop in approximately one-half the patients. Leukocytosis and hyponatremia are common on laboratory testing.",
"   </p>",
"   <p>",
"    Cerebrospinal fluid (CSF) analysis typically shows pleocytosis, often with a neutrophilic predominance and elevated protein concentration. An elevated white cell count in initial CSF examination and hyponatremia correlate with a poor prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Electroencephalography reveals generalized slowing and disorganization of the background, and epileptiform discharges may be seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/3\">",
"     3",
"    </a>",
"    ]. Magnetic resonance imaging (MRI) is more sensitive than computed tomography (CT). Both are often abnormal early in the course, with focal lesions in the basal ganglia, thalami, and brainstem being particularly common. Cortical lesions, meningeal enhancement, and periventricular white-matter changes are less common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of EEE can be made by demonstration of IgM antibody by capture immunoassay of CSF, a fourfold rise in serum antibody titers against EEE virus, or isolation of virus from or demonstration of viral antigen or genomic sequences in tissue, blood, or CSF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/4\">",
"     4",
"    </a>",
"    ]. Serum IgM antibodies alone should be confirmed by demonstration of IgG antibody by another serologic assay (eg, neutralization or hemagglutination inhibition).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;EEE virus is the most severe of the arboviral encephalitides, with a mortality of at least 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/3\">",
"     3",
"    </a>",
"    ]. Death can occur within three to five days of onset and, among survivors, complete recovery is uncommon. Sequelae include convulsions, paralysis, and mental retardation. EEE in South America is less severe.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no specific therapy for EEE. Inactivated vaccines have been successful in horses and an inactivated vaccine has been used in laboratory workers or others at high risk of exposure, but is not commercially available. No specific treatment is available. In one series, patients treated with anticonvulsants or corticosteroids had poorer outcomes than those not treated, a finding possibly resulting from patient selection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/3\">",
"     3",
"    </a>",
"    ]. One patient may have benefited from IVIG therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prevention focuses on avoidance of mosquito bites and mosquito control in suburban areas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     WESTERN EQUINE ENCEPHALITIS VIRUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Western equine encephalitis (WEE) virus (family Togaviridae, genus Alphavirus) is a complex of closely related viruses found in North and South America. Flooding, which increases breeding of Culex mosquitoes, may precipitate summer outbreaks. Large outbreaks in humans and horses occurred in the western United States in the 1950s and 1960s. However, a declining horse population, equine vaccination, and improved vector control have reduced the incidence of the disease. WEE is a potential agent of bioterrorism through the aerosol route.",
"   </p>",
"   <p>",
"    Fewer than 1 in 1000 infected adults develop encephalitis, but the frequency is greater in children, particularly infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/6\">",
"     6",
"    </a>",
"    ]. Following an incubation period of about seven days, headache, vomiting, stiff neck, and backache are typical; restlessness, irritability, and seizures are common in children. Although rare in adults and older children, neurologic sequelae are relatively common in infants. The case fatality rate is 3 to 7 percent.",
"   </p>",
"   <p>",
"    The diagnosis of WEE can be made by demonstration of IgM antibody by capture immunoassay of CSF, a fourfold rise in serum antibody titers against WEE virus, or isolation of virus from or demonstration of viral antigen or genomic sequences in tissue, blood, or CSF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/4\">",
"     4",
"    </a>",
"    ]. Serum IgM antibodies alone should be confirmed by demonstration of IgG antibody by another serologic assay (eg, neutralization or hemagglutination inhibition).",
"   </p>",
"   <p>",
"    Prevention focuses on mosquito control and personal measures to avoid mosquito bites. Inactivated vaccine is available for horses. Although inactivated vaccine has been used for laboratory staff and others at high risk of exposure, it is not commercially available for use in humans. No specific treatment is available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     JAPANESE ENCEPHALITIS VIRUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Japanese encephalitis is an arboviral encephalitis that is endemic throughout much of tropical East Asia. Issues related to Japanese encephalitis are discussed in detail separately (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/5/5208?source=see_link\">",
"     \"Japanese encephalitis: Epidemiology, diagnosis, treatment and prevention\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     LA CROSSE ENCEPHALITIS VIRUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;La Crosse virus (LAC, family Bunyaviridae, genus Bunyavirus) is the most pathogenic member of the California encephalitis serogroup, which includes the California encephalitis, trivittatus, snowshoe hare, and Jamestown Canyon viruses. LAC is transmitted via Aedes triseriatus (eastern tree hole mosquito), and mammalian hosts include the eastern chipmunk, tree squirrels, and foxes. In addition, epidemiologic evidence suggests that the newly introduced Aedes albopictus mosquito (Asian tiger mosquito) may be an important vector of human infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Human infections occur in the central and eastern United States, mostly in school-aged children from July through September [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Most infections are asymptomatic.",
"   </p>",
"   <p>",
"    The characteristics of symptomatic disease, which begins after an incubation period of three to seven days, were evaluated in a review of 127 patients who required hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/9\">",
"     9",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All of the patients were school-aged children (range 0.5 to 15 years).",
"     </li>",
"     <li>",
"      Headache, fever, and vomiting were each present in at least 70 percent of patients and disorientation in 42 percent.",
"     </li>",
"     <li>",
"      Seizures occurred in 46 percent, 62 percent of which had have a focal component and 24 percent of which progressed to status epilepticus.",
"     </li>",
"     <li>",
"      Approximately 20 percent had focal neurologic abnormalities. The findings of fever, focal neurologic signs, and focal seizures mimic herpes simplex encephalitis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/62/1001?source=see_link\">",
"       \"Herpes simplex virus type 1 encephalitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Aseptic meningitis alone, without evidence of encephalitis, occurred in 13 percent.",
"     </li>",
"     <li>",
"      Hyponatremia was present in 21 percent and was present in all 13 patients (11 percent) whose condition deteriorated in the hospital.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All of patients survived, which is consistent with a very low mortality rate in other reports. However, 12 percent of children had residual neurologic sequelae, including focal neurologic, cognitive, and behavioral deficits.",
"   </p>",
"   <p>",
"    Leukocytosis is common, with polymorphonuclear cells predominating [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/9\">",
"     9",
"    </a>",
"    ]. CSF shows pleocytosis with either neutrophilic or lymphocytic predominance. Electroencephalography is abnormal in two-thirds of patients, mainly with slowing or epileptiform discharges [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/9\">",
"     9",
"    </a>",
"    ]. Focal features or periodic lateralizing epileptiform discharges, usually with involvement of the temporal lobe, may suggest herpes simplex encephalitis.",
"   </p>",
"   <p>",
"    CT scan is generally normal, but may show generalized cerebral edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/9\">",
"     9",
"    </a>",
"    ]. MRI may show focal areas of gadolinium enhancement.",
"   </p>",
"   <p>",
"    The diagnosis of LAC can be made by demonstration of IgM antibody by capture immunoassay of CSF, a fourfold rise in serum antibody titers against LAC virus, or isolation of virus from or demonstration of viral antigen or genomic sequences in tissue, blood, or CSF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/4\">",
"     4",
"    </a>",
"    ]. Viral isolation from the CSF is rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/7\">",
"     7",
"    </a>",
"    ]. Serum IgM antibodies alone should be confirmed by demonstration of IgG antibody by another serologic assay (eg, neutralization).",
"   </p>",
"   <p>",
"    Treatment is supportive, with emphasis on control of cerebral edema and seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/9\">",
"     9",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     Ribavirin",
"    </a>",
"    has been used, but efficacy is unproven [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prevention rests on avoidance of mosquito bites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/7\">",
"     7",
"    </a>",
"    ]. A case of possible congenital infection has also been reported with IgM antibodies identified in the umbilical cord blood; however, the newborn was asymptomatic and development was normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/11\">",
"     11",
"    </a>",
"    ]. No seroconversion was documented in this case because the mother declined further testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MURRAY VALLEY ENCEPHALITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Murray Valley encephalitis (MVE) virus (family Flaviviridae, genus Flavivirus), occurs in Australia, New Guinea, and probably islands in the eastern part of the Indonesian archipelago [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/12\">",
"     12",
"    </a>",
"    ]. MVE virus is believed to be maintained in a natural cycle involving water birds and Culex annulirostris mosquitoes. Viremia has not been documented in humans, who are likely dead-end hosts.",
"   </p>",
"   <p>",
"    Only one in 1000 to 2000 infections results in clinical illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/12\">",
"     12",
"    </a>",
"    ], which resembles Japanese encephalitis. There is usually a prodromal illness with headache, fever, nausea and vomiting, anorexia, and myalgias, followed by drowsiness, malaise, irritability, mental confusion, and meningismus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/13\">",
"     13",
"    </a>",
"    ]. Seizures are more common in children. In severe cases, there may be hyperactive reflexes, spastic paresis, seizures, coma, and death.",
"   </p>",
"   <p>",
"    CT scan is normal in about two-thirds of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Reported abnormalities include mild hydrocephalus, cerebral edema, reduced attenuation extending from the thalami to the brainstem, and cerebral atrophy.",
"   </p>",
"   <p>",
"    The diagnosis of MVE can be made by demonstration of IgM antibody by capture immunoassay of CSF, a fourfold rise in serum antibody titers against MVE virus, or isolation of virus from or demonstration of viral antigen or genomic sequences in tissue, blood, or CSF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/4\">",
"     4",
"    </a>",
"    ]. Serum IgM antibodies alone should be confirmed by demonstration of IgG antibody by another serologic assay (eg, neutralization or hemagglutination inhibition).",
"   </p>",
"   <p>",
"    Approximately one-third of patients with MVE die and about half the survivors have residual neurologic deficits. Children and the elderly are at highest risk.",
"   </p>",
"   <p>",
"    There is no vaccine for MVE virus. Prevention relies on mosquito control and avoidance of mosquito bites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     VENEZUELAN EQUINE ENCEPHALITIS VIRUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Six subtypes (I-VI) within the Venezuelan equine encephalitis (VEE) virus (family Togaviridae, genus Alphavirus) complex have been identified. Five antigenic variants exist within subtype I (IAB, IC, ID, IE, IF). These subtypes and variants are classified as epizootic (can produce outbreaks of illness in animals) or enzootic (infects animals in a region, but often produces asymptomatic or sporadic illness in animals), based upon their apparent virulence and epidemiology:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epizootic variants of subtype I (IAB and IC) cause equine epizootics and are associated with more severe human disease.",
"     </li>",
"     <li>",
"      Enzootic strains (ID-F, II [Everglades], III [Mucambo, Tonate], IV [Pixuna], V [Cabassou], VI [Rio Negro]) do not cause epizootics in horses, but may produce sporadic disease in humans.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Epizootic strains are transmitted by many mosquitoes, and enzootic strains by Culex mosquitoes.",
"   </p>",
"   <p>",
"    VEE has a widespread geographic distribution from Florida to South America, where it is an important veterinary and public health problem. Focal outbreaks occur periodically, but occasionally, large regional epidemics occur, with thousands of equine and human infections. VEE is infectious via aerosols, making it an occupational risk to certain laboratory workers and a potential agent of bioterrorism.",
"   </p>",
"   <p>",
"    After an incubation period of one to six days, there is a brief febrile illness of sudden onset, characterized by malaise, nausea or vomiting, headache, and myalgia. Less than 0.5 percent of adults and less than 4 percent of children develop encephalitis, characterized by nuchal rigidity, seizures, coma, and paralysis. Long-term sequelae and fatalities are uncommon.",
"   </p>",
"   <p>",
"    The diagnosis of VEE can be made by demonstration of IgM antibody by capture immunoassay of CSF, a fourfold rise in serum antibody titers against SLE virus, or isolation of virus from or demonstration of viral antigen or genomic sequences in tissue, blood, or CSF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/15\">",
"     15",
"    </a>",
"    ]. Viremia is usually not detectable in serum. Serum IgM antibodies alone should be confirmed by demonstration of IgG antibody by another serologic assay (eg, neutralization or hemagglutination inhibition).",
"   </p>",
"   <p>",
"    Effective prevention of both human and equine disease can be accomplished by immunizing equines, which serve as the primary amplification hosts for the epizootic VEE viruses and without which there would be little human disease. During epidemics, mosquito vectors can be controlled by insecticides. Live attenuated and inactivated vaccines have been used for laboratory workers; however, human vaccines are not commercially available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TICK-BORNE ENCEPHALITIS VIRUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tick-borne encephalitis (TBE) is caused by three closely related viruses (family Flaviviridae, genus Flavivirus) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Russian spring-summer encephalitis subtype (also called far eastern subtype)",
"     </li>",
"     <li>",
"      The Siberian subtype also called Vasilchenko virus",
"     </li>",
"     <li>",
"      The Central European encephalitis subtype (also called western subtype)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Vector",
"    </span>",
"    &nbsp;&mdash;&nbsp;These viruses are maintained in natural cycles involving a variety of mammals and ticks. Ixodes persulcatus and Ixodes ricinus are responsible for transmission in Russia and Europe, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/17\">",
"     17",
"    </a>",
"    ]. Ixodes ovatus is the vector in Hokkaido. Tick-borne encephalitis exists over a wide geographical area [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/16,18\">",
"     16,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human exposure occurs through work or recreational activities in the spring and summer months in temperate zones and in fall and winter in the Mediterranean, when the ticks are most active. TBE virus is transmitted from the saliva of an infected tick within minutes of the bite; early removal of the tick may not prevent encephalitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/18\">",
"     18",
"    </a>",
"    ]. In Europe, tick activity starts in the spring and declines in the fall. Nymphal forms of I. ricinus are most important in human transmission whereas adult ticks are the dominant vector for I. persulcatus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Outbreaks have occasionally followed ingestion of unpasteurized milk products from infected sheep and goats.",
"   </p>",
"   <p>",
"    Age, severity of illness in the acute stage, and low initial neutralizing antibody titers are associated with illness severity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. The CCR5 delta 32 allele may predispose individuals to TBE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/39/24186?source=see_link&amp;anchor=H12#H12\">",
"     \"Factors affecting HIV progression\", section on 'Coreceptor usage'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incubation period of TBE generally lasts between 7 and 14 days and approximately two-thirds of patients report tick bite. The disease is characterized by a biphasic illness. In the first viremic phase, fever, fatigue, malaise, headache, and arthralgia predominate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/16,18\">",
"     16,18",
"    </a>",
"    ]. Neurological manifestations hallmark the second phase, with a clinical spectrum ranging from mild meningitis to severe encephalitis, which may be accompanied by myelitis and acute flaccid paralysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/16,18\">",
"     16,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reports of chronic and progressive disease have been noted primarily with the Siberian subtype; however, this occurs uncommonly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;CSF examination generally shows pleocytosis. Although polymorphonuclear cells may predominate at first, the CSF profile is later marked by dominance of mononuclear cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/18\">",
"     18",
"    </a>",
"    ]. The diagnosis of TBE can be made by demonstration of IgM antibody by capture immunoassay of CSF, a fourfold rise in serum antibody titers against TBE virus, or isolation of virus from or demonstration of viral antigen or genomic sequences in tissue, blood, or CSF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/15,21\">",
"     15,21",
"    </a>",
"    ]. Serum IgM antibodies alone should be confirmed by demonstration of IgG antibody by another serologic assay (eg, neutralization).",
"   </p>",
"   <p>",
"    MRI abnormalities may be noted in approximately 18 percent of patients with lesions located in the thalamus, cerebellum, brainstem, and caudate nucleus; EEG is abnormal in 77 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/18\">",
"     18",
"    </a>",
"    ]. Both modalities demonstrate only non-specific findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case fatality rates with the Siberian subtype rarely exceed 8 percent and there is a greater tendency to developing nonparalytic encephalitis and chronic TBE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/16\">",
"     16",
"    </a>",
"    ]. In comparison, the western European subtype typically produces the biphasic form and tends to be less severe, with case fatality rates of 1 to 2 percent. Children have a more favorable prognosis than adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/22\">",
"     22",
"    </a>",
"    ]. Up to one-half of patients report symptoms 6 to 12 months post-encephalitis, with severe impairment noted in 30 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Treatment and prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment is mainly supportive. In a large study of 709 patients with TBE in Germany, 12 percent of patients required intensive care and 5 percent required assisted ventilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/23\">",
"     23",
"    </a>",
"    ]. Of 230 patients who had subsequent examination at a later time, approximately one-quarter had moderate to severe sequelae.",
"   </p>",
"   <p>",
"    Effective vaccines are available in Europe and from many travel clinics in Canada; vaccines are not available in the United States. Mass vaccination has been undertaken in Austria, with protection rates of at least 96 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/24\">",
"     24",
"    </a>",
"    ]. Between the early 1970s and early 1980s, the average TBE incidence rate was 5.7 per 100,000; it dropped to 0.9 per 100,000 between the mid 1990s and 2005 among vaccinated individuals, but remained high (6 per 100,000) among unvaccinated individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Travelers with extensive outdoor exposures from camping or related activities in endemic regions during the spring and summer months should consider being vaccinated. Other prevention strategies include avoiding tick bites (eg, using insect repellents) and pasteurization of milk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/21/2394?source=see_link&amp;anchor=H3180858#H3180858\">",
"     \"Immunizations for travel\", section on 'Tick-borne encephalitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Testing for TBE can be performed at the CDC's Special Pathogens Branch (404-639-1115) or Arboviral Diseases Branch (970-221-6400) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     POWASSAN VIRUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Powassan virus (family Flaviviridae, genus Flavivirus) is related to the eastern hemisphere's tick-borne encephalitis viruses. It has been isolated from four tick species: Ixodes cookie, Ix. marxi, Ix. spinipalpus, and Dermacentor andersoni (",
"    <a class=\"graphic graphic_picture graphicRef68829 \" href=\"mobipreview.htm?21/18/21806\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Powassan virus is a rare cause of encephalitis in eastern Canada and the north central and northeastern United States. There have been more than 30 case reports since its discovery in 1958 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. However, serologic surveys have found an antibody prevalence of 1 to 4 percent, indicating that asymptomatic infection is common. Infection mostly occurs from June to September.",
"   </p>",
"   <p>",
"    The reported incubation periods range from eight to 34 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. However, few patients recall a tick bite, since Ixodid ticks are small and can be easily overlooked. Symptomatic patients typically present with fever, weakness, somnolence, gastrointestinal complaints, headache, and confusion, and seizures can occur.",
"   </p>",
"   <p>",
"    Serum and cerebrospinal fluid samples can be tested for IgM and neutralizing antibodies. The diagnosis of Powassan virus infection can be made by demonstration of IgM antibody by capture immunoassay of CSF, a fourfold rise in serum antibody titers against the virus, or isolation of virus from or demonstration of viral antigen or genomic sequences in tissue, blood, or CSF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/15\">",
"     15",
"    </a>",
"    ]. Serum IgM antibodies alone should be confirmed by demonstration of IgG antibody by another serologic assay (eg, neutralization).",
"   </p>",
"   <p>",
"    The case-fatality rate is 5 to 10 percent, with a high incidence of residual neurological dysfunction among survivors, including hemiplegia, headaches, minor memory impairment, and persistent ophthalmoplegia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/27,29,30\">",
"     27,29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no specific treatment or vaccine. Prevention of tick bites by using repellents, avoiding or clearing brushy areas, wearing light colored clothing may be effective. Removing ticks soon after outdoor exposure is advisable.",
"   </p>",
"   <p>",
"    The so-called deer tick virus is likely an antigenic subtype of Powassan virus and is maintained in Ix. scapularis ticks and white-footed mice. Human infection with deer tick virus was reported in 2009 with a fatal outcome in a 62-year-old New York state resident with chronic lymphocytic leukemia who presented with encephalitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     COLORADO TICK FEVER VIRUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Colorado tick fever virus (genus Coltivirus, family Reoviridae) is transmitted to humans in the western United States and Canada mainly by the wood tick, Dermacentor andersoni (",
"    <a class=\"graphic graphic_picture graphicRef68829 \" href=\"mobipreview.htm?21/18/21806\">",
"     picture 1",
"    </a>",
"    ). The distribution of human disease corresponds to the wood tick's distribution in mountainous areas at 4000- to 10,000-foot elevations. Transmission occurs from March to September, but peaks from April to June. Transmission via blood transfusion has been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mean incubation period is three to four days, and 90 percent of patients report tick bites or tick exposure. Fever, chills, myalgias, and prostration are common presenting symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/33\">",
"     33",
"    </a>",
"    ]. Headache often occurs during the acute febrile phase. Approximately 15 percent of patients experience a petechial or maculopapular rash and leukopenia is a common finding. Although the acute symptoms last about one week, fever may recur several days later, and fatigue is often prolonged. Five to 10 percent of children develop meningitis or encephalitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serologic tests are often not positive for 10 to 14 days after symptom onset. In comparison, reverse transcriptase polymerase chain reaction (PCR) may be diagnostic from the first day of symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/35\">",
"     35",
"    </a>",
"    ]. The virus infects marrow erythrocytic precursors, which accounts for the ability to recover the virus from peripheral blood up to six weeks after illness onset.",
"   </p>",
"   <p>",
"    Treatment is supportive and the prognosis is generally favorable. Prevention consists of avoidance of tick bites in endemic areas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     CHANDIPURA VIRUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the 1950's, outbreaks of encephalitis of unknown etiology and high mortality have occurred in children in India. In 2003 in Southern India, an outbreak of acute encephalitis in 329 children was associated with Chandipura virus (genus Vesiculovirus, family Rhabdoviridae) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/36\">",
"     36",
"    </a>",
"    ]. The affected children all tested negative for eight other potential viral causes including Japanese encephalitis (which is responsible for many encephalitis outbreaks in India), West Nile virus, dengue, and measles virus. The Chandipura virus was identified by electron microscopy, complement fixation, and neutralization tests. The observation that IgM titers directed against this virus were more frequently identified after four days of illness compared to baseline values provided further evidence supporting its pathogenetic role. Nevertheless, speculation remains whether the cause of illness is due to encephalitis or other pathology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chandipura virus encephalitis may be transmitted by sandfly bites and has been identified in Aedes aegypti mosquitoes. Illness is characterized by the rapid onset of fever followed by vomiting, altered mental status, and seizures. The mortality rate in the 2003 outbreak was 56 percent. A similar outbreak occurred in 26 children in western India in 2004, with a mortality of 78 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11535065\">",
"    <span class=\"h1\">",
"     TOSCANA VIRUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toscana virus (genus Phelbovirus, family Bunyaviridae) is transmitted to humans in southern Europe by infected Phelbotomus sandflies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/39\">",
"     39",
"    </a>",
"    ]. High seroprevalence rates in populations in endemic areas suggest that most infections are asymptomatic or clinically inconsequential. The incubation period is from a few days to two weeks. The disease is characterized by fever, headache, and gastrointestinal symptoms; decreased consciousness, paresis, and ocular findings may occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38760/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Prognosis is generally favorable. CSF examination generally shows pleocytosis. The diagnosis of Toscana virus can be made by demonstration of IgM antibody by capture immunoassay of CSF, a fourfold rise in serum antibody titers against Toscana virus, or isolation of virus from or demonstration of viral antigen or genomic sequences in tissue, blood, or CSF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/50/18209?source=see_link\">",
"       \"Patient information: Encephalitis in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9551308\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Arthropod-borne encephalitis viruses, which belong to the families Flaviviridae, Togaviridae, Bunyaviridae, and Reoviridae, are highly adapted to a particular reservoir host. These viruses are spread from animal to animal via the bite of an infected arthropod, usually a specific mosquito or tick species. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mosquito or tick becomes infected when feeding on the blood of the viremic animal. The virus then replicates in the mosquito or tick, ultimately infecting the salivary glands. The vector then transmits the virus to a new host when it injects infective salivary fluid while taking a blood meal. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Transmission cycle'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although infected humans may become ill, they usually do not develop sufficient viremia to infect feeding vectors. As a result, humans do not usually contribute to the transmission cycle. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Transmission cycle'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among the mosquito-borne encephalitis viruses, the greatest public health threat in North America is posed by the West Nile, St. Louis encephalitis, and La Crosse encephalitis viruses. Venezuelan equine encephalitis virus is of concern in Central and South America, while Japanese encephalitis virus affects persons living or traveling to parts of Asia. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Geographic distribution'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among the tick-borne viruses that cause encephalitis, tick-borne Encephalitis virus causes the greatest public health threat among residents or visitors to Eastern Europe and Asia. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Geographic distribution'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The close antigenic relationships among the flaviviruses may cause a problem with diagnosis due to cross-reactivity. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Cross-reactivity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Eastern equine encephalitis (EEE) virus (family Togaviridae, genus Alphavirus) is widely distributed throughout North, Central, and South America and the Caribbean. EEE virus is the most severe of the arboviral encephalitides, with a mortality of at least 30 percent. There is no specific therapy for EEE. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Eastern equine encephalitis virus'",
"      </a>",
"      above.) Western equine encephalitis (WEE) virus is a found in North and South America and is a potential agent of bioterrorism through the aerosol route. The case fatality rate is 3 to 7 percent. Although inactivated vaccine has been used for laboratory staff and others at high risk of exposure, it is not commercially available for use in humans. No specific treatment is available. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Western equine encephalitis virus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      La Crosse virus (LAC, family Bunyaviridae, genus Bunyavirus) is the most pathogenic member of the California encephalitis serogroup. Human infections occur in the central and eastern United States, mostly in school-aged children from July through September. Most infections are asymptomatic; of those who present with encephalitis, the mortality rates are low. Treatment is supportive, with emphasis on control of cerebral edema and seizures.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       Ribavirin",
"      </a>",
"      has been used, but efficacy is unproven. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'La Crosse encephalitis virus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Murray Valley encephalitis (MVE) virus (family Flaviviridae, genus Flavivirus), occurs in Australia, New Guinea, and probably islands in the eastern part of the Indonesian archipelago. MVE virus is believed to be maintained in a natural cycle involving water birds and Culex annulirostris mosquitoes. Viremia has not been documented in humans, who are likely dead-end hosts. Only 1 in 1000 to 2000 infections results in clinical illness; however, approximately one-third of patients with MVE die and about half the survivors have residual neurologic deficits. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Murray valley encephalitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Venezuelan equine encephalitis (VEE) has a widespread geographic distribution from Florida to South America, where it is an important veterinary and public health problem. Focal outbreaks occur periodically, but occasionally, large regional epidemics occur, with thousands of equine and human infections. VEE is infectious via aerosols, making it an occupational risk to certain laboratory workers and a potential agent of bioterrorism. Effective prevention of both human and equine disease can be accomplished by immunizing equines, which serve as the primary amplification hosts for the epizootic VEE viruses. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Venezuelan equine encephalitis virus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tick-borne encephalitis (TBE) exists over a wide geographical area, including Russia and Europe. Human exposure occurs through work or recreational activities when the ticks are most active. TBE virus is transmitted from the saliva of an infected tick within minutes of the bite; early removal of the tick may not prevent encephalitis. Case fatality rates range from two to eight percent. Treatment is mainly supportive. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Tick-borne encephalitis virus'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38760/abstract/1\">",
"      Arrigo NC, Adams AP, Weaver SC. Evolutionary patterns of eastern equine encephalitis virus in North versus South America suggest ecological differences and taxonomic revision. J Virol 2010; 84:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38760/abstract/2\">",
"      Centers for Disease Control and Prevention (CDC). Eastern equine encephalitis--New Hampshire and Massachusetts, August-September 2005. MMWR Morb Mortal Wkly Rep 2006; 55:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38760/abstract/3\">",
"      Deresiewicz RL, Thaler SJ, Hsu L, Zamani AA. Clinical and neuroradiographic manifestations of eastern equine encephalitis. N Engl J Med 1997; 336:1867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38760/abstract/4\">",
"      Case definitions for infectious conditions under public health surveillance. Centers for Disease Control and Prevention. MMWR Recomm Rep 1997; 46:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38760/abstract/5\">",
"      Golomb MR, Durand ML, Schaefer PW, et al. A case of immunotherapy-responsive eastern equine encephalitis with diffusion-weighted imaging. Neurology 2001; 56:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38760/abstract/6\">",
"      Calisher CH. Medically important arboviruses of the United States and Canada. Clin Microbiol Rev 1994; 7:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38760/abstract/7\">",
"      Erwin PC, Jones TF, Gerhardt RR, et al. La Crosse encephalitis in Eastern Tennessee: clinical, environmental, and entomological characteristics from a blinded cohort study. Am J Epidemiol 2002; 155:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38760/abstract/8\">",
"      Centers for Disease Control and Prevention (CDC). Arboviral infections of the central nervous system--United States, 1996-1997. MMWR Morb Mortal Wkly Rep 1998; 47:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38760/abstract/9\">",
"      McJunkin JE, de los Reyes EC, Irazuzta JE, et al. La Crosse encephalitis in children. N Engl J Med 2001; 344:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38760/abstract/10\">",
"      McJunkin JE, Khan R, de los Reyes EC, et al. Treatment of severe La Crosse encephalitis with intravenous ribavirin following diagnosis by brain biopsy. Pediatrics 1997; 99:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38760/abstract/11\">",
"      Centers for Disease Control and Prevention (CDC). Possible congenital infection with La Crosse encephalitis virus--West Virginia, 2006-2007. MMWR Morb Mortal Wkly Rep 2009; 58:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38760/abstract/12\">",
"      Mackenzie JS, Lindsay MD, Coelen RJ, et al. Arboviruses causing human disease in the Australasian zoogeographic region. Arch Virol 1994; 136:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38760/abstract/13\">",
"      Burrow JN, Whelan PI, Kilburn CJ, et al. Australian encephalitis in the Northern Territory: clinical and epidemiological features, 1987-1996. Aust N Z J Med 1998; 28:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38760/abstract/14\">",
"      Kienzle N, Boyes L. Murray Valley encephalitis: case report and review of neuroradiological features. Australas Radiol 2003; 47:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38760/abstract/15\">",
"      Case definitions for infectious conditions under public health surveillance. Centers for Disease Control and Prevention. MMWR Recomm Rep 1997; 46:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38760/abstract/16\">",
"      Kaiser R. Tick-borne encephalitis. Infect Dis Clin North Am 2008; 22:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38760/abstract/17\">",
"      S&uuml;ss J. Epidemiology and ecology of TBE relevant to the production of effective vaccines. Vaccine 2003; 21 Suppl 1:S19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38760/abstract/18\">",
"      Lindquist L, Vapalahti O. Tick-borne encephalitis. Lancet 2008; 371:1861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38760/abstract/19\">",
"      Kaiser R, Holzmann H. Laboratory findings in tick-borne encephalitis--correlation with clinical outcome. Infection 2000; 28:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38760/abstract/20\">",
"      Kindberg E, Mickiene A, Ax C, et al. A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis. J Infect Dis 2008; 197:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38760/abstract/21\">",
"      Holzmann H. Diagnosis of tick-borne encephalitis. Vaccine 2003; 21 Suppl 1:S36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38760/abstract/22\">",
"      Haglund M, G&uuml;nther G. Tick-borne encephalitis--pathogenesis, clinical course and long-term follow-up. Vaccine 2003; 21 Suppl 1:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38760/abstract/23\">",
"      Kaiser R. The clinical and epidemiological profile of tick-borne encephalitis in southern Germany 1994-98: a prospective study of 656 patients. Brain 1999; 122 ( Pt 11):2067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38760/abstract/24\">",
"      Barrett PN, Schober-Bendixen S, Ehrlich HJ. History of TBE vaccines. Vaccine 2003; 21 Suppl 1:S41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38760/abstract/25\">",
"      Heinz FX, Stiasny K, Holzmann H, et al. Vaccination and tick-borne encephalitis, central Europe. Emerg Infect Dis 2013; 19:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38760/abstract/26\">",
"      Centers for Disease Control and Prevention (CDC). Tick-borne encephalitis among U.S. travelers to Europe and Asia - 2000-2009. MMWR Morb Mortal Wkly Rep 2010; 59:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38760/abstract/27\">",
"      Gholam BI, Puksa S, Provias JP. Powassan encephalitis: a case report with neuropathology and literature review. CMAJ 1999; 161:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38760/abstract/28\">",
"      Centers for Disease Control and Prevention (CDC). Outbreak of Powassan encephalitis--Maine and Vermont, 1999-2001. MMWR Morb Mortal Wkly Rep 2001; 50:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38760/abstract/29\">",
"      Lessell S, Collins TE. Ophthalmoplegia in Powassan encephalitis. Neurology 2003; 60:1726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38760/abstract/30\">",
"      Hinten SR, Beckett GA, Gensheimer KF, et al. Increased recognition of Powassan encephalitis in the United States, 1999-2005. Vector Borne Zoonotic Dis 2008; 8:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38760/abstract/31\">",
"      Tavakoli NP, Wang H, Dupuis M, et al. Fatal case of deer tick virus encephalitis. N Engl J Med 2009; 360:2099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38760/abstract/32\">",
"      Transmission of Colorado tick fever virus by blood transfusion--Montana. MMWR Morb Mortal Wkly Rep 1975; 24:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38760/abstract/33\">",
"      Goodpasture HC, Poland JD, Francy DB, et al. Colorado tick fever: clinical, epidemiologic, and laboratory aspects of 228 cases in Colorado in 1973-1974. Ann Intern Med 1978; 88:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38760/abstract/34\">",
"      Spruance SL, Bailey A. Colorado Tick Fever. A review of 115 laboratory confirmed cases. Arch Intern Med 1973; 131:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38760/abstract/35\">",
"      Johnson AJ, Karabatsos N, Lanciotti RS. Detection of Colorado tick fever virus by using reverse transcriptase PCR and application of the technique in laboratory diagnosis. J Clin Microbiol 1997; 35:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38760/abstract/36\">",
"      Rao BL, Basu A, Wairagkar NS, et al. A large outbreak of acute encephalitis with high fatality rate in children in Andhra Pradesh, India, in 2003, associated with Chandipura virus. Lancet 2004; 364:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38760/abstract/37\">",
"      Jacob John T. Chandipura virus - what we know &amp; do not know. Indian J Med Res 2010; 132:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38760/abstract/38\">",
"      Chadha MS, Arankalle VA, Jadi RS, et al. An outbreak of Chandipura virus encephalitis in the eastern districts of Gujarat state, India. Am J Trop Med Hyg 2005; 73:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38760/abstract/39\">",
"      Charrel RN, Gallian P, Navarro-Mari JM, et al. Emergence of Toscana virus in Europe. Emerg Infect Dis 2005; 11:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38760/abstract/40\">",
"      Di Nicuolo G, Pagliano P, Battisti S, et al. Toscana virus central nervous system infections in southern Italy. J Clin Microbiol 2005; 43:6186.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1293 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-AD25BEE436-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_54_38760=[""].join("\n");
var outline_f37_54_38760=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9551308\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TRANSMISSION CYCLE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GEOGRAPHIC DISTRIBUTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CROSS-REACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      WEST NILE, ST. LOUIS, AND DENGUE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EASTERN EQUINE ENCEPHALITIS VIRUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      WESTERN EQUINE ENCEPHALITIS VIRUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      JAPANESE ENCEPHALITIS VIRUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      LA CROSSE ENCEPHALITIS VIRUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MURRAY VALLEY ENCEPHALITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      VENEZUELAN EQUINE ENCEPHALITIS VIRUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TICK-BORNE ENCEPHALITIS VIRUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Vector",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      POWASSAN VIRUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      COLORADO TICK FEVER VIRUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      CHANDIPURA VIRUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11535065\">",
"      TOSCANA VIRUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9551308\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/1293\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1293|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/18/21806\" title=\"picture 1\">",
"      Rocky mountain wood tick",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1293|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/61/16349\" title=\"table 1\">",
"      Zoonoses causing encephalitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/34/18985?source=related_link\">",
"      Clinical presentation and diagnosis of dengue virus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16088?source=related_link\">",
"      Epidemiology and pathogenesis of West Nile virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/39/24186?source=related_link\">",
"      Factors affecting HIV progression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/62/1001?source=related_link\">",
"      Herpes simplex virus type 1 encephalitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/21/2394?source=related_link\">",
"      Immunizations for travel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/5/5208?source=related_link\">",
"      Japanese encephalitis: Epidemiology, diagnosis, treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/50/18209?source=related_link\">",
"      Patient information: Encephalitis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38023?source=related_link\">",
"      St. Louis encephalitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/3/38968?source=related_link\">",
"      Viral encephalitis in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_54_38761="Bcl 2 staining in FL";
var content_f37_54_38761=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F64808&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F64808&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    Follicular lymphoma: bcl-2 staining",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 288px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEgAg8DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDrLa8tNQ1G6W2vLuO0jswwMKbIphgxhXBXb1zgZBwOauab9sLRvNcm2MXmWauSHBYsMtKAoDLjBXBAGCDUGkLZ6XpVlEJbn7DeM9xHaMrFrVh/rItxHKmRWYbsEdK0o7Oz/tQNDIq3hjjRd6EtPGpZivPRhu69egrz1qe82kmrf1t/X+RzfiWK2uJDJpkk1s8kP2OARfu0kdt2AZV4RSRnPXIPrmud8P3N/JYtoOu3XnaqiEXrOpkexi8xMPv/AIRmRSWAONuQeuO41zw5bzyxSWRe2vkm/wBGZYxDgEszJjODydx3DJxjvXE3lldWOoQWC+e80EU011fMARPGXLEyhCWMa5ZDHjncCDWc009UdNGUZxsn/X9fidH9nj0PVNX1LR4EurGGKO3KC4kEflgfMQq53vuAxxg54Nb1zrmoQ+I7S0NlFF5vK29wwWdxwWIUEjAGcnIwcV5z4e8WW1jYTWui6ekjvOsNlcTopkETHcbaRASQm4MARjHsa1dJZtOW31aK0s9Xuru58mKKG6nIspFYht8jAnrhcYx0PPWiNTpF2/QVSj1mr9F56euh3ry2NtqjX0guJbm2uVglaBt8cYfAC47LgruCjPT3rF12EMJ7i/8At8Jt5WjivdPhjeSVduxlVeWyCSMcHPODWZrLeLNZgtpIjb6JeWbvdG5QDELMQpXylBkLE7hkjBBz6Vn2Okz29p9q0XU9Y8yEHzAXQQopfaxVyQ5Y4ZQQCck9DVTnfSxFOko6uWu3f8SD7Vc6LfyaXp9lN9nsZ3ubqK6vIxLKu1WyNgAjVmVMKM5HpUOs2Fxdm5vorQ2uhXTxyRahYW8cpG872ZgNvmgEAk9RnqOasz6ytpqkh1O0guDJbBrEXO15TMqjGFyxLg8EkrkKAea0YtLmlvNBtvGtmkEbvO0jTIXa6lC8tIFJVFxtO0gADjOayS5ro6XLktJ/8F9dPM5mHTrC0vY7J7iZxIosZGunk8xSW3GSJhwAXJznOD8vNdPrkdzb6bY2xsYbq9WApvvWUzw4kPLDHACkEMeegrSstE0gy3bJZQyaLDAtxaSIzH7PHIocxyKzf3lDDDAnd25zj6jbQ2uoRyhvM0qcTwR3MTxui3BQYEhUfIvGRg4APOSSafI4pk+1VSS8v6/pEqC0udYXRprO3tJHt/NuGkdp7i54539Bu24GOR8wweK0vEC3jG6l1p7NLJoBHBZxsBK8JbbsKEbWLAfVe3Qk89f3EQSa309jaWrW0axj7Qpe7m4BYFcMkalcHHLZxiovGWkTz3dujarEI1g2QQSymS7ZthTyYI03MMjLFnyeRz1oUrRdg5Lyjd2/E5vU7xrxY5tQ8wzXkYdMusqxpkrGJCuDgEkBcAfd+plsIbuxvreEWZE9wistvhgJoYU3ecxOdwZmbjg7aZpn2GDUFvtXtLvTGSFPsSeUszJKxUK7Rtwy5yMheDtyCa7J5rrULyfQYp76aKKJGzfxeaFYH96sknUgAduBux2Fc8YuSu9zqnU5NEtDkNOvkt2itmt7WJ7zzVlFtO3ziUCMCIfwBQMjPOeh5rRsp7Kz1TTYmhhs33qk80qsDIqoU2SIhyz7N2GBAznjODU+n6ZqOpT2UUEC29iJzPEnmlpWQkDfk/O7ALkoNoAAxzSQWuoQy+IftMUV3G7CR4o0ZbhoopC5YbTlJAT3PPAI6URUk9RSlF3S/MpMWS0a78R28CaDC0WbaGR41iK/LHEVJ3ZyQxfk/K2c1qql3evJc2zJfWUUEjbNTfakhZVcKvAGz5cF/lzyD1FL4ntn02Z7ee6gutOjRZTCxxcEBF2kYyN4wVGSAR68mp/tkh1BbBZVuNDnt2a4udRuRC8bFG4yQdoO04HIPGOlPZ2ZLd0pL+v+Cc/pupxadqUI0S5kkRcTajbRk7ZMhWeGMNlQu4Mcryegx36rTrZNO0yfU7zzre68t7+ONXZo7SM/MqMpyoLcs2FAB25PU1BCmixaC02m2sEN7LIpgnV3ma1mK53MpI+faByONvPtWrq0z6TokWjXF9Pca5qaiW5uFhP73eFUL8uE+6ABzjk+taxTSu2Y1JczUUrf1+X9bHn2kakXs5JpZntTNdSTzXsESzLG7A7MRg7kwA3KA/rz3nhp9GE9zBLcwNPOGSK2EsjQNuUlsjgENu5DE9Rg5rO0izGh3n9pabpbW4ZWgmikiSQpG3zI4VCWdwxwFC9O+Dky6p4LWziFxollLM9yS01u0wjmL7gSqvgFT8udmOmfSpppx1tcqrKE/dbsn/X9foUNftdasrm7XWnsotOku4wbhCDklPmjjTO4AjOVyNo5B4rUXxE2oXTRWkNxpDWbI9wySK8sg2Z/dgkB9yj8cGsHUYrrw1ot5He/brK71IySLHLexvFFICQcRANuyDkE88YJFUVvIbtYrvQ7TyXt/wBxOsrIWdRhc5TaASCcj+HeMHGabnyvT/glKnzpN69n0+651j2t8lr5Vqw8y8gWKR9nEEiudjbQww5zu3c9CtGuaffXt4mqXTW0aRqkV2hkXbIm0gPhgRtJbPbBqKwvktoraWwa8F/ChhureQRmOXYzAFstkBmJ56gEelT3+sx6SlssTCIX0bxxxXEm8RAk+ZEygYLI/Ayfu81Wjjq9DK0+bRanDyD/AIV/4hnmstWeaKBkjHls+2WPG7ynx8nUkEDpnNL4Z1q70eCxuWFpHYQGW3Sb7P50yeahLeaqEnac7iep2DA613k2l3F7pU1lDDpsstzGs+JSyLcEgcxDoj/K2TjnPvXGeI9HuESRrW7vLqG4YfatOEkim5kRdoYDOdwAzggd8dKzd4u/Q2jONRcst+v9feGgtFHE0L6lGtjdvC09zcbhJc+Wq5tyuASrE7xt7EA55rX/AOEvi0u0j0vWI5dSE0oSdUhw+Tt3IYlY/L90Z6k/jWfpGpIlpBCsMjSrKZ4JiI5l+zhgotpUQ5j65BDcnaSapeEYrO3v7i11++1Swvbe6E1o5jWOI+UCoaRmAZ2DH7oOBxgnmlFtWsypxjK/Mv67nYeGItMvfElsVmEKf2jaT2ljHF5TWxSZQVZe0ZBBA7MxPvWz8RHgt/Hur3MV1NBIsKR3JWPeFUxLtIXByQ209vQnBAPFeHVJ1nQYL4QR6ims2VwAt2dyxvLHsXy1BDMV3ZLNkAMM813HxO1G90jxXrk8RAjuYEhRltzuJ8rGzzBzkl9wHIOOMYzXbQ1pnj45WrJX6GC9y8V1JeRaZPHJaufkjc/ZnGOHEgYAja3IXGG2Z71Lb63rU2s2SXN1/pqQJFfK0PmJbzDaN3BDJg5PzbkJ49KzdLkubi3gt9Ouo5HEc2qS4nH79VKH94wyysAiAqwzkemaSPSzczQTWV5pW/TInaKQyC6855D5rb92Dyd5C4wT0HFarscbR3TWw0iS61K3u7hkNwJriSKLcGUhhvXaeCq7iSMj24AqFGRHjTS3ujLGQB5TJEpBVyAWO3fCzbX4x147gcBp+rapqNldadE8UcaIsZlWRkVFPyrKq7du9yRxjkMSRmtrwpql7LY3lvfW9tEYZZrcrDI1uA7RMU3kHC4BZeSMZXHXAabuS42R1dxFpGsNaX893bi+tJZI98LCMtlcfuyv38BhhQT1PGRgYd5f2N1NcR6vbRS2e94p55mgEjfuxmeWKJvMAZsMTg7QRwOcaGm3Ubi1tUjuIbSWFoI7eeBTvlwAs+Q33MoeTleRyO3NRI1k1xFc6fceYwNrcarbSRyKWwpkRpmUGMBQThyQOmDxRYS0LOsWU1rMbCF7h1RcLbiaR4wEJIGwAO4wQh7n36DoL22h0yztjZWMeq6xEuxEurgnYvyAvyCQse5F559zya4q61RdD0/SNKe61G+u7y8ubmSeKYGORuhI2fNy2xhvIOWPbArYtNLMmnW4uJ4buZNv2y2uXUNKWUM0UjqpMjIWTaCdpDAdQaVijP1a+1TTb+0i0WOf+0bq2huby38wC5zI+GiQBQIcBS7fxc5J4rbu4Ibe6YRJpzrczQ3LJKPJZkTayxyCVWYln+baozhRyS1VrW1+zNqKRWbWur3sqXN0bhUVlACqpTemTD8nzEAnOeflqwrtC7TS6v8AaiZ/tZljOTJJtKoQGwrIoVNqrkHHTvSdkNamrHPcBHjS8t0w8TQxW0hiLZDAhW6nbwzffyc5HFNmutLTT5bi2jtbm5RVSeO7YCSRC7JICijKqSCwkUAZ9gazY2uocefPbi9upTJDJBCsZckZdEHHzMrMPMC4PGT3MGmw2UGptdJaSQpFB5RieQswmj3kzmbAG0qQGVWBySCCTU+gDpw9h4VWV5Li1vQPtEr2UzoslurKqnbuy4VSgAO0e1dD4ckxdiee9iv7FdtuyCLyFHzkuQmcEGTaQwAGBjqua84u7eB54tJjDWF5cjYRLcu+5zwnlrjKbP4fVmAHGTXpXhOwvNPspE1iwSyWYI4toTz8ijfmToVJ+7jkZI+lQV2Ko7RN7zZomlkjdVEj8qHGMYAyeDk8YBPJB7cCmxXPyK8jCSRfv7NuWPyjIz0xyBwOMetUpxHGy7iHWTC78EMygfKoPOT0688H14uJBLcSCGMwtKZkiMRZmMaHGSec8L3z6DvzvZWOYXarSqkIGYWKttBXcSc4GMDJ3HJ755q0moJBEkap5k6SkHaGxtyODj/e9cDGeab4h06xtASs9zNKSZNrOMRjA5JA6fKOKpMjiVY12Bnky3nuVYD0QcHnaPXIz7U9GhE9pBumguLgRZkZQJl2YKenHoSfXNRgLbSvJvDHcWDn5MdQScc5A79/5Mj1JYrQrHDBDHwrytH8wY/eyCfXGfXJxmrerXSSTs0HkvcKqsZGTKZDEBQAdxIYY6/kcGnZ3AZZSNc3YBYQJ1ZDghUZQfl5+XGR04PUZrlPE2h/2rp1w9rBDNvkQqrkZuSBjLsvX5c9fbIFdVeRkRwzXBi2H9zH52N4DDOCO64xj+LgD6uIkuQY4ZbdzExIRJseawJ+RsDO4ZB+pHUcVLsOLa1PHr2WOR7m3eC8urmGPckLTs7qVbJkQAqilegRht5XHBFb3hPWLSW3tIdWmuF2wGxRpf8AVSRfvFRdnJRxtA5AywyOSKueJvCcOozRvpMCJcSK0V1BkHzY3cHGH+UkAMFyR068Vw2pas0s0ltZ2zJbSbJJbZyVadljVd7Mx3btpYq2RkhOeMnGULbHUpKSO+t7yOawttsQ0q4Oy2Mvmb33qGE0QRgSpB6Ej5u5IIFdhYO9zZCFo4jcG3SS0yQyyIEAUN6NuYqee/B648x/tTTbGHThBJqBe4uWYSEFRPAyZ2iTGBJgjkEY2kgZGa7Gw1OK70jT71xL5Wn3MVvvkLAyqy7SGOACwJwR6qaSIkjb0y5a31ARrHJ9idVSJDtZbdlJCjd2yGIweRt9xW5mOWSSQzK1vNGJEcfMNpHQDv0z+NROLeVoY2+zuI5FKgfd+8PmAHGeOD2xRasks0hhkd3UlQWK7jhcg/gGFFzJ6nIySwbbm1uv9AjjYCA203ltGoH/AB8DaOFdxt7g4/CoX0qOKwt1eJLmS6k3broeU0wZlIDDJy2MkdGXJ4yTWxeQyWV/OYIo1uLpQqzOQX2YBIYDA2kqfxbj0rH1E2CmO4ga1u3YxmCOGVfL3rKuyQEnGcBU49+CDQ7IuN2WbaFZNNEc91CqzXJjWC12HDQ5Jj3A8k7TlccE4964K5124mjFtam1soolZob6WVymQ5DBeFyfnKkj72wnnArR1vUnl1P7bLbAI13HG6OztBIdmEVvL3AuTgs3GCqjPJIraHp1/q3mWuqQT20EbMjXKbvNU72ZUUAfdHOULHZuHfFCjfWxonyliea/itYDJdWE+gXl3NMLgcAM8zRmMtkAqd28cZ4I64NdDo93dX0sDrA4hSJ3WYKY2ZMhEJ38+YcE8gjGPasbUPDyalOLKa1uvsyzRzG3ikXdNgNhkUECNgQATnoDxzUzSLcXjzaVatJKGePUJt/y3cIR1Rj2yWBXjkbeaxTadz0pKMo2X9f1/XW2/rtzbafqEaSzkS3BUrbOcNPgHhT1ySK5DxtJue9N0l5aamskb2zWhCzlQTgbxwVIPKkjA5rb0iSN7uK1ErzM8Z1GNLhhvtNyn92WOTncTx26DgVmTeHvtqaz/aTtJNqS4mEM/wA1yoI2NsbCqBgBcDdwc9cU6l3sFFRg/e/r+v60OdvbqFdV1WCxmef7dLcJd2T+Wse9FURsHJDb2cE7S/K1o+HU8RX+npZz6bc6fa3UzRvd2+yJIEAYsoDDcQ5b15HAOcVJd6MYo7mC3XTbKS6VbiaS4iaZLiRWGyQAD5MYG4YPDY4zWescl7rMam4na1sY2DwIWt4RLEpKA7gzbiQzDdxtxjrWKunqdbalHT+v0G+EdO037fqRj8QPb6fOJrRB5x82KROP3kmSNmwFsjGdwGc1Fex3dzKEl1ZRexXBa1kUOI5D8o3IrOVyVjI24JByR61f1bSra003z9Pxps9/O0E9zMrypNGVyU2qNqv124GOnOarQaBZYgvdSM1xayOGaaW5ZFjhO4IGA4KkEgdyxApNP4UUpJvnb/Ip+FY18Qao9t9ma4aa4knDTSyg7VJLM/O1lDbOuCWHTrXS3NrBZ+DJzqssN+tvdRTrA7SASAYLKcNzxzxkAkZFamkWN5f6RdyRJcR2fmtKslzKbRn2YVlXyxlIuOncjJPNc1dus9vo8kCXN1BC7TmO9GI3gZ1G5pAehJKoDz6gjq1Dkjch1Pazsnon/Wv4DLGbUGPkWsE5RrNZoo9Pk2RQ26jcYuRjGAoPdix64qfVtJk06z1Fri2MLQaXFcG6iuJBF5zHYsW3Iy/bfjkYyAMZ1dZuNSs9UuNWXz7VpPLhjjdj9miYYZFwMEg5wCoxkHPWubOuWYurO71qGfU9Qku1W2UXafIY2J2uAP3hycjjoAOO4+VXUhx55WlHbyObhkm1rULq+vrcxMsKeTclAkccmSscjlQOMA4Xqdw7kVtQaZeD+zdQmm0y2u4YY7W106yiZi6uC+64Ck4fJ/hyeMVJdabq081tPr95LNavdC2fTo0MDAFSAM4KhcMiqTk88AdnRQTaWt9cSGBby1hK+bl/tELt5uxI+oVBu2E8ZK8EVitNzolJPb+ug200mzvpNP06OW51XUYJFSczIsVtsjYZX5m5BVgxAJYsB07aup2OlafqkkZk1hgJo4pJVkjgt4VCb0jYk5LsmATznp1FTWf2m8gt7G1is47OO1luY/tQYSygEbw7dF3tggAjgjJzxUokjvvEOj3t5a2xne2jeOOLAWQZIykbnIBAHOTjafWnZW23MXKV9Xtf+v6/EZoWuus8J0E+Zp9wXmENyjKSuwZZWzhYw+1enJYdOatf2dcXVtHcX8NvFFLIriC3hRZYJFwg+Y5yeeQfTFV/EN0NRur2PZdxjaEhl0+IphARuSQuNgUEZPrx6VcVpLuK8s7KaOVLQtctcyMkrLFv3rsIIDAH+Ltg/SqtfR6kPS0krdzE1Cwuv7DW0tYNKSaFAIWecGWR0dg3lxkj+8o3kkcE+lQwWOox2uiPe6eszyOsQAeJth8ziFmctu2qWYdxk5JAqa5e51lzYWWyVZLiMR3FxCY1tJd2Qu7oQP7vPGfalheNfDL6f5bX4R5LqJ45kjEriQj73Bwc52cHb3qNHr5G15JW8/zNDw94ftJGbWNRS11A6YZJDHCQyyXEe0qqdPuhMAnrvIxxXP6/a3WuCHWbi6vlnuCrvp8rYkWRiFCIpXcYQFHXGOT711E1kbfwbY6baxwS3d04luVRjEHhAIUcYIBY547ZNYmoTWRs5Fhup9OjhnBb7aS/l/e3lJtu/BIC4ycckdeblbl5TOk25ua9Pl/wWXPCRhtbT+1bjTZY4ZokhkuIlHncgI21h823uQOnGKdbWl/a6xeJbG6+06dJBAogTMckQ3KjNtVg8mxupOV6nrWadEmnmha7kNlGLqX5LqV0EzMgcMrkjccBCo6A5HqBci1XWX0m70uZHktFMiZdlV5WJASB2BXYPvc9cFRk5pRdlZ3HJczbi077+hja3dQC/wDtdzNZaiPtUbR3UgQLcQLjeQcgyEYIIwozx7Vkfbb+Y3otZLa4m1ORw6LEsVxtViYygXAVmB27lHGAM112taOsfh4xLcpNai4k8+wCsGj2nISLaCCwIzgk54zXLR2sd5HqUcUUNv8AaIUFo6y7RCg+Yu5ONruNqgckYbp1rOSkmb05RcfT+v8AgnUabdWN5pflW1sYbm5uNk9u4Kss6Hd9/wDiOQOCeM59q1LrR1aCa4XT5r2znkTGPLRecCR+mOG4Prhq4K/spc2h1DV455hPtiVlklMB+ZQgd/lbpz82ct3rZ0XWx/wjF1aXqTGTzzBdWPmcmRSGLhWBOwn0PUVrGaekkY1KT+KD/P8A4BrXVtPZXU0epWNrDDZgTM0dy8ixRkHMgjc/NEAApBwQ57DFat0+TDcXFs4guMxtKkg8xAUVgRgkk7sgcggHHSqVxqtrfpZ6czrab5mjkhjiLvdE4O9ecBN5YNn1AqOzmFle6lJDaRxQWlulutpLIzuF6jd33Bn5ZeVwTmrTS9DJqT3WpN408OWmsaQIrazt1hikkaSOLCTzzKu2FBjhV5O4jHQd6y9YshomoQyB7bU9VXTlZ7C4AlkhUk58ovkhMZXg5zg9627uDTb/AESO28K3sFlrF1AkFsGi+dEAyQuem7JYtzn3qWHTEvNCksdSRTfFJRbzSP5d0qI3DLtJcg4J685xgZwKcL3aIjUcElJ6dnv/AMMchplro9j4u8P6lE2o273Wq21qIZdhM0onQLNtDZRNu9MNz0rpvi/qyaP8RluXnSZ4Io5oQkpD2z5jGw9QN4UnGBkEnr15bQ7SPT/Fvhq+nhSSPUbmzMVwqBxJIbiPBcqcbguRnJ5zkda0PjdLayfEK+g3osm2NZJI42aeNjFHtC8gHgnj3PNa4ezg9P6scuP/AIsdb6fqZiHUNfvri/0my08sxRpUjlO0J8xb5m2/OOMqAWbI7CtK31RU0rULvU0khjMym4vCggCsx3JI0ZXdHuKqo8sHkMuK5vTXh1Ca71CKJ3luJliQC1U4Hzb5XOfvhVPIA543ZIrpbPxBPCt5d38Et3qscvnrGygmEpHtBwxXEjlwflLBQvY81pY5GULO+uxf3i3E9pcNc+XGLu3mbYr4IMgAABL7SxGBlt3IxWh4ftLaVr+y0qO6hsI9Plt7gM7Rr9oiMg8wuBgsVGS2D9cjFZNvJLqFq1lci5ht7VZbiW9VjlWJ2tlWJJjXDYCZwzHAGeel0TSTa6RNc6yHea3SSGUyYZpXIBkOGycAEjCgBvlznqaIZn6jBpOtWems+oapBe2zpKsrSklYkwzEErvTeWAOCQMAZxwbtrexz2Oo2F7PGIb2V5ZrqKDY6o+1kX7QTufazD5lBJxnoDixpWmT3GkML9pZUkM5hSWMNJGgTDQxgHPmNsPBYD5gcdjWu9PuLnUy2o2/7kTRXUjPI0kIkAX5ShPygBpQoRgNzng7abJRJbWNnZyedpqpMZJ/O8+EpFM0ZIBUllG0Pj5mVs9ByCabc2F3bwR6bpun3MtvqD+dvMuHnBU7MSKeFQMx4XACqveoIrhvs2mf2DC1taQr9luotyZjyck72wCTgAgYGFIPJArcS/jgtTbzS3Eaxt9m+2xKAiqWLxjfypfAUFvugg9QcVD7lbaERvLXRo763tY7osCtrLfDeUUrG22GN8YwgXadv94nIPFaVpaRXMtxJcKLmZkQDbKSkNyy4KcZZV2iP5g3Iz3qvHZxRyW1zJcLbXEkjB5ZJB5xVVYFVXISRdhAAXqeQOM1HYjUYZ7YtNFbXRkWa6CP0UBVb7xPykKAcj+JQvehiuVbDTJpdS0uztoZIJEHkoXYSLC0O3DBdxxkKu5tvPcnqcu6ubzSIb+JLq4hJ85Y7aaTcC4YBSpI3MTxgNjgZJxjNnVtRistZDR2MdojQ+WuUUiNlK7mITcAqbg2OowADhq5e4kuvEPiLbbWK3d9qN4SxljBV4kXYGC5BKZVgScd+Rmp30NFdanRaDFcvrWn2dxbSZ3KwltrlFKkK0YYjJOwkAlh/Fjvg16LGjXFz9oedH3Ltklc8l8cMB0Az0AHX61zug6DpWli3u5Uh/tO4BilkdgWYlxkhyAwyACB1HPJINbU11vnYyiAQogLI5JPybiS3HXJHHBOM81rBNGFSXMywt7PJYFXtQ4m2GZC5z5gKEjcOoAI6DsfelkKXU0+oWubQxSlZQx4cAADI+8RnkDAHQgYOaZcJ512pKKGMJONicc7iFx1BI6j0PWnXJhZfmgYrndGzMRvDAttOMkY3dau6M7D7iRiGeRpHuVG4ySD7rEHoew4I5H61LcTq0887Os3kvGEwc+WRwpHqMtwCf8AGqMSEgMpG35R5bqei/NwxzkE55Ix17nFMuJkt7jF2qQFGBCYG0fMM5HXHKgHplhTt0FcfA9w7fLL8qksMEMc9lbB254xycn27WXhi+yxu08iMA5m2nLxL1I+XII5yOh7802d4TNNIm1gjBQT8pDbc7Bjv0HQ06OC3WX7bdmOW3d9pUgbgwB68468Y75HA71ckUTxC3aZt8KlDtRBk7f4R2wSRjaBjp+JbRKbSaWJCIIyspDMqJlecbgOOMZzxz3oE11OkyTbInLHaJAVwQvByOgDNj8B061UuUgvJkBGzy/likGWPCjBI6EkcA8HqakaLG7yraB4VVoI23RzAfKuflyCSP4icgjncMDivOfHtjt12S6L3Wm28bG4jjaDO+Riu6SPaMtw4BAI4GTnpXo19HHZ6rHm3YyPC0vnDlgQBtG3nJwOQcHgYzyaxvFqyxQx3kcPmPYlrnzpFJMZ25fbIvzIcAjkBTlfYVL1RcHZnnCXF09hPBYJpw0yGZpAkjiOObEqEP5IZREMrsDKFJEmMdTW14MvGsdC1UXV/GLsFofOSUhPtHls7SptypYMwU8gE9weDgX622pQWtxYTGSLXI4obu0uZPNmhMhGQihOWTYOh7cjnFXoo49k+o2lz9i0u3uoo7hLWUNIJNoBwpwEYeXuaPByCy88Gs7G56z4UkmfTJFne5xZysYDdthygJRiW7jqQxz8pU9ea0Yo4YNRlcI2IyJDEvJLAMmR65XGQT/DmsDwmbe/ubrU4EYySMrO00mGCeXuU+WCQgw2Ao6ZbPORXTPbEiEJLJFJHIzgDDblPr0GM0jGWjMLxPai2ezeGJAQjAoWYrsHzFSR2JABbtkdRxXHeKNJs7HS0tlUWzPcNY2hWBcIEDP5oj7thVG9cEg5A5we48QxShxJPcxJAytHcOwIBQKxYIpbbu7cgjivNp9ZlnVLfSZZrq/jnAWWRlXEm1VMbkEqu7CuAe2BwaGy4K6MCFvteu2oS5tsXMiokQZoZJBKGEpYNko5UtxngMOATmvZLO0EEYYIRbi5b5UIGSE25CnGPzPU+tcB4Cglk8QyXJkgKbpJUggyoiPCsdmSTuUZJzyRyK7+1Rp2kt0mkudyq+0hiVfJ3MG6HgqCMcHoccDVImbOV0+3vLFdMlFmjLbGQy3Kkh5mJKsCrEkDHIbJ6Dis+3u5re6jl+xvFPeRl7uOzuSVYO5YPGCB82XHIxlT6jFdFY3VjaWV4wnjj06SJTDC42LgAknaRhTk4Yc5+U96xdXNzqdlf/2FZQS6tKqsAlxkosZUbZFwcYBUqowc49DXI1poz14O7fMvmXtOkM13HH4iWztjMftC2rQkbgm/ID9ODhgD706yv0bUrS4v54jLIPs0TsAqh1wChPYksDjPXGKbo8C6v4kv7S7muhPYQxiKUqMKyHazr1AYs33TyAOetSaiJ9O1iNFtp1aR1jEmC8HlncXJJO2ORjxuOR0z7NLS4nZycetv6sVbnXbKO2fW5I5FDRG0iNwCIx5rKAz4JIBZQCQDx7c1WsLa91XxCzJLYsEeGa7F0nnQpIEIX7MWx93JIxjOD2Fa+g6Tb3MsWoaeZNNMcZja38tXiKEDzIsAkFRkAYxzkimahoX2ywuIrW8mttYhl+02slvIyGJsKnUhhtA+Xp6DrzRyt6sftIRvFb7ehjXd752vp5k9xBDFcJIs9sPLabzQV3E9ApB49171ct2tdHkg8rTIxqFyxiubC3mWUhBKZBLz94kHIA56+grZtCg1HWWnE9sYriONTMEZrqRVwH38lv4eMAAg9ya5y90ZLvS5Ik02eOzigZULX43LIjgoCclVYqABwT823oaTTjqWpRnZPRaf10NjxZrUmn3ukokY+xSRrLBILhY1kYDCxgdxjrn1FZTajp2nQTQTXM0EL3S2FpFLEZVu3AIBAHJyRk5GMkDocVDJ/Z9tBKHsWu4ri5fzrORyBb89kUZEjN908KMcYGKyYoobiSxsLRZEtVjkmu2nRZIrdERw0wONzyE4ALHkqOgqJTblc0hSSjbt/X3mZaaszwu2qvqDG3uJHit2nV5bRjgKcADcSQvsq8AVFpmiXd/qNtqM7SrcQSxO915KokUSgqGBVgGI2MSQAcYzVG23W1qbyO6slhluVhjUSKJCM7gEVkHGFGG6krgV1+oWMNzDcXt008f2e1kuJY33LJezPn5SMdlGDgAc8965dZ7nbJqnt/X9f8ORwadbXs5mlhubWe61Bbho7yQyC4YRjCtnHyjcDk+3rV64C6lptxeyrFBYyPI0NnJcbRblwFB3jhlLK3BG3IHvWlBcCximn1v7NNbQZnjNzFmSOHy8KzleAdxI54IHHasOzn/tO0ngsNPtRJp6LIHaB4yVbDBnfI3Kxy21cjpWlraM5ruWvRdf6+RorqtxothbWKkhoRI24wpsZmBJyoIWTOAQeMhuOeKzdESySystalv5rW7u533Jtyib/laPDZyp+XCr/Fx71e1Ozg1NIEtraW6jinltt6sVSMlD5nyZBBXCkNkZPHSoPEF7G0+m3cl9Z/2fDb/aFtwpNvFIGCBpVxuIL7AOByCaLPr0BWei0b3/AB0+ZWtGaJNQlRpbvSmtHuGk83cGg5+dVYbjuPz56r0xjFURrMOoTNqS3VoyW6Bw9pvSaZQwAgJwAgAJGc/xDOa0rTToptJhkh0+z1G4eVENoCY0jd0KseoJHORnoGB7Vk/ZP7OtwBdSPLFGIr2yRMxBY3K7JTxkg8lv9nOOQazd0rm0eVtrqWE+xW9vNb3cDi2vnEEEdpdIIohE6FlILZViCwLYOe2KYkEzan5lgttc3ZgE1sJJALdIUO0EEn7ygbjx0XODmreg6bPczoi2RuXsI/KMMbgq+GBBKgjIxhQM5IAOeMVhaFYafd65/ZLNIb3UXL28yIqxucEEEEZU9d2OwGKNXYd0ubXb+u/Y6PVdavNZ1+CGBzDLHakoRAG2rnLNGdpLcAjJGCM9OM0ypgnylrdXkEqxLHFdOIjbRyEIzMrY+YkAqCerZOOtHhy3DOmmic+dIk32O5hkYy7xNhyGHCR5LfI2c4zVKU29xrUge4v54CdkvO5oyuVClj8qr/EcE5x7VUm3qxRil7sdEiSdhNbGC41C8kCjbPZ3QKttcny0UruUYZNoIBJGa2pLqXR7a4juZHu3ijbz2tVkZ/PiXODIAFB2MoyWzjBGCKz9Lf7Pol1eadJbW13ZsksMNxHFJGGZRhlkz1QeYQOSMZrKh1W9j0y605rGSWwiZbpnZz5c7DGFbPG0gZ45IPc0J2+YOLlp0X9f1/wDf/4SG6lCfZk/tKCeEzxmJG+0RFiAjAsVOATjLc4PPANPtLUyWunhjL5kUJGxFWzETrgO7jYd2RzvBIPPGax/PuIUNzb2586ZReFo8sEXaqjdxuULuOASfqDmrml3dpBHNa2qNOZJlh8yKKQ+aVYMUYSOWUjByRgYJI5zgUr7ilC3wo6GO6vbHRri91i5ur2C3upbtf3RRSVG2MArnCcE8DcSeQAcVz0zyW02qXGpWFuviS9aKYTXUi3KWKueI3Y/OueSGVSMnFbFhezie7t4Z9QguZ7jyo7a3gFwrAqdjRlsBV4+8+R161z5+z65Hdx2Ev2eSd43nQOFkZmUmSOQkFZOSWGO4UjFaSnoZU4Wbv8A1+n+ZauIP7O0+aUyLNfIdn9o2bCb7Qka5lAPAR92Bkg8L68VpLeW8WoLf2+V1TcpjaSIf6YCdrQ5cZBPJ6DjB55rhrXX30a7lsdPuRcWf7z9+8QDKXJDJ5Z6MDznpknvzXX/ANqyTxWN5Ekl9dlgIZkRBNDIRtILrjJ+bJBBOR0yKUZx6F1Kclvrc6vWWs9PtrHU7y0ZdOaXZcQbDILcvuy+VyQM8DGME4HWi5sLLV9PY2VzYXVvMkaWt3bMUfbGwJV5FJLYb+HjuD1JrI0q4ttQt7uIm6huRCwgt5WeONfm25XGMHcMlScg5xWtb393pkijUXU28UgjtmtLTzGEZZVJcDlsnO4gcda6oyi/Q8+UJR0T1Rm6ONNtdTtrSSzmmuJNTtHc/ZgIrWYTqQc5OxmVtwAzw2M5rE+LN5NJ8RtYDqZbOzEY8qW389Hb7OJNgH8IOFHuTxyCK7291OZJdNiuLWCBptRtUS3mmywAuk+ZQo5OAT16YzXmXxtmkg+IGussW4v9mjR8CVlzGm4qp+6eV5HPPGM5raEUo2Rx1pOU1J9u9yHTY4tC0WSW5RLsXksvl4hkhFttbcWSULjduZOBjhMDdSWMNrDrNibqTUHOwXEUcQM8sLfdL4j3HIcSZ+UYwOTUMVnI11aTXemalcWyRS3ADSHzJjGQFBG7EZZjHljk8MegAp114elspli1nTpooo0ghaG3iLksA5X7pBZFYKA7Y+Yj+HNCIbRc8GwHXL6e8kcRyvslUFmTzXUFdrBjyvBPGAcjI646t44JNttBDHDCCksahvs6tM0mPl7HCkEOOcMMZNc/pN9JHd6a+gSW8sqWsVvEtwVlxGxASOPB+WTEbF2zkbvpnV1u7ltb8R7JJfKjKGGR5JTar+7kVyeMgZOW/ughSc0ImW5oLcH+wfKtb6d/3DSQvIwZ58KMKyqS24sAOVJIB5rMTUbQapqd5JZCJ4nQbvOAjkcLvVgjcjJaT5FVifmzjANMtYmsJXc3givJrhoo4biXzZEH3VdChVSxCvlcn5SccgrWPFHq9rctcXtq8mqFPs1jFdTKFZvO3M0QVuQ4LMGC4HKjIGKHqJI3NHe007yhFeXc9/psk87gKsSu552HA3HZvXIA5HGCAa1JLcg2q30Ml8RMGs9v3QWABZsA8LknJO44BxzWVZW0tgLy50KK4vXuhFcyDakjs74G9gwXAVS4IBBOzGBmtuK8uoNNllCxQlZy0lnb/vZJF8zjIY5YmLBIx1PsKkGzR+0xx2Etu1zDdSKWIaQMPtLY4TnCYGQNvOAeeTVJpUe/BvFRhJEYw1wRwq42u4AHVlGCAQRgAZBxXnuHuURbK5R7SST99CYsFRjYCU25G7kgjglFO4VTbXIb67gOo3MAYo8MRWRfNAB2RuuOGOfOUg9SRwD1m1h2uYXiCGV9MtQ9vp94PKFk115isxIc+YoUj5FDAHzGwTsGR3qz4MmsW8SSTQSrDLuD+TaquJSiSRmRccIvzKSD1bnkEVm+JJpYrVNQ82WS7uACmnQTbnjG+SMvtOcxuB0zncWIHNVNA0yW61eJIrrzds88Uc6WhU7mUIRIAdzcnI39NvNNFvY9RiWSOdhEhR9zTuknlsSrBgN3y5yvP3eRk+uKtIDPK0rMY1mRZYwIiVTcMAdOBnJ5xjJ6Cqc0ibJ4o2geEkJCj5BmXkHOSB0GQe53HPrPDKYrnEhPlOgiCjJY56EjIyBnpzx+FbXObca42srNHICku/ZtAeNC2Mkc4bOSM9R0xjmZpfKhmYRv8rMjO0gY7QMAsc/T8c+tRLNKsC3FzIUV5HVXGG2YPp97cwGSOmMc84qK1xtCGLy3EpiO+VcYDcAnkgFSBxznpxQu7D0JhHDG6KH2w/d3ZwyFiOAccjIwB+fGMOBnjijTyfJjCDamRvSMjJJz8w5yST/PFFxEkk37/ToYWlGFiwPmUHg46buN3r04GOHwpJLJKIHaa4kYjy3h2jacAsM8ADjjrgcZNO/URDp4jhaWIu0lwYgUWfLOm75FXOP9kAHAxgkk5qVonEIYtcQCJgvmK5BRvlLEfLzk55HUjGeSKbqUbRXRjlRJCW3kISwIAJAXPXJJz9DwKYskiW8kRYuXUEs0m0hR0PqzcHuBgZ4wapaiZJHCbmJHa6dr0iZlRxuUqMKAWPOSSCOQeuPWltSy3Ut03zLIehj2EyLljkd1BwMcYIPaq4sI/wDRXW8jimhJ6MRgtHtBQZ7AYxntmm3SmRB5MMwlOHebIwArAYOOBy2cjOfXmpkNFyLZJBcLFK0cj/fZFwZOTyC3AJ6Y5BGOa5/xYiXuhanZXl4qQzpHbO6xMRE27O4qOWXaEBGfY10N8fOhh8xkf7QwDwvGvlvLxsZu4OcNgenpzXOaysIsp5kFq09qykBpWVdiAHy96425y3zDkb+4pN6DitTi7rR4NB1fR31ZrKRN0s7SSStPA1u21Hh2qvD7cbCePu8k4FVL+WZL+zX7FK0uoO97c25gZnndcnJX74dV3lDjqVwckmpb/Szp6aDMb9rFJJEiV9wSFUdnbKyMmAm4r2wR0IZat/25FpN3JAkT29l5ck6ugLGQDloFZsNtCkuAWySFBGcCpSZq32JvCTyabr+k3lzdXkl5q7486VEX7RIdwfcgA3dzgjdn8Cfa7JvMsofJCNtAYs0owQOvzDggV4bexwaZZ21ndTxNqL3H2lTNbFPJiG0KoABZWby1+XrlfpXsFvPHc2lvPZzj7DMqYDpuVg4yoBx8uCRnPpg1G5NRFfxXANS0twLM322J5ooQduR/czxycuM/3frXm93HI9tK3lhD5ZNvOXC288jKI2DzNghkw3yknAU4Oa9aiktVlnaKVizIJXZkwNhA+6ewGOnrXkuttFbal/ZkMi2qx30ltLbMCVdWk81JI93yjIJwpBCkvTCD6DfD2pQ2GowXUq3kQjcWLZIkjUSOhCiRMluGUZ4zkEnAxXoo8n7dPaXEIuYlY3AABLDcxCspIAIPzDn8OteQDRL7xDMZtNt9PeWS4F80ZvQC8JRBGsaEFlAZDubC4BOM9vTtLjXTorm1M0ct/uE8sNrLnyjIS21dyjCgDuD+fNaJ20FNJ6jLy1QTGN0aNPs6Qlrk5STaR8pOO4OCWHt2qncvfW95a3OjWFrNdpJ9n2lWWWJGjXfyflbBUYOSMfXFb8UhvdQe1tTG32ZyJZdpVojnOF/v579qzdatZdPguLm0yZVi8+2hlUbY5VY7juzkE5zgdulYOOl0ejCevK9yz4UgkSe+mu4Tb3U8pQlQqx3AQtiRFBJG7JJJ598YrU120hv9MkgntxcFRvEEm3DMBkLzkDJ4z71h+Hr7zvEk0d5FDFfG0hCEBlEkRG9zFnkgMyjPtXT6vZzXdq4t5VhlP8RGRnB7fXFXHWOhjVbjVTehxejza/ptvo2nXFpbSrKrtJcxv8sNuAuwEk/PKGIHAwcZ9ql1NJJr9p9SLtBaK4jgJCLModWBYgctvBYY/Kn3U8OYzqk2yGOWMr9iJ8tmKqoi24yFBXJz+HWtrRreK3hOml1uLmN2uJVkBwokclcZJ6c8Z7dqzS5vdR0Sny++1r/X/DGFrERtdLsrrS4vNu/OS5gWJlH2gH5VUg9FVWJz3xmnx6RbXeszNqbSx28SNO8RnJLyEFfMftxgFc5zgHtWvNYW0WZCLhp3l8r7SrbyCWyepIA9sdKz1Zt94ZJFWO3tZGvI7UnzGZs+Wq/xBsZ4Oe2ORQ466hGbcfdfz6mPHY273VrqUJje4tNMO65aXElwnIxIBldqlWyRyTXCafe28epTRaFZsmjwtFcXMbxMieVwQ7DoQCSBk5O/nOK6B9UtpFmE7ajaXunbsCWPzJwuCoQLgBN2VyxA4LeuasaRZafqNtdX1xJNGfEUg82US7II2UK627A4OC4Yrj+HPNc0rT2O+DdJNy2/p/lsXrewS1tp7i60i2vNUvZ/s6m1MUiW8QBKbQ/CgoCcDkHPrV+//tCBjewTWqXtvbs019cr5sUY52qR94liw/AVnzX8Opy2sdm9xFZW8mLeNVTfFMBy6bSc5BIyeADxWnr8kIjmuprk/YbpR55AJWUjoDnnkEA4HbkU01a8XsYtPmSkt/6t93Tv3MG01K4lm1DVZ5o7c3EsaySxrl2ZGyE2AnJ2gAY+XnnPNR3l3NP/AGoNDd7mHURI0ls8akBehlQ4HTqQTjoBxWnewwC1EEkYu4nCGM6fCoCQjDlSVxtbcOo5x71i3Ns0sdxJp5ghkSAlbSQFEdd2WUHk5ZUX5WAzzzzWUlJaXN4crd7W/IyXYSxXU11etZ2kUG03EW2RX28IPKGOScDd9etXNDsxNK+rf2pcx3Nz/o900VwXLSsh2uz7Pm2kuu3GMYxVLWTPdW9yJ1tmZ4rdlVR5kcse87cZ43KzFSD2+grpU1R9G1DUreG3Flbt5Ze84VbWQqDGzRdChJIdv7uDUQtc2qX5dN/+GMO2uLSzs0eW5t4bx5nLOgaXyQFALNjAyW28nAAB7mr9qBqB1qwm8q11a6hEgvLiQMgkTaSg6HJCn5vTB5qvFBbXOmxLc2F21lFcGZ7lIlEVzGwG9gTy2HJ247dQeau3em2SK9xNbzRebGIjZXjiR8glTJv3HgcY6YBNOKa1Jk09Ov8Awf6/UxV8y/NxBC88EsceLptNkdfLDviN2kbliMg469TnFdLDvv8AUITqWsJbm4VkjmayjEglULu/3eCoByNwqullPf6nqOox2D2M9vGwkZ8us4VFXy9jcBv4hkHOfassX9jdeH71L/StPN6HjuLhGkNo4iR8Jt253sDldq4ODgnNXHTcmXv7L8m1f8P6sXHk0uHWJrVrj7XqDr5d1C9m5iu2feyHgEshJHQY4xziqc86vp+nXsIsLSxlmV5obeM26+eRtIUfdyuRwDkk/ky21W7lgsjcobHTrO4YSahDA5WGJc7I8j5sgZGRk89uanmuNNFlZSaVdXE1hFL5cbyDeJeV3Zj28g7t3J3Um01psUotOz3/AK8hI7ufXLm58uFYnwjLbwy+aj7S0bFicgFQxz1wDwKra66R6iZblJodUijikgKYuvLlQ7V2q5A2NvA2gcBc8nONKFWSC3sJrfTZZo5fstqotlR7lBjcy+Xj5t5yQ3BGDx1p7w2Mulait1Y/YryOFjLBDC8kmGY8BRhhznlcYycZos+gcyT20/r+tiCw1G9l0uNtQntW066Z7nyYGYSvIrHGFYbVXIyS3ygiq2l3cMVrb3V5ZyQ26uzm4cRBraRdoMasCflxuIYdd3Wljile6juNRs5xqK6QUAgLHarbiuQzElgVJIPy89M1Udbm30aOxjmWbTNSiSS0uYYQqTuWWRvMA+YgY24XsOvJpXa1Y7Rei6/1/Xc2NJggjvXuNTS1vYZV+w26W05QqURSsbM23DBCTjpg9c1Je20GrXbvHbvBNHGt4pMIEIEblVCc/MMKMNznHQA1DrkKXXk3EF7aIqSh7nTY4hdZuWGXePnIUKFyDwAevWsvxNa20s97JEkj/wClHEcisZCr4+VcNgNvJ4+7jPSieitbQmC5mnfX+vkVoNTstO8PwLrtgt/NcJIYoWgVpZXbcrKm0AiJmUurkcZKgVJY3YlGlW9/HYgoosG+yKozKcr5fl5yzHeMuMHrx0NaNpqFnpk01pq00un3sYEUvlQFJbbyyBEI8ZLIRJgsQFGe9SpHpMMWqpamVNJu5GvrW/WJZfKnMauJPLxu4aJzvOQM9AKpeYSkley/ry/rUmsRe3UUaXf2lZ1vmjsZY4ZTb3UC4wGKDdHgE53nLZJJ9OklsEudWbTLuwlZI0VS4YLEsLcYU9Q3bjnGOc1w+mazrdzLd2ulrHNqN3fxu/2i5DRyxtlgUKbUAIDbuBu7Zrfu7/XIZ9O09La5MySu6T3ILRyrg7o0kXgDJ+QknOAMem0XG1zCpCXNa6/rr/X/AADcvtHFxcaRcJ594lrqljPCwuDiPdcoGPHLAL2Jx+Vcz8Ufm+I2sfY4g+oRMjpvXJib7NGFmTHzHBYcDuhzjGRe0m+vbPW9AXWEEes3FxbwzR+YVjmBmiYFSqbWZATwTxgjJq18WdMvLXxFqeo3NypgvpILWytY8+dKWjCMFKgEYO44J7544rqpNcrseXiYuM0m76HHWaQad4Us72WR112+ujbQlijTxEsDvVZemUVsMSfv988a+qatefZ7/RSiWxRYkbcPmmVgyZVwx2phd29woHzADpVS6eNJUv1t5H1K4MSRObxVkjij5/eSE7drLtGVB6kDPSsXWNQn1fR5LfZAt2kCJdX6s0bbN7GNXDqoY4DEKTk7SRmqtcxR0dqlroohvbWys7jULcxG2itZSBMDtjyEX5ACwfLkDHAIzimXOr2EBvLOP7Y7ziMzGBXeSeISSSSNtT5tvmEoVGAcDB6gv8NqNPtbi8MbPcIq3qo8gIkYtsQM+GXarA4yWxknsoFnSrFrKGWeW7FhZzPL5ahTK87xsxZQRgeWGGRnGQo7c0X01I0uRx6ZDaXVhq1sLSc/aZpEEpkXyzEXYsVJALqC2BwcA45JFILJtalm1nWIbtHBMQWC5fzwrSrtKtwVXrhSAQuOBmtCx062WdZLuFI3l22+4XQwhZnLBwxPy5DEkjJ+bnk55vUbq90/VHvr+8QPZLLfyqFYebh08ssQo2jh9oOAQc8mou3sWkN0k/bPEivp8015p9oY45jHcti5EmVfMjNlYwWzgd8nPWuhla0vfEMTSsAbdfOljMQQJKRtwTtDbuFQDkbT1JIIxDdyXc1jNFpUdtZrCqul7CqvKyRylNgZiAW8xmUkcFeade60tx4qstU1GGeKylie6aO4tkllCwjCtGvBwo+fdn7xXqEoeoHUiV4fFFxpF5NCY5bCWT5mYuE3DYzc/dyzgsf7vI+Yk4mmFne+ae9tmlj09D5dvHGuJjuZRjcRkx+WG7ZZDncKzNTv72V7CGS/huYopmezuJ2MryuRsU7GwzKu1mDE7MscnrhLi4ibSpb++uLaGO3SSe3tkiVg8yqfvKHYqWEYUnAyGAxgk1N+g+Uj1m2+0a0g+1pe/YyJcRzeVJbhWBVBgZ3KejfMQEzxk4u+C7OQ6pLNaX8t/aTtI0l2geJpixXcmd+PvHIZxgjOMYNY0STIt1qd2br7TeQ4sZjMA8JT/WFUPymNHbaC5ztyecc9z4AhBso/NtxHM93MkhVPKWVVKnfjgsrdAeh2nB5xVRFN2R0s5leORy2yW32ebsPDsSpz0xjscHpg5Gc1Csq7WN0vlzNMSsnnBljH3sHHrjBPIOO3GFgE3kRpdS/aRv8APWZUwG7ZbjO4YwPXPTvUVxJNDem3t5BKituQSKY22Hbk7gckDODgfxZ7GtDAnZWkilWJ0WJFjlLjbtPOCMgH5vz4wDStCIhPLZoERQHk3qXQ4GMYGME8ZI6nPSqbQ7YV8p4iDhiSpO4nBD7QcbiCw+pGenM9jcyW6SCSQxugwzKRHE43t82Rn5VAbIzknPrTAllWGKOKW7aNgCUZxuUOTkMcgng7fu9Rjqaci+TfTzSPidgWIDn5OD97HQYGOp4X2zVeZortpFEitFA5iO+QSfuwp4HOFyeD36k8ipnuwg2osQM4HmtO+2UgDn5e2cDOAevFD2ERzCVpfJM8kONqEBPNQY5T5Qeo6cdz24yjvO29zGheOMgGP5VYb8kDPTK/y4plpDcK0jLIskbRhFJQbTnC54xkEkZDfWn221rlZRIqvGoUIyjIdwcKfTjJz16k57XdCBpHeWVIXYzMsm24DEbeOpzyfwA6Y9aj8t41mEgUs0m8opDRs45xnOAobaTknHf0p0ip9guPstw73qkbsYI2qQAevIz1xk/oaguZYGWxgsLby3jlf91IMBmG4NnHGWySAeqjPWk5DSLJkCK/zoiyRs5QEozYHHPHTGBnHX0xVSSeaK0himgW6m8vykt1iChmDHuc4HKHJOeSTjFMFw6vetEsM1w/MnlN8hZdpEb85B2MenYduakvTcPBcfMbl5D5KLNlxllGdyoAQDg8jPAzxnlSQLQtNCGCw3GyWzkUt5Yjzwqk4A47nGDyTyK5jxdpEEemT3dw8ECzx7EtQ6ICmAyrk8MDt+YNksW68DPSK8dnbs0f2uOQqqn7TIfMVNv3jySDnHB5wPxOf4mvok0W9NvNE90lsxaB1zJhiAHXJBzuwcMOvGM8UvQavc5CeG6+16asuoSMiXEt0qyorSwQq6gZDtgrvwFz1HI6ED0rwnbtHpK2V0twLnKwSxoOIWAAG5hjONi5Ix16VyGhaZbwR3KfZbWO4iEhvHRmzKd2UKqSwOU8w9OCWyFJr0K0fy0KlnMu7dhV2hhtOTxx2Bx9BWRc2P8At5uHu2eISpGy8AgqVPysc+mQwPTBX8a888ViTRtW06za4+23GYZbdrlQ3l7ZcNJu6lsMqgjGNoOT0ru7ySWe/R2UmA/JJiRRtwflYc8jBYYznkHGRWD4vsYp9RtJJ8NcwWt1KDIhEbDYBsY4wF5Lc9CuecU0THc88vdV1S000afZSrp811cGO4uo13y5bkxb8H5VJGQMnkkYFdd8NrOQ6RNPfpbx3N2UlaYgt5h2AlmYE7+d3O7r2BGK4i0uYYrK9i1C5vpnCiZQzqU3ZCLMXUbUXqQ2CcADGeDHa61Pb6jDe6eJLO5uS9o0EUjSzbkHmPKF3lVRywPC8kk4HNVHQ0kr6HoFobSeO9mlnaJ5EmuEkSMRzOgVC3CtlMvye5+UVq6lcfa9ISW381TEiBkEYfJfG0joQeMZwQBnIrmPDqRRWt1b31vFLqcwBvbK3udi2pkc8RqQMbvkJwxzz6V1ayWtrdXUsNpcQ3MK/cjKs209OvdtpxnsK54aqx6VRWlp0Oe1izsNP8QCW3u5LGzt5USUIyhYS6bdiBvmCqcOQpAwT6Vvx69cXd2lna21w11G3E88oMKo3Cs5Hc4ztGSoIz1xXI/Zb/UL+8mtpXu7aaCT7R9lQNctG0rKiRFs5VcsSxAyBxW/q9rJdaddrq8TQWJuFPm2kwV22bs/OGB3cBSCBgnPNKLd20VOMdFLV/195eutQuVkjhurSWwkZSsN4ZFus3ChsRyIOMMvKk4znHBqjplpcwabpstg8xvdRUXDG+yXjYLux3A5JXb06dK5vUo7pNV1CGwt9Zjt3G2SJIsRQ225jG6ZyHOTyf8AaI7Cup0a0sJdVtdRjmguU+yQRRSSu7nP8TDdwrZCDHBOTTUnJ2YpRVON1/X9epY128hTThJqtsRbTTRNcYuExEC6gOCCGGGGSMVnaxcw2uu2DWK3ZBmSSM24YFwPvhyR8wwCQG75x2p3iC5+xtdNDbmXVbxY2gjuQIcPG3CiUDhjluSeowKxXvdTtLaK51VdROnykTOVco8UoYM6Fs8xuP3YHcfNxnFKpLUqlT0v+Hf+vxLGuWs+n+I9W1XTmt59JuLMR3a3ELSPK4JbZuJAO7gc9j7VkWVxBZW15brL5KajCkcjWV0I4YnKkFzg4XDAgBSSckVf8R6Rfzx2reILq4M+oQSh7S1BZf3eTDlcja3IUsMjkZx1p3gr7Zd32qy2sFmLO3MjWdrIpj+zyPt3I6ZwCNp5GcEk9zWUledjoi0qd27/APA0X4lp5Y/7UupItR+xIhXyzFaks1vty4bAwNxJIYAn5Rk1pf2bYz29lLHF51m7rBbCVRvTlg7eWeACGwcgHgGopDA/2B9YNy13FAkJPm/6O6kcuXAUOfVePpWZqM+NOiR/JSUXK+VIctGgyMCTHR8Z6E/dBPWlorkJOVraE02+0luIrFoZJs43tABHAoB3MxGeBwPUZrF0PTtM1HbY3WoSWl2yiOW2YttkRNzeZlj6ZAOfTOa0dc0bWrS6xbWjQoyK8l0cALIGztV92QhwCeD+tQ3MVjdXFzq1npaXk8lsWgAiJgbBMYZRkDr1kGQeMVDi09UbRknH3Xv1VtxBfwXsqW0lpdS20AMEczSDNyipjYp28cocnnnvVQQ2FxY3JiuoE32kSSC4iaSRBuJ8qQYOAVON3VcCr8S3Gnx2aTxeRPHBtRb6TzEVv7qooxnGT1GCeSai0Owa91rdEIAkokVod+2OcgYUqwB5AYDaScAnFQk21fcq6SbWiRlW1jcDWbcabaTtYy3DLb3LyCSC2JXbgbTwR2PX1z21haxy3VvNqCC7dWkDwqd6y+qqchl9NpPGaoQaVHo8FldXkG7U45/miCeZHMuGdEXGQGDKp3kAgcZ61p+HdTsJJoiI5rya9UxGSOERRoCQSCe79898HmiMUtGOcm9Y62Kl79ssZhJBJLb3EkTec0mAHOWZUbnk4bBIIPy4yciki061tPECXd7cWosLmxQzXBt1KvcLkOcjlCCwYAYx1rT0+5jh1CPU7Kxm1WOC4ZZ1t51wq7DgjcR827Hy+nYmue1PUNNu/DGq3E8MInkuhA0VvJIMxufk+Vs73wCcgYH4VS2uJXbtbye3X8i4uo3mnJt1q7KQiRSlzAd+yORSykRg9HwxZzkjJPGaBpttLZT3ml3N1ptgJJPMt87mlcjYNkeMZwM7hj2qOO21jVtde3FhFDObeJkkaIr+6xtZXBOQM4O/lsAAAUeJrB7WO2jlsrKG3CYtvLKvtm3Z3szMGCjpkk9uMkUa2btoNct0k7NmgnmSOv2Nri21SWdbdVBZoZYVj27ghxkldpbJyMD0xS6lKkmnyQmztllhmURxMpSScsBj1x1yG4Ax1HNWNEv7S0udNja+tpZIBKk4NwhERXCopUdgATn9OlO1SaHUNSntF1NEG0TrJJEFZNoBZIcEEj7x5I7AZq7XjvqZXanZrTvqGn6rcWUWv2Ng+pSa4nyu97cPcW5Red0bPtJGDhgvPcZxmsUx3N9ZW0pezi0qFJDYIIyXSLhiIiDkA4Cgnd1ODmjWz9psLwXc6X1yVMhkK+ZHdESb4wQPmG0EoR6EAHtVi/k07TtPngto0AmliuRHdpuRGTDJGCOQoODg8cn0xSlPm0excIcuqWr/AK/r7husX1tYyjT9P01I1gWJpGlG7zZZCSrIcAuOHJJOMcGoJJ9Uc3FtLLcWUkMK77TZiNSMuW3fMvU5wSeox0qmi3Udjdahe25t0Fw1va207udz5Z32ZJCqBjKkAHpnmnTX+m6xdxm7eGwYqGtkuVeQxLgt5ijkbs4z6DNZuRooWWmvnvqaRM0XiezkWSSxS68qVr62RWBk/wBYYyxXOxvlHHHy84qvqIutbs5VX7NNPcxboEgMokHJ3RjkKOAXxkMQTUsV3Pb4nhjnm+32ZmiuJbZoxZOg2MuTwN2DjHUgHnNX9P1x9J0O71C7huLudkkW1niUbAQTvAKn5VHDM2B1PSr3917GbvH3o7/1/T9DE0k31z4ke7057iK4vm2PCIjLbwwW6DasnGScEKGJzkkZ4IrVtLAXK2MTWzWrNEJZFS4kEcbK3lHy0GQHZScMSOVyPbE1+w2GSaNNSkvJLWK5u2tZX22m8qN8wX/WFlVcAehzitTR9Qa4toLW6nvInuIUt0mntSYiu/eQpAyWY7sBuVB4zjNODto9wmm1zR/r+v63L0Fhql34i0mbUL77Y9nqFlF9q8osJVWaLn5vuMx5JTrznitL4pWkY8ZT7riK3vLpN8E8cbtJGsaRkEDayiTzABnqVkAxkA1qaZJaTa1DJFcqSJbYmMPuPM8YUn0yO2KreMrRbL4iajeqsSNdxr5l1KMlVSIBY0zwDuw57kY6YBHdSjaLfdni4qblUS7I5PR7C8m0kTWt3bTC5M8kN1tYNHHyiNtcbVUEE47DAByc1SeC4mtotPa402CyigX7TLOrPLI6cM5zgH5pBlcYQEAEkjHR6nqwZJIovtc9xp4/evbD94vQBtsnDF2VeT0DHryazdUu4YnilSO+gurKAiIE7wJsbwxUYDMAMlQcEBj1FW9Hoc6uU/7A1S10e4tcXcb3KpJFK9wI0e4D5BKn0BU4wOmSAAc9fps1jb6TDbySCC3jg3yRMo8uJkyNx3n/AFYkAO5cgtt9a5ieeVoNWWK4uoIlZTbJHv8ANZDHyoTPBdnfJDDOOBwKrpqAuIrnRksZfM06OWOJPPMgu8R7iockOp3BcbQRu3ED5chNXGagjhv9IklW4jvoLpBeCKV23W28g+azDIJIQnGQeSAcmoILV4rK5Z4o5ZiY4NPkVvNkMi5QxhWwEBZCST8uHA7VTguYfEEVtcT4sPJSSM/Z2VpI2J+YlB8wBwilXO49O+aXU9Qe2jtfsJvz5J8qbcTKkrqgQguSDkhsHgZOMcihiRFrmtyadaW9y1ytzeJIsl9HMJEjugSVEAY4H7s7xuXPGzrnFYN3qd7ql1omm2LtJL5m1GZECpCrbnAUEsSAnAJOVUc9zTF7dLq+mfarSKztbCZEt4MHz41PzsV2ksTuByx9CMAcV6B4F8PnSdBs7xyp1a7jG+SZQwhVmJ2LjBPBz+PIpJXLk1FHC3cOpWs0c15YTLbS2809mk0CQ7BK4D72LDAAOcsBz61XiljEb/aC6Rbgjw2yB03FHIbd6qCGz14wa9tMLvsu1lMl28gCwhtoUEDc2MHPYEjPBODWNc6JZSXWnCaJ7Zbe6kvzLbsI8SkksCcFiPp1yRgCqaXQlVH1OCvYbO4hOo6dahb9Wj8q1kPzNtfdtDY2u2xlJ69H5NeheDkmj8OW9jceTJc4dwkXypHG53iMjjaMspCjquCPSs9PB9i8EvnSt5quCsYYNGBtI2oXJ5GWI6YyuQdoretgLOJbeC7jO1NyxyhSyAdAdm3oN3HcAH1qVoKbuh8Lp5n2bdMQkZjVg3+qIYnnPB2jI681MzbZpXSVlzhcZ3YcDgbh04Ygj1OeACKPPtXt/OVod3zEEuQ2wrnnrzkZ59+lQvtjurR3kmWYEo0hiUpI+fmLcDaxG4cHjkc4Jqr3IsOMtvblUuFWaEOJI1cspcbQBwBz8xyM9CT3qd2gnjlw/AJdogoUDac7QMdSCpbJ4GM8VUtTsv7Sdz5kSqDIpDBCSQV3jB9jgdT7Gprmc3F1btcyldyhg8jKY9z4IUbfQg9cjjnvTsIhvcxqo1B9qZVp5Qc5kOMsx7jPsQevtWlYxW8Mt19ouJ/s8JRRIpz5oK/fyR6kDGMZbOeuG6fCSiwumwoq/OTuwhYqFZck7tpJyOOOcYqrNM1yiRxESw27lYyzBPO3Dvg8HPXqeelF76IVh1qZZY4rZZI4oH/dt5I2B8ZGBuOQRhQT05PXjEcsVzLMIY1YOMHYDyjDccnA+9w4z3H50sstvfzfaJbe1jjKqXEox5WExtIBI6j1xwPrUUJmt47R5UVYHRRGJHAl+YsHAA+7jJJXoA3r0q9gJ7cJdW4jWNIAXJYg+btl+bKtz3IOOg4Iz605ncXQglWEuyBiHDAFiVRRnbgHqOoz6cZoDq5tXlmaMEh0AfcY87wowM+hbncBz06hdKhgk05vKO8OSd/mhnYtuZg56Y4A5xwT+JtqwJGjUPaRmKRLziSaRQFYMAd0rDJ4x0x1PXvVeUyLA8guYpYJUUsu5VLkDaN5bIO5gxx6jtyaZJiJJZplaNkm81ZHkHyZ5KjvlWBHcZPTNXdRaG6jdru5aW2SQzbpJ8KueGAUjA5Ukck85xzigBZ2We2Ro4obS3WUxDI8tXJKkM428Hk+n5E44/Xddskjhg17T2fUVuN0J4jimEWWkBYgsqjJbft5ALLjity8Se9ttv2TYl3A253HmbSTnJG7DMBllPOd2Ohrkr20uL9J9T03fDqdxJ9glZovtThCFCs7Bf3XLEGQ7cA9CKi1tC1rqzR8OQXdmb+2ne4sbZnlJd7pJl3EDaofbk5AY/KOgGQOK7nw/eieW4nkljlt5WVolOWRFJYPzjGQwOB1woPGQK8+8Lxj+1NUn0uOP+yopI0WUzH540d1D/KWUqBsALBWw3frXReHGlhe3ngFvHMIZVkt4LdS3NzsCNtOMr5nBwOmTnnE9Spao6y0D213PFe/OsgLRqcnZhiqqSOT1H5fjWP4209L+xhWdYFid97PdYUqofcX2gAttDkbBkndg5rZuYbePULRLyOA3DMsih3IYsBubGBzg5OO/Wobgzrp07okVxMrPIISgJJ52gEkc5AbqOPzpJ6mfmeb6hoX2S0guJZHg0qWRZXmj2Rx71UlYzv5iLSAH5hwMAHJJGc2mm1tRbXNlFAIAgyJA5hkKLiNw7Ltwm77xbJYbTjNddqGjG8026t7uwtJC/MAihYxQyFG2SYyVUZwOBnLZJORTpbO3Okid7q8by5TJHcXVuJgZHH7wsp+QgcKMD5W3AdTVp2Lvci0iVfKutOvbtpZWmgullswQsQwojhlK5wTjGBwcfWtmS4srexWGSaFru2RLjUfMPnTLCrtnG0HJU54x04xXK+Do9Xh0+W7SzjW9f8Ad+VanJdtxIeU9HIGOQenSl1DWby2vmv9LWLT4takiV9Ud1Y2pCkCJscBSQOOxDEnmuSM7Ruz2Z0nKbSZTea+1/U7K4XTtQ+yWRltUaEyQMts5JiLZwGAGeCMnpzmodC8QaJpGtarFpsjT2wjEpuBbsju8QZUjJYk4DZbcqj398DS59Rlu/8AiX6jfXk07m3aW9nV/Mj5VG6ZDADIGcryRyavx6RLDd/2RcwOL+znh+wvbRq1w4CEliP4cgktnHb1rDnb95HY6UUuWW3b9TWfxNc3HiDTdO1CS8V7S1KL9jeQXF1M0eX2jG35VB5IGe2eldrY6vpGpaJb3MFxBcqoaVInPlu08a4dGBA5xg9OvIrjdNOsW3ha8n0bSYzJM0kbajF5ctw4L7CrCTBQ85CgnirOsxReHtfgTSBBp0v2ciLUbi3E0b7hy8hz8j/Jtyc43ccZrWE2ldnPUpRk+WOlv6d+3yOz8NSR3+lGB7wTiTdNab1O9UPJSQtySpPcAjjjvWXIdSsLm9m+1q2nQbIpEuICpiQK4VyD8uNzAA4wcc881l+Etbk1GxjvbxGa8ieH9/LIsUsgETKZWGQSmWwN2eBmtG+8Qq9up1CAzMIg0ioQI2K/fSVskccAdQTnFac6cUzD2U4zate5Rnsglpp9vfeIZYppwZklhlczTIp4GccL82G2kE4XHIrJ8N6jBo9paR2Nz/aNzM32nGWa5S4ZWEgMZXcBjbyTls81rTeIYX060ni0cXMoVZ0wwYhGZvunbtV9wwA2COp9Kx9Dk1K7vJnkubkvJc/aWtWkKuIggCk4ILhiT054zx0rGTV1Y6Yxbi+f9DXvNQuL+4guNNijsntpSJl1BlZVKqBsRguVck/N17VYkjtk1bVNIuL+Wa4xDfIl0/mwrJjB3BFDbAAuNx6g+9T6+LddOecebq1lcwrKkU8citEd21W2nGAM4J4PAGDnNZl5LYnVtXaSD7LrSY3ZnUSIq54il4BDnaNr4B6U3o7MiNpL3Vb/AIdd9SvpOnXNtOovpb2JS6gG4Y+QuU3OhAyGQEADGDVvSWKYv2uLIafbk2sf7vywgKgOijqq5AAU4+brWNPKAlrZ3Esuku4kS5tNzRoxyzGYg5HJ4Vc4zk9Klnf7FpC3DwY1OSAQWWmWXyu0jhd0rAjIkG7ghc98VkmtjeUW9+ppXWspPHf20wSS+zJHHZxg7WZOjuSuBs27ien6Vz/h+WHbH/ast19lEUcaG2maNbedn+Y7WOTgYOefvfStWZtOh1BZdP01r2BIFtWjLMEwkbF4zz+8ALNkEcn8qr6cttrjXVrJqDWt1fyTx2tsLXyZI8HeoJPy4yCfm9BQ3eWjHFKMXo0jZikW5s7YWmo2P9nmT7cq3oAkIQ/eUDhgRk+wIzXOR3t9dW+m2mlabMWhVWMbSJM8oRhkRsMKMrzhTxyMVcitZntjf2a2KzpYqWusr8hwFAjIGNuQA4PJ7YpLn/iS3NnZaHrEl7Is73N1LaskrxK6/Lkf3SfmIPsBTburvYUVZtLV/wBb2LNkq3i6jBa2q2rpdO0l1JGIhOHJEfmQY3F1zwxxjZ1rVs9F0XTVErajbXeqPGohiZWcRyAnA8tCGbLZIB+lcbd6hca80bXVzJeamscp+zhMFIkBAMmzHJyCRk5xwOtMntrGI211aLG9pfzrbSTNL5YWdVLIVCAMFOSAScg56d0pre1xulJ6OVvT+v8AI7PwtfQ6kmpapJE0erkPbRXMUQZtm8iNmj6H5s4xn7uDWPDHJbX4OuRCIw2xjmjaVVBzws0aH/VlSMkg9QO/FU7XVZZL24sWk2WkbAmFV8wphSS0hQZdVfHyE5PHPFVZTZ2t7PYPrRjtncLc/uj5LlTuAZA2QcKw2knOaftbpAqNpS8/Xb+uh1WnJpOoXzX95bQXFlaW7xS3DKVfcuC7k7QGyM5wTz+dYEF0yahcw2+nxahp322SRXeJ43dEAdpF+Q5YZboex4Gch/iHV7rUNIhMjxJpqszzeVF8pZvmXch5K7c8j7x9cVG+o3W+xtNJnhtLe1lEkEKtiFjk7y7LkBmRgu3Ofm6dRSc03YcKckr/AIX2t+psxajaymW71SJoh8qgkmdWGA/yNxuyFB6kLg8VFOb/AFTUL6OzvILESoUN5bRSY8p1BHkrncW2McsFCjHXnFVtSWLTNOkv/D11dx6ZNNumgLHEgz0VhkBDnA46jBHFZWl6ndaTawX0FzarPDIZWh8ss0ayKvyM38W1M/KpHI47inz8rtISp8ycoempTnWVYLb+27ew1J7ZY1iW4kGYwFwFygJAYHPzKDu57V093LcQTJaafBJPaWpt/OhSGNGR0G53L5JPHG3rjvnFYeuW7XjtdrHbukmb+S7WJfmRlzkyDGD8wAUDPzHOagsLqG5XTvPhtrUwh98tuFTyCAMS4znOUUbTwetZqXK2jZx5kpHWtdacujWlm2p3EMMsRk81g8qzReYCfkO5kQsQoJGVx6CrAgJ0CKW8hinitbX57qU5WKEyfcwCA+QMs/GcnqOK4V5V1DQhcXKzzRXp828n84FQm8EMW6ggHBToOmO9bs89nfi5g1ewv9BtJNrJJNMPtEsUagCJUHUHL53AqC+fStFO976GE6XLs+v9ef8AXyB9N1C7tnufDxKRpbPG19dysIxgqE2nBO0H5QuMMM9MVT8Jo91rj6Zp8Bu9QyGcytIsMfynzMxknDjOBznnPFI2oKmkR28vhuK08MIsZ+yyyNFMbjOVn849QOR8wC5+tcz9iOja9BczPbXh1BwZ/NtWCWzOMhg4x84XJJGCMHgAjKVk0aJSakn8v+DZ/wDAPT7VBpPjOwtZb+NrS4uIIhHbDG2dLiEqHznqoI7D5TnJNdF4yjjuPFmpRyqZJQItigksieWBlQFPJJccnPrxisZ7aG78V2F2LpYJLXULWDakZlScmZco3PysuzIPOMUnxOvLy18ZX0QhvI9NdYnuUit1YXSEIjNu68ZVexG0nOBXo0lZNeZ4OLfNOPe2pmX8EMMcSi6dzcHY5RnJmZeSC4BDYx8pAAwD1yMI9msd7qiPBdyQXsaoHgTbLEdvyuJMBXzzngsvGByaXTZTFarPLa29tpsBNlEscXz+VvAAVkzjadwyMD5c9a05r23eMQusYjdgUe3XexZcbVx1V8bl49ycZql5nM79DD0aLEKJqQj33M9vcJbx7o3DuY9yOpyNwdWx3IPO0k1PLeCTUtRks9Te3S5XdaBtojjkzhnIYAhXKkbs4ySOM8sury4jEbSRXNiskhvI8SLJbmVndjvdRnHygdhgjgcmk1KSzs7Ke1tfI1q+u4wsVvsBj2KcFd/zFFBOMnkMeFyTgGZnlJBpd5KLmGKVjEYzFG9v5LBSq7m2hthXyxvyRkDINWtL1C4SCAJDGVlv7aR4ZZU8wSBxGSONuA2DuO0ncMds1r6ynvJtS0mBndjdb5baWRtkW9SA7lf+WeQQAp428ZPFWh4aP9py6pLN5Mlu6S7UiBYJ8uMEZJTI6YB+90zyknLUbaWjKPwv0y1b7deG3uNTCzvGs9yvmO43HedxUAMXAHfseN1egSMJC0kk4WWAkZUgyHcQcKwzgAuO/YDjrVaHbZqLawzHEXCOkP3FXced2epyTlu/c5qa6EcdwUsYoVAfaAmY2fIywA9CVPAPOcdMVZk9XcR1eVrdcrukO0yEDOVGVJKkjdgnB+vGAKlt0tYb6b7QXtkK+RA4Y7FcZJXIPIOec44XHpUD5knjlCqHwGR3GAcksqknquR9OvauG1HxDcXw1GLRJo2VEuMqts5x5SqV27htds7uBhc45NTJlRVzvXuyBdIE3F080eXtkY8YUhtxxu429Tk1YmidEcRTwLcpHtjjKDGeCecjKkknnnnFYWi6pB/YlkDLaRCO2t0jkvHWEOAFAwOuAAG/u9eeuLN3qNtfahEVAQSSPagltu9RuYt3B4VWHdgTz2qXJbIOVltraS7h+0Rv5Bfh0TajAqDyMDqAWGBngnmm29yzXM8YEzMvyZUhchSMsDnJOT8xwBxx3qaAsrW5QNMWYgsOckHkqOMZLdSelMjkjeaRJ1VJI1CglQCqjHIx/CMgkDnirT7iaJ9rXkqzq6O8bBPJjbu4JJySOPlXBPpxUhiFqk1shjlVCArkEouGUn3OMjGSM8c1XDbbSSaS0Y2gVWlMkQ+c9SQM8AH5QD2OaDDG7XEajyrd23OqtkBGZlOOM4IUHbjPSkIheRXZY2mdZxmdUXe+SQ21l3DbkcnsM+pxU379zcMwRBvBDIxAB6Fjx7dOnA9zUttcCQwlEVvLG4uuWyG6blPOAM/Q+mTVINMU89YVBbBHlOpLKDxtIzkZf8Oeoq0Jk90HuMwzQyXYmdGkAfacgnAzj7vbjA7VNFK9hqkH2q2fKM4GMEJx8rbh246YPB79o54XmWCS2t1WYSbhCr5ZCASzMAcg5HA75J4pty893FFJNPG9peL5pIAVJGwCrBG+YEAA+lLTYCojs8xeb7OiSs7RM3zbQx+VQ2MYKk9AeByakeOK5vYo7h1ikedlkZ5N+1hGdo2jqxDHrkbQMetPnlBtrZtrwiW4jleWSTcXflc452qORnjGOTxy4eTbNG7s26JEjuAwbnHALZON2MncOo55yRTAppGs1qsNxHG1rE2xUWXsfm2AjJA3Kx+pxwKmaNwrGykeZIyjruRC6lfvIQOgznk5zkEHg4bbeXPf2725kW3ikcs+Q+EKgKoJbIOR8vHc4wDysU6SadI7QugjYnzHYF1wm7C9Nwz1OT15NAFu4Rhcx26xAoiCXy5k+VmJIKgZxkhic5zwRXnXiK6nubrVZITaSvpKoqWT28jSTPuBOTlQWU5YA/LwOMc136IN0KwpG9yZti7o9uP723kgnblsenpXK+PLqc3gilvbY3QhjlO+IhYtjOWIkXbncpcHBJ+UdicSyo7lC2sdO0lJo7uSzlxNuJgBtri9IV2Hy9gu37uCGAHUZFdR8PY1/wCEesTHFEtzLb5TEgcFXmDAllBwSQeny/L2AzXD6pcF282fVFS3AiuLJ33K0jmNxEIlDYRCjqPvAZyNpOTXqXg25KaPZxy3STpGny7lRRNl3VGBT5TkLjaBwOT7RdlS2Ne4hM0SzXAikuIC8qtncgwxBUOQOe3GMYPWoNL8mXT44pJ1uJZALeaSUH946jJGTjPB4PoO+DVu7kdIXcRlmLmKJVj3NHuJz+jc+wrG065a3ntbRQrM0JY7c4TJ3JweASfMGB6e9JEDr+zf7Qk0b3rBsSeVDKTCHUjD4zjAIJOODyTk1nz6OLiaK4umjbymAaaREZZVMf3gNnDbj69Ca2b62jktpJhDFNBGrSKssfBY9W5BOSu4YxznFSqjlg3moqMxL8lkY4AGO6/dPAA6njmrSC559b3Wpf2npsguLBJbdZYI8SNE82Nys0YXIK52EgjII6Yrnb3VNQvfFOozrJYTGwijjvZY4Y1J35DNF1HLYyx59RitLSrlL2xW5utMlkiFrASYbhQ6IZhK2WyFCsAdz5B+XBOSKh07Sg1pqD2Ph140vJ3tI7ieZU+2KZAyYIHAQIfnGCwPPrXA7taM+kVottry6epbbw/ZQfaor2W71CCeAXFqemA7LkPJkb9xYjbjjjB710lhLewwXM0pTUNUiTyrIRx/vJIBs3ttGA4zj5hnOAD0rLvdRE7SR3ccFuLkeTLbwwMFjaPByX+9txnOOm0fWrTxXJRdat5p/tlu7+WkE4lSyDKAoZOSyYIOB0xmiLSehE+Zpc/9f11sQ6jqEW2C2n86O4lV4QbdvL8nexXzACxAYhThf4cZqtqiSawI7C51SC205m3rFcwAuqqigCVuoAJOCc5bkVJ5s+laT5drcQ21x5mVnaIy29064ICDO8M2c9DnnHSqV8rWetrd3MX9pRRPIhgVnjc7oldWcHliGY4GOg78VLb6lxS6edv6ehzep2f2W/s7bT9UDW1qxhgmEhWWRZEbCRqFEjHer9DgEkdDXYaVc2XiDQnVklka4Z3MYTLwFQGQ/N0O4ggHrziszWLexg0fQ9OsY0bUmu2uZpDHuuH2vvLfvMbtwXAJIAHpT5tdt9E8Q3OmTWVxaSXcouUjtGjnWOFI8BcNjeBznaeCvHTJcbRZUrzStv8A8Hf9TastTttT0R9WbVTLM+3zEMXkK+0DLOgPqxweOG59az7GyvI4tPlstPhW/mV7NLxblt0RjGYI9vyjB+YHruGCO1OtrPz9Bh1W0kmm1mzRrK6SaKPdPau2MhW4ZFDABu4GOcVNqdg2oWNlYXU8IghuNzXiy7pIJ8fOoCZAZDlgSePlAHFU76N9jJWTcV3/AK00utiG8vpb+VoNUsppCmrE3rbm8v5UAGHB2pgyEdMfJzzydLUtNNnbXltplvDOk8jN51yPtEj8giJ9wG1Mq3OeAMiuV0u7h07XZIDdMsl7G8jJfBjFG/mr5bLhtv70DJDDggcjJrsfs9xLc30NzeIbsSl5LpiC7ygcRyKMqq4IAAxwO/NSndNsqa5Gktv66HIa/p14120Vy62Is4j5rLcfaBOdrbFVcBtgDEehAB4qXWYldreG7URaiEil+zrcGTc/lqpmGPmUHKjBbqSa3oHuFc6jcpJp8OnJH/pEy7obtA+2SMjAIC7ieM8qOgGKwNVka51yOLTkurmS4kllBkjVNyMrAEu+CB3HYDGBWU0ktOptTk5Oz6CQ263GpXdrNbf6RFFHMIApMa4wN/AyNoC9jnnJJOa0LzQ/JtpJ4ZJ3ws8MAeEu/GcTP0+Y9fTnjNZum6veXKRkWUdzKkUUIZjtMaLwS7A5TscDjk5zkGty9utS1xftQ06P+y7eNkCyyM/2qRWO50I4z1AB79KIqMot9Qm5xklsjK0uOKaC+t7poft0CgxkorJGNpCoqDIwzFmJ4OeMVBFJInhq2uVu2kdGZLZ7e3XDeU3JYlQWBLMcHoCPwn1a323ourye0hea4WSCOOBomjD4B8zg4YgE8nGTwM1BHLNpdnLaJcSXDi/DxzzT4ECNkAjAAYFA3B6ZPGaT0umUlezQ66sprfwmt7DqFpLpumSI9s4JClSM7Co+/t3E88/L71Q06G8jubnTyJVtpyblD5BUTSSD91IRuwFCknjkBeuTW1qUhhuk052kxNB/qyQBcBslgY8YAyV57bOOtLGlxa2r3Ed9NdWKQMoufsheKDKgbEZvvkkAEgcDjim1d6dAUmlr12Kj2NpJYWYuIIhdRxEvNGDGCI5BkFSoZCQMk55yCfaDR7+0urC7+2lFTVGMwjZhE0K9CS/RVIJBH3mzgdKdpMdxJdXUf2e2M9hDGITekGNp1dRtAbcrMc4LAc+nFQ6pcXFtFNNql5cT6zuljggCxzRxKSFDn5QVbJYDjPI6Gp2VyrX93+u/3G5b2WlWQ0iUanJPFaR7Z4I7rchjHOXQk5UE5xzyRUlvcQaNp84s0S1mcu0LK3mAtx82dvMhDK/pzVK2sls/D63F8Lq3kvZ40a2Z4o5Y4twUJtC7tp2YPcY9qoaNPqP2CDSNOJmjE0hR54kdAowjBmzwVBY7dvPHpir5mmkZ8nMm276ieRZ4WO0t7kvBIbmSUSlVjztOFPBPzAsVJXB7VYvfP8thPbWhWGZpp5ViKFoGXcFZCflwEHHOSx455bJa2rJ5dvcSW88NzujNpIzIXJBL+YyhUfarBywxheMVs6ZqGnWs15BqtzNdCZSWjtJcyq6KMpGVAVnDAZCnAAGc0lG7tccp2V0r2+8yJNLEllfA6dbRWWoKsrxzNLF84jL+VCBgN2wMccDoOCwttLECW2mQtBql8wIS7QNvKqMWwXGSPusAefmPOKg0+8vbpWtL9r64v4Hd3tmVHgt/LZdxZXBDPtdT8vAzxzXRW81u2nXUkl0kjrO0seW8hpQQWEYYnIcBCPlx6DrTikxTco7nO6DefYNSu4fOFzNcq/kKiK5tJflDSCELjlsYGRnBGDXR6U1091dXRuLnUJDbmN1uAgmlVSXbgqckHBOCqjpjIzT9O0+1S0m1e0lbTfIkTUIozGjRxpIhG3KkMdxYMMngjiqOty22i/2PdwR3ci3W61t7XzGd5guGYMq9MljknkY6nNNJxWpEpRqSslr/AE/6sVrq3Gq3FxKjbY932K5Td5skqMmY5ACAoIyW39umKxzcS6v4o0o6jAJtDS5FlZCS3Ecj7sK0zkZDAshz/ujHFX3vb/TNR8rSvs1raSXD2VxBOqSm4cx5H3chhuflfQgetLoSa217bQNqT6nb6LdlIJWCrDMyjLLg/MpTDDdkgs2BgLThroU9NfLQ7HRbeG2k0CO7i+z6g9zA7x26bGVxOu4ykcnczMTu6k1X+IEsX/Cwb2K+8w21xNDaOAVbfGYkfZtCFtpZeuepx/EKtQlYV8N37WEkNzcajBHIwhG5d1wgKMxw23PIIBBx6Vi/Ei6eX4h+IrZBLczQwKY4WciPAgjfYM4CuWUHI6gYJFehT+E8PE61L+v5lAysnlXekCKS5UboLi4tZ47faCVMa4OQ5ycMRz2ALZNo315ZWsVs2mxaZfPFvm/stTJJiLKoyEr82Sqqckng9TxXMahdf2paKLuWGJLiUPHJLGyqE2gqZHwWYFSgJDBQzc4IFPTW41sZobme5ls/tKIlv5o80kqC8m0sGznBwNq4yDzkFsxsX5H1WAWuqT6z56lllhgTTkaUIw2t8ynDjy2wBtHO35eCKbp94NTu7iLw7PeS30lsu5ZowiKzsC0pmjYbDzv24LZ7cYGXZTav4kSNIborBZNmR0t3WMpvwrBtytvZSSOFGCOMEmu3tbeKDy4rHbZWYUfvI0wC3y7mwMc5Bz65xjiqUb7kN22DT7SK30e1htmimlEcaPIwURzOATv3Kcktk5Yjq4NazWsiXKySZTMu1irgsjqc8EnHQ9QPTkcVSsXnknuIBbfukckxhgpdlUKHDYxwSQQMHvjgVMrRhi1ruEijdLIcuRkYBz0HQeuMZ9qt+Rn6joQ81vDIsqgp8zgzZO7PLFVBA6txyN34CpFSVI0j8zMEnzFFUkrtA5BHIAAAzn36UXccccLSJE2MBHjVhJglVxkgdRtBGDnOSMDilMbzwyT5jdHkKybHx8425JGAwLZOccYwT6VF7jGa9IzZjnM07GIDyYm3SfMpBCgZIJyATnAzxXn0eoW41G3vLWJY7ma0khezjQborwMoOzPIBUgbzkbT7ZHoFpsa0m3LdLKkbIkiFCyMeVDlflc4JIwfTuK4CXSbo6l4iF75xgtmLC5ljwItznKFkfjdwSRkg4BBwKiaNaZXklV7mGK4FiosijRT3kOw78bSiB/mWHLkqCNpww52g10nhG4lv7uS8nV4nsrSKOD7VGi+ZHjllyQyfMJdwxzlfTnN19NLuvD0IhubiS8d/LudkhfaNpZQHK4J+YqJB8oPJxg1a8FanaQX7LJai6uLpzbkWmZdmPkV2fO0oMIGYcfOCQahPqVJaHbBn85kMhSRgUBaLPyAkYBz8pOAM8dOT2qUmWaecIsedjTiG32kq2CN7nHGT2zx9KjhcxwyzzynZFMkLqxJ3AN+ZPYY7sc9qkk2v5CQtJCmZBiSRfnZiGGcYOeOBjp7njRmKE8ua3tWiZWWHBdZFbKhSeRnGCdyr1zgHpT7e0SyEbsFMczswTcCxdiSwZgOCSeo4+bpSo1zGoUGWSHIJTaNqEkLsJx1/wADTFiL27tIsaNEqibaNpbBwW2dCc5AbrwPTFNMTQanHDO0U0EMaBYN+9tzuitkDI55OW+7zn060gS3a1u5nEsdyMNwny4GR83bnBGOowKiPkLcI7zPGCWM8YjKGN8n5MH5SPl574OQOSaW2OoO3lQxyyq5ff8ANtWU7R0yQM5yemAPpVXshWCP7L9ilZHliu5SFDxqQQj5+Yt34z09R1qKRCXjWJshRvO1h5bjA+UkjPJwe34UsX2eC9u7eZ45LlV3o6uGUBcjJUgYABB2jJ+apkMq3DyJbrH50bqDIWjAOFBHXKYHYErnnOTSvZjGXFpcNvtVeBGdPuEsZQGBVh7YzxjrjmltoHuJYJI5LR7m3XCpKGcKQpXcCQORjpjvTILcfZiYWlmdoR5QceYWyN2MHB4x16cDpUEWLqV21G4jhuIodhWVPkcEBsqzHIGMDkfnQ9QJL5fs94sc9xbTPsDxxRxruMygFWXjIYAjJOQMDGOajW1eSSZLdPKhlwnkAYVRj5gQDzxgccZYjJxTpeHVACg8rBiE6xPt+Xu2OcnPGOnfJxwvj3U/lS10qW3sJobJ5ZmEiSGIOgVAyodoBBbnJPyg8dy6QJNkHjjxJe2wms9NZ9NunUM97CGVpYx8hEWM5yzEBgF4IrlL6/gfzZbWK+82zJO6CR1+0W4wSzMo2oFZixHy4AAxkVPqRhuEk8t4IgzyxTwyny1eMeWNuSiGNDIh3ZOACAv8VdPoRuoLbVWvQqRPARai8CkMD5w5jdv3bKXBA5kZV4xyKXma7Iove3enz6gh02WLV7hYo97Rb4ZV8sQsfLCDDHHG9jyFxkV6l4L8yG2tIpXP+jWwhcSlcwSeYQ4+XGDwV3KSOcdq41klt9JSW8vFjCXAaQF0k8+beEiMew4RQSrEkZJOGzjNdFo2pQao0H2WT7XKZPs1/eJEowX3YiGRkkHByDnO4DOcVO+wpHYOEs99ykpXchErFNzZBHzkk8fe/LNYWlqzS+ZnyJnUmMrIHAP3txIOSdztz6Hgc1v7FijvrhpGkuUAbYse4OAGOApGSxBGRnqB0HFc9DCottTBlmRjdRtNI0fzKrFAdgPylBjpzgbhjIFSQjTtgt1br5qKJ1fBRXLlWGGznPY9jxmrMbO6q6rHt2qVLZPy4wOmfesrTpHc+fAg2NJu8tVEYVCSgGcAE5Ut/eGRWpLiII0TjKkgM249+pH6fjVpks8i1yQQ6dpltqt/HZWdyVH2HertFDtJKtGABgsOAc7c98VZ8LS32o+dDc3aRLFNELayvonMUMe0eW2ACfvHauOD19Ki8Qzzz/EbUmT7Hb39pb7rOZghkmeJFG3JBAVizNxxgHkYrU0W2GhaPdXmuNc/2jc3R+0MAzXSptJVgFJx8wOMdB61wcrcvJH0jlamu7/r+mXL24vZDaahOkET2+6ebzmEb20qswIEXO/IClcge/pTLGza20WWe2s1ja6WRZ3QJHKwZiS/XlhkfKPQ9eKdZpJrGo6hdXFxFc6SloDCn7yKGdCAQ4DdcHfnLZ5zUfipLTTtJ83Sr91EzeSsMMjSBjlG2EFsDhenIwT1ptWTkSndqC3/AK0K8GoSyXkn2dUttWW3gj08Xqb9wZihlZyMiTPcDGBitC4iurma4EEs0mvmaO8cNEJYoXSLauDwdrgc8Dp2rPxeRvJq8c9zd23KStd7JUZVUERomQwUMVJYD+lWLS3juNNDSeXPqPmKUnjZoyIGXy+QMDbwwVc55zSTdrDkktV/Xr5DpLey8TW8KandKmsvGXiaEiQK0inKoxxyo3dvl6gmuNgs7j+3DZW9sLmSxVTOBFviCrEcOqYBIJwCxIUsSSK6KG8Gi3Wnwz2RQ2vnBZ3YiF1GRHtRfvv1yW6A464p8MciaTb/ANm2ctvMBJJFdSwmOVQgaRYlyCpUkkMD970qXZ77mkW4Xts9itpup2F5oNhK6C5nUtbafBHDGUeMkMVII2qEfaRuORtGK6C20+yvvD8slh/Zl9fW8y/a4raRpEaTcwViq42sdxDceoOcCuKh+3Prl2lwLWWK7kiN7JFJtWTcFbzCCoIXYcjoPlIresoLHdLb2V04tJnEHnSL5QQQrvE+4DJ3NjAyKcJX0aFUp21Tt1/r8Sz/AMI7axeIjb31hFDpUkZhgsbaYlHd85bcF3IvBwrfLn8KzNIsG/4S6X/jzh1PTnS2L3qyIlyQ7bmyfvuyOpJPQ4AGK6F9duJ5dI1qJ7V7aRfIZLklDCxYjdESu7OFJYEYBrnNfnu4NVbVxbw3TLOIpJdLmwW6s6FgMlhy245GO/AqpuKV0TT9pK6fa3z/AK3JdQH9oaj52spNc2s0s9uEuJ1gt5IgSylQvzMqqW+bHfrmuw1EXEE9lapAs095BLsVXJWQBFwgcqQoHHXA/OvMDp8sdrqGpJFJcSWshiureZQQisu5ZhLydy84XGMc5wa3Na8Vya1pEl1CpmhtrqONvIQNOqbc7CpJB3YwWz0J4BqIzsm3uy50XJxUdlp/kVp7KT7NNcQQTxyTKYF+wuhWZg4L7353c5HQY4FRD7TaCa2Zmj08X3lSQxtJLjywzA45X5gp3KMcjPNSastxrVl9lh0+eeW1QzW8UkTQtbiX5sED5m6tg9xzWZqsLabpUIlijhdVjuJGbeTICdmGQHJBYMTznB9Kwemx0x10e/8AVjd1JY4r54tJS+u7jzY3EaS5UMVDDOeGJBB68EnjinRX1qLC4ln+ypfRytGYppvnZScCMooAGN5JbqCorAmZpVjs3tZ40ndmNnYgxrG2/aFRs52BcAZAHPNLNJPYRLo0tjHFPaXElzMxIkWXkfIG7HDZJJ7ZwetPn1bQvZ3STNW8vYNO1KWPSrmXy2SOJIxMrOkSqwdo8g7QG2kkk5z05q1pY1tdBnt9MvALMb4reymm/eXUkhywRj8oIySMHkVS0+7jvNburXVYoLa9MpljEUBmcKi8oYR95WVWOc8EAnoK07u9vbjVReZt2Z0RlitomQW75CKjFj8uCQ25h64q13M5L7Nvv1KmrXb3z6ZoDRxWk1pOZnaNz5u5QU2hSMb24JGDnPHJzVK9tZ/tU1vrNxO99cNtFsAH8xVwodmIUIoJz1ONpNdF/Yh8h7iHU3fUJG3yKJ1G+YAERMw+YsGUg85+Y1g6rEwZTo015a6dOxuolLtsYNy21x124Y46kdqU07e8OnJXtH+v6/QpXEEVlL/ad8y3E0axyTuy+bIqNkRumSco2M9Rye+asabHFa6lDLCsgvHlkleV1VrNEABDIXI3FiTljjocUunRXYlkNhc2s8ds8fmG0j81UUL8n70rz8oC7D09zVJ5ytnLazi2ltAhaTzFGyNslVZmHUjc2Soxkc1GiNdZaXNq9N9e3mZYA9tAI5zbxv8Au5T85LLIpC4Y7gSWJ4HoBVZQ1u7S3lxZNc7VN0YiHeVcHMYZgwDAnJIwMDPJNT6SsV1Z6HYa1pt5a2cSmR2lGzepIEYVBg7CckMQCQKgsrawguIn0O/juITcuk9rNDt/hK/OxUcYxwScAZ6mraZmmtv+G+8u32pg3K28GqCV5gwTZafZ0WJiiypG2CuAQrFjzxSTXN7bwxq4kubMzSQuIpFmZXl3hWB24fDI+Bg43deK0Y9JtLKC1v8AUZWutJlxGotohIluWCKQWUcH7uCMc8nOKbaGygt5pIb1bPTxJLFCpl85ppA7fdLZP3iW25AyMjirae7MlKNrRV/6/P5ENjptgNBnmuY74XEEscSiVd0wDJtWNFGRtwTjoPer5h+waXc2880cLNMYmuWkaYxoFU8OV+TGAcHgkHknig6vCi202q6vcTafIzx7Y7baYFVT+8kc59hgZ+mOlHUYp4PDxvVexECDy0ZTuD2+4eWDycjLOWzg7hkdaLRSuibyk7S6sxPEGINGTSXaOdrS9MMMkMUYn8xcOGb5wEQsTgkHJIHAwKt6HKhvftl3au8WFkSI5m+zBiVBGDnOQGbJIAzXPXOojxFFfDYbCS4lQymYSlrpwd+JmBzhtqhQB2zgV6douhWerKusQ3k8by2jIzW86skXmKu4A43uMLjBJwM45qqUHN3RVaapQ9/+v+H/AK7E8dxE+q6cL9ojYi7sVtot+11uGnRgQvAKYVsHOTgjBqj8T4ZpPGWo2dppoNzfSwqJ0VGd08pVdwMj5lGAN3ABY5qt4e1OK/1DTRKYZbZbnTzApLM5cTogGWAJVfvA4JyTkjpW18WoJ7m91CBEikaSeD7LyBiZYwwV24KqWEfVl4yRz17qTvH5ni4uLjUSfY4K8uLp7LTrS4uI3vbeBkUmaRUjCk5O1+hcAgocggADPBqbwxDqGq6hFeXtpZnT3eQLbPbFi+4KGAOAEUknaQCQEAyck1R8R29pLBCqRQR2VzA0CzszPDMVVSjqr/MOWfY+SCRz79H4Rns5NHsbeGcyzpkiz377gT5IkLNgfMBn06DAFWkrnPJu2htDZbaen2Xz7eHia32uy+YxAJTOMk7cqc89qfcQSXEfmJGpdgpzEAXZBtDI3y5zjPB5Oe2KEjk/dRX00EExm8xoEkDBiCSdp55IPIyeO1Qo7TWhlYBEY/JDJFuUFcMcAcnJUd+2Pert1Rl6k8cMd1EBJujlbKoBgqehX5eo4wpz6560hnb7IyX8MUfklstvIDDJwG56EnGPaktWjSAPLPEDJ++iZ8BiyuAytgDGQeCeOfcVGk0DwtbQIhcuqR28e3fGQuw7RjdgjcR/XBwgJiN7SRvMskq4B8tUwqkbyRjoOepxwD7Ymdw95Jut7iaOM5jjYblSPjavAKjOAecYBqCAsJS0riRIjvkEgK53KQN2D32seCc8YxipkSBpTc3kv+jlHDQRxknYHIGDkk5JGASOvHWhgPkt4Ba3cAaCUbkjAEuWPYjAOCfv/gDjtXnWk+LNSh10qZJb2xtp/tG+WBoXht5OfmABG3lTz/dz16egLbT2k0sVxchbmTc3lSrwWZgrBQ2DwPTPU44rnPGegR6vFd3hF1eXRlO+JSrBlIUGPkhU52tuBz85wOoGbXMtTSDSOeVrYXVvKYWu7GJN8cYkkI2NMzDIQH5Bhsh1zj075viJPtFvFO5mjuJ1+z3V5bRKQ0IkRsJtbDYUYBUAHBx0wNtPB954cttUi0fFxcY/0GeG4CMjsoDMwJzsO7A5zxyO5lW3tptFtLXMek6sJZFudrTRrCv7x/mRFCjPyt/dy/fNRZrU15kzurO9tdS0mOdb2WdLhVdJhEAWIbHOBgZPOBjoD0q5NOWCiR4Xtipj3MBkx5BZgQQAQTgkDt15ryXw3ezeGrxrYvJd3jkrDaW87LutxwD5ZBxIqqpAB5G7Jr0/TtSstUkeeCWQ2jqcQn5BtOeinpnjkHae/QYrQycWhVE87vc3ksjLjEbTFsouV4yuBzwOB1PrnMl3OUlWQs6xNwFVGO3IADKeeMMM+wzSyxyOiSS5+1s7Wzl2Crj5mxg57ZweSCQBwaZaxsFaV1dXlBEsiwjMjvlDuAxuHA4OSBiqRBIZ4nHlvFIYBnfOqNIyMRnJP8WRx+AHJNHkSLBbGB7uXKyBJ0PlOqgdV9PUk4PSmrJN5qCwYYSR/P8ALcqWbJ6jncNygBB05xVeOVbie5E6XEmz5EjEm9eMltpC4DErg5HbHHGX5gJua7MB83dAGDSK6hpEJyoZuQ2/K57npyOz7i4WLT3F2MKkqIHuZGMbhuwHHPBGBxxk5xWbqmpywXv2UFbq4kjjgeFmVVLs/KljhQVB6ElvmHTk1bub2W3tbgWsMs8x8yOKVVBUyY5TJYBnB3EgDgFsdDUuXYpR7l6JTGojtnRYwgDoDnAOSACRk567s5Jz61kapr9hpEjQXV2ZLi53NtVcSqAu4ruwdgYiQ/MwHAx1FcZ4qu9c03UUb7RdwWuFUQySNbhICFUAAFtvzbhkEthR83zCqFhowuLxr94pLS7sp7cpK9ykpvX2uS7I7MN24YJPYYHzZp8wKBW8TeIbjxfe2MccJtbZhst5IvORYzvwuWOA3yZyeACOWPGLFnobav4jhtUmk1FY0Nu18u57aQCUtv8AlBVQCp+8+75gemMek6zo2i2GmXdxesL5zZ+U6RW8SrGrElnAAXYDu4LHp05zUGgWWpx21+sgFvMR5cc0EqyxR7RhTtI6rgADLHHJySDUKXYvoee3ul3sltewN5eJ5pI3lWD7O5AQkNGztncQRgr97gHJaui0zQC32TVJzsjs7UtK4TYJXEavCWdSGdjhssVyCRwRnMesR3GmWc0GpWMN5qBn8m1uCjSYjMK4aOUBVyWQZDcjOKn+e3SOaTSdTvo1uxLEsd0FBOz93EYAQEAjcOSR3+oFMW5JuuJPDun6TZSINTumE8RlfaUKYcqGHzkhfRc/MCOSCNHw5bXcFnbzRyYiiIltMh1AQTFv3mCesTNndtI3LxnNKkRvN9zplutm7sC0kZcSBcqxDRJgru3fK7ZJBG7ApNOtYrK03R/a/wCz7VQiQNdGdLoENlck9mZMNjkH5hwCEtRM721YC3SSBv3Th5FwnI43fPtz82cnIx1xiqMtrJdXE0jeZ5L+XtAyArqC7Fs/wkhevvyM1ZSaW0HmzPbQoUczqrDATZlcnON3HPY5zU1k7NbGEuheNOWXILFeMgHOAffpUkHP2sTW8CyfYY7CGU7/AC4hkAFwWyoI6k8MMAc/jqQHEaNEiqitsiRCxIABHTnOORg9M+wpxVx5glYGRm+WNXOWDHPboc8enXgVSsZFjjfbGLeLAVDMCF5wx4+8TnI5xjt3q07iZ4joHiGXQ9fmEstlFe+W9sxurQt+73fKPvELgAr/AMC59a7nUH1a/wBMZr6TdHHcu1wsbLvLDDJHGecHZlRjG0jr3rm9K04jUJ1sIYWgMEBee4QvJNM5OS3OeG25X35rtb+aSLU1iMYtNJ8rDvCgRFudqYLHILbl3LkdCB0rz4p2tfQ+lquPOmlqc6t//atverY209hDd28Uduk670ik2HDBmBJLgYA2jJ69atWEpbVIXvjcLO0vm2sdzKII42WNSV24O0EnG7v2Aosra3uFj0qW4Et/qFx9lnHKL5KE+WGIPzEDHOT+GKtHNza3lzYSxWltbo9lExUFDxhnP8W4MAoIzjd7UK7BtLT+u3qZtxcQ6jZX1xPdfaSbV7gpBIHICnbwMZfKADJ6Yya39M1C/fTPtcM0WopDIZh5UkcaykhVEDNjaCDzn73PFZmhS2nheNft7RTGOzEUlymWBQFnd2GOFDEqAATyD3qnpNiLSa9ukW1iuJ4CwwT5KSNko0h5+bnG3GBjrjinG61uKUVK6tp0Ol1G41HUNOjvppLCCFGUoit+7DMNxDZ+8d3ykj06dayZLDUFuWuwFu7eGWJV0y3IRJOSMrJ0+5gkgA8HvS6M7SqbjzbUTvK15KI7djAQ4Iy5z1YL0HzdauS2ljqV/P8Aa5bKW1S2SKTAKxoGOBIEJ6E5ORg4A5602ubUlP2fu9PQ4GGSTRdaMkVrdIY90Lz7GUGJWKHIOeRIrDjPGea7rSoYjZ2/l+TiV180RpuVZVywGORxv4PbdXFa7Ck0bTXSy+YbySGO+slzGVQFucnABOSoABPBOeld9oWnRR6Pb32hNKLqVYYJ5pIiRIMgSvs3EZOSSckEg4qaUbvQ1xE0opvcoeL0tXWDUo4WTU4PLSW5mC4mhZipXd2YMRz9KlutNtrbTLd5p43MMYsswusaozuSfnUYLbMdcAnkZJq3E7G8uLOW1ktzZSbR9oYGB2PIKSFeXOFbbnINXLmSS502Kawje6uGkWGa3nIaIbOMyAgZUYz9elbOKbbZzqbSSOeOl6hokE9xNqGvyxQziVjFBEY7tFTMbSocbh0Qj0Ge9c74js5dIWDUXRdDl1FUjjwHaK3Mg3M5cqQwP3cNnGc+9duNR+06gNEkh+0NBKTNYySsVVUUkeWw5ZPugIwOM8ZxVkL9p0Oztri4jufkjmntbld8bEHYybT80eMgYPXHAyM1LgpbFRqyg05Lf8v6/qx57bzvpOtxTQTCaO3MUHmWcqxyshI5LfdUdhn096t2j63rmrtaXTKL92eGIyKmURQSG3KcjHyjpgk9e9VJfDIt7q8/si7uiNKgeQW97ADbygqcqpzgsu4gE7sDBzml1jw/caNe2UcLKtrNaLOs0qNNKshHJ3jIP3AM8BTJ1rn5JJa7HZzQk9N/Qmu9Y1ZtSt5bUvb3hSO2uYbVyWleNvmXzA37zA+Y5zw3ek0W0uZZJbljPAl26y2duYndrht3yEuw2pGrgFjgE49KoWc8MmnWqRXCZmSSQpEPJSC5O4EEkY3YC55GR3qDVpdUvJoYtQ85LeLalpFFFmJQoHJKEbuhzio5tbsvk05Vodzoenx29ydQ1maK7vWtljlupLj5Z9wJMYPXn17njpV+20kQ2dpaXd1Zy3sryTXsMczK7RHBUAAZIXI644x1rltWltje3Vzp+pL5UccUEFi0LuJpTySu4fKgz8vXAPBFLp93fWSabcaVeRNatcvzucyMSmwl48nKxkjP05B5rZNJ2ZzShKS5k7fh0/rb9DvhFFbXEkMjTS3PmbxEzlWdXXLBT/EemfzrjVX7Lb341CS1uX0xzEsUSNKkGRhhxjnlecEZ4rM06W4vNYN1cS22nJJOUEryrJL8uPMPP3s5AA4GCcEUl7f6e0Fw73VkLqFZYXhWFwx3Ha8atk8bTuCnhcNz3pOfMvQcKTg7XvexuCS3vrYwaHpjaTdG0DlbaXDsNwG5kyNvG4jGeDjPakuPDt3cXFzFBo1rLsQWggiVAJ45MF3ZeNuP73r0qDR7m0dIZLHTc3avCDdtcRjzbYbVK53ggDGeepPGarLq8uqavLfWiaebbT5GtZpLl3WYQMysEBbhnXJI5yKbs9WCUk2o7eev6l9RYtHLNd200q2zC0S7tpGkuoUABjiYkLuVhnacggfqsV5qVjZwW9lp2oyySXLGGMFfug7tg+Utj5eQcH9KbpjnVzfPDB/Yqxj7TNDE6yNdMSQH2MQG3BW4yDz9BUbTi8SO30fU7iyuLiZb9biQbGjcjBDbTsUfKx7g9aLvSQrLWNv+AXFvI4ry9meY3E8m6WaKBzHHcY2thiFwsqngg4yOM9qgtjqFvcXQsobby/MZoDLZNIbpOT+7wSTgL94/KAeTmsK41KWPUYFF5ptgtvIqRyLYtL5twRlpSoAVzjA3Z43DOM1Oki20ci+frabizxPb2zyssL4Qi4QEr8rBvlU5I4Gc0k7lOHKvUqandu+iQxR3JktpbZJXHkiNVC7Gd1bBULvXPGSAeeBiqd/qNzpgFuYksiZVjuFRmaPUSyfK7Bsq3XJHA+bOK6nS/K1HWLGz1qy1LiGZViEIhtZohJuDlZGLkA7Rs7/KOgqOPw9qq3FpYXupTWUE0EjlpCHdZsDhAeI2CjIlwDk4B4FP2Ut0P2sI6P1/r7uwzw1oWofYF1DVdZW0somaJwbpZWAQBDEueM42jJOQOBnNdNM6R3pWRLyPWpoUhIjla3QqELiNifvYX5gFGc9cCr3hrTbGDTVgezjKXaLcSLOAJMx4CsYwSueF5zkkc5NWjPLfXDrFcea0U5kjnxuYwnhsADh8s6/L/D1rqhTUUrHDUrOcnfb7jJt7KO113RJ47iaDTTcRGC3LooM0l3ETuOTuOMEKMYOcdam8d3lxB421Q+ZP5CumIhbu6nbDExYEJjvg5Pb2NKdKtn1LS7v+0bSKG31K0RbSEEReYJo1CAZGSARzg4Na/jdUk8S3KzMyjzI0BKgqQYhgBT94hsHHp145HRRjo0zzsXP3099DgBLZ2mkyTahJNYyT3CwBNzske5VRRtU8AADqOvXINY2lwar4XvZpPD5ttTt54PtbQNcrIkwXnfGw+YMQGJU8Y4y2MV2eoacPJZJybiYDe6JMPML7AVdgRhsnjHI6egrk7K6VYXmv7mKAtePLDHbJ5su5SHKMvyhTuYgM/XHXgGqlGxhF8yNrRfEVhJPDarHDbST7ZIo5HwSdm4MpA+UKflwfvYJHpWw0sMsskMTwpNvCiPIZlCgkhx/CMjHTJzkdzXKXsWl6xbw/2zpUMeqXC8ywl8RSbVbcSQSCMYIPqcgjFV9P02+0aeFdKuWmiOx5hcI8wiUMWVSBgJgEqBnquSKSlYHBM7yNMmO3dYYWILCMvty2cLztIBABxkkcdKUlmmZ5UXzpAMyTpsYYAABP+1kHPP3iOK4mPxXcWF/ew67p80tskisIoL0ys6D5TjAy2CFJAK5JIwelX38U6Usj7tP1OECQQM8scigncVLHDcEhhw2BjJp8y6k8jR1BjRZY5XxvI3BUYMFOAByODxnBGfzqS5WWRo5YpJHZ5SEkhXZGq5HJ+bk4IGevXiuA/wCE4tYVgKaVLPHJMjXIEywRRAkKn38+YOoLKNv5U3UvHuLXzpbNE8t9s9soj2ouRn95nYCFUcY5BB7UnLUFBvY7m8dIdPtrghDaApGriM/RiGxliSck/UH2XK3drHOG8zduGx3LeaFY52LwcKVJGRjnjpk+d3/jDVzc/wBn2mkyaaVjVzFFNHMVjwHA5O0DawyNuSCfau48Na1cavpE7Ji0ETRRXDR9EYoP9WQD8mO5ONwI6CpV20U1ZGxNG0dqsNsZppJLZSocgNs+8V3EnbwDzk9qj1TSLG6g1JyixXZhZYryM7pIHbAALKASOOORwO2ch6TTeUTGFMYk3OEBOTwSd2RwTn8s+lOtJzAJBF5scZcRmNWYFoyx546DnkenQ54F8uhnc861/R7m5hu0it4mubNDJsilUZZfK8xY5MndGxx+7IDZ5yMnOT/al/DqkUqW0XnXEcXnCGFMASKNqnC7NispCnHU8gniu9+IMH2KzhjSVrW7Qq0EUEKNJKgU7y46ABGIzkjPUc5GVcFVstHfU4rKe/ktDCTbBnmitm+cY+YKcAuTtyRlcZ61g7LQ6Iu6uzK0LUfE2sNLqBKyfYbUbpriQBbhELFwikDcGQZ64BzkgEYnt/HTXd/LHPp1tFbfao1hLK4VkY8ytIDgbeTgY3A8eoTW/CGm3QhvtCupEtFcxBvs6h1cEJll3BzncPug9SSOapWmhXLSWHm6JcMbdODOwhhxlgshRwSSAoJOVwdmRgGnddAsmacni7WY9VnfToYLsRK6yJFBPEs4jBBZSFID5OMEsRg+ua1vO8Q6qbxtRuDpOkxR4EEluFmkzhj5asCSwO7nkElQBnNYulG00zTik99ftek+ZFb2QMUcK8yKSzLsJf5wSwLEkEEda1I/EGtakyQaVvtfPkjc3c0BeNSMK+SxzkEKFChAOpPeldvQGktSG20G30u5aa7ZJ47uNobie7jaae7UNuXy142ABWDMwVcdB3pL7XtJs0tp5bFLi4MeJB9o3rFJ8zMoyu0NlACcBiMY65OrN4UTUrnytReeWMlViEEn3gSxK+Wz7AuRkbtx+ZhxxSQeEdGgljgRZ4yylN7Su7R9SP8AlptAXjIwQcknvVKDe5LnFHE6j4oZdUmOl6OwaVZopXilV1Gdu0bmJQKXIySoJ6ckGsseJdQuNceGxjuA8RZU8mRTMWdkGDuXAHyE/KOB3BzXc3ngqyn0a1it7O2igtbjAW3gKi4BGWRtpG45I2cn5gATgmsjXLa08Nautr4auIobqaBjKiJGEmjIUFpZGJ2HKn5QOpbA6mm4RW+41K+xydzczeVLdkL9pUqSkglBeZG3qGGGKr8oDLkenTkdLa6z9n1DT7iMXrXU6i3ghsf30RO9hM0TM21gSV5PC4xknNczYiXT5ppYdPUQ75iTImIyHjCkREOuc7ivyj5T361f0jT7a4S2S8FnqFvczCWJJ0Mf2RY9skiSKcFshVRRuIwSRik0rFXNzWtX1K/W+iEb6nALV7W5fYuUtmbdFOApHTYQxGc7vatPUp7az1ifVmhim02e1iS2ZJCLq6ixtVC5GFQqcrvA6/eBU1UW2j/teZbHTprS1k8mE2rqUKR7c7XlJUsucFTnKkEHGRnu9B0yyj8L38khBW9RnaeWTKeWR8gH8Qi+Y4XORkg0bEMxTa6dHrhk0y0voJLkFbbIMzptOGIUsx24GS/zDcAM9qigeWLU7hUuCmoTxtZoJo1KRMCpBKsMjcjBRGSWbO7nis+O4N3Jdm0heGCFSlytzJhwxfzPJjbcSAoG4EcYHsKwbbxTZXd+TBmzuZWY3Vx5Zb7OQgRWIU7QzfL8wBJUDIBAwBZnr3ht3nsJZZ7cw30TNBcQxTCVH2Dg5PQbSpAOMdMYxWkDuQTRqskZwFwQqlc9R+GD9RWZ4JuLhNemtJgqxNAQcsriR1cgSIykjaUwCoxg44q1bzC5muZrUr9jlbaAE3HOcAYxjpg9+vbFD8jLqWvMik8u4aVFiU/N8uSV7c9jn9DjrWdKyR3cci3bxoUUL5zKyjhsA5ONxAzz6CrjHBkusReU/lqxIZOEO4kg9cBhgBQc9/SO4Sa5uHNvu8rIByc4bnjaRjGAO/WnFITPK1utPh8QaxHttLXdLuspNpV2uCdznYxDAEchuB93FaHijI1DTrm7jGnW7oYnkAaTyHx99DjOSAQVznO0981xWuSX0/jS7l06B0uBIBEtx+7QkYwqswwUZeCOuRwcYrutLtbC7/s2bVMR2KRo0Kht0UsgwzYHLFQz4BzgY/CuG920fSyioWl5fp/X4lDRNKk1YrpVtYX1rq+mwbLvULtylyYXXMewjoQq7cD7vqaoi9XWrW0W4tWkkmaMwR2U3mb9wCxmfkMjfLkkdya6mCxQ22rgQpNeXYaGWzs2dvIg4X5xnIPc8jqTis2Xw8tje20Gm20D3jI7yr0gjc5EaEhQCQOec/gaJRdhQqK7v/Xfrtf/AIBX05NT1K7OjXv2UTaR+9luLdGePH3CseeO/U5HGetF/DNoOpvJeC+WCab7RI0ksa28u1htL9MHKE7R6dDWpe2cOlafY2dlZxXOuCSNpLq0cwITk5YsSfkBBBGMDkYBqtfwXmp6TqU/im5hN+HVIURwqvbiUb8pg4yM7WyD83UU+W3qCndp/Z/H1/Uj0i6m1y71SXV4idSnVCLZ40hM2wHYxIAGMFj6jI55rTlu1sDp+mymeG5MqwzafBEYVm5+Zlb7oJH8JPbtWZfDT5I7V4lmu7W1WNhcxsVmK5UJvJB3PuB6ZBCqD1q/4hOk2cs09/qXnp55nitZpmRniIDdcYDZ2thuOKV+txNJtK2nb+v+B6lPULePM1xZ2V+GutQ8uxt7+5VY5HlZUcmNCMEBWYEHdgHmuubEONPtr24kighklla1O8x8geWF/EYA+b868zRZtb1e006Yva6Qzv8AZLZz5hEUYKmaKQDDZC4zxtySOldVqWlvc2Nyli6fYdKYfYxa7gxlUqwe4fqSpXOR1IBNawk2noZ1aaTSb/rY1dOa3i0cXerLBEDN5cP2mPYjSyY+8rAYO7sT170yDTka4vrW2t7ma8WBXe8jlCMJgNoBQkANyW44xjvim3+pamNIA1CWFtOndZo7yVREY1JV40CHJfJ4yQOBz60kmqJZyXEO2G0nnIvp1mndZCWAXlwDvb5V+UAAAACqvHYySm7tdf6/pf8AAKyaHq2sGeW+ubfzwyGNJoi0sqrtGS4O5CAPugnnkHmpLL7bA+nvcXk8sMgyjSxllGSfuSFt209MEkiqN74hsbS4M9hqj/2gsbYWe/8A9HEbELtJxtDqwyAQD161De3Wl3V1qlvqt7Dai0O6zuIbkrazRyIdrMF3Yc4Y7eMkZAGaj3em5qlN6SWnp8jYutR0jUXWVL6F0DCMxylXA3djtw8ajnPUc81G9raXcciwy3bW8B2x3Cuf3Kc9Tt+RSu0dcHr2rg11N9OmWC01qC8WONIxGIWimuU6hhkHPzEZ6ZGeldXB4w/s1Io5VluoXZ2WaPZ5cBBKtGmB+8xxxzjPepVRP4i5UJQ+DX+vQdeeGkuoAluLGOLzDOZVhMoOQclD/wAtPlIBB6/MaZF4PktbW/8A7DeSwvJ3RmllLOkkOMsvkL8uM9BjPv1qrd61/Z8tleXMwjtC6idpyDJDMUD42oQzHYy/dGMdhWuuosup/wDE2uFs5DHm0aJ3berDgrG/zdm4IA9DTioPoEnVS0Zz2t6Xbi/azvTHZT24SOO+NmJFuMlWYfxME2kjHIUj8KrSWesWFreWFiF1HSvKk+z+XPI0SMHTaf3ZyW2hmKsBzkY5FdlHrWnCZ0lltcxp5oVpC4+bn05H8jir8TW0kUqwPH5UjiGYoQGMsrAEPj7p5Ht0wOKapxb0Ye3nFJNHm9zZ/wBjTWN7fabb39nbCaVokm3NsGfmdmxgOTkDJK7MetRxT36aLbQxWlzHp8s8wVXtI+X8weWokwz7QDnJI+7wK9LjsrGTzoJNNEnllo5B5SSjKH7hyo5+bjHXHUms670zTL+5WK6vtssCyBd0XkJI5wCcg/eXOCRzyOal0LbMqOKT+Jfr/XqcTb2rWfiO90/xM11eQWkUbo0K+bHCSFKkJgHg4yOc+grHhttYa3tZrUx6naRXEgVFhWXOQFOYeWXKjoTngdOtegajb2dvqUq6bqivFHNseCVSFj2gK67yPm+YDpkgnpV+ODTrq4nXU4boks0kmy6iZPMKBS2MKyvs/iwPXNT7HW239dzT6xZKVr/12OZu9Su77wfba7bRaLci3jBXTniB8sB2CkoVzkgHaM8HI5zUUllaQaTp013p9itzqJSLyZ4xBFHsIVZBLtwSFx8uON3XjNegqthLYRw3Ut3H5oRoXCjzigwoO4A9Omcfj3rNkurXT9VeHTXismhjWGG4lDyM3opU8csCO2citHTS1bOeNZu6iv6/4cwdC8Gz6hb2i6mzx6RC7yxxHUGlPbDJvQZ34/vYUDjrmp9Ts7m1txb22vXLyXBWJzP5k5RRkCOBFIjGOpZwSp7mtnTb4rb3EF7a+ZJZu6NvjKMhxuIVQAAMcgZrNm1hrfS9LtNHe00/TYSk5JzEYQWILNztZRuLEYI6c0/dS0FepKWu34fqOe8stDvbW1W00tkNs87w7Xab92QfNdxnJL4x6YJPtp6XDpyk3uradb4uSLe3FyqwPIrAHDq7/MSRwcDp0o1aN2Etza38LLcSpG+owRhGkVQVI3BGUYPOBwT3pkmm3DQXImDx2YFuTNHEz3U0iFQhlxyyj5sjIGG6VSTTsQ2pRve1/UXS0+y6ZDHeyy6g2oFzIZ12osY5LZK87QBxwP6yQ2813JFqE3m2yyKXt7aBcPNkAoVI+6cZO0jknnFRW+qaf9nkIkgtrRnYpKcRqSpAEbZ7jPHbgetVNe1J9LjkuL/zJbgXWJri3t3RpSuzy4wxJDbsnn5eho5lYXLJyst3/X9f1aK4vwvirQr2G0vraefU7S1uvtTABN0iFfkU8tgBSw4UnvXa+JNkfjWctDDIGUFy43EKUQFcZPUKewHua5DXbzRNT8SeGNRs/s14H1W1jeSOVj9ncTL5eVBwG5KkEd89qv8Ajnxbbab441WxSa5GoIY/LW3Adh+6jbp6kdB32n156KL0lr1ODGq7hpbT9QgsF8gx2dvEdh81Cx+6mM8kAkHDYAI6ZPFeVePtOWz123n026uLmTUYGubuxknkYbUZVUbQwIHOAp6jtgGte5+Ikd3AZNJQXiqqRLNcSYUPtb5SeSM5K47lTzxk4d3qdtqmvz3gTSX+2g2skU100crDhY3LqTiJWTOBgjkHJ5rRy6HPGLWpPp2rSXMF7dvBcNp8skMA3xJMLdCMA7W3OVIOQASOVGcgiupivY7iK0tLJgLXesE9usspIXJUAMc7QHBGCSBj7pHNQQLcabHqaXM9sdN2xee87hRdDC+X5ckZJGSQeeANpIIyKzzZ+XZo+jJFBfPPI1wkjm7kRiQUiRlzsKj5SxBHIPBrJ6ljbh/7SWey0nRzFIGjd7q5lQAsnzFgVOPMIbIAJ3dRnFWfCcts9vC9rAYNX87fbzXOXjUqBkDAJjOwnDEbjheKa9nJo32u5aWS3uGnQzvJPuW8JjMQVmVR98sCGwo6jPGK5/V7kWt/aJaGU3N46CaBWjRmbYsihRGuNhUfM+MFsY6E0NXGdrrV4sd4dR05FkSSMRLA+3CylXKlMjjARs5JHIAAPWM6daGF7PR7XRNSu50DoMqj52shPlycZI4+m4cDFc7aajbPGt5dmOMoVSY6ZNhp4CSCJPkCOuYgexwxyc1tzfaYtKjtb1JbW1dUTz1tgrABt/ltHGoWOBxnn5WGAc8EUrCNGx0zxE007SWdraGJYWkt7iJdt66I2eg2lgQMEAjtkAGsaAO9zJOJpdPFvG0sdwURlliYINyKieWecgZHOCAFJzXQXM9xEdJt9CnjNrLYGKC1uJ5IjOwAxuMZO1SBnOOcY43VVnlm02W4sdSt42EQjlhtHmYC6cAShYzIQXIUchemFztzzL2GmWdN8RrJFcPcTveMBGSTbCRQjLmKQEEEiQdSRgYAxxV7UNcg00WaXUDK8hZRPF5i55GPMJwqo3zDcDjA4GORjW989okVvqtvELSLgwyxLBKsQ+cORn7ig/dB4C9TmopBEYHQNFLeySRub1P9W6BwxB3DaSAEKqmc7iO4pO9rAkr3ITqBuYrNpIbK9QGVmhmZnFuGySzdz86Ag4GCeBjituyub/XriSe30mYQQCXf5rmSOVNpVhH97cQWDALjP97PTEhuLGGEynUL1mSIxI28q0gXCkzL0KhgQp64XBJPNdN4bF5p0lp9s1C+hQxC2s4F3QxOFG4P5LZG0ZHPynkDOeKGNnJy3saXqyarJbyLDbSTwwT2yHa28AYMhUFdxLZY5YhVw1b+kz/2hCphvrKEpKVeMMrC8Z3DBWyo5y27A7k9BUfiKT+0YmujHpUkax+YlxMVh85mypKFmIVCpG4MVJPCkc4rSiTSLnT9QlDQStC7RwgiW1lRwTLuYOcIFM77AMkMoB4oeorlfTUtvEF9cNbR3EVt++i2CYRCLKfLNAAT8xDEjaMJk8Zau1tV0yHRbiztraFYTGrooYvGVwNpAP8AvAAHB79qwvCdzZQ2ljHHDY2ESbIoCYWGwEtsT5sNvKlXyc4Dc9Od1YLdIYPLnke78vy2AdjtYsAfQ46nJ7nIxgCtY2ZlNu5aSV0Do6rG9wn7u3fEkm4qFyMtjAHYcc8HvVWS3mkLBiBJhllTcrFmUAqBsPJBBHTOCakuZHglmkmjaGKJ2Dqyf6vaMcEY+XaPXvwcDFQxFVS1NuAEcea0W4DgYbcWwc8EZ9Ce2AK1VlqjPUNRS5+x3IgSFpB80q4ARgzYC4OeSOAFxyScivKvHWtpqV8bC00uSwt4Qlm7CQPM8SfOZCwDYG91HO48nOM4r1gpLcIBcsm+IhkleQCM8kgqcYwM4xwSR9K8/wBaurW41iBtOeIX2qPJYR3Eq7YlgAEb453A7ygAypwBjHOZlbqXA5zR4ka5V9aQX/2V1SSBJAzSxyooiiIUqHZTvG3IGV5AHJ7ez0aTVbyWKxwbW5iEi3pZj9nBLQlYkDc4WMgMCV9O1c4ZIdLW4lWFbiKzQTW80377yWkJSXCFuFORlQxCBeueK7rRLBdD0karFpawXtwiw2tuzlMAgcOcqAPlOMKNqkYBJOc2rmrdjE1ITaTrFp4ZgvbONb/e07xxKGjDECLam7fuBHJ5J4HAArUvNRB8EWuh6hrKW+tsv2aWe3VHyIiPM3cqNgVlzjGegyaBZaw+lDWpLeG4uovN3WsLfZgwAZFUnOWO7Lc49K4YxzXa6TB4fjsY2urFVdGlKwiNAM5cLjy8qAcqpG3qCclNXElcuWVvpln4dmmubWSxM4eCG5hu4hJckqCi7GLMOMZKHIyQMljXIHUtPls9FUxCaOxtXxMWdVfGCAkYwYRknOcknpkZFbXiW7Q6k2n2MbTrYQm1hnj8yWQgbJA4C42cgFipwQV3H+GqEE81pPsvNPsbVxuVIpQ/nKuC4VlBKMG3A7jyWyM8DFR7sGeoeCdVstT1G1lnE3nxxhTIzFY5VbJZgg6ZIHGBgs2OuK9I1SCC30+yt7FVt7dCBEsWFULwNoHrjpXj3hHUNMtfEAFzaXdrJ9ladYY0LoiHYw2kDaFIUnIzg8A9a9aTzGmEJCiMKzhwu/L8Fm9Bznt24qWZy3I0SYsjktbxrlMMNz5Zt2ecgDnH6YqCOIWrWsLBGIXAldWDORu6j0AIxz/F0ovryzs4bJJpXjubkACHo7qhBO1eu/AHboD0FWGF0Lox3BR4C5YRlgAT8wA6Z6Y4Pv6ctaEnhvxDulfVtMu9LuLmG9DMUiZSgtNiujKeQFxke/HFXPhNaw6hLBa2kchslXzpZLoM4kMZAVImGFwd7FhzyorpPHstrrlpdaLc3RT7MRLLNDHIq3Ww7WRXI27laQZGSOmcdvJLmyvtHtru1kuURIyZJhalUH2duwO4kSFs/JwPl6muOceWd9z6Wk/a0uXZ/wBeh6dq9ybm/t4dPjK3t20UpKBoXLMxwZSpHoADzjvxTvFN3daro88dreWpvFdjEFO4RuqgiM7gQ7Nk5bIHbqDXOadoU2kafcajbppcsdvL5LWTFmYSKm1WZ1BD4yCCMjg9810GkWi21np7XAstSW6eFVu7eUeV5sZKlgo4C7FJKkcHce+KnV3uD5YtNa2LFrBBYaLptlLFJHLPArPA0QlluFYb2YYPJLdc8d61tOmgubqWWA288ACLcXEduGYqpCiJwexG49iKydV15bq/TTNLIiVtvkBiSzIpzlE2g4JKtkngIRiuetvFen22q2H2NJorCLO8zO0bTSMG3S7RnsMjJ6joKOdRdkSqU5xu1qdZfHTdI1Jl+zpM1sF2RuFihBYtsATHTg88+vpXHa5dyavDeTxW3myztcSwzrkbiOCEXacjGQuSOc8VZM2pTTxNFEsEWoPbyafK0sWWz8gK785wFIJ28dutdX4a8PQ+HkvHmluL3UXUFC7mTZIxYK24DjbuIJGT1xQoObtsh88aK5nqyv4X8pxdalbfbLaN3Szhs57bb9kCqAEywON3APOCTnqaNQ0KeWx0uyvdamc3Uk5js4o/Lafd8x5BX5gEbrnrWpqDXekWEsJu459V82BvtE8QkbeRkKAWGSeSM425HWue1+e1j0ma0LyfbbFXMU2HD5ZSCYyQS+c4JBGOOa1doqzMoNzlzR/rT/g+o46bp+oa6LhLWS3klAtTDIVE8riMbVz8wjx8wx3A3E8VnasojuoPCnh+4kv1aMyPIpDrDcru8xnVed64A+Y7RnPYViwahNIl8+rqo2DeYLi2O95n2jcQrKd5wAM8cc+lO061khTN7aztYNBKDIzbN7rtBGAu5SQQMfj6mudzTWiOtUmnq9vzL2rSy2emWsixLpgurcXUk4uVa6EiAjJKnLKxJ+6M5bJPHGXfWqQ2kEFjLHpaXDLfTlLWWJowqAAYwSSoJIO3JyWz3raspbW78N3s6WVpp0AiSe1khfDzIHyRIXPzMAuANv8AD1rsI7G8aZNSt445NVuLL55bqIyR7io+aYHkptAUKMYPPeqUOYl1VT3Xf+up57IVvZL6d72e2u4N08U9+5cttAAiRmAZSVAJLKR0A70WdxFFod1BObK40hZlVLe1fP2Y5zkORw+SzEj+6STitCaO7bw0w1V7iTbNHqaztblAzGIZRSBlEAHVRnt6VKWtbyM/2Q7x2F0+TFIWNuxZTkfPnAjOCVx3A5qPM0T0sLbWUeh3d1baPbtqWt5lt49RlKuhLplG2MPlAUgZ4DY4z2z7y4Gk20qtY3MGrNN+7ijV5PtSMfmbzcsVywUgD0xzV6LSzbaf5N9KtvbveeUrQkRSSybCAwj53BssF56554rQ157e2+zRRr/plkgbyhcGSeKI/MjzEj5ANxzg/wB0AU3dp9CU1zJb3/r+l0OakkEmphtFs2vtStYUxE9v8nmMzF8YC4I5+/wfepjos6QX19Lq8NkbOYi3gluGjkvJoyNxDBgATk4ILAdOD009NMraHexW96W0uTzXvGkgUPLGMEPGrj5sY6bu9SWNjK0a6pfQR3FvLiWygv2yNu8sxKMp2AnoQeh5pJX1sU5NaJmfZeJ9S0tUuIobiexkbfNbCZoyXfBZdvJc4JIY8Hr1rYsFlur27vZtSl0uzUSm40+SRDMoJAULGoHXAO/uABzisW2WYXGsJaahpUUV4JZ1m8raLY/dA3LllA6KTwORjvWxZpfTNNb2NjbWc0Ept57zzDJNIgj3FXQL8yENkbeh5pxk3vqRUjFapWZWufEeuTaXeWy6Tbz6aGZfNuZVLSZb5f3aOWZyTjGeeM1jzanfPIsgsLOK+hmkgWNrZo4ZAqnKumSxfGfm7HA9K17+2tJTHbPqQN/YrbRi9Fptmg+YjcVjAYsdwXDdM54NXtR0GAJm0OmJafaykF7aSiOQgj/VySuTl8ZJOOc9RTlzSV0wjKEHZq1zmrrxLrUEj3EtotzFOSGS+iAjGNhCrtweDn8hyea6DU9c0uGNpdWvBFdM6zW0Vujzp0Xcly0YBY4O447dDxXP31pfWbzzify5LiZY+R5yAowDlFXoMMM/Mvp6VXlXyIpN+mWcittMX2eMwL5LgqFBDtgnBweTWcZtb/iaulCVraeh2Hhq5OpaqEmZLO9h3JF+/KNNG2SVCsMhQvAbj61diuNRezjsNQspFtp0YMIiFkjbnJBGQcKBkHrn3ritTspZo4ZzPAktt+4isYro795BY7lzlmbJyeSc1dvZWtB5txpWq21pBMpliy6RrvBJAVuQvKjBPK/pam0jKVJN/wBf5nc20F7c2/8AaV04ltDEXlhkjKsec4MY+VWBxjIOMVNJcxTK8l8senxW0itaSB+JRt5DY5yeRggjj1rP07xXp5sW/s63lt7cukGbiR1+ckLheDuBzhSx5wRzT7QWMINreQ301irMn20r5hSTnjg/KuMYAB5PY10ppr3WcTjK75lbsRtCLovaS3MeovdRSzXULRICMsFV9wwN235cdeM0lzPqGt6PcGw1FrVI45IYJVJjkmiAJPl7S2X+VFLcEc8Co4tQvZ7jUbKyt4xcQ8I00GFhiHOcEbizAE5xkkgcAZqVXfUL8WqiwFikWZUbIMYzncjdCWwST2xiknctprV9P6/r/hjN8HXaXOrW7agA98mpW0SRJGVjjCyxAMHPLsVyWJA5Jqb4r6Ok3jrVZL60ila6iQWDwRMs6uqQ7yz/ADLjAGCVz26c1o3V1HeeKbB/tIgU39j5dsSkiyZmjbcpQHJ4OSTxT/Hkdjf+P9Se6uIWuNNeFo4JgvyKYlZmU4z82UXHJJH4V0UdIteZ5+Nd6kZW6HI3GgPYWb6gsCWV7GPs7xWzb44QQjqGIJxhj/Dzjed2KvarqPh6IXF5cy/ar37QS5nX7Od3JwV252g/OFPUHJzzUt1Yx3Cw2+pXllc6HEYpmgbaWs5WJbapAXd3xu5JdmIAIqBba2TUxrJsZXukfaqxBY5IpAudrbyUyQxYlSobjGOKs5b3I7jTdHQ3E5eFGlBNzEVkmuJgNhbbG+4LwqnICkYJ9KhuLLT70t/ZFvcm6jgjMaW7xyg2/wA5kDMPlAYKmWOSCQc8YpiafaF5/ItRNLDzbvdsiRbXLfLJuZmd2w2W5ZuORyau2VvFDqRm003dtbXU+Z1ZhH5zHk+SvIfCkAqDgqAPWlewxdPvYkUajeabZy2wjHlXDyCIwQhV3IxOAWLE+Xjg7RnaSCcLVdES4/tR9Gs7uPTTHHCn2aA2+8LsbaEYcjoQ68nOORXRw6eUtRZ6PeXsqRyLGmmxIq7kUEMHjHyrHgrkhj0A4NWE0WwujM+nRcRuPMndIisYYghGUH5jkHHDdAAaV+gbM59dHuXuLKHRryT7Qsk0du7mFJWXaWVi3ZcsvO5sZPGevVSTswjt/OudT0+JBDI9wyyRiRiEZ1lweVJOCRjCtt5zl76bavpbIkVu67lGYvMDvjczb1AA3Fsgdeo4NaFqguLiGaXUZYysBg2PJhH4wvAHb5sEg8Ag45pckn0E5o5+LTop73TtPgMMunRx+aqW1wZPPm5YF8jaXJ3MCM559gNOWzkvNR04332RL+FjKqsjT+X/ALMTnHOEKMoPbOOak1HRxqsNnFLKq3Mbb1MeYQuOEI2AYG3B9+RjnApahpNkkEFzb217HNDC4gKgNJAWBDPgkAELnjknJ6EUpJ3GmmJc6vrtxO0OlWdleQRjalr5bRNJLnCkhgCnAOMKcE4x0NZ1toqHQrKTWJLcS/6PEgSUTLbyBsSEjOAPlAIGRnBzuY1bksorwTT6baS3bC6gZX8zCMqBNjFc4zyu0KoIAIJ+aoDpMn/CQpOrySWcdyZykQ8l4z85Mnl5UZALkDHIXIHGQhk9rbSaJcWSX13G0I82GSZXV2Z925Cf3Y2ttULgBiBwMlt1WYtYk1HVbu5xJHBAQmJ1uAYWVsOm7q+c7iTxjHGBmqGt67awNZXd9YvBaN5N00skLSSNyGCbeTG3AJJ/uhV6AmZFmlxdzy3cOn+d5z+ZatGkkfmN+7RH2lsHYS4UnAPqKNhlm0Wx1S2Q3a38U7q5JaF42tl3bFAfKpIpZd3QrjJ9c1Le2hs9Luo4bm7WB4pzMsl1E/mSu2wO6vghwQSo3D5T2HFamuX7/bb6/knihsbadbecmzkYhAwC/MwwQrZfKAAf3sE1WmtJkkEptrQxyt9kiUx/vZYyvyruHLEAnD7jjJBAH3S4jH1HTNPt9Mtgt/Jbtdp9m860hWRlj+8PkZdp/wBWOGIbaw71s+Db9bnRXNybKSeyb7G0oG1XbOd2AcqPmUBT02nn0pXWiXksCaSkfnqtuJTCQxa4zlpNsh+8OXwQVJPy5AxWXFqd2niFrOKeyhmuFYzSXCs8pi8wtucMmVQqP4jltpGec1UW0KST0O4treG6hkmjZXjjCb2nVUBUDBQqeo3cepOQKZBPZ+fCs9+sCXIbY9yGWPywpdsn+EndySMc+tcPe+ILoWUZlEk8rTtYNIilWmJG9H4zkYIIVgCGz0GMYNxpMupPrMN1qiSXs7iLbLM4M+2QEDGFBwoJYZxGD3yMaOd9iFT7mr4i1az1CG2h0qWwmshOZHjkfylQqcbiNy7gdzHdjBGOQaZp1hB4Zv7D+2NTLQWK/bIw0D3MfnhFADdVjADMAELZ+8cba0LzwxqF9Z6da2cNxGYnSForcpEizlXJDbSGEQBA3Pk89CRiuw07SdN8OwG6a7+0XcX7yRpJPNS3QAJIUCphBjnGAeevFQ30L0Rj+GfDUk962o6pLcGB189UK7wfmPlfvCTgLwQFA3febIIUa9xeyXdy94JbD7BOpt5EkcNhkZmOeBj5eTjOWICmp4501sI7/bLiIzF48xLHDA20FA4b5/mRt3TnHGOK5q3Vki1p71rUWt1CDd/bMyI7RxyMq7eWkIXYzKMYBwKTEtdyne3Jt7uwkmmgMd8POgtjNNHCy9SU287mA/hAwASe+akeo2l1erYCJbfFs0SNJgXDp8mIVJwY/wCJsA+ueuKitrkvd3VzaCCCxS3jtEtZogrPM3y7Vj6qqhZFUD5gHxwM4z75rC1No8t3Lc3plWdVtIXaV3OZANhwFx8/3VYjDdNuKLFXtuc1JcWk922mzatLZwWwl8zdcESMwKEqUAIIIBGc4y2eTTvMddNtvItZU2w+Q1tPBiS2ccw7XLZBwMkYHK5OanmtbR7i0kMkd08c8xulmgLRsDgKo2gKApIIfqCBwKaEiF3KujC8nU2rfa76ZVd+WCygKQp2hlPzLyec4BrQR1vgeN/N0y1c3Sbw0QmknZVaFfmUhVUfJjHI46dM17LKhgu0hhhWSJE84HzCoJHqMHPXOM9evFeTeDLTN08LLeT/AGTTjJvNvw5kBHLZ3OjK3ABGNgGBzXrhZre+sIA88kjMSDGMqCqgYYDovPU9MDioZE9zhLrUrhtbvZ5WtZoY5vOCzkIIIl2KdwwdxJJOMgn5FFd1KIvsbyunmlgrtF/qiWOOoOdpxnqfUVwQ0+VJLq381JjptpM8UTsVi3u339xPU5fnnuARgV0mkXwj8J2TxySXWxfs/mKd28qxB+6cZ+X16VTWhLKsEGo2WtT2+o6itxpl62ywVABIjbMurYHsTk+vrRc+HRLpE6tcSXtvFH5MNtNtP2YqBghyN27Kgkkn73GKkN9qUsCyxW9lbu8rmGN4yXKj/WNgdCMZ7Z9ea57W/FBsfFcMtsl1JatGxuYSATtEe7hANxOFPcdxg4rGTilqepCNST93dfp/X33Mfwt4XOi2OmeILOS5Ni0MaxWiSG4kiuWk2B1RtqtktyDgjrk81peJ9CtdX1i1urHM9jHHI7T27qrwzbx5pC4O7IYk8E5XqMmtXUdXtLyOymgczRI6Tw3AWMm3ZhwQpGWIDEY4OcAU83E9vYi4kln1B545JI7e3Ks0g3YHyKAwxg/iSCTWaUWuVG/PU5ud7nMweATLLItxr6rOjpi4MhNxI6KBsOGAUdG9fmP473hTwdpej3VyJpDql2W/fhoy8YLZGBuJwQC2ec4IzW9asUhujeWvlTPtmkEULFuVGNwPJcDIyOBise4kXTYQB5NhYzTgtevOA58wfPsjTOZDwoLDA5ParUIxd7GbrVKiceYuabplrZXcqrDp8skS5jEsAIiiVj8yk52novX+HtVLxLr76dJC9tOk0H2xN9xMq+VEeWJJ/i2DHHGTxnNRQ6le3drJp+mzS7YQ0G9d0jydAzPu5c45PQVSTTdKGn3lztlgspUZgZIkKNtB2nZt+XG4MGbkk96Td1aJUYe9eoUNXt5dAs7XUr3+zL+SLzZZtMuJ9sswY4jkbqCwZslcALkAfdFVo2srnRbvX/E+qTql1I8ZtLO6YvMA+Y4cAZRAVPTDd81FrNzDY2sdhDBbHBlmlluPuJuCyPjb87SEYGCAvNUrTTtPi0uzvrVhNq1zub7OtkjGIRxtKojAADHJXO05w+O1YOWtl/TOyMPdvLq9/L9PX/gFq4hu9TvP7WWC3uL3AjuUaSKNYhhsKn32fbkbicNnuauaTo0519prq4jubiOBJG1GXzFCKF2qjA/7W3JPHGPWr1laabcwT6gumWuo6uxE5URpbPbuypu4UlmUMVZcDsM81Vvxd6wI01C/u7F9P04R3FyuHw28KNoTJflWYE52g5PWp5Vv1Fzt6LRf18/66kDql5pP2q+SK5SAizlv5QPNHOCq7clgQWIPAzgdM1valfXq2lvYw6PeSifzorecyrJMIggDFhgFD/8AW61isy6XZah9jj8y5u4o9sEcKyJcZTh1YD5W3O3Pc8mruvWV/Z2lxZpq0AswmGW3cyyOVUZZsEkHJyV/2DRHRClZyV/luR6le3usi3gjRtP0gBYrecW2HTcdrr823bj5R0/GqN74fFpqENuIPsoypeOe2aYyrC+WZ2+8pPquM5X6VHELF/Ds72+sWN/eyWslxFFeQSvKwAzgLztI+Y4B/untVy1u1tr6e+LCbUHb7QrywgswbYq4O5SG7EAHoMik2nqy0nHSG3oYcmqxPcvcObM38dwwICBotgBKyROybkJLMAMH7wrobpIpbtRopusS2SQ3FtcRbVcAZ3O6sCegGVHWuZu1RLKD7VEi3Rj80SSq7BtrM42KPm353DnsM+mNoNHNp8K2c6XEeXEy3E2GdvllyqHG3pgkkn5jUxk3uaTilZosWtzYRywtZW0pvQBK7WqvKkWcAQBSQF4OGbHapLKK912SW9uonWGO6SeSOWVljUoApOGbd90EBckEqM9qtaZqayXmpW9glpHJfSLaxNE+xECKWJC8kEDOMjnnqKn02CaQS2MDCSCSV1ZLwjzMqMszH+Lcx4IPA9KtK9uqMHK1+j8+3UpSm3jK3097ZafYRoga4j2oJWIOQ+BnuvHIxUOoa+mp6bHqF3DPHdl3a2ukmG2Tb0ITjcpIABxjgZ4pNVjtIPtRS1sDrHzNcSbFNvFK6dSchtwxzxwCOOKo2W2R3Op28rXUxjjgubULF5SDG5dwx5eSRtzjODk9BUyb+E0jGLSl2/r+vyKkaJqcqadBrkL/AGi1EV1cNBukgZdz7JO5UZbcRkAc9qpmIwafcSXcVkEtGHyTb8qrNgCLcBtyF6Dn5varWqxT6lo9jJJeDcl8bV9OjhVn8oKQTgj5jjqeQdxq7rs8Wsaqbm2jiFqZfmil2/ZkwvyPnhVbcD1GeTWbSsbKTv5f5fdv+hDCbkBQJCLZ8wwwNJhPKZc9CA2Bt+Z8+lQzTzT6TZXhnkgZ5k8gSqypsCgq+8feBI4IwRnvS6dNLe3V49u1xc6UtrI9wlqgeSMMdm5OQu7AxlcZBYVt6e1lfaa154gukhnHlNBFFEAwJ/druA+QgFNoB6YPNEYqS0JnLkeq/wAzJg0i9QTX1ybBIFKNbsBHMsk7N90nO4EE4GcjAGSKl07SNRu7GZtP1OSLXJTuurWQmNliydrHc3l5+XpxkHB4wK3/ALRDb6fdWaXAvLp1RhFDbIYCWJ4GAAD8pJBPBrKv9MXUL63XWyI1eONZ0Zwdsh+bEhGSEwcDvxg9avlUdiFUlK99Pl+hV0CWTQNdkl1O3uvs1pdbGeKELbkzgEyNkjasROBtB+9xiumstOnvFkXTLu2u9JaQGO3dmKTqPvAyfe39e+PlGa46S2u7mJp4b55bmN2tLcowBId8ZywB5455HOO1bfhG9bRtNurfdslimzcQqvmNKuF3EkN877eewUDr2OlOeqTWhFaDs5Rev9f18zciv0tIb+7vdQP2mK4ScTi5zK8aHPkyKDhCo+Xbk7q1dAnjPh7UCiGa1jSRonjgdmkQ54G/nIJPTjjiub0qYyCO63wLmCUNK+9JC0bHGQcszYPGAeB1NdHYobC6vXspIn8+MxrGzFHiQbipVSTn5mPAAPIz0ropt7nFWikmuv8Akc9NaWlh4p8LWaWcitDNaiGJIWVSizxAOzLkEKH/AIv4hiug8eSeT4l1kyWi3JZYfJjRgyj5U3SuGG1XU7cc52jIB5FVbKUxQaZps7X0DnVrWRkuMufkuIyBvHGCxXA69c1L46snu/GmqmMrNAscCtFukTy5mXAcgDD/ACnGeccDIGa2gkos48VJuav0X6nn9zNPKrytql1MYWENvDcLiZHP33KZ+UgBRhQQehwatPcRLAkenW/2OGUC1nDje5LxbFaVQm7AV93y4yoA424qOSOTSZXju2nLqEe6l8n7VJHDhwZDIAQCyqCRzjbjPcyWd5/ZN3Zwo6/YhG8D2scpRJ0yfLMcwZjI4VsMO3bgAFmImu6gtpfRS6jZwXu3P2APtKb1Tku6qC2cgFTnGODnitawt/Ou47+WQLFC0rW9uiKwdHAjGHHUAZBAIxkcnFU9P0cWupyS63HC6pM8sUYkMnlkocKFIHBXqSN3ybiOQa62My/YZJ45pY4bedYIlJUbNzfeUEnGVdeD6dMVUVcicraIpwRWsloqrpohgEUQVQdpGR85CKCB97vjJGOnNWkuElntLeSIxGPAM7R5Xkgtux2HyjPT8KJJWaJpp7chlcSGcbhGCw5RsDaAB6DjFKE8rIudk0pkw4jUusQwu04bucEHgH0GBWpiLLAYfLsxLHdyjYxmRQx56hVY8ZORx0BAJ6EuuAu91X9xlPLKsuXDHqpIyWI5zj0x3qUj7NBFZSQoZgyK9zkHcBkeWCOcAYPU9CM56RrKsaM4SAz/APLICLYQMlizcZ5bafXikmA+1mjggjJui9yirJHKHbCoV3bRnG48exA59qLW3uboy+U3lyMVLCPG0DIIbLnk9c7R3xnINNkkS/aO0eRmaRVXyl2nzFyp5Xj5vvDGehz2oP2gOsc0cttJGPuuoKMSxynJ9ApJ79PaluGxBdxsT56WqC5keEPIC/lsxOCcqwbnnI57Hnk1meJUSe2klvQk2pQkxqnlCLccgZUsPlU8ZYnbkjletbF0La+sZbQRzGJ0YxsYzlMg8rjJI59+uOeaz9XvIIrAaLqktncGyQzW8UxVxdxpuIbcBtjl+QkDgdM9MDGceV3WxtCVylL5tutvDNdGOaRBCZGtxc+ZMGyHlZgQ6Nu65ySoJPNPmlmN/eyRzRTWxaNftgkO6eUMpktkjyVOUJB6cYB3HoWo2QX+mSidrRSlyPtETuVCyHgbcsXYt8zBuAMgY6GtTXEkf2W0aS1T7QVizZqUgWR0Id5CSFO5XILcsHX73Ws7o0tqVY5biCS4n0+ya2kLMAstoD9nUyqpRVwFLBdh5HbGeaZYTSQXF9MxuZbhW8iCaRT+/LPyHTG1thJZQCOvJwa25z9ss9Zs74+RLaQOkkMd2rrGxZGDiOTIK/MMMwAJUgYGDVqS6jtE86aKHe0SyQWcrqYom2EPgRglyU6ALyAAMc0aCuZC6g+o6cuoXplvbaMeUiQwRqzAOyn90x+XgZDBhkH7p21piESz2sWs2a6q/lLbeXNECscWC7BZGUBnOE+XPbg9zm3ujiewjVL2C50eJhdTJESku9o9u2ZWYDYMpgAZBX5lJyal0srJYyTRzzTSpKnl28anDLuBjJC4ZYwqkHbhfvZ3A0wK621vpmoB7m3upruC4bFxNhFVZV2tIowA3Q8oDt4BHNJHNcqtuWur2FmuRCs1s5G1CMHjAPIC87T83qTxoadLfLpN1I15LZQWVwypHGglSd2YKkbcbtoBAJGQ3Dbs5rN8NpZraC5DRM7XJkaYtJCk0kmGjRFfbhTv5I+UEDO5iTTWquxXsa/h61tilzA0To9ym4qsq5lJ4CEF9xOEUfMOpO0gdY7KaVYyybSkOSxVnt1khBGGWJQNyruwSMk4AxzmobK7uo1m/cramK18lIni2yKSm7qB8jlV4DbzlRjAJqylsm+PTt0cdrEwYCSYvIqHJ2KUYGJgc9WIO3PPFVtuS7lOWK6W8ijtg15FNKizSSzLFGieXgjIUMu7kZ27gMdB1La0tJb60lnvX1CeUMDJOimFQMoYVTk8jfyc59ehGrM01vH5dlJb2tghjknE7l9wXaU2tjCqq+pILDHTJqmsclzZRx2dwywyqiSSzP8AvYAThhIwBDfJvwWPUYpDMi/0i7lvIGsZ5pjp5MUyvKrorMciSbtJkcjCD5jknGarLp76frtpqptk+12DtOkeXlVeCDIzKACMgkgDPzswHWp7hrY397M1vf6jHbCaS3vPKKtGRuzFlSSyggBQQcsRwBSGFLCCwttFsrs28ksTzQPL9nZBu6LFj5slz0b7qgZOMUwMSHShBpctoUNu0Uge7lhuo2TZMfMViwKiRA+1Q2OBnOeKrXNpdX1tYXmpWsciWgZxHLLksGVY9rMMsUyq4Vm/jznHXuNUtSumm2g+z2i6fJKk5tpk8y2kyGQrGWwyfMxwT2OQaoatplo17bSai0aqU+RomdorhY5Ff7uc/dctg5UFVXceKFq9A5jN0KKTyoZba1g3nUoSYwzTo0SqAYS+SwKIzMo4GCuDnIr1S5jYXzxx2nmQM+xpDJgkklc/MRgYIO4H6CuWs7WWwttJjnuGMzROL7yWSIJEFxvzgNjGD1/hPbg9BLNM5laIFbKSLLyCMyGU42+Xx0wc80zOTOcVWu9bEUEsXm28M6S7rf55YkZA0Kt1zhlO8gnOCPvZq74YS2Hgi3sraOKGO1YIgWcIGThlZXPUkNz05z0qjCWi1+ymkdG8/wC1ToW2kQL5UQUnOGJxEwOOTsbniuj8NWjWtgYYxi2AX96ykF/lX5whyRuPOOgFU9BdDmpk8Nx+Tqtze2e+RjAJopSY2fouxT1OQBgcE81BHq9vc6jHpkwtbqHUP3lrcBhi4fHCsE+YJgjcwyM49afrptdOvrCLVdGuJ9KtFEtvJAysscq5/emMEH5eBnB2g5xWDe6xp9smrXP2WC1a4tMiey2zGCONRmIfMrFxkMcDAGM8Vyydme1CPMr6vsJoF5e5tpHCS2suoP8AbngQyfZmjBJjlDDCgELg9156muk0PVLiGK7u2EE5eLawWEW8mFBPlr75bnJrm7hr37NBZ65I9zPOj3CXa3yb2Ytw6IFCuwTHBJAEZzXVWl/anS2ntiJWW382MMo3sjjdjOAGZ9uSOgJFKD10ZdZXWqvcnu721azsrh4roxwWxaRpFEhjUruw8mSeCBwM571y/wBjUafHFZzQqbgyuhU/MRt+ZkI4bBGPQelat9qNrPGXhuo4JLmzX92zCH91gSN8vUYyAR6GrVt9uv8AR7RtUjW0vZEJECxjMcQYYK8EBiM5PpjjrTa52RBumkc5b2k82jqJm1ZHjdJo2hw7AI2CflI+UcE+2epq14vvtPN3aQ2mlXE9xcFXlaFvKZoyrDfvyMheTtyOQKnkitrbVtDs2uNRtWWVkmkcGNZSUZipP94gjLDHGR1rjo7zUJJrSW2aaziinkWH77rHGUJWQB0O5doJJxk5HSs37qsdMFzy5v8Agf1sVJ9NmutTKWktjFdJHmIwyiNbiBFDEydS+VwMj5tx74rsvDHhy+XSbsXEgsdYEQkiyxaW0MqBRsBPyYQEEkZJznoKxI9K/taa9nuJLyw1OO2RFbUY/tUHMbboWKcgjduAblQR3wKv2rWFta2txBqcd1cWxMbyQo7EgbCIg56sRyTnBx0rOEVF3ZdWbnHli/w/pWL1m+mx3sf2GwuZ7y182KaWeaSOQICF3SHOHBwflP8As1HrcGjXt3PdXMU01munhxBHP5O9idp3YwVRV4PJ+9W5c2+kaRqX2tL68W5vIHMKmT5GQD+LON2CwPrx3ri7l1s9P8uwkvpXiSG0nihQ20ckkg8xxtwCoIB+/wB8Z6VcvdVnYzp++7xv/W/+RHquq2jW9tZ6HZNaWDMhaVJnLOHGAknHQkcAZBx7VdsbKbTb2RPJtNKmt3zcNGjeXaBMkurEYO4EnBIGWPXpUVpbi0lV7bTXsIL6GO5tUeVpcNGdwIQA7sJvIyOoPtT7TV2XWmNyzXRCeW160jiK5DqAqhcYVQPn557ZNYre7N9bWjt9/wDX9dB7aNPbwPLYp51xDdboUt3MUTbVjLOxYdCpbODg5xWRquoWMet3EN1DFHp8Uh8qzeIyy3Em9CxTDD5Rj5Sc9cCptRum1GOayZmS2lnEG+6A3POoAMYG7gKpzzjkjqOKg0wRyTWNq4sLaGxQvdaouGYSF2WPduON2VGNoOCcGlo9EXFNLml/X9bHU6dpVxFNue4trCO3hKukgeRxvLc9fTGAegb2rCvQov5VHl3WqWsJjmnNmsc2GwokTGd4AH8S8jHHOapWeqy3GqiG1WGztp5xLNLaAGZs8gSoeDnK5HGPQ81TFu8WqmCJB9ouHcoskUeUEeQ7lwMg8hhxxgYzzQ5q1ooI03zNyf8AX9eZ14vbHRdM3m3tZbSGWN8QH9/tPy7mwCGcHJxkHANZ0n9n3VndyWqahbCFzKwJDGaLcxwrE4jyxBGO+RWSdSuoGjFl9ss7SODa0dxk+exjyWKktwSWcAHPPXis1LyZ9MnjieaK18pWYlsCUsTtUjHPIzjgnBpSqdBwovc6CC4l0+SR7exnMepoUuJ2s5LiAR8DzcDB4yxx83fHFVXllh1J7a7vGS285NLeLZve4gBRvlUD5S2ODnIB5rWt9be1sGNwxYwxxw2yrMsUIjViVZvlyWO3pggDjOawrG6js7Y3usxNMGmVYo4yIjcIuPM3Hk4G7696JNaJDinq2v8AgnRXVtdW+iw2tpP9msYcxKowWhdW27y+MljkKx49hkVQ+yXtza3lvZWJsrJw17slc26wgnafmfIkIwxOQOvbijWWsdOgEgt21S4vZJmmQQEpbsNuAxTPmMdwUN0brVA3TXt5dTpbxxWnlfZo4ri+cGb95uZBnjaO/QZ65pyavqTCLaugvbW7SVQ08dzFfRbraWMrFGzKu754+ASDk44zzjrWze6bpiuRZ3q29usA88EIkLnaGZF29SwK/McqpJ6nmq0Gh6TZWKT3lvJa3bRo6yLKJIV3LlG+7gKMnHByR06VJZqdP1LUo4JYbMMhB3xboktHwAIwp3Ydl6nkY79lFW3HKV/he34/mT29rez6Je/2bLbwWiwktblMtEynLkfwg5CgN/EDnFXtJtb/AFbzoNQuCZJLKNXjXBjVByEdtgHmZ2ncOMAjnms7SmkvdW8mzjiW2ZZLeKWJ3LvGmCCVYbcDcSoJ3YHrUIubm4ksI9RvGtlumYQyFSqJsO3zNmOdqhtpx1+pNUml/X9dzOUW7r/h/wCtC1qlrcRm7igit7tpoTHcPMy7TsPAjbHBOTwox8vTpWT5ksl6JY7U4W22xZcSDaAuVcqBuXnbk9iK2WSa3SX+y7C5Fo+YIXuY12DghmDEgI7Y6E+3U4rnlvNPQG4YyLIxIWwmU/KPlLy5U4LANwODn2qXvYuGxt+F9Reya2ivbKIT3Un+kTwkyqsYZmChUz8ytgADoOfWuut7W7vIJ47tU0/UZzc3kbRqskqRcIAARhsgDp0yO9YXh8iARFDbzXOl7Jp7mRWtd0JbEeYwPvMQDnvjB65rUs3eGdINTimVWEkK3YkQeW88j5+cYYDHljBweR3rspKyszir6ybjo/66fcXYpBYalYNcpm4nu7KOaUKZF8x7lCoIHKHbjkjGTzirHj9Eu/E96uoP9l06CaBhePeBFLiLPlEP8q5yGBA5wfmySBjyR32ma14akt28mR7y1sr57lzLLIvnRsFDL8rYOQW7cA81c8b2e7xvr6NE161ykTxWjyKUyIQpfaRhQMKdzBucgdQK6YfC0eZiV76a7fqY08V1r2jyLDJP/Z8kTSxx+eqrEw42s6EqRk5GDlgrZ4rEuLW/GoaZJqktrDLFD9i0+3t51/eOBtACn5QTuUleQAfvAAk6h0aVbaMaTp8djcC5WN5dNZcyoDjLx8RMpXadxAI5A54GbNd6toltBPpUN/GrLMn7m2jVJJmZgcIqgljn7v8ADtTk4OW0YJsq6aVs/F9gst3eu1lcThp7uXlpfkjOSVB5QnCnhhtIavRJLqONSzQIrBFUoSCsnBwQc8DOM8nA9a82vry303xSmoC5knga5RheTTkRkcxyjOMlV8xQR0wp6AA16K7QKqi62xggmTypCyz4CszqT/DuA6H0qqdiKi1JJLlkjjhSTmMefG74Uj5Ryqn7w5GeO1RytcRA5uH3yIJF3FQ3IxluSM43HoMc+1TQl/JjmltJvLKFH38MSwOMk8sD6Hpwfao51imkV7mQOs0e8ReZwBkKd5J4VuRgAYwAecVSIE3C5u2mWGM+fbKmxEJOAMYHBAJB7Aev0mMcEl1aOJhdW86gu8eWDAclTnkH0HHP5VVdJbctJJbZZ0MPn3EYTqBzgccEcHkn8aktGFuyz+V8ikSCNiBj5sqRxjlvTrjFAEkVuYrXzYXEa3En3fulEX7xAxnnsc8AHHXNWYnuXuWM7rcOfMAAZWYKpUYBySfbtnr0qCZ0LXSlQqufNVEXaT8wPyD0zjP0q3JC9zMkjBVkRQv2lUG0ABuXOcbc9wM5waT8wIrdFuLQzsr7POPmALlQpYAMxHrj6cA46CvP/Et0lvqhubWK9SbyPKa6iYQrasm4YcAAyJ82WJBOW4J4FdzZypbSeW8c25yEgZJAjYBx8qjlgCDz6e3Nc7rlhDc6ownvGshEgjFlduI4jbAAs2VPOCEUhiVGMkVNR6eRpS0Zq6Pq8mpafDc3DW+2GP7NLdRsu6ZmGFULjow/9m6YxUAstL0tDePawQtKqGKLYbiRcKf3ckWSi7QiqSp6KSOea5XwVqckuk2Ag8qddPEjTRxQKVJ8tvLkdiQzEDA2sOAQRnOK9GuY57CP7RIZrhzLDIDebWWzygjLJjBJ6ZPPJOPSsNVoaPQxFQHw89xBM0KXF3C8gClZU34CoMHgbSh5IwCSec1Se2mkvIrHT5rKd5EVJDDiRGBQHZuHzY4zt3Ak7uCDWnFaX11p2pWG5ke+WIGaHaixhpgsskakE5wzn5hzVbU7aKD93awJZ3RnWOE+fIjMGJ2qwhGd7DqgXG08k4Jp7hsOtJ4bDbeSpcKilrdHPloY1xukXIIAB3A8BmOw56ZF+G3+ztfWmnWEdzZxwNFHBAIxFGxR22sONpYCNvTG0epqG30e+i8QW9lqd21vbW4jltfIkKxzN/Eu0/LvBZsAAk/e4wKz/PabWI7mJ73zA6tbQyfMZBwDHggDJO4n5uSuc9qLsVrlzU5LnzbTRrRZbOyvLU5uCwRmQAbNhBy5AzuBGBk89zCbJ47r7DA6zWckfkmaBoo5AFZdpYsMB/lzuyOg74Fad5o8cEU8szx3zRJ5CTeaYtpKoHaQM2C3yjnPQAdzVJ7dtNdLKBJl8qEFlDMIWZflV45WAO4hgCnTLdcDmhXJb64vzqgR47iGCyKixZSXEmCPLeR8HkbWXPQ5OTg1HAqoDHdQvFHaTq8kM5IWVW3bomY4EjFgGB3HBYdjirohlMcq29tutVkMEkZJaMQNHnKsWywAIDMuMnBB61UvJLHQ7y6l1CMywxhJUilkdPLG/aHIG5WY/KFB6hWwBjBSYeRaksZZvO0/TvMgtlhjaVTIJSUK7dqlsgHox3Ak44yeQmlKyN5NuyXXyjfHGDH+7BwE2nkMVAypHzFcjGaFaa2hMNrCp1VlLW5hQDZFjAYAnB25AIHVieO9Z1lFJ5ltLbLcre29uqNObLPmIu1iS3Ac5LbQQMNknGMUxG3qEc9xBfB7KW3kYKrXIkRnzxkLzjK/KeepHTnmAQRO0t7PCC4k8tLiOPdPE2duxUYNg43ZbHVmIxUDrawX0tylzcO8m2Gb7DGP3jMd6bnAIbKsDuGMAHd2q41vf3er3S2N3uuLiZIpwsoP2eMA7TGOqlc5z/ebrjiqJMaxsNL3W17BprukQmKytKzLlSy4dG5K5ZhnH944xipg81tPaLaXssFkA2Jjcyh5ZCpbAEhJZc7SMAqcYIzmoXuLQS3S2WnrHtfDz3K+XGIkkU8qFBJZzwCCSAx4BqiySaVqNxcNcTQQmJZil2u9RLtSUjePm+4SoBIT5QOKCtzqtChsnFwlu3k3G7zJzcuXuF7BmDHdjOFycrlSK0rG58oXdrC8EkgkfYXUqNwDcDHDMccgYwPwrl5A+nZvIAl95dtIIreHcGICqCTk/MOVXBLN8q8kiuumm3TLcRhpbO4iHnKqlG3DDK6qepwwB5zn1PFKV9yDl4Leax1bSIT5BkuJJ4zNJt+VBGw3EcYwSvTru7853bN5Dp73UZkZlL2oA+U7Uk4PPsOuB14ArO8VXSpokN/JLFOLO4RpDEQS67sgg9+QMoeoBGK0oboTW8i28S/bIzkK8nmuVYI7cjBxluntnFNe9Zieh5At1q+p6sh+1aHa3FtNGqx2FxI9nI0mxWQ53bCCozxtwxPUZqxcW1jquvX9tFmK2hgeeC3vHU+dNMWCzIDkuS7MBkfdxkVq+LrcS6xGYY7aHTrfSmjlSCHyhKGYKuH/AIZFJQIMHB3c81UutOht9FvNN1nTLq0gjumis7hWLTShtkkYhbaSpLRtkjjIA71yON27n0UZ6K39f1+phKNDk8i3e4muzDa/ZriWPzYmi2MyNEoX5DvMhHBAxnHTFej2V9aafrH2OG023cNnCJUZN8kKEjAMgOMBQOPoTXldrFbajLqf9qTbtzIlxY2g8uOS4ZdoYKFbzTlDkhR8+egrR8Paoup2uqRtcXNnK0e6Ib9sckaIAUyCASu0AA+hGDis4zcXoaVaPOtWetaU9pe5uraKyllWUwXJKhngXoyEHkfdHHfGaajxtJ9n8x5Y0Kxr5pBMudzBQ2ecAAkHsKyPCbTGW7lvltvtDGKze6gcubzEKlJD0ywV+SOtdHYXDC/ezV1AZPOhkVTudV2q2cnAOfT1+tdsHzJXPLqLkbsc4LuZtVhP2X7dJA6SnYfuHa6tLuJO/bn7oORjvXL3j3fhvWbC61K5/tW1SEwQ28jyBYWceX5jL8zD5CF45JY59+rv7u40y0kks1gS4Yyxho/9XFuYn96O2AOo4J6VxmpacdXu9Ymu7tfs1vYl7DWZx5XnNwVLMq/OAFGAeTgmsJ36bnZRSesvh/r/ADMTSJbpre0tdFjvLVL6O6gMaGNpOZgQecFU+YfMckkYFd7YeGILC4ni0tbXzYLyF442H7koIzGUZsHDthmYkHG4CvPtFnJ1CKSxWwgN0sVsi6hExVXadjhCBklQuTz34Oa73Tr2aG9vLE2stjDHH+8ewB2PcIwBbLhiEKYIGDnnnNYU7byOnEc20f69Tob+ztru5hMlmfNtYt8E5OTCcMNqgYGOenOQOay7ySz0O3tZhYTztHOUugke5Cyx/wCskGMtw2ePQ+lZUviSxuNLhudLlt9RMUkfnXcIlAgLAjczFeox93OeVA61z5v57fT9WZ7FNVtbjaY557jbPHIRkFo2yWKrs7AAY5q5TRhToy67dv6+82UvL3Oo6rJaW09lczSqLtLjzf3TJzER1DAbcALwGIPemzakgh1SzlMl7bCOKOR7aJYXV5W2FjxgIAoAwPXpmpry9VdMSSNXayEUcs6W6usySlVU5dWAYBdpByeema5vS763sRZDTo5ZYp4TbTB5PNkDbiUlG4eqg9RwCO+aylO2lzohT5lew7xJbwWbPcQ3UdjdgIJ4ktC6SqzgIRgctjAJBzxnFWtM8ua9N5rCfYNGcSD7ReJ52TyEXaFwFBIc7vTsagfWLgWcN6jx2F1E7rbXVynytF7JgqhLA47nOPeoV1w3GnNNdvHHfCKW5ZbiBy0kxDAnbnG044AHoOtQmr3NeWTjyjrzVo7m3bTLKPTobgACCSNHiEqRtIqttA2tuILEk9MCpbJ21qxvU1BUk020kkuUNhLJsy4Csy4DOUwD6AZ9Kj07TtKgOmQQajcmGa1kg3BCxEjjLbV5BbpgjIFRW19AWOnW0pt4p51ilu4gV82LIIO1WyY1QkcHJOc44FF9bsfKre6iCyt5YJLGTT7VVt7hZbiF7iYDeiuecEYHTBGTwRxzUsi21wlqii4gufI3SJMuxFbg7snGBgkKMe9PvVtWtp9PUPc6XaXQkgkcsfLUEgZcHO0huRjkjPNSfari2ScOscRjk+zyW7MJpstHgNGrfMw2NhTn5Sc44qeVMrme5FLYi3gR47SeG+8p5pTu85FQkMsbKSQhbPbnJHQ0hsrqCzt9Su5IGtzJ5txFhd0jFcYXcBhVDcgHrW3LohNxLLpNz9nswjN5X2goVidU3Zwch1xjj3PHSqeoS272si3NiGvbyHyrhJEUlW3DGwsvGBj5hz1puKW4o1HLY1LTV4Z7S1ju7Ew2tzaiaG6kc7JI4ycHH3mfhcg4GBx2rKvpr+S/8xb6zMc8L7VijSV5YyAUVl+8rFgevCgDJ606G5+1xStokl3FFC26GyljRBEDtWQLk7PUBSOe3rS3WlQPq1zDpNzfarLKgec3CNGjFORl1AAPQg9wO4q3doiKjF/1+uxSmtHuLIWcAtgYmASLEhxKyscdc5wDjDEDFSWV1pllcpbwrdQW52WjTt5g2dZGG5jgsWwOSOCB1FV7LTrpItRvZhGwCJJBJ9pLTb2G3yVkUlOCDkAcZzkVXl+1Stdf6eHa42Nc2aOx3Mowm6Qjj5iRkc1lsa76XNXSY0kS2WWe5SIXMyyiZWZpCUZlJG4AjJK4HBJqVP7PSJ7iJdYutTKoscU0BQTBSB5eWyowDuJ9Fp2nRafqGmyyWsj2itai7ktZDK4kQgrJ8xBAYHad2MjHHcVpWlzJJ4jlttH1KJbHZDsnSTzJCrAcAkgbiQQw9hnHStIq1rmMpauxE2i74sP5P9rW4H22wacupZnJLI5O0Nz0HXHbpWNqFja6YttaBy17L+8NsUDxOqyEFguOWZehPoetdhpMLW9gNIjvxdwPNuuZGcs0BByCGcEAnG4jselctbRWr6rLpzyXdtJdXLRTTIvnIYdrGMxvwEyRjAOSx71cop2aIpzd3d6L+v6/MZZ6IuuJNdylxGcC8QAL5T4LbmUMDIvGSARjPGa7SK0s7q5igEVzaQuFilcSFmmwcrukPUleBknIAGc1wWla3IWjWGW5u4SzqY5IlaV7mXGXdiBgELj1BHbNeial5/8AZmjfabSaaBpIJpWhD+ZlTuGIzz94AHOAB1OM1rRUbaGeJc00n8i34R023GkWjXdrCJf7ShdNkZAQi6jwy55ydqkn1zVb4i6u+neMNUe8sY3gjWFY5ESQsUZBksBnfhlPGAAOvvtJqsDNbNZ267Z7+zLxquxxI08QLEdDgEZIJ6VmfFW7s4tdmtriaKJ52jEhaIt+7KqvXsfmOGGCMd+ld0VHksjw67k6t5dTnre7k1CC6hVrlLSII8k15crMzEMWOAhyOoXv05yQRVyw0uFNMTUbS4mkv3f5oplU/Z3ClgoG0bCu/hxz8zHk1WtDcWemLfxLHdnyRNHEibHXBO87l+VsjccNnBJII7yalcyETmyXUTd386XDmPaTCqqihFQZ+ToB95snntUehBxGu6kzTR+Teq1xL+8t5GtWVo9i7nDsqlnPVsEdME88Vq6d4vv9KtbqyuNNkvbmzaM3F6lyAizOh3MxbbhCBjOR0IGAQK5TUpRZ3Zm0u7TZDIUtbVZpCWQYJYPnLlmaQHOTlTz2M8tmNKuftFpevkqYriC6mLspZhtDsDhAecZA2gfdp7FNJ7nbS+LdPlhsp2+zeS21/NglDrER84YhwCoCjlm4LNt681p6dr1hcPLFp9yxlS5dH2qrMQvfacHJyGJ2kcjrmuANwssF1cSSzXktxNIcxXAWWxgOMmQrlWO85+6cngMe2ra6RJrptrzRtLuIbkuJBePJ5cTsilQwyA3GAMKuPUZ5DTZLij0FI5Le3gjW4e1gWECVnUBBjG1eehGRgYzz2JxUJkt4oohcRDyoJCYyo4HU8Furdflxk896WGCQx7obmIqkTGQyjALAgttX7uT9AcHtip3eGSR45hNBZzRJ+6ZAJFZgDuyo+Zs9wRgE9eRV3MiaQI7zfaZj5e7ytqnIZsAnOPukcjHPUVMUe2eYrO32ORcl1wvmk7SCARjOQenX2FU90dv9p3KiN8gjdiEyQ3zk9ckZGeAMEck1aQCElbuVXZIiqIzbwBuB2t0wMMcY59cikwEUNdQyzXk86KxJWSFVDqBxwcc5z8xUA46dclkhubUC3t0VbVfl8gry+QeVy3+0cjFSwXJWWV4o4JSillijBwGC8YIzyMdRxj3qtC4muzdzuUjcBYn+bawySTzjoTgDPTnNUl9wmZ+reGbsmO40y2tI7iWRYXt4ZXtSArguzFH2gAMeQCc9Ac1QvV1Kw162ivZJZIU1RYrf94cbmj+XLlSWKsHO0A4yh+UVsXN2LG1unJMEkkT2/nRkIpPZfMZTgja2MdehI4rCv7iK/wBP0bbcpNfiKOUvcSMZvMJHlgHorDqTg8Ke9c817xvC9i/He6Sl5cNcPHaLMRBETlJWRAhkBQDcU2kfMQduQTu4Ik1i8tDDARqDJ5k8oa7kVo/KZDulTzCRtwpVMj+6Rkc0R3Vxp1vc77UQ6pabAbiCNsTQpFho92CdwLNj5fmI6DPFjRbG5ubaaKYmSxdfKhEqoIgRli7qgAL7lw2eSTycZpW1C/UhtZLnWtdm/tG1k89WCRyvF0BZixRWYgAJ8gb7wDMeehnWyQGyubjzxOs0yTwjDl8SMQ7uF+QqPmHygFtoJzzVWG5i1PUPOuZLVgjeZIYXLRu0atHkkNlcmTcFxgdTVXSoZpp0vTeJA723myySkyi4kyrRorMQ+FKpuXbn5/XFNAzd8QNeNctFDO8kHltamJR5hnVsEOMFdmCCvXGcZzUOpaTFHJEJpNVkuLeLC3k1wIYgFABG7OQrbsng/MAcju+HU7NrZ7+bT4/trSAssckbIZXHzHzGIC4CcDrgL3PGXdJbaSZLnVpBrC5ZIpj5aB13/NG8gBB2p2bjAbOMZoYkSrLcwy+VeXq6bOSJlSOIm1CBV2L5pG7GODtGCTjPXJrjpZrpNzJdXwS2MkjCV2fcCwyrKV2uCG2qMZwwxjAzla1cNLBLDcXEAs7qVp2ne2V1ht4wMMEf5sdDkLtG7d71iadprWi6TJeXEsboHEExLLDbo8gK+WASzj5ywAJU5AbtQirG0msRX/2J0tb+G2eOb7Q4QQvbQb2AOFBYbpAg2DHTjIzVfT9euI7fTLuQsupR2sqyW6o7yFUcZAycs3GO3c8Gqd3FdCeXNtqN1LJErmd5RuuszKY0kDKAgIVvXIOParsertPcy2rTSyWlqgj2eY1xKzMVl8wquFjBUkKxCghsYxzTfcLG5M0Nw1pLpt6PLmtZbSLzn8uVnByrhsthC7FDHtzyPbN/SzNZ2cEl5etIXh+zmJHiGRj75PGccHOOAD17c3f6m018ZJLkqxuw1rGLtYfkZFXc+0BXPGWQ7hwenBpovxqlxGjXNtHDKvkXFxbzDAVVYu6ZJULkHGVHOeuM0EtHQSRtaRhUS7skfNuzGEGeVVRUR2KkEgMCMgZwy8AGqq3VtcXV5BqMXkR3jLZpbvOAjMyMSxOAw++Acc/XnNu2tjeNbypHZyXcardxxEjd905BBJG1jtbhiwwBzxhq/akS3eVXsUkSVJoI5hLC/CtgFApcnBHY4YZzjFUrEskhils47OSzlmLw5lW2ily8iKMKFRjkIAzDay53KpxkVueEp47nQ4J4DJ5crNHIkgjTa/JIO04IGQv4A/Tm7rS7a8gihvUNvFNAEgureUkzmVWCqARlzkkj3QEjFa+hzyJd6hp5jkmms7lWlcrHtmcqGZwVwBkZJ4GGJwMUPYljpI4Y9Puhe2ccliWUtGEJiG0khmXjnIySMcgE1X0+YyRxOkjm6WzgeZXIRgTuyShJKkk9CemOuKuNdILa8a7+fzFOHEYClWU4DL1GcdD1wemKxdCM8MuorZJYmF5Axk87GYwsewDGdoBLgKSehPeiOiB6s5vxnb2OmyW2oXNlLeRzET20YvH3IU3M6uy5BRSxbPOQMDnFYfieW11PTYYNO0v7ObK7hnhuYpiIreZgThWwWZCpEgYDHykECtjxToEOkXuoW9oJ7dEMU1kIXaQoN2+QupP3d2cKMDjisCEWM/hHR9UvTcaqftKQyWsFvGWgt9zAmVc4TOB82eCxHeuRtqTSPoafK4xk3f7zpLBre01tpp7e9t5IFlWCG/AlmeNvmlliYcDa24DcdpLZzWF4QfTotL1G7iS01MJAUjkmUTSmZgGiiGR5ec78gc56k7qTU4LTXr7z42uLjUpY8XEEADNpkUeR5WyMgEM2wlsYw2cnmtCPSNJfWJ9PvILn+0rZPNnlkkQqvmNhYm2kHnO/YOnqKlt30KSSXvN3/wAjd0y407RtIWNAumRWc73q27wkeZkEHZweOcAD0GDirF/eJevBLe60mnoSzK0O8SbQwZAXGVVR8wOeOnFcxqnheW0TTrW0uNJt7uyg3xxpM67mklYAK3zA4O07ehPGDWjOmn3i3kElhfQiUQRahi4+zlHHAdUzl1PGCBjINUnJaP8Ar7jJwg/eT/L9TpNMlsTp0lzZSzyRJ5scNtIw23Mm8/IWcfMxwFA7buOa5zxpZtb+HreJLqfT7SGCbzoY0Sby38tmVGPG3nMYx68nmurW5NzcPpt0n2yHYDFc2b7mCg45K8Ag5HJ3ZBOKwNY1eHUtEE0lub6RJDay26KGZZGX5Gx0Y/LnnptNaTa5bGVHm57r+u39M5vVNDgtn0PZHf3eoQPGzxxTqsdvIEDFGUsdhB+bK55BznNNsL67s31OLRreSCW6YOZZibi4mXaZHjAHyqI+DkdN2M9qw7vUb6fw/cKt0b6SzuvOLRb0Wdm2K4DcORtzkDncSOetb8Nxe6e728DaQ1vPpAvkuVjl2wwANmOE8sCc5+bqQMA1ypXeh6DTUbS1f/BF0yS4Hhy3to76xv8AT7qNpFka1WLNwTv/AHiPgjbknzUPBxxisCza0urezt4ZhZXBhNlcWzzRyS3Yyf3zMedoAAxgE4GKl0e0tG1iI6leRpp5tWijmmhMsbxspIBUr8nCgZHO5cV1+lWFzqmiXyTyW1zY6jEJ4biKFo5Y5GICszlfvKAMKOmM96Xxqw21Sf8AX/DMyrCGzeVbmbUk0+EFbST7JagO8pjAZQrZG1SoyW6be2av6hBd39vaW+o3Wh2urSW7GxngtzDIyq2cK6EoflIUKoJG4nvil1O0fTdPt9Nu5/tV/G6yW4gKxy328BWZkc8ldgbPIPB+mBe3QuPCttIHjudSS4kuvJuECAIhz8iggvzswvB5x0pv3fdfUzS52pJ/1/W9/Q0rGB9Ut7pVtpru6uIURczrDbyLt3bsA8OAM/3vpWNfS3G+2uXvYHjby2gu5JzJ8qsFVMZy21sk7QSM8ngVNqN7Lpos9PfTrUXLQItzcNCIUTcvDiNGIY7Wx2wQM8cVa1nRrGz0/T9S1Sdlm+yYuI7GMxJayggRuMdAwzkn72c8YxUct1p0Nk7SV+uxiwvq01091JkWkU5BaWaQFWyMMSfnEfK7enAI71vX0kmk68tgxtNUAiktysMG2JC4wcMDgZb5iOwGMd65v7QZ2i1F5p59Oc+RI+CrSYwp34Oc7R6DJHAFWfltL+3uLAKseoRtNbojeYFGB+5kyeHGFPqcntUXe6NHFNmjHDLpt0b23nZlDPbsJ5fLYgD7pA527sgE0/VLe82LFHLCI5Y/tCtG25lO4EBXBLDlxhuh5qTTlt21VJRHNHbwqQY9iQ7jgt5mJD3wxyOu4VSBkk07T0lvI7mziRFa4jj3C3HJVVfI46ZI7insiVdtFyx0OKZ5tZuIZ5r9RILiOCZXJULwDkqwUnrtz05xVm4uUgie6ht1h1KS2VYILqZPNtbUrgN8x5dzuODkBe4zVG3lt3vlk1N72NWxJDJbDY8+WZAduOc/Occ9M1pu0FxFff2hdIIZkzJcm2M5nhDKuxSeY8bQgPJyeKuNmtCJ3vd6/wBbFjUFa/t7bT/7Me4t5w09pCNsIVAAWVmHfdghe4zzUBNs+sQw2twbWVRGjBLVj5m1vmEpLZZTyMdiSKypbaO3vpro+TPp+m3RKIg38kZUtIDhGBwCB/tZ5NTzOJYDrV6tot7qsCiSMzb0iQH9275APJzlgCOc+9D7sSjslt/X6f1qQyaW88flRxsdNkMssNicxiRf3gDRrhWQjlyo5OAuTioNK8wM8K26RXsZUGO9tFSG8gC7xHJu+6DnIwDyRSWFhBHeWtnquoSRW7O8crxWzPvwylAZj9xQCBlCcE+9XtP1mKxkTR/NjextpJkuluSs/nDfkxhhy3yjIPBGD2qNndmjvay1HW96twy2bmSeARNJaPbSHBzGT5IAYqVB3HLHOegq3oc9k2s3bve3Ud87zeTJhm3ouEKrhRmUAZIA9sHmsAT3EOpXo0lIY3nnVpILWTNsEQbshySA+3BKjH49KLG9v7vekab7R5fPneTYZMhdqvluQcZfK4Pc4FNSSYpQumdJBqkFnoNzaW8dtNqs32i4092YwM7cqSdxIzwRglTgGsPUWkh8Nzaqm9dJt7pZjHbySRGWQfKfl6BELHofvAmq91DfX+iz69bR3GtPHcsXvEmj8xW3AIcYwT0ygB65qay1ECDe/n3tylu9v9mstxiiUMXadwQQSPmXD+p71d+jJUEtVrrr/X9dzS8MxW+jbLtYbma4jgAa2IURRO6AMcAMGAGDknIPaux0rVLrT0t28Ryz3X2uQrboEVpI8qWydv8AssOSR8vUVzWj+HbmzsbN7Sz5lQzTrc+WwkLFpFYKen3gApI7c1t6JoV89szXwu7SeFGKrAIjJKUQABiVK5IGBgcY71vTUo6I5a7pzu21+v8AwCd50m17QT9rldY9Tt4ntnK7YfnQqBgDnO08ewPaqvxGsUm+Jd6LW68i9Zkmf5X+ZFgQbVXHL5Ucr24PSq+ivBqXiLRWmZYXhubWe3tbqNXMmZYwZlmUYLFcEqDxxkDpXR/FGzbUPEZTyrMSQTQvFI84WQjC7wAcBe3zZzkD2NdVPWLZ5eLXLUivL9Tl3sJXt71LxJVtbdw8t3bTbBKvQKBglSd5ZkzkHAFYOqNqENtYW95p9tJZzW6kSWdwUMWJAiFmYgKWzjoRu+mK24A8MzuNRtbnT53kedIR5ZEa8F3GRlwVBLBcEnriuYhM2rahPKIDZmF43iCJhMSbB94MQMko21R1ywI5pmCMU/aLfR7qWCRrdiY5VltrpC0byFVK7VO/nGc9QSwx6dzonhjQvskE8MCTMIUd/tLfvQY0YS4Rvl+8COMnkHtiuS0xH02WW4W3NzeNcN5VreEM6tz5wAGGVixDZHIzhRnNb/w1aC9tb/y9RSMgD9wrsEUFn+f5juK5AAfgZHPQg3Emex2cVoILWCXT9Phd9/lrsUmLaWyDzyAu4kAEkEcAYNSRCHUkX7WweG4IW5uN2HlU7iEXHKn5U79z6ilFwkscUpdopnBMACgBh/ECVJ5+Y9fyBqWEmdf3wtWkYlFBcbZHAPO0/ex04BwBn0pvbUyGOPL+fcQ0aHZuUvsfsMDnHAOBgckk8YpbImOVlDtLuwFZ0wCCMZz1wT3Ld6mlWzTT7eVXQzD95GyExySAfNtZx94Lngn60qLaLCkht5Et/KIkTdtYEnOMsucY7demM0Kz1EQLuW3CE2iyJgSbVyVQDdnrlgTtyffvjNWEimiuASdzXDbj5aZwn3SMnGCdoPPPJwO9Kgsfssrwy75siPMYHlv2DZPIwMc9h9aWC134bEzpF86yByrs6kNjPIGfz9RyaYEk6GLWoLWL/SYQdisGO8EnJ5BHqVz0wpzz1k1G5KrBZ3GzFqxTbGCw27RwWPOc9fQEdc1QaRXeTzQGVVABXleevAO/BGRwOME49LPySrCPssccckmFaVWd5MMozhucfgSevFFtVcDF8Z3Hl+Go7e1mkS4uLiIuI5VLGFGBySwycvge+/nGaxdKzMkEWrXH2e4aLzllgjCBJnRSNhj++CgIweQBuz3qtHeWuqeLbiS7ddUWR2tra1SMOLUhxunO/DDkbRjt9MHUnmv7qWwjkubaJLFPmREQrHEzKEZZAPvbQV2sQeOhPXnerOhKysaU93a3mmaeupRNdQyx7VuTCWSXcAUYvvD7QdrHPPPI71oPcC0021tLWG+sLUKkJhlCsY0DbQAWJByTtJJ54rH1Cxj1GO2c3SzSWVwPs8rQxu8rb4z8uR8uwErggMf5X7i2vLVzO81r9rmIkeA3JMbOACMrjdhuhAODwRjNLpuIcLJJozFcRy2WnQbrhri5lkW4VHiAk3MMA7lyOc4bPy8A1mWYNjJjRpLW3u1uQ8aSWkhe1hIzuARcyA7Sc/KSMHJwAbSXK3VvefabG1drLMkU37wiXeof/VjGAXKqFbOcdazr2PUrWzWG/kvrVWn80NFBtZg7ImSiN3bn5uNuRxtWnqBBqsl3eTxNqOo/Zrpm8xbYYikkAZ12jYB5aMq8CRgfcYOaMamxknOqwfY5VvBdQW90G89JHU4LDcckBio+bDeoAweh1CCWTQ5bOM2kl4qIA0YaVlJdju34G6RQTjcODu61VmFvplreJJIjypbGKW7iEio7gqwMa5xwcnHQknOBRcZh3kqWUaia9iM0yuY7lW8yYMCzNHhgFYEbQoZevQHjObqt29rJq1tGl9HLbzsswk/e7pQQ2+QD7pG8dwv3fmPQMnj1OKaxv9Qt309pmaUmNVMkTBt21Ud88YX5cjAwcAZFEU91LYvY2lgp1C+aS4kbYF+0tIOImBLDyzH85By2cdcmqUe479gbxBA08l64huWlhX93AXmuIyirgSt8oiDkF+NxBUlck4qvoNpql/bW6RW1xfWiXhgzv+WVQQzF45Cvm7gQdxGQFxgA5rt/C3gpNJs7i01aK3ui0m6CJ5XiREcbZPM3HDEgDCkDg9M5z080+yNCsCTrGWKKqj7nICjkAHA68feAGc1pymTmeXxeHvFNnCl3caYbh22uYIbxXMRLIfLEe3aPuMS68gnkFRgxyx6voSIqMFi08D/SpUeUXErmRNkb/KiEJj5QNu7A4r06FY2ms/s1wsayxh4ppHZmaLHzEg/KOSuB0AzjGMUumQ7ozBYyxwK29vJMp+YBvXsOMBickHFPlQufueZeEfEBlvbPT7Frq3ijhmlAdPIZVBLuRtLAfMn3iGyM4bANej2d1cXFjGwWe9iW5IHzH92RgeX5+PmwSQdwyV4Bz047xB4QneY3GiR3K3qSqG04kHKkkbwCQNmWJPPGWGDWP4GuYVsYbb+yZZLyOVGmijdIkeFgAhX+HafLMYcbTnaCcENWc421LTUj0rF3Z6rcSvcxyaZKBKMxSedlhjahQ5kUZX5eoJyMAVDoF/A+oi10+FS/kR+eVdXLkj5WaTlm4CEAnlW9QcNVl06B7UiKGS1CXEtuWMnlyr+8WRdxzsJUjHqGGec1FolzCLpFZ4oxPMuC2Qse4eWgBXhnLMuTk8MB83UBLR1MiNZaqSZIHjkgRCY4CzDy8MUfaeAC5PP97064/g6e2nvLwWapNbW0phY+QEUhFGAp6ZHmE55yCCD69LPJLO25QokiUbPMbZ1AAVu5JYNjrwazLSJR4iuoX3ov73yEkYFQNyljgdABswO2fwoTIOH8QC7ktbm8bTNQjupd9qEkVz5vmMihgVYMFIyeCMA+pxXA6bqj6d4hs0060uodERtl1a2yxqHIUbiZG4dd0ZIU8jaR3zW54q1c3UMWyU/YRObBo7HUFmls5HA2FACdyOUbd83p3FUIZXfUTcyaMWubiD7UAD5hu2jZARt4ByN78Y28A964pt30PpaMbQ94tQX8WseGpotPt9d+0XEwt1DMkFrIVZcDcCArFcjqehHJqnpkOmWz2moy2k+nxOz2Vzb3koYTttxkAZkIHJ5J9R2ptiLyKwN1HBIbzR5ZSJXbf5McjAxgKSVycsGIU7cdQaueFLK41iR73TbfZeWKFrdDPveRt6+YxDt8u1sruGMrnjpUq8rWRo7RTd7L+v8AgHZ6Lo2p2h01Y55IoFaeVZLpA33sABo1ID8AkHgjI9837LRU0nXJdQ869vJUjS3WMvkOrgKqsWztCkFg2Rjca5rX76zl1q2v7a8lD26vDbGeV8/b92BGisQmDvySTwFAyK6qRp0hsI9UurhJsgNcuyqzOrABWTn75Y8DjIHPSuiFuhw1Obr16DdelmOnX9npbJBNdRkrLbsd0Tf3iwGNnvzg5qpJp0dtEitJbDTbhFSaKaMP5CIpVFj29XRznd1OSa0bzRIrm7hTPki2bz4goBYllKMjL0wQc9OKdc2sCRSw2M0tj9o2xsyABs9cKCPkxycgc5qnFvVkRmkkonAf2RNYXxttQsftN/GIoEjgmeONWRV2M2CThuuTjqc1R0WW8jtRp9tcowimCSSq/lSWkjuUijJGWaMOSdxH8RA711XiGxuxbvOqSS31zazQeYgxLICwY7FP3WCrnPoSK5UwLpKabd2s1pcNAIvMFrKGeRl++5I+Q7WwVDcc5ydtckoqMj0IT5493/l/X+Zow6HrtrpMUVlEsF1azyz3E16F2whz83k4JAUlieedp9c11OjatLJBEh2JG9u8kotpVmYBGEchAGeCT+XTkVxN9rcYSz1HTlkiFxNJm3kkaRpmHAE0jHashBkwq/L09K3NDutX+2acgtlUSoptfs7I7SNGSJZZQMFxhsA/dBPrzTTXNoRUjKUbysQXMk1hqlnqt9p15PPaROzSWIbENurFVQRuuWPDYJI+Vj6Cq2uXNrHcW1zrz2sUAux50kQj3WjMwOQU+YfuzgrySTkelMuNS1STXvEFosl48d1OiTwNaiZnjSMfMCOAOQuCDlS3etdhf3V1e6gumWM4eKO1jl8swwkg7XGz+P5SSGUjBBGeKW+iKs42b/r+tSISLp99eX10La5tdTtGNvFPGPI8tGAjQ5+dsLtP1XoM5rEt7iWawNje3m6ylnBBDGMzDOSGCg5clFG3O3Gara3a3lmQJGH9nXkgW1Dy7ljyAu9XbLbiCc5zzirRMi/YY9Jv7sPHEyfYoNjzRtCRkrydqvu5zjIGMCs7tuzNlBJX/rQhLXlxJd3elaJE8/ml5CYdvlRKAXUKBjack5Y59DVOKN5La3tkma0RlVnhhVFxHvOMSFT825h3zhQM4q5F/aKabqek3Ik+1CcXN0EGwIwU7UdsAbQDnA3HOeOmKsM09voN6NT8wTSWySC7ilkjDXHmfKjZwrKi4O1VPFItMRhavbtBCRcwmcTvcRRFZ22gAL3243YIORx3rSuJRHdTPLaaUogij/cRLhCMcHaD977vQjkA1jyvNLY/ZobgK+0F/I+RplxkNg4JLYGGzgg+1bFrCLe6EtxNb3CqIo53jV0GW+6rKepzgHALE89BSVxy03HOBe/YtOaZDKoaVJ1kUhbg4BiOc8EZJ9O3erkM11Yac0GoJb3E1tcNbtBMTJIrnLqwXO0IBnBOc+map3lo0OnXF3eWcEAZjbSPvODIDnO0HLEggbgDgZzUEc1tBLfyXU32q+Yx28dvPH5gMOfnCsMlW4GM5PAprQhq601Rf0ebWbm0l8kw2ki7wsjbIxJySc8YUgE9B0A6VDo81jDb6beCwinMEMjXF5fzMyTnLJgL82SW2qvGAeo6GrOm3FzpumLf2heFlcqY/LDy72PEg3gDkAc47YojUtq9zcX2nrBfCOR5GuJBFiTy9wcLjCgLg9+W6Va0t3Ilrft5FC81e4v7efTtcgjmYjzraKCQxtbO3cnJ3cHG3H8POKnnMV7ZW9udMuBclvM86CVBLcRlSMSlRlsHJB61f1Q6Ut4t3Gt1I80Cz4ManexGRhQMAYBJ9/rVOTxHZjT7ldPt7V7uCElrh/laVt2FQEg7j8xyABxS2b5mNapcsS7qOjzyXb362O6zcqIbSJw0BeJOHDEfN0GTgZ24pjt5WjytfXQngVliVoEhZxIUYHI25JJLdPu59BUGm391rC2oRxtgwZIpNqRIiru3PhgSvJHGM5Gap3TSEtBpelpFqM1uTBHpoF24DSMA3mFvmRimCPQc8ZFXvqluRZ/DJ7D9Xu7G3YWl/ZXelRqbeYoFEu9Dk+YG6bz8o55x0z0qTR5pbmOUWNpdQHZ9ndrYDLIXYnftXAwCCDzgk57VSuLayuL2xeW/VPtsIN3PMDIbEZChQTtA2sRyPu9D0rqGgt9Dyl1cNIGyqEylZLtsBQwZR8y4+b0zjOaEm22xyklFLqa13qMdv5U6zQwW+xYXFxENkrKByWGCH+baDgjjtVDS13eI4Z7hUCwb0e28xxiMqMGJQT82cb9u7jrjNWrabULiOG3uZbKC4Zo7a4ls4y0NsoUkNh8fMfXpz0OKTx1bWjw6JpempDFGoPkrC5UwMcYbcoyoCBznPXsa6HqubscUbJ8nf8inoF2IfEkFneQXNrdJqUElvFdSeeqRyXUWQHJ4YgZAAAIbPaur8erE3i68BQSx+TmdCpIHyIPuhgGYhlwTggAgHoK5rTpEm1bQylkYltdTt4YY2ZrgmPzUG9pMA4/iGfT3qX4t6nDaeKtUEssc2PKikSe7aL7OjIhDRKAwJByx+Xdz6AVtSuoM4cbrUWnQx2iWPxDGba0uGe3H2u4W3jERiyAQspO5s4yoKjJBAOAKil0m0kS5trh7ia7kVCY7dTDchZDuGV5AVdzBTtCkBhnk4gv9SunkvhAzQNh1nuBEQDJlVVN+ScOMNk/KQV6EEjYj1S+SVNQsrGK6Ewe0SJFDkSLu2oZFUsWG52O75csuPe9WcrOC1DTZbHUp7GC5NzYwOCJLyMDEgyHBI+8+x2C45yemSDR4f1rT9H8a3SXEkkytakJdSPI3kpGmQuCobeD8u0DqeO+NF9Sk06Np7fTBPZXFu6SoZC5DnADrGBlEJXGc5x/F0rkGhl85p4hcBZURWSYKphOVIKMfmYllyucMV4BPWmtNynqj3iN9zQ+XJNJuljaOXG7zQD8rIv8AeIOOQQDn1pqsWjmn85ZlkOQ6lSSMEZDDGcAjPqTkAA4rk/hvrK6hpU634tY76O6ljuLcREsB6sgOAxZsjHBwO9dNtjlhMaT2sMSoT9okCgRkAZQx7fu5IU56fUVfqYPQtxRo7R26SKwEhjCRoGZlDDC46ADaTwejcjsGSv5qbDtZyofzEOViUE8Moz04I7cHqcVWnmEVyZikAjUrlVfMQ+620A8M2CT2/i6nGJ7SGayn86zRlBKOFhUjbvXOSueepA5PPtxRewFuVioUS7jGMFV80sd4yM89R8oOPl9+c0yz+0O0lugMbrCJD5s3y7M9FVR8wBGcdMbvmqG3eJbZZ70XNuq4lcNH5hcA7dnPGeQSOCMdcVaMVvdQf6BBdNdspLOr5zyRgYOAAf4c7Tj2NJtLcLNhdFUncxSGNrb95JdK5w7NzkEAA5GRjJwoGRzXFfEvVL2CC002B7RXumaWSSSciSGJEYLlh0AG45OCWXHIyaua74hitLSSy0m8W5vldrZ3jlZlUtwHw4ChiQ+OSAFz93iuW0HTbi9tpL/UJJrnUJka5+03MQCyW8aALKigfuz5cucnBJXAHJqJPQ0hHW7Oq0nQLw2kAtpEQzRxAmBm2IWUK5IAySpWPaWwAQ574rqL25Sw8tyXNxKrCNkYsgJJ2Kfl25O3H3RjcOeQTzUBmtIZp9IkFvYM7SvdPEJVuwQuxFRDgbVTP3gPm4yTVjVo2j1GYWl6ZbhpfNjgj+UMJAI9ic8hTtLHoeo5U4yKeos+rwSyJcwDULpy6K8ceHldl2Z3B9u4x9TjgbmJwa0L7UdONnJaQywfYLVibmWNwUtsZIUo3J43NtxycYPrlOLca5ZLHCk2pyQsI/8ASkuJIkYsjKwGVRRnqSewJOKVz9u1KW0ax0658rEzs52Jabo3BkaQL+8BK7VAUHp1OMsNB+mT+fcLNd39wdRnIg2yYhjcqJW+YdX2gn73QAnnANOuLm4a0unvpkmsZFCWl20nkpdAKgM7AtvUK2AcEFh1yTmsexvhDaWFzavfzSStLbJdThkMYIwWZDkM+SCN3GG4J6DWkexNvp3lRzLFNG8t3Ik2HRRkp8jhcruOcqMjCjHanbUGXE0W3sZfslrNchm2faYpG+cHgqGcfeCKOOSDkg54xyGr2dnaXdydtxHbKEn+0ASo1jCyqgcRr8pIJDMM9Cp5wK6aI/2nbRSW1nLBbJExT7NMptZoDgLvJAJIBVtvIxkDGMVDri2hmljvFE1jDD51zaujO7ygYeOJ1XOP9W+MkHsRtNHkwTPPvFo1Ke+sBLerKqLPA0LMxlEZAEiSSFvvuAgKrk8njrXqnh/T7CyWJLKNIzJDbf8AHvncpySXdvvOTuAy3Jxn1rzHXdNgkuYp9HiQpez+fFY2sQlmj4ZZRu3ZcggcLzk9QMmvRfDR+16PZO0mbp7URFgNrOQTggHGQMFQc4GSozwRrHW1iJ7G3cz+XLmGaFW6IquN0kpJOTkH5SSM4yeue9U5pporD7TMqxiBmIwcL8zZ3HODkHtwflqxGJPtLZcq7bdvmKHbdsGcg/KxIQcfUcZqGBQzrExaFlYh0kTKfd68jnvjHODnk1aRlctSSXKs0d5dvHczkMUEf7sjBIwwPHBwQepOBUQZkgj82RIlAaJYJQCqqAAWLYABPJz049qqxshjcvKHkdGjRUUqXXBYBfUqMHgDJOCam+0FzFI8cK7Y1WR3mCDaTggITz3yw9xz0pPQaLNqjQTB5AZppWDws5LHYwXKAnBDEEHI4POTnJrhfEKSWeq3CaTJDcag0AaBVRCXIZtybVHJBVQvHzmRlPPNddNfRtFfGC6gTMh2usmU+XkqOdyk4JG0YP5VwXiu5FtrOpyxXUVrdy2yuQ7gRwwqw/dHI3A7wgCKQwb8SJepUb3Ow8HX1k0yWO5p7mdAEkmB8xtjEHIJKrkljtyM9cHml1HTl02+iv7SS6SVXzNA8Zm83DLL5SnBC7V8zaU+ViMZJGKzNKZ5NMc3kcWnXNys2S9wUd1ZnQ4LMWQYy4X5RuPU5zWpdPc6rZSzJcWyqNqpby7ljI3bdwlwCzlWKgYxuJB5wazXYt9zuJMqHWMu+JMrApBxyACTwcY7dQM4qO1G27tY53AMYf8AeNgEjgcjo3QdfXPWs6yuJdzRTxyFnto43AQbdpdxuGDknGDjJ9jVy0tfP16zfM6qqSopYAoW+XPB54zwT6+1LqZnkGp+Hmh0x4fDc8zOlzJdT2EltGsEtuihSfLUYZ8hSMnIJJwKyodQsCYCuiouuRzGK1UTpIfOQqXDpnIJC45/unHpXYa1YiDWCZo/sOp6hZCwdthe3t4toPmJISMEAbSRgE7c4rgb2G8mWWwjf7N4igkMgccFY1jMkm7glFLbSF5LE571yzjZn0lKXNHX+v8AgFjVpLW01TWIYS1nFbbrNXnvG8oSkiSU5iw5bHAHIzmumGtM7v8A21eyadaTkhWlhaK6t/mRdykDJVsxqSe7Dt05fwrHFrN75NxqkcJuBHEttqFy5yylWJSNhu37x1ye/HIFbcmk6hqd7d2l3LeXEUjeQbtkVGDAecAWI+6GCnjnJHcVKve6Lmo7N6o63RdO1C9toYoI5NOVJ59waPDyRB/kLKxYOrEFiflbPfBqrp1+lysz28wmnjnnluryOLeJFbCxsq9HBK44yV2gDHWk0bX59QxZSW9y+oDJvGa4Zlm2ctt34zuzgYyMewqKbX57XXrECxmtYI1WG6hbEioJMCOFQgAUhjyxOOK3vGyaOTlndpo6SHUri1lkRdOnEdu/z3bOnlsnOTgHczKAc8fSpdYupLZY57GCa7TUpoUDKuSocgA8kAADk88HFcqt9p17dzyN4alvBNcrb2s96Io1eT7pC5fccBGwQP6121oRHYMytJPHHIfJIHueB6Ecg5xjHpWkXzaGFSKg07f1/Xoc/fWGmHWlhu5Lz7feSMUcud8Uyj/WJ6/KoGOgXtg1yuseHLZdHUQubnV7RN00NvuFu87DarfUYPT6elegXn+nfZ44jPBDLI/mESfZ5UdGxuHuTgZPBDc1yt/YztqaHUppIre7IjV2RQsqsT5ibwud+Au0Y6DjrWVSK6I3oVJd/wCv6/zOIa5XS9BeGVtSht7KbbNcSfvfOmV3CxAEBcjnOOgbv1q7ZB9I020vL5Ak2oSrNZW8MTW4QgbZQXT5oV6Zxkc8gVs6bHcJLql1pLi00qZybOPUYw4jZHAfMLYGc7gp6kHHUViTzXmn380bR2mHBmuGiQbnJJXdLyQCS3IXAJxnmuZpR1Z3KXPoi/eSKslsJ53cyCOK8u8KZIAW+aN5gQchBkDHIZieCK6Dw5NHpBn0mct/YpupzBeTO0ighAQkbEYzu3Y7YU85rjtQu7W9XWdJstQit9PuWhjjtpYnZpGKf6zcfmx8pXgEDjPJFS+JI45E0qWSTT7u1EC3Ec0G6KORXUqTKN2xHHTIAIzQpct2TKnz2i+pfkz4j+y3Vjf2s1lDD5E/2tQBuxgoiE8llfhh357Vj3lnLHcRHULWS2nWPylcFSqTxsAOpJV1ABBbC4OcYq5pVs+ranBbWdzpWl2dtNmFGRd0LF9zKpPPmb04LN+YNM1c2EsUk93qtzqNxqFzbO9pcoJbiDDbChbhC79PYAckGpspK5pGTjLl/r/I1LSaLU9We4vILRLRrqOd5XvCHE0WIo3TcQpywLHqOh5753i++Fh4ylltoBcX90iyuyyLJGkgLZKnpjGwFFBq7r2tLbSzWUY+wizi8txJFHCUJkJUMd2FYLszzlqqWUcmveIoLRLKKSyZZUnk8tJIxsUMshcZQPkqOByOtEnze4hQXL772sZOnXUmmyWV3M0LaqJyHt5QWlDEEZBTO5dxIUe3pVq3vLq3tIhfwqPtG7aWAmkOVkDOP+ecuMAcg4JxVbxBvju7e1tzbJdGbyPOiKpC8iIvyYPCg8Ekcgj3rd0jT/ttx4bu7cGbTLmxg/e747dZJ1yDHKCMucll7Z9ehpRhJ7FznFK8imdO01tPsP7O1OLzzC32mRoS4ZRuRmiL/dxgggdcHr0qTTSJdStbKxsECo3k+VKVt9iISDKUIHzqcnbnnjtVCErai5tp7u4nR7qTz5LaxfZDIH3NaqCQzIw+Y4wMAYNA36dqMsdzZSy31xHILWK2DqryswCgFsnPzE/eBG3FNqzDdNX/AK/A10upG1OaGyv713k1ONlkhQSNtZRuclcgKcFggyMAkgGn6876/Hb6pbwvaPf2hkuPtEqhEJPlqgVsEHCnGOv4VQl0/UIr+1tpJIbaSzA3M9uWSXhTK2xTksN+DwOAck07UFa71YXC3L32nLFJYW6tD5EbbjhFAUYIjyThscYAJ61WtmmRZcycSnbCbVtXt7C6Fxqc8lo7mCWUiKOQAhQG8w8AKpJPPGOKdBKFitkS1v7ayW5ae2e3aPeZo9qbA2Siq5BPudoHXku9HFrdXczi52Wt5FbfZrVApmHlqGKTKf3YzncDlT0z3rWj0m9jmjhhvZbRr8SLA6uZvIjwGAX+6y4VQfUj60oxfUqUlbR/1/XkaPhOz07w/pcmqz+ZJf3kcrXN2zHekrsCqvCegxjk9+TUlxqWmS6bbXVpMs98lwWSAAxiSQlt28JtwobOSeOO9V7otLfOs+nXC20kJnffbeXcOINrnc4UnAbAA5Bz6VcfwykenrM0sENvHHuuRFERJLIcMgLM3yrhuema3vK1l0OR8t+ab1f9W/QS+v7nUdPu53e0S7jj80GJFjEqKeVIIdgvyqxxjIb0waZcRC9gtdQivryzEm4OUkTeDv58mE5Ck5+bJGQfaqk/my2lvFLDBDf7QrXYhWFliHyp54U/Lyuc4IwQO9XtcvNOm1GK1g+yvamE3DypCys5L7mMjD5gucDjPOD7Ut7tjtayiiewiuXtPtTvGdHQC1SSR/30oPABZflIXkZ528gZqG9R9As4LyG8ls1ui0AmnbDxl2ChSFz8oUBUc8DvxS2mnWlwt5FpNzcT2qyJcWUN0j7IijYk2NkKzbcgKQMYBweadZeEmt2ybW71GMqpVL29KQIqNn7ykt5h5kyUVQccVootrQzc4p6v5f8ADm7oGpw3B0/TrZZJLaG5s3WYoAW/fxsuVHQkEHJ9DmsD4k3Tr8SfEMEVnFLIYYyPMcsMJCpL+WMFhiTacZYfKQQcAX9EQ2Wq2NvoMFtNZ/2hbxTXgchjGLhDgBgvmHPBb5uCCDzU/wAQtJum+IWpapZT2sAkihtHIQmRiqh2VhtwRtcYJPcAcgY6KV+WzPMxVlUvHqjzTW/Dd7oOlmfSWa3spI/NubEXRRIgoUuFXrIOPcgHvWjpmnapcWF1Z6TOlncMkMcrRzBC8XlZPfJZRIqhxtO0oCDgmta+urp72Ww00IlpZSMJXuCGScIFByrHDAZ7FT/FzgZit2ubp7ya7CPNYuPNMTpC8sJIGSeyjB+Vv4QCCcc1LXYwV7ajLhdVt9XgS/t47eOdzFFb2gIeBeVcdmJ+WJiThScdea4vUdIjt7eKK4T7VeQTqk7zzoCN+R5flFsjoGBLL1JOAK76WEXtylxaXubcymAXO93L26KAGXAIVgQV2kjlf9qsk3sd1cXVrDNNZ6/cN5TXVy+6IpInCOqjhyVJ4Bb0POBK2uNPoafhLUru0nktr+K4jlkndLO4fBLlScRF1DEhc5GTjJOO9dRL5xIjZ0TaoZWWMZwFB5ByCDgfkD615/baf/bN2bW5tVefTp4T/aEqKtxKCdyjBYHy15GTuJCkHB5NmWbWbewjvXuJJoYCjugKFEUtwsrtubJUqwbDDHGetVGdiJQvsdLq2owaOiT3DJGsspYoPnClurBUG0NnOTnA79AKwIPHPhy41YtLJePFBG8gJiDFmUldq85JKkEZ/AdDXDa3peoRRQlWMsqtIshklkmjchkUS75VCBTxkqMe+KvaZo15eTy2M5t7jVfORLe4inzFCRB90qind0A5+UFevXJcrkXU7G/8eaall5oe4eOOTyYUMG2QZI3Budq4AJAIIOceoqnq97faiYLyzigj02NIbkCY5MoA2qr5yXXhskgY3YPAyX6Hpdtc2Ud9qL3drqIAEFlDKHl8j7xClgxK/PyWIVc8kYFbVgtppWlf2pJCunxpEqxNcbJ5JyXKkOYmJIO5MqcYPTrxDfcaSWxTgsNP+zSaxdS2lxpdsoIUQJudFY7S4ywjC5xhQMgAk5FatzI17emW1t7jTm1B90+pxQbTEqorOpBUHBXClj97PBOMU64vpVmkvN6RIsRjW0iMYaJ0DEMSSATgZ5brgdRWVqd+9pbadO0UepaHbhbiXyXBMrLuAkfkbtpOB2Zj7ZMsa1LFvHPBpumWv2BLkWhjgkC27NEqysHEhgU8qUOPr16KKklvZ9VW5vAZppLi4jh38oluNwdFjiwcuEXJC9Tt5GStZNzq2oR6kLiayivog5lglu28mJIsHEasMglmZNxLYXcB1pLszSQWl2Z7jULa8CwNE92s4tFLARkxqAcu4O4rwBgYOaGu4GtG9vZX1vZM1y93aiO8aFbUldh/dCAjOBg4B4IJkYnkcR6TN/amr3OranCtuZVSWwtIkJu+c7hFuwCN20KvGMHjNZkdxexX+nRWd3NK9oFAeS0LNDKXKvEcvlpScnK52gccYyltB/xMEsUvVXz4XVnnjMrTW2FIZZA2UOEVQpb1B4Bp26gbN/c3NqfsxmluLNoz5ksA2ySzb/kBBU4IVSAAOgIx0FW7iyaxvYrGZLuV4EjmTbEzhdpYKTj7qDYdys2eD8vQ1StN1zotlcJYGc74/LnuJAYowzB8+YUU7tzEDJHGMnqKzfEl3cyLLBHe3E81rMIr6a3iKi5hAwS7E58pNzAMmSQxB68CuLc6SytNM3zQWTyEvcfZo5443EVuC+5YzvOGcA5LY5L57HF3VreS9d4tkkVncRzFo7eBYnJG1JiWbkZx0XqpBya42DWBZXWrW4hlWVIy8EMgDfZii7o3MaAmOQhhnP8ACMDnIPS2t/am+Oob2ECcMt1csghZ2JUISm4j5CVUfLweflAA7iscRr+lvY2F9eTPdiKJHNnLDGfOgYOVMexQFCBQCd2M4B5DEGv4d8UjR7wi4ubo2VsiRRxXMPyQrGuGdlQ5YBQCvHAJ4ya29fvYIrBfNuwsdvBie2WcH7QvO1nl+TzH2gEpjsAc1happN/PNf63cwSS3sAWzO+Lc8blQGcsy4Kgbs5JI39Mcmk11G1dHc2niHR7uOIWl5ZzSXHmyKpkEbISQdpG3BfD7uTnIXAySBsi4tnnL3M8QuMKfKO1Z3UZAUoWGBtLZJGM4rxy88NwWFjdbZZFjSYgi/t/JRZHIQrsbCyLtLEEEEsM8CltdKhkultzJbPp8lqx8+8iGGMihWZM/MpwQDktz8w6iq5vMj2Z7DK5lka3W2E0WBksm1gvULt28ccYHTv1qjqGq6Xpe4z3FoLdEAExuPLWR9pONhGDk8jng9TxXnF3PqsN2LUXV/PbvDMy3XmPBIyOPvIq48tuCojBH0OTU2n6RLK2kpBKLXzyiSz75I2WMkMjIGA25YAFdu0bsk8kAbfUXIa3iHxPBqzRQRW+oRMk0Ef2mN0RriGT51hkBclTyOB97B7ZFcrZXmqa7q9tJfyzxwXEhEtu9sZY5W3fxOVwyFogpJIIAGKtaVp0l2j6Zc6TZ+SkLFGgCy28hWQsQ7swO8sOcn7pIGN1aviewuL28m0zSLuP7FJMXmit45SQsZKsrE/wKCcIvynBwARyr20KSsJYCMala314ul2em2BjjW1t2JeFTHIwgO8Eshk6McckgcAGvRLSVILO5upJZ3lmZZ1hK7gqqfk2qxyUzjDkY75yc1wOl2sFwl1aPdQ6bZxSK0f2W2MZt5C3zSqWyScFhs2fLv6Zrt2jWDw8sq2sVpF5LPHLJI8gZONrOx5OQQzD8O1G4paGno0UNpazCFII385pIto3NFE8jFV7fxGQDB2jIxkV0aiKwaxvzzEkkgymWJ3LjJxwfu1yOg2xPmSTSSLaXEMcRtXdtkeBnhf4QQ3UnJK+1dLaIsnhiKKUwtJJKf4cqr8ntjPGeTzzzUvclo8f1rQddv8AUprLUbp7jSbS3eY/aVM6ysrfdTG0IzqMgHcAeBirV7oa6A6a9NBM0975KJcpEB9nJZHzNtySSQQWJwMAe9a0F7JqWk6fZ6jDPKlyWS83RKhjgAYBS/BIyOoXkH8aVhfWf2ywbV557G5gjgTyTiaychVQjI+ZNpJZmPpWCjF6nuc81p+BBNBZ2/iy7vZdPYXlzbsVgQRs1yrFMyRMc7STtB56EdK09Qs0tpoWhtJtRuUufMjb5T5Kg5VeF+UcDDYz83PSo9OksbEiLR9rLbM0IgtgX3KP4Scckkdc4yBzWlq+28tozFcSo6hpf3EhWYuRgx4QgsQDx2yB7VaSs9TNyfMl0OM1TSTc+If7VvrG503Qre3+1XEkLYma5Lf6pTk5O443LtyDgVsahrflaeLTQRZQLIXlk+2SNNFHEkhT5FwXJyVJOOO2aYbYapBE02sa5AixnybPVHETSoePnCgEsSQFJJPGMZNR6PpGi2Ly3FlqF5pxmhUiVGwkDIQuwFgOHyBgjnnnNTbXQ0unFc2tvWxr6hbXl5e6e6fZrdYGZJIZyA7fKh86IdGIPQ8Yz0zV+8L2UyvBePJET/pbyOGJULjfsxk9xjjn2zWbqmr3UsthdRjSrScM1vHPOTcypkjcAAMclecntnNQauLHVpmTUpbmC6tFSZ7izmwnzIQCVBBGMng8E+tU5LpuZKLdubYliad01SWGaO+v4gYFhYGNJQz8YUjAJX5iVB7cjPHCRXUl1bW8sGoSfZI5VgKyb2lt5FKEptyyHLYwx7N613+my6N4cnlnu2hlv4IFXz1tmFyyu5Ayeg6gYBHQ1yeva7pV0sVtpv8AbNlaxtPHIIF8pYTu+Z2HY4ThSM4bNZVEravU6KLfM7Rdu5M+pLeaXHb363NxqE0whuJLgrFFOucI7sRtZwQAOgPXHU1DI1hfzX1s6G1sPtYlZ7KFJHRduN0kjA5BJ+6BgdRUuraTq1nd2Zt41ubKNmYNdP58SIAANwXcAoVS3KZBPXOBSPe6fBp0KW0CtO8n2k3VnG7W/wC8BVVUHawyDjsOTxWbUupquX7P4dCzHpMI+ZIJ5pISLHT7to5ImiRhysm0kABmGHIDZJ61y1t4ev5VsYZrW7vmeVoLloVDRSKkuTkHbtAI6t6ZB5xXVXFggvJdKsb/AFHbbSq7FZdsUUmVfeveT0GehAqSRTZajfzvDLqlnqKCRmtpVglikDAHK8fM25Rwwz6daHBPdBGo4rR7/wBf8E56KO6mhLQadJdS3e+eG2lgVUuIUzsDFfm835A3mchhjkdKyLS1t0aVoo5rfT7i0Mci3WyVoS8uRJjKFQMEb/5GvRLuJpVhsjcMlghaB4LzMLwklcDzcHIV2yMMOvXinQQG1ubyGe10mJoUEKzgNOZoMEJu4JyOM5z3Oc9H7IFiLLY5bW9GWwtlvdDtrbWkaFc36BWuIp8t+8A3HIIOQvIAWs+20PUr2wjFpHq58PSRNOPs0RjDyIBhY0fDnkY3HPDY7VrxaQdPaOztblhcWyhHSytyio5RlSUMTkjGRnrlvlq0mmWGpLHc6lf3UmoWknnWMVxebBGjFckDGCAO/XjpkGlyJvUr2ritHf5FGaG/Xw9beJIlu7h7oi2WymlRI0iMhYbmwCQwAG8EN3PSs++0C+vNVs70xWMV06NCqKdwWVMviPCkEfNtBPcknNeiTT2CyXkX9qMCpBi3Orpa8hFxwQMYIwc457Vku9vaaxcFljKXF0zzW5uMKnyhDOpXhc5Udc854FXKEX1M6daWtkYb2F3pUi3Oni2ub6WaOYWk2WZd7LtaZdwy4xwy4CkYHFad9b3UusNPJdb5JFCveWtu6oxzt2spBUcHGeBx75qppr+e+jW11e20LTTzSRTX9p5uxGbA2SnGDuztXpxjtWra3F8dMg0z7Jcx4naaWUQMUlYHBc44ZSdrgD34pJJocpNPXf8AT+kS6PoELWcJuN1tK7yRCYN1XOCoOeM4657VrLpml6gt6z6pG1xFy4j+RVRSGUHu4zzu9fpWJpT2w1yT7ZBNfahdRsRL5mIo+DuBDEDntx29q1VglW7hgiLrZxQss8wcKVwSQQwycEYGBx+VXBK2iMarlf4rFi8gWSxe/m0xt+5jLaCZn8lB14XIJ2jO31I561l6rLDALT7NFdA3gLW0/k+ckR28YVGHBGBgcE9a2r6S5itBcWt5chUZzMjQ5DjIypOCeMfjk1BJc20unQWsVrDDbyGJI4xCyvAwPD4PQdTjA6881cl0MoSe5y+p2d7cXaxy+ReTaZaiaaOU7ZIRIGLDapzuK8BecBea0dKj1Ca1tI7u3t3+3WoBVkdx8qgKOGVCCrEc8DPFSNHPCdOYXksmY2+0+X88xYjBY5PTI6Dpkk9auahHHNPbWpuZZbaCLyreNWJMssh4V04UhVVvmJ4z+cRjqayndJf1/VzL1DStUl02Sewl0lZ7Eo0myAh7dD0VXOTuxnkg4B4qpb2xlhm0+XUUvNUinCeXYSIFjHJJnZsE4LH67RgVuT291p0kA0lXurEqwitwQVjxkkbxyQRgBmztwe1W7Xw8h+1tFeMI3hVY3gZVVjknceOWOQC2TkKOlUqd9kL23Krt/wBf1/XUjXTp4bORUntYLWQKbTypCkt1IWJcdTtHTovr2qJY53lgsVklkSOEyRKY/L88xuVZd2CcDgHPXdkVU1WztrwLaNDHe3EUWbombaAAw/ebOcbdo6c4Jxmobu7kuNkmj3Yt0Hl/aZRIFSQuAI5GDr83yjp34HUUOSRKi31/r+v67KNXvEn8JG/Ux+dqtukPnBQ677hP3CAZBRUGQwI3bfwra+J9xcweLXWaOaO0mMcKrbgLcXG5VAaJyMNhiVMZ5B+bOGArjdF1WWPxPplkLW8KPe2dsLi6CxmXy7uPLImM7RzzgcHFepeKtZ0HVNZ1vw3r6C3MaIQ1yuEmjaNT5kb9AVYlecHK8VpSleDOLHR5JrT+rnma6VJbvdPcWckF+JNyrFJjIRDsIwdu8DGOOTz3yGXeu3Vmf9KF01/O0iSQQwFFEBQMXYnOSuYx3wCOcVLtmsZ18nVrsWtiiwzlo1mfeG2p8xyfmyr5J4xwSMitK7kIiSO4WJxco3KgsY48LhQu0O6kscBmyOTxjFX6nIYk91c3evQrNIkL3AKyiAH95HiR8lGIAyM8sN2DxjitsaXb3EotNQCSafcRxSlVBQKyqqgvjkjDJjBBAIzWebczapfIlzNJG6+UpSUqydowWbAKrxyNxyGBBHFFzEbK4hfS4o7SY7jJaRRMGmVmIaRjlVB+TgHkdR0Wi4x8ukWMMFqkli/2H97BDc52zRKQRtBY5dz84z2B75NZstu2l30wjSaNbqMzPLIGEOxVYAYyyxsAcHggknAHIF4afrNnrd1dxxJcW4kRmIYebKQ4KS5YfUfNgZxmpLzS47WWD+z4YftFvbKzpHIZUaV5ApjKsQr79xORgkqOQDinfQEzj57lbvUZLyDUFhmhcRSwRszMwAUgFjjYSGyQGHIIwOa3bj+1NL0qzEDf2fp9uVhju0KNlX4i83CsViZm5IckdfYbV/ctB4guLjTWWKS0YQ5NmqM5II8pwQCQMb1C8sCCcheauomxuIXS6ur2EmMmS389pEyxKqX2n93gkNjjocg4GJ8rFXMe1s5WvVg077beyW6yNHbCVns488Fpdku4vlecnrjjgAoLW4aKC2t/Ju2luHMlqt2+/JABQuSTCuF+6wOcnJ6iurMxFoqNNFaFYjmZVMckjBt27G0Z3DbkehIOOKRY7e2R7zzV0uIDFxPIw3FlUkKxByCoPQtnnjNNiuY1+93c3CSrJcQwki3uoVl3FhtIjwFQRqm8OuM4+bryapxQzQ3NlqP9neXexyGCGGGMRFjuVf3hCAOCN53EAAIV6NmrQuoFttNFnJHa2csHmRqpxI6KzYgWI5xJ5jg7jnAZgeF5hW80yK6tmkmhudQsYm3u2XkumYZ/dPuBwgOMNsU59anRDRqwWd/4QtIZBd6bZSQ7rNWnjIRQWBJZFJVYlOMBQPmZCx6is/UdHuNIlsbLSHsrZJJftO4PsWRMuQyP5ZBRkJXyydqsVwe5XW7K1jvYNQ1CC4F47i5ltYiyCOPy8FHbczqrAHAHo2RnbWpbLYGDT4ra4W51MW62t5FIhKSK8RywGG5+dd2OqrglcAUrgYi3Onabq1omk28Gl3qGeUJDdYYt5ayKSEDRl3HrnCj5WPNVZ7m11S9sdFRftpnMOyPzXRw5wxKIigKu5SWbJJB+hG7reNXh1nUdXhujPpzRyJDaxmCC4dP+WGx3Ds23bjlR129DXN+H08ue3ura0vAQZUmltNqpZeYnDJhmxkyH5ipZeobgin5gblrqLPPp5tg9sZVe1gQTGMAJISA+0EmTPBjAJXdknkCpJL+GW4utusJHpkac27SMoEowCwAxhHKKodn+8T8vXdm6I+jagdLsLXUJ0Szhm2zx3TQSW7FCVYcfMQY1HYMzK2DipWeM6nAbN7ywgsYo7YW9qftLSAM7K6N92QZmJIbK/Ic4IzTsBo6fNpt3DZiWJbG5C/aII5wzi4eQfKhlz8oZgjbW5JBJGMVp3ItdP0S7GoQ3V3aPcx2MVuvyxtJ5jNuJyN5wxYgZ4BHJwK5W30rzdeDtcLfO4hN5c3B3YQNtIk3jAk+VQNrZ5XGFJrTW/vLzxrfwzahbNoDwq9s1rEbkw+QQsuA2VEn3huO48krwaTEMsdPtYbjUrDTdQW306HEv7+6VxNhAWVk5Kgg8qzE7V5BHAg1az0dLNoNS1O6hit5wIbx3kmdRwWhSTBDLlgCoHBA4wcVBo9roesXfnRQTW1ncwS/bIzIFlQEEpIGQ7Qg3qqgg5OGyCpqvJZXM1hHGHsJYEtZUtLAFLVgnmqwDMGL+YWjBIYEE7xu5Bo6jLsmm6dcfa4G+2Xfnh5LkXkybA7RYKqc7gdwVenyj3GBYsdPe1ksXv44k8wvJbzXcouIfKVSX2knJKncw7k56cEJpmoadcWt7NqFvGqLcpG0UdxJGqOvlqAUjB5LZcnALd8gHGddaraX16uo2ltZGEyQtdwMkgmdVDM7RISAGxt6quAuDwaEw1N5JDptm1zqk8NlbSAhJLS4J2nYrbXKZLNgA4X1IA5Bpmp20bKlxdeQZ7zEkQkSWSRgVZiUi2HawBHy7sKAc9BXDaTr1o0t897La28Dxma3hcOZPs7KSsIXDAMNwYkkD5UUcDAXVvEdyDcRafp3navBGqz3CWZEz4+UNGoIKuVVQOuAOM9apRdyWzvbm1aHTpZpbtpb92+03FsHjuczsdu1WBVwVCEHJxkH72BV3Sba2022I/th4Yo5/Mke3HmhpNhDW4ZeCFTZgYyMN+HnGm67Jb2rfbZowd/2lI4kgCyt8hHBXO5ck8A5zxkrTItXaWS7he6h024upIZURIE8mNXcvllUZUkbm4JYeaBxzQ4yDQ9EuZ4bvxjLpls9lqTJNvWOWYl4o8hWCDJBO8A7s7huHAFa8s62SmOGJLm3TcHM+GUStIQUbJyBgj5R09O1ebrf2un63bWb6xbyJJNLM95bQGR/KYErty+FkLEpkKeR+W/pmuR6ZZ2sN8iw2u9oZxLbuJLsY27YmDMu5jkgFt20DHAFNJiaOg8P3k32u9tNirOqNPcrjIllZgCEYtyBk46DcDgYrqdLWG4juNKkOZMieNWzhsABjx1+9+ozXG3L22nS6VdeeJrCCX7Ky2zKhzvIZ5S53yBMn5e24tnOK6nw7DJZa1dTO7YAMe1l3Pxxu3Dkg8cHnj6VMt7onof/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left panel: Neoplastic cells within the lymph node follicle from a patient with follicular lymphoma show strong immunostaining (brown color) for bcl-2. The lymphocytes in the thin mantles and the interfollicular regions also show bcl-2 reactivity. Right panel: In comparison, the germinal centers in a reactive follicle are bcl-2 negative, with the positive cells being located in the mantle and interfollicular regions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Warnke, RA, Weiss, LM, Chan, JK, Cleary, ML, Dorfman, RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_54_38761=[""].join("\n");
var outline_f37_54_38761=null;
var title_f37_54_38762="Clinical features, staging, and treatment of anal cancer";
var content_f37_54_38762=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features, staging, and treatment of anal cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/54/38762/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/54/38762/contributors\">",
"     David P Ryan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/54/38762/contributors\">",
"     Christopher G Willett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/54/38762/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/54/38762/contributors\">",
"     Richard M Goldberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/54/38762/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/54/38762/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/54/38762/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anal cancer comprises 2.4 percent of all digestive system malignancies in the United States; 7060 new cases are diagnosed annually [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/1\">",
"     1",
"    </a>",
"    ]. The incidence of anal cancer in the general population has increased over the last 30 years, from 10 to about 20 per million [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/2\">",
"     2",
"    </a>",
"    ]. A higher incidence has been associated with female gender, infection with human papillomavirus (HPV), lifetime number of sexual partners, genital warts, cigarette smoking, receptive anal intercourse, and infection with human immunodeficiency virus (HIV) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/3\">",
"     3",
"    </a>",
"    ]. Thus, from an etiologic standpoint, anal cancer is more similar to genital malignancies than it is to other gastrointestinal tract cancers.",
"   </p>",
"   <p>",
"    Substantial progress has been made in understanding the pathophysiology and the management of anal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/4\">",
"     4",
"    </a>",
"    ]. In the 1960s, this malignancy was thought to be due to chronic perianal inflammation and was treated routinely by abdominoperineal resection, necessitating a permanent colostomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/5\">",
"     5",
"    </a>",
"    ]. As a result of carefully conducted epidemiologic and clinical studies, it is now known that anal cancer is closely associated with HPV infection and that cure of anal cancer is possible in the majority of patients with preservation of the anal sphincter. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26455?source=see_link\">",
"     \"Virology of human papillomavirus infections and the link to cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Anal canal versus perianal skin cancers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anus consists of a glandular mucosa-lined anal canal, and the epidermis-lined perianal \"margin\" (",
"    <a class=\"graphic graphic_figure graphicRef62539 \" href=\"mobipreview.htm?14/30/14819\">",
"     figure 1",
"    </a>",
"    ). The anus encompasses mucosa of three different histologic types: glandular, transitional, and squamous (proximal to distal, respectively). Distally, the squamous mucosa (which is devoid of the epidermal appendages, hair follicles, apocrine glands, and sweat glands) merges with the hair-bearing perianal skin (true epidermis). This mucocutaneous junction has been referred to as the anal \"verge\" or margin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/29/12761?source=see_link\">",
"     \"Classification and epidemiology of anal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two distinct categories of tumors arise in the anal region:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tumors that develop from any of the three types of mucosa are termed anal canal cancers. Tumors arising in the transitional or squamous mucosa are squamous cell cancers and appear to behave similarly, despite their sometimes variable morphologic appearance. By convention, most series that report outcomes of \"anal cancer\" refer exclusively to these tumors. The term \"anal cancer\" by common definition refers to squamous cell cancers arising within the mucosa of the anus, and the two terms will be used interchangeably throughout this review.",
"      <br/>",
"      <br/>",
"      Basaloid (also termed junctional or cloacogenic) carcinoma is a variant of SCC that arises from epithelial transitional zone. However, these terms have largely been abandoned because these tumors are now recognized as nonkeratinizing types of squamous cell carcinoma. Tumors arising within the anal canal above the dentate line are termed nonkeratinizing SCCs, while those arising within the anal canal distal to the dentate line are termed keratinizing SCCs.",
"      <br/>",
"      <br/>",
"      Adenocarcinomas arising from glandular elements within the anal canal are rare, but appear to share a similar natural history to rectal adenocarcinomas, and are treated similarly.",
"     </li>",
"     <li>",
"      Tumors arising within the hair-bearing skin at or distal to the squamous mucocutaneous junction have been referred to as anal margin cancers. However, the preferred term is perianal skin cancers. With the exception of melanomas, tumors arising on the perianal skin behave biologically like skin cancers. Although there are essentially no prospective data validating this practice, they are staged, classified, and treated as skin cancers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]. However, the regional nodal drainage (relevant to the N category) is specific to this anatomic site. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Staging'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic review will focus on the clinical features, staging, and treatment of invasive anal canal cancers. The local anatomy, classification, and epidemiology of anal cancer are discussed separately, as is the diagnosis and management of anal intraepithelial neoplasia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/29/12761?source=see_link\">",
"     \"Classification and epidemiology of anal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/33/1562?source=see_link\">",
"     \"Anal intraepithelial neoplasia: Diagnosis, screening, prevention, and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rectal bleeding is the most common initial symptom of anal cancer, occurring in about 45 percent of patients. Anorectal pain or the sensation of a rectal mass is present in 30 percent, while 20 percent have no tumor-related symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Bleeding from a mass at or just above the anal sphincter (",
"    <a class=\"graphic graphic_figure graphicRef62539 \" href=\"mobipreview.htm?14/30/14819\">",
"     figure 1",
"    </a>",
"    ) may be falsely attributed to hemorrhoids and may delay the diagnosis.",
"   </p>",
"   <p>",
"    Among patients with anal squamous cell carcinoma (SCC), a history of anorectal condyloma is present in about 50 percent of homosexual men and less than 30 percent of women and heterosexual men; these values are much greater than in normal controls (1 to 2 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/11\">",
"     11",
"    </a>",
"    ]. Tumors of the perianal skin, especially Bowen's disease or Paget disease, may present with pruritus ani or a bleeding erythematous eczematoid plaque. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/29/12761?source=see_link\">",
"     \"Classification and epidemiology of anal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumors that arise within any of the mucosal surfaces of the anus are staged and treated as anal canal cancers. The American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (IUCC) have jointly established a TNM staging system for anal canal cancers that is based upon tumor",
"    <span class=\"nowrap\">",
"     size/invasion",
"    </span>",
"    of adjacent structures and the presence or absence of nodal or distant metastases (",
"    <a class=\"graphic graphic_table graphicRef72273 \" href=\"mobipreview.htm?15/60/16333\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At initial presentation, most patients have a T1 or T2 lesion and fewer than 20 percent are node-positive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/10,13-17\">",
"     10,13-17",
"    </a>",
"    ]. The probability of nodal spread is directly related to tumor size and location. It is far more common in cancers that originate in the anal canal than on the perianal skin.",
"   </p>",
"   <p>",
"    Tumor size (T stage) and nodal status (N stage) are the most significant prognostic factors for patients with anal SCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/14,15,17\">",
"     14,15,17",
"    </a>",
"    ]. In the above series of 270 patients, the five-year survival by stage was [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/15\">",
"     15",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H21\">",
"     'Prognosis'",
"    </a>",
"    below):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      T1 &mdash; 86 percent",
"     </li>",
"     <li>",
"      T2 &mdash; 86 percent",
"     </li>",
"     <li>",
"      T3 &mdash; 60 percent",
"     </li>",
"     <li>",
"      T4 &mdash; 45 percent",
"     </li>",
"     <li>",
"      N0 &mdash; 76 percent",
"     </li>",
"     <li>",
"      Node-positive &mdash; 54 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Perianal skin cancers",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCCs arising in the perianal skin behave biologically like squamous cell skin carcinomas, and they are classified and staged (",
"    <a class=\"graphic graphic_table graphicRef78140 \" href=\"mobipreview.htm?5/0/5134\">",
"     table 2",
"    </a>",
"    ) similarly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/18\">",
"     18",
"    </a>",
"    ]. However, the nodal drainage pattern (relevant to the N category) is unique to this site, and staged according to the anal cancer algorithm (",
"    <a class=\"graphic graphic_table graphicRef72273 \" href=\"mobipreview.htm?15/60/16333\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Sites of lymphatic drainage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphatic drainage of anal canal and perianal skin cancers is dependent upon the anatomic site of origin (",
"    <a class=\"graphic graphic_figure graphicRef62539 \" href=\"mobipreview.htm?14/30/14819\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/13,14,19\">",
"     13,14,19",
"    </a>",
"    ]. Tumors originating above the dentate line, similar to rectal cancers, drain to the perirectal and paravertebral nodes. In contrast, tumors arising below the dentate line drain to the inguinal and femoral nodes, areas that are rarely involved by rectal cancer. In the",
"    <span class=\"nowrap\">",
"     AJCC/UICC",
"    </span>",
"    staging system, perirectal nodes are N1 nodes; metastases in the unilateral internal iliac or superficial inguinal nodes are scored as N2 disease, and N3 nodal disease refers to metastases in both perirectal and inguinal nodes, or bilateral internal iliac or inguinal nodes (",
"    <a class=\"graphic graphic_table graphicRef72273 \" href=\"mobipreview.htm?15/60/16333\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Staging evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, both the staging and treatment of anal cancer was surgical, and consisted of abdominoperineal resection and inguinal lymph node dissection. However, combined chemoradiotherapy has emerged as the preferred method of treatment, with radiation therapy (RT) administered to the sites of primary disease and lymphatic spread, usually with prophylactic irradiation of clinically negative groins This strategy has significantly reduced the rates of locoregional recurrence and led to markedly improved control of gross nodal disease. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'RT dose and schedule'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Surgical staging is no longer performed routinely. Clinical staging for anal canal cancers consists of physical examination and biopsy of the primary tumor, palpation of the groin, CT of the chest, CT or MRI of the abdomen and pelvis, and PET scan. For women, a gynecologic examination should be done, including screening for cervical cancer.",
"   </p>",
"   <p>",
"    The same staging evaluation is recommended for SCCs of the perianal skin, although guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    do not include a PET scan in this situation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     PET scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sensitivity of physical examination and",
"    <span class=\"nowrap\">",
"     CT/MRI",
"    </span>",
"    is suboptimal to detect inguinal nodal metastases, many of which are &le;5 mm and below the limit of detection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/20\">",
"     20",
"    </a>",
"    ]. Adding an integrated",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scan to the staging workup has a significant impact on therapy planning, particularly identifying those patients who need higher dose RT to the groin, and those with otherwise occult metastatic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/21-24\">",
"     21-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, in a study of 61 patients with anal cancer, in which the majority of abnormal nodes were histologically biopsied, the sensitivity for nodal regional disease by PET versus conventional imaging (CT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    MRI) was 89 and 62 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/22\">",
"     22",
"    </a>",
"    ]. The staging PET scan altered management in only three patients (two percent), but changed the radiation fields in eight (13 percent).",
"   </p>",
"   <p>",
"    Guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    suggest consideration of a PET scan as a component of the pretreatment staging evaluation for anal canal cancers (but not perianal skin cancers), but emphasize that it does not replace a diagnostic CT. We include integrated",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    in the pretreatment staging workup of anal canal cancers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT OF LOCALIZED SCC OF THE ANAL CANAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment modalities for anal canal cancer include resection, combined modality therapy (chemotherapy plus RT) and RT alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, abdominoperineal resection (APR) was routinely performed for tumors arising in the anal canal. This radical procedure requires removal of the anorectum with creation of a permanent colostomy. In early series, the overall probability of five-year survival following APR for anal canal cancer was 40 to 70 percent, with a perioperative mortality of 3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/8,10,14,16,17,19,25\">",
"     8,10,14,16,17,19,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    APR fell out of favor as initial therapy as accumulating experience demonstrated that SCC of the anal \"margin\" had a favorable prognosis and rarely required radical surgery. Wide local excision (WLE, with 1 cm margins of normal tissue) could be performed with primary closure. Although local recurrence rates were as high as 50 percent, a second local excision or inguinal lymphadenectomy salvaged the majority. The five-year survival for patients with cancers less than 2 cm in greatest dimension was over 80 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/10,14,19\">",
"     10,14,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the tumor encompassed over one-half of the circumference of the anus, APR was recommended because of poor anal sphincter control after WLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/19\">",
"     19",
"    </a>",
"    ]. However, in these cases, performance of an APR did not provide better overall survival compared with local excision.",
"   </p>",
"   <p>",
"    These early series of local excision should be interpreted cautiously since they included a mix of patients with both anal canal cancers of the distal squamous mucosa and those with perianal skin cancers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Combined modality therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extending prior observations of a radiation-potentiating effect of concomitant fluoropyrimidines in a variety of gastrointestinal malignancies, investigators at Wayne State devised a protocol of preoperative treatment with chemotherapy plus RT as a means of decreasing the surgical failure rate for patients with anal canal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/26\">",
"     26",
"    </a>",
"    ]. The &ldquo;Nigro&rdquo; regimen consisted of 5-FU (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day by continuous infusion days 1 through 4 and 29 through 32),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    (10 to 15",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1 only), and intermediate dose RT (30 Gy). The finding that the first three patients had complete pathologic responses led to the development of strategies that were directed at preservation of the anal sphincter.",
"   </p>",
"   <p>",
"    In a follow-up series, patients with anal canal cancer were initially treated with chemoradiotherapy (same regimen) and subjected to subsequent surgery (typically an APR) only if there was residual tumor in a postradiation biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/27\">",
"     27",
"    </a>",
"    ]. The majority of patients treated with chemoradiotherapy were cured (five-year overall survival 67 percent) without an APR (five-year colostomy-free survival 59 percent).",
"   </p>",
"   <p>",
"    These findings were subsequently confirmed by multiple investigators using a variety of regimens. Taken together, the use of combined chemoradiotherapy results in local failure rates of 14 to 37 percent, five-year overall survival rates of 72 to 89 percent, and five-year colostomy-free survival rates of 70 to 86 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/27-33\">",
"     27-33",
"    </a>",
"    ]. As a result of these data, the use of concurrent RT with infusional 5-FU and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    became the standard of care for patients with SCC of the anal canal. (See",
"    <a class=\"local\" href=\"#H8331342\">",
"     'Colostomy rates'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Versus RT alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The necessity of including chemotherapy in the nonoperative treatment regimen for anal cancer has been addressed in at least two randomized trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Anal Cancer Trial Working Party of the United Kingdom Coordination Committee on Cancer Research (UKCCCR) randomly assigned 585 patients with T1 to T4 SCC of the anal canal or margin to receive either RT alone (45 Gy external beam in 20 or 25 fractions over four to five weeks plus a 15 Gy external beam or 25 Gy brachytherapy boost), or RT plus concurrent infusional 5-FU (1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      for four days or 750",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      for five days during the first and the final weeks of radiotherapy) and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"       mitomycin",
"      </a>",
"      (12",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 1 only) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/34\">",
"       34",
"      </a>",
"      ]. Chemoradiotherapy was associated with significant reductions in local failure (61 versus 39 percent) and cause-related mortality (28 versus 39 percent). More acute morbidity, including six deaths, occurred with combined modality therapy; late morbidity was similar.",
"      <br/>",
"      <br/>",
"      Overall survival was similar between the two groups, and this was attributed to an early increase in non-anal cancer deaths in the first five years, which disappeared by year 10 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/35\">",
"       35",
"      </a>",
"      ]. Only 11 patients in the chemoradiotherapy group suffered a locoregional relapse as a first event after five years.",
"     </li>",
"     <li>",
"      In a second trial, The European Organization for the Research and Treatment of Cancer (EORTC) randomly assigned 110 patients with locally advanced (T3- 4 or N1-3) anal cancer to receive RT (45 Gy with a 15 or 30 Gy boost) with or without concurrent infusional 5-FU (750",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day on days 1 through 5 and 29 through 33) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"       mitomycin",
"      </a>",
"      (15",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      day 1 only) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/36\">",
"       36",
"      </a>",
"      ]. Chemoradiotherapy was associated with a significantly higher pathologic complete remission rate (80 versus 54 percent), an 18 percent higher five-year locoregional control rate, a 32 percent higher colostomy-free rate, and higher event-free and progression-free survival. Overall survival was not significantly different and, in contrast to the UKCCCR trial, the incidence of acute and late side effects and treatment-related mortality did not differ between the groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Role of mitomycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    has been questioned since it does not sensitize tumor cells to the effects of RT, has only modest antitumor activity against SCCs, and is associated with renal, pulmonary, and bone marrow toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36826?source=see_link\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/46/33513?source=see_link\">",
"     \"Mitomycin-C pulmonary toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The need for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    in curative treatment of anal cancer was addressed in a joint trial from the Radiation Therapy Oncology Group (RTOG) and the Eastern Cooperative Oncology Group (ECOG) in which 310 patients with anal cancer of any tumor or nodal stage were randomly assigned to combined modality therapy with or without mitomycin (using the Wayne State regimen) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/39\">",
"     39",
"    </a>",
"    ]. Patients who received mitomycin had significantly better four-year colostomy-free survival (71 versus 59 percent) and disease-free survival (73 versus 51 percent), but pathologic complete response rates and overall survival were similar. Grade 4 toxicity (23 versus 7 percent) and fatal neutropenic sepsis (4 versus 1 patient) were significantly more common in the mitomycin group.",
"   </p>",
"   <p>",
"    The authors concluded that, despite greater toxicity, the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    in a definitive complete response regimen for anal cancer was justified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Replacement of mitomycin by cisplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     Cisplatin",
"    </a>",
"    is more active in the treatment of SCCs in general than is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    . Early uncontrolled studies suggested encouraging colostomy-free and overall survival rates with the substitution of cisplatin for mitomycin in the treatment of anal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/28-30,40\">",
"     28-30,40",
"    </a>",
"    ]. This issue has been addressed in two large controlled studies, with conflicting results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The substitution of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"       mitomycin",
"      </a>",
"      in the treatment of anal canal cancer was not supported by the results of the US Intergroup trial (RTOG 98-11) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/41,43\">",
"       41,43",
"      </a>",
"      ]. Induction chemotherapy plus concurrent chemoradiotherapy using cisplatin and 5-FU (with RT begun on day 57 after two courses of cisplatin and 5-FU) was directly compared to the standard regimen of mitomycin, 5-FU and RT. The chemotherapy drugs in both arms were given during weeks 1 and 5 of RT. The trial enrolled 682 non-HIV-infected patients with SCC of the anal canal, 27 percent &gt;5 cm, and 26 percent clinically node-positive.",
"      <br/>",
"      <br/>",
"      In the latest update, there were significant differences favoring",
"      <span class=\"nowrap\">",
"       FU/mitomycin",
"      </span>",
"      in five-year disease-free survival (68 versus 58 percent, p=0.006) and overall survival (78 versus 71 percent, p=0.026 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/43\">",
"       43",
"      </a>",
"      ]).",
"      <span class=\"nowrap\">",
"       FU/mitomycin",
"      </span>",
"      was also associated with a statistically nonsignificant trend toward fewer locoregional failures (20 versus 26 percent) and colostomy rates (cumulative rate 17 versus 12 percent). Hematologic toxicity was worse in the mitomycin group, but nonhematologic toxicity and late RT-related toxicity were similar in the two groups.",
"     </li>",
"     <li>",
"      On the other hand, the therapeutic equivalence of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"       mitomycin",
"      </a>",
"      when used in combination with infusional 5-FU concurrent with RT was suggested in the ACT II randomized trial of 940 non-HIV infected patients with anal SCC (30 percent node-positive, 43 percent",
"      <span class=\"nowrap\">",
"       T3/4)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/42\">",
"       42",
"      </a>",
"      ]. Treatment consisted of RT in both arms (50.4 Gy in 28 fractions) with concurrent infusional 5-FU (1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day on days 1 to 4 and 29 to 32) and either cisplatin (60",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1 and 29) or mitomycin (12",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      day 1 only). There was a second randomization to receive or not receive maintenance chemotherapy starting four weeks after chemoradiotherapy (two courses of cisplatin plus 5-FU, administered four weeks apart).",
"      <br/>",
"      <br/>",
"      In a preliminary report presented at the 2009 ASCO meeting, patients receiving mitomycin had more acute grade 3 or 4 hematologic toxicity (25 versus 13 percent), but no higher rates of febrile neutropenia (3.1 versus 3.2 percent) during chemoradiotherapy. Rates of grade 3 or 4 nonhematologic toxicity were similar (61 versus 65 percent). The complete response rate at six months (the primary endpoint) was 95 percent with both cisplatin and mitomycin, and the three-year colostomy rate was not significantly different (13.7 versus 11.3 percent). Three year RFS was similar with or without the use of maintenance therapy (75 percent for both arms) as was overall survival (84 versus 85 percent).",
"      <br/>",
"      <br/>",
"      Final publication of these data is pending.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, these data suggest that 5-FU plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    remains the standard of care, but that 5-FU and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    could be considered a reasonable approach as well. There appears to be no role for induction chemotherapy or a continuation of chemotherapy beyond concurrent chemoradiotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Capecitabine as an alternative to infusional 5-FU",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least some data suggest that substituting daily oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    for infusional 5-FU in conjunction with IV",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    during RT is well tolerated with minimal toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/44\">",
"     44",
"    </a>",
"    ]. In a phase II trial of 31 patients, 77 percent had a complete clinical response four weeks after completion of therapy. At a median follow-up of 14 months, there were three locoregional recurrences. Before this approach can be adopted, longer-term follow-up and phase III trials with the Wayne State regimen as the control arm are needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H594205038\">",
"    <span class=\"h3\">",
"     Can chemotherapy be eliminated for early stage tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials demonstrate the superiority of chemoradiotherapy over RT alone in terms of disease-free survival, local relapse, and colostomy-free survival, but whether these benefits apply to early stage disease (T1-2, N0 (",
"    <a class=\"graphic graphic_table graphicRef72273 \" href=\"mobipreview.htm?15/60/16333\">",
"     table 1",
"    </a>",
"    )) is unclear. Only one of the two randomized trials described above enrolled patients with T1 or 2 tumors, and results were not analyzed according to primary tumor stage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Versus RT alone'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Several retrospective series report excellent outcomes for patients with T1-2, N0, M0 disease with RT alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. However, not all reports are favorable. A retrospective series of 146 patients with T1-2, N0, M0 anal SCC treated with RT alone (n = 71) or chemoradiotherapy (n = 75) reported a twofold higher rate of locoregional failure with RT alone (five year locoregional control 76 versus 87 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/48\">",
"     48",
"    </a>",
"    ].",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    guidelines recommend definitive chemoradiotherapy for all patients with anal canal SCC, even those with T1-2, N0, M0 tumors. We agree with this approach. However, for the extremely elderly population with T1N0 tumors, or those with significant comorbidities, elimination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    and administration of 5-FU alone during RT could be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     RT dose and schedule",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are typically treated with external beam RT using fields that initially encompass the pelvis from the S1-S2 level, inguinal lymph nodes (even if palpably negative), and anus. After a dose of 30 to 36 Gy is reached, the treatment fields are reduced to the low pelvis encompassing the anal tumor, and the total dose to the primary tumor is 45 to 50 Gy in daily 2 Gy fractions. If there is palpable or radiographic evidence of inguinal node metastases, an RT boost is typically added to the affected groin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/39\">",
"     39",
"    </a>",
"    ]. Chemotherapy (typically the Wayne State regimen of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    C and 5-FU, see above) is administered concurrently with the first and fifth weeks of RT.",
"   </p>",
"   <p>",
"    Compared to historical series of abdominoperineal resection and inguinal lymph node dissection, this strategy has significantly reduced the rates of locoregional recurrence and led to markedly improved control of gross nodal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. Rates of inguinal node recurrence are &lt;5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/15,50\">",
"     15,50",
"    </a>",
"    ]; rates are higher when elective inguinal node irradiation (for those with no palpable or radiographic evidence of inguinal nodal disease) is omitted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    This chemoradiotherapy regimen is effective but can be toxic. During the five to six week course of irradiation and chemotherapy, there is frequently marked regression of the tumor as well as a brisk perineal skin reaction. In the US Intergroup trial described above, 19 percent of patients treated with RT and concurrent",
"    <span class=\"nowrap\">",
"     5-FU/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"      mitomycin",
"     </a>",
"    </span>",
"    experienced acute grade 4 to 5 hematologic toxicity (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Role of mitomycin'",
"    </a>",
"    above). In the two trials comparing RT with and without chemotherapy described above, significant acute gastrointestinal toxicity occurred in 33 to 45 of patients treated with chemoradiotherapy while 49 to 76 percent of patients had significant acute dermatologic toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/34,36\">",
"     34,36",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Versus RT alone'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    RT using lower chemotherapy doses has been used for elderly patients with anal canal SCC. One report evaluated 58 patients &ge;75 years of age who received RT (39.6 Gy followed by a delayed boost of 20 Gy) with or without infusional 5-FU (median dose 600",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day, days 1 through 4, and 29 through 32) plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    (median dose 9.5",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1 only) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/53\">",
"     53",
"    </a>",
"    ]. The toxicity of this regimen was comparable to that seen in younger patients treated with higher chemotherapy doses, and efficacy was preserved (five-year survival and local control rates were 54 and 79 percent, respectively).",
"   </p>",
"   <p>",
"    The optimal dose of external beam RT for the treatment of anal canal cancer is the subject of considerable debate. At least two retrospective studies suggest that 30 Gy of RT with concurrent chemotherapy after an excisional biopsy might be adequate for selected patients with early stage disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. In the larger report, the entire group of 25 patients had a five-year colostomy-free survival of 91 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, other retrospective reports suggest that total dose is a significant prognostic factor for both local control and survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. In a series of 50 patients with nonmetastatic anal cancer, RT doses of &ge;54 Gy were associated with significantly better overall survival (84 versus 47 percent), disease-free survival (74 versus 56 percent) and local control (77 versus 61 percent) compared to lower doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/57\">",
"     57",
"    </a>",
"    ]. Most of these patients also received concurrent 5-FU and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    .",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN guidelines",
"    </a>",
"    recommend a minimum dose of 45 Gy for all patients. Two trials have evaluated the potential benefit of higher doses of external beam RT above 54 Gy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an RTOG study, 47 patients with anal cancers &ge;2 cm received 59.4 Gy RT in a \"split dose\" schedule (two week delay after 36 Gy) plus concurrent 5-FU and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"       mitomycin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/59\">",
"       59",
"      </a>",
"      ], and the results compared to those of a previous RTOG trial in which patients were treated with 45 Gy in a continuous schedule plus the same chemotherapy regimen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/39\">",
"       39",
"      </a>",
"      ]. Although cross-trial comparisons such as these can be misleading, the patients receiving 59.4 Gy had comparable toxicity, but the two-year colostomy rate was much higher than expected (30 versus 9 percent in the previous trial).",
"     </li>",
"     <li>",
"      A similar split-course schedule of RT was studied in an ECOG trial in which 19 patients received 59.4 Gy concurrent with two courses of infusional 5-FU and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/60\">",
"       60",
"      </a>",
"      ]. Although the response rate was 95 percent, toxicity, particularly hematologic, was prohibitive.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN guidelines",
"    </a>",
"    recommend that patients with T3, or T4, or node-positive disease, or T2 residual disease after 45 Gy receive an additional boost of 10 to 14 Gy in 2Gy fractions (total dose 55 to 59 Gy).",
"   </p>",
"   <p>",
"    Brachytherapy provides another means of dose intensification, sparing the surrounding normal structures. In several series, the addition of brachytherapy provided a complete pathologic response rate of 83 percent (range 73 to 91 percent), a local control rate of 81 percent (range 73 to 89 percent) and a five-year survival rate of 70 percent (range 60 to 84 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/29,30,61-66\">",
"     29,30,61-66",
"    </a>",
"    ]. However, anal necrosis range developed in 2 to 76 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/29,30,63,65\">",
"     29,30,63,65",
"    </a>",
"    ], and many patients required surgical therapy (APR) for complications.",
"   </p>",
"   <p>",
"    The incidence of late toxicity from RT, such as anal ulcers, stenosis, and necrosis, is also dose-dependent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/61\">",
"     61",
"    </a>",
"    ]. The development of such toxicities may necessitate a colostomy in 6 to 12 percent of patients who are otherwise free of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/15,49,62\">",
"     15,49,62",
"    </a>",
"    ]. In a review of late radiation complications in 144 patients with anal cancer who were treated with either RT alone or with chemotherapy, after five years, 10 percent required an APR for late treatment-related complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/61\">",
"     61",
"    </a>",
"    ]. The serious complication rate was much higher in those patients who had at least 39 Gy of external beam RT to the pelvis before the boost to the tumor (23 versus 7 percent in those who received less than 39 Gy).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     3D-CRT and IMRT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Promising approaches to minimize toxicity while maximizing local control include newer three-dimensional treatment planning and computer-controlled delivery techniques such as three-dimensional conformal RT (3D-CRT) and intensity-modulated RT (IMRT).",
"   </p>",
"   <p>",
"    3D-CRT is typically implemented with a set of fixed radiation beams, which are chosen based upon the shape and size of the target. The success of 3D-CRT was shown in a series of 62 consecutive patients undergoing combined chemotherapy (5-FU with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ) and 3D-CRT (54 Gy in 30 fractions) for T2-4, node-negative (n = 60) or positive (n = 40) anal canal SCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/67\">",
"     67",
"    </a>",
"    ]. All were able to complete treatment without interruption for toxicity. Grade 3 or worse skin toxicity was observed in 12 patients (compared to 26 of 60 historical control patients who were treated with conventional split-course RT [45 to 58.9 Gy] plus concurrent chemotherapy). At a mean follow-up of 44 months, local control and overall survival rates were 85 and 81 percent. These values compare favorably to outcomes in the conventionally treated historical group (local control and overall survival rates 61 and 54 percent, respectively), although the lack of a contemporaneously treated, randomly assigned control group limits interpretation.",
"   </p>",
"   <p>",
"    IMRT uses the same 3D radiation treatment planning used for 3D-CRT, but there are variable, computer-controlled intensities within each RT beam, in contrast to the uniform doses within each 3D-CRT beam. Compared to most other treatment techniques, IMRT can achieve a higher degree of accuracy in conforming the radiation to the planned target while sparing normal tissue. The advantages of IMRT are particularly evident when the target volumes have complex shapes or concave regions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32630?source=see_link\">",
"     \"Intensity-modulated radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several retrospective reports support the safety of IMRT in conjunction with concurrent chemotherapy for anal SCC, with promising early efficacy results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/68-71\">",
"     68-71",
"    </a>",
"    ]. A representative review of experience at three different centers included 53 patients (62 T1-2, 8 HIV-positive) who underwent IMRT (median 45 Gy to the pelvis and inguinal nodes with a boost to the primary site and involved nodes to a median dose of 51.5 Gy), and all received concurrent chemotherapy (5-FU plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    in 48,",
"    <span class=\"nowrap\">",
"     5-FU/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"      cisplatin",
"     </a>",
"    </span>",
"    in one, and 5-FU alone in four) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/68\">",
"     68",
"    </a>",
"    ]. During treatment, rates of acute grade 3 or worse dermatologic and gastrointestinal toxicity were 38 and 17 percent, while 34 percent had acute grade 4 neutropenia. A treatment break was necessary in 42 percent of patients, lasting a median of four days.",
"   </p>",
"   <p>",
"    There were 49 complete responses (93 percent), one partial response and three patients had stable disease. At a median follow-up of 14.5 months, the 18-month rates of overall and colostomy-free survival were 93 and 84 percent, and 84 percent were free of local failure.",
"   </p>",
"   <p>",
"    A confirmatory phase II study was conducted by the RTOG. In a preliminary report outcomes with IMRT in conjunction with FU and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    C were compared to those from the",
"    <span class=\"nowrap\">",
"     FU/mitomycin",
"    </span>",
"    control arm of the RTOG 98-11 trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/72\">",
"     72",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Replacement of mitomycin by cisplatin'",
"    </a>",
"    above.) There were lower than expected rates of acute grade 3 or higher dermatologic (20 versus 50 percent in RTOG 98-11) and gastrointestinal (20 versus 35 percent) toxicity with IMRT. There was also less grade 2 or higher hematologic toxicity. After a median follow-up of 27 months, the two-year rates of DFS and overall survival with IMRT were 77 and 86 percent, respectively. &nbsp;",
"   </p>",
"   <p>",
"    However, 81 percent of the patients enrolled in this trial required a change in the radiation treatment plan following pretreatment central review, illustrating the learning curve for practitioners using this treatment method [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/72\">",
"     72",
"    </a>",
"    ]. Given the high cure rates with conventional RT, and the limitations of salvage therapies, careful delineation of target regions is critical; guidelines are available from the RTOG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/73\">",
"     73",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Assessing the response to primary chemoradiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clinical assessment of response by physical examination is typically performed from six to eight weeks following the completion of therapy. Early assessment of response by MRI is unhelpful and not recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is considerable controversy regarding the optimal time to assess response posttreatment. SCCs regress slowly and continue to decrease in size for up to 26 weeks following therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/49,75\">",
"     49,75",
"    </a>",
"    ]. This was shown in an analysis of data from the ACT II trial, in which 940 patients were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    plus either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    during concurrent RT, and then were further randomized to receive or not receive maintenance chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/75\">",
"     75",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Replacement of mitomycin by cisplatin'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The protocol required three response assessments, at 11 and 18 weeks (with digital rectal examination [DRE] with or without examination under anesthesia [EUA]), and at 26 weeks, DRE, EUA, abdomen and pelvis CT, and chest x-ray. Biopsies were not routinely performed. In a preliminary report presented at the 2012 meeting of the American Society of Clinical Oncology, the complete clinical response (cCR) rate increased over time in both chemoradiotherapy groups (65, 75, and 84 percent at 11, 18, and 26 weeks in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    group, and the corresponding rates in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    group were 58, 77, and 85 percent, respectively). At 26 weeks, the percentage of patients in cCR was similar in the groups who did versus did not receive maintenance chemotherapy (85 versus 82 percent). Sixty percent of those not in a cCR at 11 weeks achieved it at 26 weeks. Furthermore, the greatest separation in outcomes between complete responders and those who did not achieve a complete cCR occurred when the assessment took place at 26 weeks (PFS 83 versus 45 percent, HR for progression 0.21, 95% CI 0.15-0.29; overall survival 93 versus 61 percent, HR for death 0.21, 95% CI 0.15-0.31). These data support the view that anal SCCs continue to regress for up to 26 weeks after the completion of chemoradiotherapy and that the decision to pursue APR for persisting disease should be deferred until at least 26 weeks. &nbsp;",
"   </p>",
"   <p>",
"    NCCN guidelines recommend posttreatment reevaluation with digital rectal examination at 8 to 12 weeks after chemoradiotherapy, with the response classified clinically as a complete response, persistent disease, or progressive disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a clinical complete response, reevaluation every three to six months with DRE, anoscopy, and inguinal node palpation is recommended for five years.",
"     </li>",
"     <li>",
"      Patients with persistent disease should be watched for an additional four weeks to see if there is further regression.",
"     </li>",
"     <li>",
"      Patients who appear to have progressive disease require histologic confirmation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We agree with these guidelines. Progression of disease at any time, or a clinical suspicion for persisting disease at 26 weeks after completion of combined modality therapy should prompt a biopsy with APR for those who have biopsy-proven disease",
"    <span class=\"nowrap\">",
"     persistence/recurrence.",
"    </span>",
"    (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Surgical therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     HIV-positive men",
"    </span>",
"    &nbsp;&mdash;&nbsp;A combined modality approach has been used successfully in HIV-positive patients, and most data suggest that response to therapy, local control, and survival are as good as in non-HIV-infected patients, particularly in the era of potent antiretroviral therapy (previously called highly active antiretroviral therapy, HAART) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/76-82\">",
"     76-82",
"    </a>",
"    ]. In some series, acute treatment-related toxicity has been worse than expected, particularly with RT doses &gt;30 Gy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/76,81,83\">",
"     76,81,83",
"    </a>",
"    ], but this has not been a universal finding. Diverting colostomy or APR is required for toxicity management in 6 to 12 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/15,61\">",
"     15,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A low CD4 count does not necessarily predict for greater treatment-related toxicity. The relationship between treatment tolerance and CD4 count has been directly addressed only in small observational studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An early report of 17 patients seen before the era of potent antiretroviral therapy found that no patient with a pretreatment CD4 count &ge;200",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      required hospitalization during treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/83\">",
"       83",
"      </a>",
"      ]. In contrast, four of the eight with counts &lt;200",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      needed hospitalization for myelosuppression, diarrhea, or moist desquamation, and four required a colostomy for a therapy-related complication or",
"      <span class=\"nowrap\">",
"       persisting/recurrent",
"      </span>",
"      disease. Similar findings have been noted by others [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/84\">",
"       84",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Three later series totaling 59 patients treated in the era of potent antiretroviral therapy did not find a significant relationship between the CD4 count and treatment-related toxicity, even if the CD4 counts were &lt;200 to 300",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/77,80,85\">",
"       77,80,85",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, HIV-positive patients should be treated similarly to non-HIV-positive individuals. However, patients with active",
"    <span class=\"nowrap\">",
"     HIV/AIDS-related",
"    </span>",
"    complications or a history of complications (eg, opportunistic infections, other malignancies) may not tolerate full dose therapy, or may not tolerate",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    , and require dosage adjustment or treatment without mitomycin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main prognostic factors are tumor diameter and nodal status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/87\">",
"     87",
"    </a>",
"    ]. In a cohort study of 19,195 patients with squamous cell anal cancer who were reported to the National Cancer Database between 1985 and 2000, five-year overall survival rates, stratified according to AJCC stage (",
"    <a class=\"graphic graphic_table graphicRef72273 \" href=\"mobipreview.htm?15/60/16333\">",
"     table 1",
"    </a>",
"    ) were as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/88\">",
"     88",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage I &mdash; 70 percent",
"     </li>",
"     <li>",
"      Stage II &mdash; 59 percent",
"     </li>",
"     <li>",
"      Stage III &mdash; 41 percent",
"     </li>",
"     <li>",
"      Stage IV &mdash; 19 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Stage for stage, the prognosis of nonsquamous cell cancers is worse than that for squamous cell cancers (",
"    <a class=\"graphic graphic_table graphicRef52279 \" href=\"mobipreview.htm?26/31/27131\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Palpable, clinically positive lymph nodes and male sex are also prognostic factors for locoregional failure and overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/36,87,89\">",
"     36,87,89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8331342\">",
"    <span class=\"h4\">",
"     Colostomy rates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colostomy-free survival is a measure of anal sphincter preservation after treatment with RT or chemoradiotherapy. Multiple investigators using a variety of regimens report five-year colostomy-free survival rates of 70 to 86 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/27-33\">",
"     27-33",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Combined modality therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Failure to control anal cancer and complications of treatment are alternative indications for a colostomy, but in most cases, colostomy is required for recurrent tumor:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of 235 patients diagnosed with anal cancer between 1995 and 2003 and treated with curative-intent RT or chemoradiotherapy at four different Danish centers, the five-year cumulative incidences of tumor-related and treatment related colostomy were 26 and 8 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/90\">",
"       90",
"      </a>",
"      ]. Large tumor size (&gt;6 cm) was associated with a higher risk of tumor-related colostomy, while a history of prior excision was a risk factor for therapy-related colostomy.",
"     </li>",
"     <li>",
"      Similarly, in an analysis of data from RTOG trial 98-11 (discussed above), five-year colostomy rates among patients treated initially with chemoradiotherapy were 9 percent for those with node-positive disease, and 19 percent for tumors &gt;5 cm in diameter, regardless of nodal status [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/91\">",
"       91",
"      </a>",
"      ]. Overall, 78 percent of the colostomies were performed for persistent or recurrent disease. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Replacement of mitomycin by cisplatin'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Quality of life issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic RT can cause late toxicity, potentially impacting on quality of life (QOL). Only limited data are available on long-term QOL in patients undergoing chemoradiotherapy for invasive anal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/92-94\">",
"     92-94",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report included 50 respondents (of 92 suitable for the study, 37 women, HIV status unknown in 48, negative in two) who were identified from the records of the British Columbia Cancer Agency as having received nonsurgical treatment for anal cancer, and asked to participate in a QOL study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/92\">",
"       92",
"      </a>",
"      ]. The patient-reported QOL assessment instruments were the EORTC QLQ-C30 (general QOL) and CR38 (colorectal-specific), and they were completed an average of 62 months from diagnosis. Responses were compared with those of 50 age- and gender-matched control volunteers who had not previously undergone oncologic treatment to the pelvis.",
"      <br/>",
"      <br/>",
"      Significant lower scores were recorded in the treated group for global QOL and both general (physical, social and role function) and",
"      <span class=\"nowrap\">",
"       site/disease-specific",
"      </span>",
"      measures, including gastrointestinal symptoms, chemotherapy side-effect symptoms, and male and female sexual problems.",
"     </li>",
"     <li>",
"      Another study assessed patient-reported outcomes of 32 patients who received chemoradiotherapy for invasive anal cancer (81 percent female, 94 percent HIV-negative) using the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) scale and the Medical Outcomes Study (MPS) Sexual Problems Scale [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/94\">",
"       94",
"      </a>",
"      ]. The median time between treatment and survey participation was five years. Overall QOL was acceptable, but sexual function scores were poor after treatment. However, there was no baseline pretreatment assessment or control group for comparison.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Taken together, the available data support the view that chemotherapy is a necessary component of nonoperative therapy for anal cancer. Globally, combined modality therapy with RT and concurrent chemotherapy is considered the standard of care for squamous cell cancer of the anal canal.",
"   </p>",
"   <p>",
"    RT plus concurrent 5-FU plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    remains the standard regimen for concurrent chemoradiotherapy at most centers and in published guidelines of the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    . Although the original regimen described as the \"Wayne State protocol\" used infusional 5-FU 1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1 to 4 and 29 to 32 (plus mitomycin 10 to 15",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1 only) concurrent with RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/26\">",
"     26",
"    </a>",
"    ],",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    guidelines suggest a modified version as was used in RTOG 98-11 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/39\">",
"     39",
"    </a>",
"    ]. This regimen consists of infusional 5-FU 1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1 to 4 and 29 to 32, plus mitomycin 10",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1 and 29 (if tolerated), maximum 20 mg per dose.",
"   </p>",
"   <p>",
"    The day 29",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    dose is reduced to 7.5",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    if the nadir white blood cell count (WBC) is",
"    <span class=\"nowrap\">",
"     &lt;2400/microL",
"    </span>",
"    but more than",
"    <span class=\"nowrap\">",
"     1000/microL,",
"    </span>",
"    or if the nadir platelet count is more than",
"    <span class=\"nowrap\">",
"     50,000/microL",
"    </span>",
"    but less than",
"    <span class=\"nowrap\">",
"     85,000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/39\">",
"     39",
"    </a>",
"    ]. If the nadir WBC is",
"    <span class=\"nowrap\">",
"     &lt;1000/microL",
"    </span>",
"    or the nadir platelet count is",
"    <span class=\"nowrap\">",
"     &lt;50,000/microL,",
"    </span>",
"    the day 29 dose of mitomycin is reduced to 5",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </span>",
"    If the day 28 WBC",
"    <span class=\"nowrap\">",
"     &lt;2400/microL",
"    </span>",
"    or platelet count",
"    <span class=\"nowrap\">",
"     &lt;85,000/microL,",
"    </span>",
"    we delay the start of the second cycle of therapy by one week.",
"   </p>",
"   <p>",
"    HIV-positive patients are generally treated similarly to those without HIV infection. Although outcomes appear to be comparable, treatment-related toxicity may be worse, particularly if the CD4 count is &lt;200",
"    <span class=\"nowrap\">",
"     cells/mm3.",
"    </span>",
"    Patients with a history of HIV-related complications may require dosage adjustment or treatment without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Treatment of locally advanced disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with large",
"    <span class=\"nowrap\">",
"     (T3/4)",
"    </span>",
"    primary tumors or",
"    <span class=\"nowrap\">",
"     N2/3",
"    </span>",
"    nodal metastases have a cure rate of approximately 50 to 60 percent with standard chemoradiotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/95\">",
"     95",
"    </a>",
"    ]. This poor-risk group was the target population for CALGB trial 9281 in which two cycles of induction 5-FU plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    followed by concurrent split-course RT concurrent with 5-FU plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    were given to 45 patients with",
"    <span class=\"nowrap\">",
"     T3/4",
"    </span>",
"    SCC of the anal canal without extensive nodal involvement or",
"    <span class=\"nowrap\">",
"     N2/3",
"    </span>",
"    disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/96\">",
"     96",
"    </a>",
"    ]. A third cycle of 5-FU and cisplatin with a radiation boost was given to patients with persistent primary site or bulky N2 or N3 disease at presentation.",
"   </p>",
"   <p>",
"    Induction chemotherapy alone resulted in eight complete responses, and the complete response rate at the completion of therapy was 82 percent. At a median follow-up of four years, 61 percent remained disease-free, and 50 percent were both colostomy-free and disease-free.",
"   </p>",
"   <p>",
"    Additional support for this approach comes from a population-based analysis of 308 consecutive patients treated for epidermoid anal canal cancer in Sweden according to defined protocols (RT alone, chemoradiotherapy or neoadjuvant chemotherapy followed by RT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/97\">",
"     97",
"    </a>",
"    ]. Among the 142 patients with",
"    <span class=\"nowrap\">",
"     T3/4",
"    </span>",
"    or node-positive tumors, those treated with neoadjuvant platinum-based chemotherapy had significantly higher complete response rates and five-year overall survival than did those who received RT with or without concurrent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    On the other hand, an argument against this approach is provided by results from the RTOG trial discussed above which directly compared two cycles of induction",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"      cisplatin",
"     </a>",
"     /5-FU",
"    </span>",
"    followed by concurrent chemoradiotherapy with these two drugs versus the standard approach of RT with concurrent 5-FU and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    in patients with anal cancer (26 percent &ge;5 cm, 26 percent clinically node-positive) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/41\">",
"     41",
"    </a>",
"    ]. Although disease-free and overall survival were comparable in both groups, the group receiving induction",
"    <span class=\"nowrap\">",
"     cisplatin/5-FU",
"    </span>",
"    had significantly inferior colostomy-free survival. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Replacement of mitomycin by cisplatin'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    These results could not be confirmed in the four-arm UNICANCER ACCORD 03 trial, which studied the addition of induction chemotherapy with or without dose intensification of RT to standard-dose concurrent chemoradiotherapy for locally advanced anal canal carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/98\">",
"     98",
"    </a>",
"    ]. Five-year colostomy-free survival rates, the primary outcome measure, were not significantly different in the groups that did or did not receive induction chemotherapy (77 versus 75 percent). However, while there was no advantage or disadvantage to induction chemotherapy versus the control arms, all treatment arms used the backbone of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and FU during RT, and the question of equivalence of FU plus cisplatin versus FU plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    remains unanswered. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Replacement of mitomycin by cisplatin'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A different approach has been taken by the EORTC, which is administering concurrent infusional 5-FU and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    with a shortened irradiation scheme to patients with locally advanced anal squamous cell cancer (SCC, T2 lesions &gt;4 cm, T3-4, or N1-3 disease) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/99\">",
"     99",
"    </a>",
"    ]. Eighty-eight percent of 43 patients achieved local control, while 81 percent were colostomy-free, and 84 percent were free of severe late toxicity.",
"   </p>",
"   <p>",
"    We approach patients with",
"    <span class=\"nowrap\">",
"     T3/4",
"    </span>",
"    primary tumors or",
"    <span class=\"nowrap\">",
"     N2/3",
"    </span>",
"    disease similarly to those with less advanced stage disease (ie, using the same regimen of RT plus concomitant 5-FU (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    by continuous infusion on days 1 through 4 and 29 through 32)) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1 and 29).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Surgical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical therapy may be necessary for patients with recurrent or persistent disease after chemoradiotherapy. Although prognosis is poor overall, APR offers the potential for long-term survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/100-102\">",
"     100-102",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Recurrent disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postchemoradiotherapy local recurrences can be successfully salvaged with surgery, but locally recurrent anal SCC can be a difficult clinical problem that is associated with profound morbidity and long-term disease control in only about 25 to 40 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/58,100,102-105\">",
"     58,100,102-105",
"    </a>",
"    ]. In a series of 185 consecutive patients with anal cancer treated with either RT alone or chemoradiotherapy, 42 developed local failure requiring salvage therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/103\">",
"     103",
"    </a>",
"    ]. Twenty-six patients (62 percent) underwent potentially curative surgery, including 23 APRs and three local excisions. The five-year rates of overall survival, secondary local control, and locoregional control were 45, 53, and 43 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Persistent disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;APR is also the treatment of choice for patients who have persisting disease after completion of combined modality therapy; however, the optimal time to assess for persisting disease is controversial. While some have performed this assessment at 6 or 12 weeks posttreatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/34,39,49\">",
"     34,39,49",
"    </a>",
"    ], a preliminary report of data from the ACT-II trial suggests that regression continues for up to 26 weeks. In keeping with the guidelines of the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    , we advocate that the initial posttreatment assessment occur at week 8 to 12 and that patients with persistent disease be watched for an additional four weeks to see if there is further regression. Patients who have a clinical suspicion of persistent disease at 26 weeks should undergo biopsy, and those with histologic confirmation of persisting disease should be offered APR. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Assessing the response to primary chemoradiotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The results of surgical salvage are similar to those for patients with locally recurrent disease. This was shown in a series of 111 patients with anal cancer who were treated with chemoradiotherapy or RT alone, followed by APR for persistent (n = 61) or recurrent (n = 50) disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/102\">",
"     102",
"    </a>",
"    ]. The estimated five-year survival rate disease free was 30 percent. In univariate analysis, outcomes were similar for patients with persistent versus recurrent disease. In multivariate analysis, only three factors significantly influenced prognosis: the status of the surgical margin, perineural",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lymphatic invasion, and whether or not the nodes in the resected specimen were involved with tumor.",
"   </p>",
"   <p>",
"    The relative efficacy of nonsurgical salvage in patients with persistent disease is not known. However, at least some of these patients may be successfully salvaged with further sphincter-sparing therapy. As an example, the",
"    <span class=\"nowrap\">",
"     RTOG/ECOG",
"    </span>",
"    treated 22 patients who had persistent disease following primary chemoradiotherapy with 5-FU,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , and RT (9 Gy boost) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/39\">",
"     39",
"    </a>",
"    ]. Twelve (55 percent) were rendered disease-free after surgical therapy; among these patients, four required subsequent APR and are free of disease, four died (three with recurrent disease), and four remain disease free. Of the 10 patients who had unsuccessful nonoperative salvage therapy, nine underwent APR. After four years, three were alive without disease and seven had died, six with recurrent disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H441718822\">",
"    <span class=\"h2\">",
"     Posttreatment surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no prospective trials to guide the posttreatment surveillance strategy for patients treated for anal cancer. For patients who have a complete remission from initial chemoradiotherapy, guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    suggest the following every three to six months for five years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Digital rectal examination",
"     </li>",
"     <li>",
"      Anoscopy",
"     </li>",
"     <li>",
"      Inguinal node palpation",
"     </li>",
"     <li>",
"      If initially T3-4 disease or inguinal node-positive, or for those with persistent disease at the initial posttreatment biopsy who regress on serial examinations, consider imaging of the",
"      <span class=\"nowrap\">",
"       chest/abdomen",
"      </span>",
"      and pelvis annually for three years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients who undergo APR for biopsy-proven persistent or recurrent disease, they suggest inguinal node palpation every three to six months for five years, and annual radiographic imaging of the",
"    <span class=\"nowrap\">",
"     chest/abdomen/pelvis",
"    </span>",
"    for three years.",
"   </p>",
"   <p>",
"    We agree with this approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Treatment of metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The liver is the most frequent site of distant metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/19,32,106\">",
"     19,32,106",
"    </a>",
"    ]. However, the development of distant metastases is infrequent overall in patients with SCC of the anal canal. In the UKCCCR and EORTC trials described above, for example, distant metastases developed following combined modality therapy in 10 and 17 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/34,36\">",
"     34,36",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Versus RT alone'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Systemic chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only widely published active regimen for treatment for metastatic disease is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    plus 5-FU [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/107-111\">",
"     107-111",
"    </a>",
"    ]. The role of other combination regimens such as",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"      mitomycin",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"      doxorubicin",
"     </a>",
"     /cisplatin",
"    </span>",
"    is uncertain, particularly for second-line therapy in patients who have received prior FU plus mitomycin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/112\">",
"     112",
"    </a>",
"    ].",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    guidelines recommend cisplatin plus 5-FU as a first-line regimen.",
"   </p>",
"   <p>",
"    Single case reports and small series describe activity for single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/113\">",
"     113",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/114\">",
"     114",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/115\">",
"     115",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    with or without irinotecan (in patients whose tumors do not have mutated K-ras) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/116-118\">",
"     116-118",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no published experience with newer agents such as the taxanes or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Role of regional therapy for liver metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given that the liver is the most common site of metastatic disease, regional therapy may be considered in the setting of limited, isolated hepatic metastases. There is far less experience with resection or nonsurgical local ablative procedures than there is with isolated liver colorectal or neuroendocrine cancer liver metastases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41850?source=see_link\">",
"     \"Management of potentially resectable colorectal cancer liver metastases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/32/6665?source=see_link\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of regional therapy was addressed in a multicenter analysis of 52 patients who underwent hepatic resection (n = 47), radiofrequency ablation (n = 3), or both (n = 2) for metastatic SCC at eight major cancer centers; 27 for metastatic anal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/119\">",
"     119",
"    </a>",
"    ]. The majority had received some form of systemic therapy prior to resection. At a median follow-up of 18 months, 33 patients had recurred, 21 in the liver. The actuarial disease-free survival rates at three and five years were each 19 percent. When the analysis was restricted to the 27 patients with metastatic anal cancer, the median disease-free and overall survival durations were 9.6 and 22.3 months. In multivariate analysis, hepatic metastasis size &gt;5 cm and positive surgical resections margins were both associated with a twofold higher risk of recurrence.",
"   </p>",
"   <p>",
"    These data suggest that there may be a subset of patients with isolated hepatic metastases who stand to benefit from resection, but selection criteria are undefined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Paraaortic nodal involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated paraaortic lymph node involvement is rare and considered M1 (stage IV) disease (",
"    <a class=\"graphic graphic_table graphicRef72273 \" href=\"mobipreview.htm?15/60/16333\">",
"     table 1",
"    </a>",
"    ). The optimal management of these patients is undefined.",
"   </p>",
"   <p>",
"    Limited data suggest that some of these patients can potentially be treated with a definitive approach using combined chemoradiotherapy. One report detailed outcomes in six patients with anal SCC and histologically documented paraaortic nodal metastases who were treated with intensity-modulated RT (IMRT) and concurrent infusional 5-FU plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/120\">",
"     120",
"    </a>",
"    ]. The primary tumor and involved nodes were treated to a median dose of 57.5 Gy, while uninvolved nodal regions were treated with a median dose of 45 Gy.",
"   </p>",
"   <p>",
"    Four of the six patients developed grade 3 acute gastrointestinal toxicity during RT. At a median follow-up of 25 months, no patient had a locoregional failure in the pelvic or paraaortic region, and four remained alive; two developed distant metastases.",
"   </p>",
"   <p>",
"    While these data provide some support for definitive chemoradiotherapy in the setting of isolated paraaortic nodal metastases, these patients remain at high risk for the development of additional metastatic disease. Whether additional courses of adjuvant chemotherapy might be beneficial is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     TREATMENT OF LOCALIZED ADENOCARCINOMA OF THE ANAL CANAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary adenocarcinoma of the anal canal is rare, and many of these tumors represent rectal cancer with downward spread. Determination of the anatomic site of origin of carcinomas that overlap the anorectal junction can be problematic. For staging purposes, such tumors are classified as rectal cancers if their epicenter is located more than 2 cm proximal to the dentate line or proximal to the anorectal ring on digital examination, and as anal canal cancers if their epicenter is 2 cm or less from the dentate line [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of adenocarcinomas arising in the anal canal should follow the same principles as those applied to the treatment of rectal cancer. The primary treatment is surgical resection (typically an APR), and the roles of chemotherapy and RT in the preoperative or postoperative period should be as adjuvant therapy to improve local and systemic control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/17,121-124\">",
"     17,121-124",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6041?source=see_link\">",
"     \"Pretreatment local staging evaluation for rectal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/51/4922?source=see_link\">",
"     \"Adjuvant therapy for resected rectal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/22/42346?source=see_link\">",
"     \"Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The primary importance of resection in the management of adenocarcinomas arising in the anal canal was illustrated in a series from M D Anderson Cancer Center in which 16 patients with adenocarcinoma of the anal canal were treated with primary RT or chemoradiation without surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/125\">",
"     125",
"    </a>",
"    ]. There was an unacceptable rate of both local and systemic recurrence at five years (54 and 66 percent, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery, typically an APR, should be considered the primary therapy for adenocarcinoma involving the anal canal, given the poor data for chemoradiotherapy alone. Chemotherapy and RT are appropriate adjuncts to surgical resection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H594204919\">",
"    <span class=\"h1\">",
"     TREATMENT OF PERIANAL SKIN CANCERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCC of the perianal skin (anal margin) is relatively rare, occurring 3 to 5 times less frequently than anal canal SCC. As noted above, SCCs of the perianal skin are classified and staged as skin cancers. They differ in natural history from cancers of the anal canal, and usually have a more favorable outcome. The main prognostic factors are histologic differentiation, T stage, and lymph node involvement at diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a lack of prospective data regarding optimal treatment of perianal skin cancers. For a localized lesion, surgery is often performed as long as sphincteric muscles are not compromised. The role of sentinel lymph node biopsy in this setting is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/126,127\">",
"     126,127",
"    </a>",
"    ]. After excision of a perianal skin cancer with high- risk histologic features (eg, poorly differentiated histology, perineural invasion), postoperative radiation therapy is often pursued, but there are no trials proving benefit.",
"   </p>",
"   <p>",
"    If sphincter function could be compromised by surgery, or if there is evidence of nodal involvement, chemoradiation is an effective treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/7,128,129\">",
"     7,128,129",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    recommend local excision alone for well-differentiated T1 (",
"    <a class=\"graphic graphic_table graphicRef78140 \" href=\"mobipreview.htm?5/0/5134\">",
"     table 2",
"    </a>",
"    ) lesions, and definitive chemoradiotherapy for patients with T2 or higher primaries, or node-positive disease, however, this recommendation is consensus-based and not evidence-based.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/32/22018?source=see_link\">",
"       \"Patient information: Anal cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two distinct categories of tumors arise in the anal region:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tumors that develop from any of the three types of lining mucosa (glandular, transitional, and squamous) are termed anal canal cancers, and staged and treated similarly. The vast majority are squamous cell cancers. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tumors arising within the hair-bearing skin at or distal to the squamous mucocutaneous junction (",
"      <a class=\"graphic graphic_figure graphicRef62539 \" href=\"mobipreview.htm?14/30/14819\">",
"       figure 1",
"      </a>",
"      ) have been referred to as anal margin cancers. However, the preferred term is perianal skin cancers. With the exception of melanomas, tumors arising on the perianal skin are classified as skin rather than anal canal cancers. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anal canal versus perianal skin cancers'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Squamous cell anal canal cancer",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pretreatment clinical staging consists of physical examination and biopsy of the primary tumor, palpation of the groin, CT of the chest, CT or MRI of the abdomen and pelvis, and an integrated",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      scan. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Staging evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Combined chemoradiotherapy has emerged as the preferred method of treatment because it can cure many patients while preserving the anal sphincter. We suggest initial concurrent chemoradiotherapy rather than surgery for most patients with anal canal squamous cell cancers, even those with T1-2, N0, M0 tumors (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Combined modality therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest the concurrent use of 5-FU plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"       mitomycin",
"      </a>",
"      during RT rather than 5-FU alone or 5-FU plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/86\">",
"       86",
"      </a>",
"      ]. Although the original regimen described as the \"Wayne State or Nigro regimen\" used infusional 5-FU 1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1 to 4 and 29 to 32, (plus mitomycin 10 to 15",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 1 only) concurrent with RT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/26\">",
"       26",
"      </a>",
"      ], NCCN guidelines suggest a modified Wayne State regimen as was used in RTOG 98-11 trial described above [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/54/38762/abstract/39\">",
"       39",
"      </a>",
"      ]. The chemotherapy consists of infusional 5-FU 1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1 to 4 and 29 to 32, plus mitomycin 10",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1 and 29 (as tolerated), maximum 20 mg per dose. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Role of mitomycin'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Replacement of mitomycin by cisplatin'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The day 29 mitomycin dose is reduced to 7.5",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      if the nadir white blood cell count (WBC) is",
"      <span class=\"nowrap\">",
"       &lt;2400/microL",
"      </span>",
"      but more than",
"      <span class=\"nowrap\">",
"       1000/microL,",
"      </span>",
"      or if the nadir platelet count is more than",
"      <span class=\"nowrap\">",
"       50,000/microL",
"      </span>",
"      but less than",
"      <span class=\"nowrap\">",
"       85,000/microL.",
"      </span>",
"      If the nadir WBC is",
"      <span class=\"nowrap\">",
"       &lt;1000/microL",
"      </span>",
"      or the nadir platelet count is",
"      <span class=\"nowrap\">",
"       &lt;50,000/microL,",
"      </span>",
"      the day 29 dose of mitomycin is reduced to 5",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       .",
"      </span>",
"      If the day 28 WBC",
"      <span class=\"nowrap\">",
"       &lt;2400/microL",
"      </span>",
"      or platelet count",
"      <span class=\"nowrap\">",
"       &lt;85,000/microL,",
"      </span>",
"      we delay the start of the second cycle of therapy by one week.",
"     </li>",
"     <li>",
"      HIV-positive individuals are approached similarly to other patients. Although cancer outcomes do not seem to differ compared to non HIV-infected patients, treatment-related toxicity may be worse. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'HIV-positive men'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment response should be assessed clinically 8 to 12 weeks after completion of chemoradiotherapy. We suggest not performing a posttreatment biopsy as long as the physical examination does not suggest progressive disease, an approach that is also recommended by the",
"      <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"       National Comprehensive Cancer Network (NCCN)",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Assessing the response to primary chemoradiotherapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For patients with a clinical complete response, we suggest reexamination every three to six months. If there is suspicion of persisting disease, we suggest a reevaluation every four weeks. For patients with evidence of progressive disease at any point, or persisting disease at 26 weeks after completion of combined modality therapy and no evidence of metastatic disease, surgical treatment is recommended. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Surgical therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Systemic chemotherapy is appropriate for the rare patient who develops metastatic disease. Although few data are available to guide the choice of regimen, we initiate therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      plus 5-FU. The role of regional therapy for patients with limited, isolated hepatic metastases remains incompletely defined and must be addressed on a case by case basis. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Treatment of metastatic disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Adenocarcinoma of the anal canal",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with adenocarcinoma of the anal canal, we suggest surgery (typically an APR) rather than initial chemoradiotherapy (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). The postoperative approach should parallel treatment of rectal adenocarcinoma. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Treatment of localized adenocarcinoma of the anal canal'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/51/4922?source=see_link\">",
"     \"Adjuvant therapy for resected rectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H594205186\">",
"    <span class=\"h2\">",
"     Treatment of perianal skin cancers",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with T1, N0 well differentiated cancers of the perianal skin, excision alone is adequate if negative margins can be achieved without compromise of the sphincter muscles. For patients with high-risk histologic features, postoperative radiation therapy is an option. If sphincter function could be compromised by surgery, or if there is evidence of nodal involvement, chemoradiation may be considered, with surgery reserved for persistent or recurrent disease. &nbsp;",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/1\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/2\">",
"      Johnson LG, Madeleine MM, Newcomer LM, et al. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. Cancer 2004; 101:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/3\">",
"      Palefsky JM. Anal human papillomavirus infection and anal cancer in HIV-positive individuals: an emerging problem. AIDS 1994; 8:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/4\">",
"      Myerson RJ, Karnell LH, Menck HR. The National Cancer Data Base report on carcinoma of the anus. Cancer 1997; 80:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/5\">",
"      Klotz RG Jr, Pamukcoglu T, Souilliard DH. Transitional cloacogenic carcinoma of the anal canal. Clinicopathologic study of three hundred seventy-three cases. Cancer 1967; 20:1727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/6\">",
"      Chapet O, Gerard JP, Mornex F, et al. Prognostic factors of squamous cell carcinoma of the anal margin treated by radiotherapy: the Lyon experience. Int J Colorectal Dis 2007; 22:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/7\">",
"      Khanfir K, Ozsahin M, Bieri S, et al. Patterns of failure and outcome in patients with carcinoma of the anal margin. Ann Surg Oncol 2008; 15:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/8\">",
"      Singh R, Nime F, Mittelman A. Malignant epithelial tumors of the anal canal. Cancer 1981; 48:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/9\">",
"      Schneider TC, Schulte WJ. Management of carcinoma of anal canal. Surgery 1981; 90:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/10\">",
"      Schraut WH, Wang CH, Dawson PJ, Block GE. Depth of invasion, location, and size of cancer of the anus dictate operative treatment. Cancer 1983; 51:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/11\">",
"      Daling JR, Weiss NS, Hislop TG, et al. Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N Engl J Med 1987; 317:973.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.165.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/13\">",
"      Frost DB, Richards PC, Montague ED, et al. Epidermoid cancer of the anorectum. Cancer 1984; 53:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/14\">",
"      Pintor MP, Northover JM, Nicholls RJ. Squamous cell carcinoma of the anus at one hospital from 1948 to 1984. Br J Surg 1989; 76:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/15\">",
"      Touboul E, Schlienger M, Buffat L, et al. Epidermoid carcinoma of the anal canal. Results of curative-intent radiation therapy in a series of 270 patients. Cancer 1994; 73:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/16\">",
"      Boman BM, Moertel CG, O'Connell MJ, et al. Carcinoma of the anal canal. A clinical and pathologic study of 188 cases. Cancer 1984; 54:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/17\">",
"      Klas JV, Rothenberger DA, Wong WD, Madoff RD. Malignant tumors of the anal canal: the spectrum of disease, treatment, and outcomes. Cancer 1999; 85:1686.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th ed, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.301.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/19\">",
"      Greenall MJ, Quan SH, Stearns MW, et al. Epidermoid cancer of the anal margin. Pathologic features, treatment, and clinical results. Am J Surg 1985; 149:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/20\">",
"      Wade DS, Herrera L, Castillo NB, Petrelli NJ. Metastases to the lymph nodes in epidermoid carcinoma of the anal canal studied by a clearing technique. Surg Gynecol Obstet 1989; 169:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/21\">",
"      Cotter SE, Grigsby PW, Siegel BA, et al. FDG-PET/CT in the evaluation of anal carcinoma. Int J Radiat Oncol Biol Phys 2006; 65:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/22\">",
"      Winton Ed, Heriot AG, Ng M, et al. The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer. Br J Cancer 2009; 100:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/23\">",
"      Sveistrup J, Loft A, Berthelsen AK, et al. Positron emission tomography/computed tomography in the staging and treatment of anal cancer. Int J Radiat Oncol Biol Phys 2012; 83:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/24\">",
"      Mistrangelo M, Pelosi E, Bell&ograve; M, et al. Role of positron emission tomography-computed tomography in the management of anal cancer. Int J Radiat Oncol Biol Phys 2012; 84:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/25\">",
"      Dougherty BG, Evans HL. Carcinoma of the anal canal: a study of 79 cases. Am J Clin Pathol 1985; 83:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/26\">",
"      Nigro ND, Vaitkevicius VK, Considine B Jr. Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum 1974; 17:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/27\">",
"      Leichman L, Nigro N, Vaitkevicius VK, et al. Cancer of the anal canal. Model for preoperative adjuvant combined modality therapy. Am J Med 1985; 78:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/28\">",
"      Doci R, Zucali R, La Monica G, et al. Primary chemoradiation therapy with fluorouracil and cisplatin for cancer of the anus: results in 35 consecutive patients. J Clin Oncol 1996; 14:3121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/29\">",
"      Peiffert D, Seitz JF, Rougier P, et al. Preliminary results of a phase II study of high-dose radiation therapy and neoadjuvant plus concomitant 5-fluorouracil with CDDP chemotherapy for patients with anal canal cancer: a French cooperative study. Ann Oncol 1997; 8:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/30\">",
"      Gerard JP, Ayzac L, Hun D, et al. Treatment of anal canal carcinoma with high dose radiation therapy and concomitant fluorouracil-cisplatinum. Long-term results in 95 patients. Radiother Oncol 1998; 46:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/31\">",
"      Sischy B, Doggett RL, Krall JM, et al. Definitive irradiation and chemotherapy for radiosensitization in management of anal carcinoma: interim report on Radiation Therapy Oncology Group study no. 8314. J Natl Cancer Inst 1989; 81:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/32\">",
"      Allal A, Kurtz JM, Pipard G, et al. Chemoradiotherapy versus radiotherapy alone for anal cancer: a retrospective comparison. Int J Radiat Oncol Biol Phys 1993; 27:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/33\">",
"      Martenson JA, Lipsitz SR, Lefkopoulou M, et al. Results of combined modality therapy for patients with anal cancer (E7283). An Eastern Cooperative Oncology Group study. Cancer 1995; 76:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/34\">",
"      Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 1996; 348:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/35\">",
"      Northover J, Glynne-Jones R, Sebag-Montefiore D, et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer 2010; 102:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/36\">",
"      Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997; 15:2040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/37\">",
"      Kantarjian HM, Keating MJ, Walters RS, et al. Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol 1986; 4:1748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/38\">",
"      Pedersen-Bjergaard J, Philip P, Larsen SO, et al. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series. Leukemia 1993; 7:1975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/39\">",
"      Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 1996; 14:2527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/40\">",
"      Hung A, Crane C, Delclos M, et al. Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index. Cancer 2003; 97:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/41\">",
"      Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 2008; 299:1914.",
"     </a>",
"    </li>",
"    <li>",
"     James R, Wan S, Glynne-Jones R, et al. A randomized trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus (ACT II) (abstract # LBA4009). J Clin Oncol 2009; 27:797s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/43\">",
"      Gunderson LL, Winter KA, Ajani JA, et al. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol 2012; 30:4344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/44\">",
"      Glynne-Jones R, Meadows H, Wan S, et al. EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer. Int J Radiat Oncol Biol Phys 2008; 72:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/45\">",
"      Deniaud-Alexandre E, Touboul E, Tiret E, et al. Results of definitive irradiation in a series of 305 epidermoid carcinomas of the anal canal. Int J Radiat Oncol Biol Phys 2003; 56:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/46\">",
"      Newman G, Calverley DC, Acker BD, et al. The management of carcinoma of the anal canal by external beam radiotherapy, experience in Vancouver 1971-1988. Radiother Oncol 1992; 25:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/47\">",
"      Martenson JA Jr, Gunderson LL. External radiation therapy without chemotherapy in the management of anal cancer. Cancer 1993; 71:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/48\">",
"      Zilli T, Schick U, Ozsahin M, et al. Node-negative T1-T2 anal cancer: radiotherapy alone or concomitant chemoradiotherapy? Radiother Oncol 2012; 102:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/49\">",
"      Cummings BJ, Keane TJ, O'Sullivan B, et al. Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C. Int J Radiat Oncol Biol Phys 1991; 21:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/50\">",
"      Myerson RJ, Kong F, Birnbaum EH, et al. Radiation therapy for epidermoid carcinoma of the anal canal, clinical and treatment factors associated with outcome. Radiother Oncol 2001; 61:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/51\">",
"      Ortholan C, Resbeut M, Hannoun-Levi JM, et al. Anal canal cancer: management of inguinal nodes and benefit of prophylactic inguinal irradiation (CORS-03 Study). Int J Radiat Oncol Biol Phys 2012; 82:1988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/52\">",
"      Matthews JH, Burmeister BH, Borg M, et al. T1-2 anal carcinoma requires elective inguinal radiation treatment--the results of Trans Tasman Radiation Oncology Group study TROG 99.02. Radiother Oncol 2011; 98:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/53\">",
"      Allal AS, Obradovic M, Laurencet F, et al. Treatment of anal carcinoma in the elderly: feasibility and outcome of radical radiotherapy with or without concomitant chemotherapy. Cancer 1999; 85:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/54\">",
"      Hu K, Minsky BD, Cohen AM, et al. 30 Gy may be an adequate dose in patients with anal cancer treated with excisional biopsy followed by combined-modality therapy. J Surg Oncol 1999; 70:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/55\">",
"      Hatfield P, Cooper R, Sebag-Montefiore D. Involved-field, low-dose chemoradiotherapy for early-stage anal carcinoma. Int J Radiat Oncol Biol Phys 2008; 70:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/56\">",
"      Hughes LL, Rich TA, Delclos L, et al. Radiotherapy for anal cancer: experience from 1979-1987. Int J Radiat Oncol Biol Phys 1989; 17:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/57\">",
"      Constantinou EC, Daly W, Fung CY, et al. Time-dose considerations in the treatment of anal cancer. Int J Radiat Oncol Biol Phys 1997; 39:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/58\">",
"      Renehan AG, Saunders MP, Schofield PF, O'Dwyer ST. Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer. Br J Surg 2005; 92:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/59\">",
"      John M, Pajak T, Flam M, et al. Dose escalation in chemoradiation for anal cancer: preliminary results of RTOG 92-08. Cancer J Sci Am 1996; 2:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/60\">",
"      Martenson JA, Lipsitz SR, Wagner H Jr, et al. Initial results of a phase II trial of high dose radiation therapy, 5-fluorouracil, and cisplatin for patients with anal cancer (E4292): an Eastern Cooperative Oncology Group study. Int J Radiat Oncol Biol Phys 1996; 35:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/61\">",
"      Allal AS, Mermillod B, Roth AD, et al. Impact of clinical and therapeutic factors on major late complications after radiotherapy with or without concomitant chemotherapy for anal carcinoma. Int J Radiat Oncol Biol Phys 1997; 39:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/62\">",
"      Wagner JP, Mahe MA, Romestaing P, et al. Radiation therapy in the conservative treatment of carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 1994; 29:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/63\">",
"      Papillon J, Montbarbon JF. Epidermoid carcinoma of the anal canal. A series of 276 cases. Dis Colon Rectum 1987; 30:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/64\">",
"      Sandhu AP, Symonds RP, Robertson AG, et al. Interstitial iridium-192 implantation combined with external radiotherapy in anal cancer: ten years experience. Int J Radiat Oncol Biol Phys 1998; 40:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/65\">",
"      Roed H, Engelholm SA, Svendsen LB, et al. Pulsed dose rate (PDR) brachytherapy of anal carcinoma. Radiother Oncol 1996; 41:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/66\">",
"      L&ouml;hnert M, Doniec JM, Kov&aacute;cs G, et al. New method of radiotherapy for anal cancer with three-dimensional tumor reconstruction based on endoanal ultrasound and ultrasound-guided afterloading therapy. Dis Colon Rectum 1998; 41:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/67\">",
"      Vuong T, Kopek N, Ducruet T, et al. Conformal therapy improves the therapeutic index of patients with anal canal cancer treated with combined chemotherapy and external beam radiotherapy. Int J Radiat Oncol Biol Phys 2007; 67:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/68\">",
"      Salama JK, Mell LK, Schomas DA, et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol 2007; 25:4581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/69\">",
"      Pepek JM, Willett CG, Wu QJ, et al. Intensity-modulated radiation therapy for anal malignancies: a preliminary toxicity and disease outcomes analysis. Int J Radiat Oncol Biol Phys 2010; 78:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/70\">",
"      Bazan JG, Hara W, Hsu A, et al. Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. Cancer 2011; 117:3342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/71\">",
"      Kachnic LA, Tsai HK, Coen JJ, et al. Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy. Int J Radiat Oncol Biol Phys 2012; 82:153.",
"     </a>",
"    </li>",
"    <li>",
"     Kachnic, LA, Winter, KA, Myuerson, RJ, et al. Two-year outcomes of RTOG 0529: A phase II evaluation of dose-painted IMRT in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal (abstract 368). Data presented at the 2011 ASCO GI Cancers Symposium, January 22, 2011, San Francisco, CA. Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=103&amp;abstractID=71101 (Accessed on March 25, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/73\">",
"      Myerson RJ, Garofalo MC, El Naqa I, et al. Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys 2009; 74:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/74\">",
"      Goh V, Gollub FK, Liaw J, et al. Magnetic resonance imaging assessment of squamous cell carcinoma of the anal canal before and after chemoradiation: can MRI predict for eventual clinical outcome? Int J Radiat Oncol Biol Phys 2010; 78:715.",
"     </a>",
"    </li>",
"    <li>",
"     Glynne-Jones R, James R, Meadows H, et al. Optimum time to assess complete clinical response (CR) following chemoradiation (CRT) using mitomycin C (MMC) or cisplatin (CisP) with or without maintenance CisP/FU in squamous cell carcinoma of the anus. J Clin Oncol 30, 2012 (suppl; abstr 4004). Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=114&amp;abstractID=98280 (Accessed on June 14, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/76\">",
"      Oehler-J&auml;nne C, Huguet F, Provencher S, et al. HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy. J Clin Oncol 2008; 26:2550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/77\">",
"      Edelman S, Johnstone PA. Combined modality therapy for HIV-infected patients with squamous cell carcinoma of the anus: outcomes and toxicities. Int J Radiat Oncol Biol Phys 2006; 66:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/78\">",
"      Cleator S, Fife K, Nelson M, et al. Treatment of HIV-associated invasive anal cancer with combined chemoradiation. Eur J Cancer 2000; 36:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/79\">",
"      Chiao EY, Giordano TP, Richardson P, El-Serag HB. Human immunodeficiency virus-associated squamous cell cancer of the anus: epidemiology and outcomes in the highly active antiretroviral therapy era. J Clin Oncol 2008; 26:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/80\">",
"      Seo Y, Kinsella MT, Reynolds HL, et al. Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients. Int J Radiat Oncol Biol Phys 2009; 75:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/81\">",
"      Peddada AV, Smith DE, Rao AR, et al. Chemotherapy and low-dose radiotherapy in the treatment of HIV-infected patients with carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 1997; 37:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/82\">",
"      Fraunholz I, Rabeneck D, Gerstein J, et al. Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for anal carcinoma: are there differences between HIV-positive and HIV-negative patients in the era of highly active antiretroviral therapy? Radiother Oncol 2011; 98:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/83\">",
"      Hoffman R, Welton ML, Klencke B, et al. The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer. Int J Radiat Oncol Biol Phys 1999; 44:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/84\">",
"      Place RJ, Gregorcyk SG, Huber PJ, Simmang CL. Outcome analysis of HIV-positive patients with anal squamous cell carcinoma. Dis Colon Rectum 2001; 44:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/85\">",
"      Stadler RF, Gregorcyk SG, Euhus DM, et al. Outcome of HIV-infected patients with invasive squamous-cell carcinoma of the anal canal in the era of highly active antiretroviral therapy. Dis Colon Rectum 2004; 47:1305.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/87\">",
"      Ajani JA, Winter KA, Gunderson LL, et al. Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). Cancer 2010; 116:4007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/88\">",
"      Bilimoria KY, Bentrem DJ, Rock CE, et al. Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base. Dis Colon Rectum 2009; 52:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/89\">",
"      Glynne-Jones R, Sebag-Montefiore D, Adams R, et al. Prognostic factors for recurrence and survival in anal cancer: generating hypotheses from the mature outcomes of the first United Kingdom Coordinating Committee on Cancer Research Anal Cancer Trial (ACT I). Cancer 2013; 119:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/90\">",
"      Sunesen KG, N&oslash;rgaard M, Lundby L, et al. Cause-specific colostomy rates after radiotherapy for anal cancer: a Danish multicentre cohort study. J Clin Oncol 2011; 29:3535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/91\">",
"      Ajani JA, Winter KA, Gunderson LL, et al. US intergroup anal carcinoma trial: tumor diameter predicts for colostomy. J Clin Oncol 2009; 27:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/92\">",
"      Jephcott CR, Paltiel C, Hay J. Quality of life after non-surgical treatment of anal carcinoma: a case control study of long-term survivors. Clin Oncol (R Coll Radiol) 2004; 16:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/93\">",
"      Allal AS, Sprangers MA, Laurencet F, et al. Assessment of long-term quality of life in patients with anal carcinomas treated by radiotherapy with or without chemotherapy. Br J Cancer 1999; 80:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/94\">",
"      Das P, Cantor SB, Parker CL, et al. Long-term quality of life after radiotherapy for the treatment of anal cancer. Cancer 2010; 116:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/95\">",
"      Das P, Bhatia S, Eng C, et al. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys 2007; 68:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/96\">",
"      Meropol NJ, Niedzwiecki D, Shank B, et al. Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281). J Clin Oncol 2008; 26:3229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/97\">",
"      Nilsson PJ, Svensson C, Goldman S, et al. Epidermoid anal cancer: a review of a population-based series of 308 consecutive patients treated according to prospective protocols. Int J Radiat Oncol Biol Phys 2005; 61:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/98\">",
"      Peiffert D, Tournier-Rangeard L, G&eacute;rard JP, et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol 2012; 30:1941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/99\">",
"      Bosset JF, Roelofsen F, Morgan DA, et al. Shortened irradiation scheme, continuous infusion of 5-fluorouracil and fractionation of mitomycin C in locally advanced anal carcinomas. Results of a phase II study of the European Organization for Research and Treatment of Cancer. Radiotherapy and Gastrointestinal Cooperative Groups. Eur J Cancer 2003; 39:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/100\">",
"      Eeson G, Foo M, Harrow S, et al. Outcomes of salvage surgery for epidermoid carcinoma of the anus following failed combined modality treatment. Am J Surg 2011; 201:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/101\">",
"      Lef&egrave;vre JH, Corte H, Tiret E, et al. Abdominoperineal resection for squamous cell anal carcinoma: survival and risk factors for recurrence. Ann Surg Oncol 2012; 19:4186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/102\">",
"      Correa JH, Castro LS, Kesley R, et al. Salvage abdominoperineal resection for anal cancer following chemoradiation: A proposed scoring system for predicting postoperative survival. J Surg Oncol 2013; 107:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/103\">",
"      Allal AS, Laurencet FM, Reymond MA, et al. Effectiveness of surgical salvage therapy for patients with locally uncontrolled anal carcinoma after sphincter-conserving treatment. Cancer 1999; 86:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/104\">",
"      Schiller DE, Cummings BJ, Rai S, et al. Outcomes of salvage surgery for squamous cell carcinoma of the anal canal. Ann Surg Oncol 2007; 14:2780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/105\">",
"      Mariani P, Ghanneme A, De la Rochefordi&egrave;re A, et al. Abdominoperineal resection for anal cancer. Dis Colon Rectum 2008; 51:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/106\">",
"      Tanum G, Tveit K, Karlsen KO, Hauer-Jensen M. Chemotherapy and radiation therapy for anal carcinoma. Survival and late morbidity. Cancer 1991; 67:2462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/107\">",
"      Faivre C, Rougier P, Ducreux M, et al. [5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer]. Bull Cancer 1999; 86:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/108\">",
"      Jaiyesimi IA, Pazdur R. Cisplatin and 5-fluorouracil as salvage therapy for recurrent metastatic squamous cell carcinoma of the anal canal. Am J Clin Oncol 1993; 16:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/109\">",
"      Tanum G. Treatment of relapsing anal carcinoma. Acta Oncol 1993; 32:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/110\">",
"      Khater R, Frenay M, Bourry J, et al. Cisplatin plus 5-fluorouracil in the treatment of metastatic anal squamous cell carcinoma: a report of two cases. Cancer Treat Rep 1986; 70:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/111\">",
"      Ajani JA, Carrasco CH, Jackson DE, Wallace S. Combination of cisplatin plus fluoropyrimidine chemotherapy effective against liver metastases from carcinoma of the anal canal. Am J Med 1989; 87:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/112\">",
"      Jhawer M, Mani S, Lefkopoulou M, et al. Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and Bleomycin-CCNU in patients with advanced cancer of the anal canal: An eastern cooperative oncology group study E7282. Invest New Drugs 2006; 24:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/113\">",
"      Evans TR, Mansi JL, Glees JP. Response of metastatic anal carcinoma to single agent carboplatin. Clin Oncol (R Coll Radiol) 1993; 5:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/114\">",
"      Fisher WB, Herbst KD, Sims JE, Critchfield CF. Metastatic cloacogenic carcinoma of the anus: sequential responses to adriamycin and cis-dichlorodiammineplatinum(II). Cancer Treat Rep 1978; 62:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/115\">",
"      Grifaichi F, Padovani A, Romeo F, et al. Response of metastatic epidermoid anal cancer to single agent irinotecan: a case report. Tumori 2001; 87:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/116\">",
"      Phan LK, Hoff PM. Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: report of a case. Dis Colon Rectum 2007; 50:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/117\">",
"      Lukan N, Str&ouml;bel P, Willer A, et al. Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status. Oncology 2009; 77:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/118\">",
"      Saif MW, Kontny E, Syrigos KN, Shahrokni A. The Role of EGFR Inhibitors in the Treatment of Metastatic Anal Canal Carcinoma: A Case Series. J Oncol 2011; 2011:125467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/119\">",
"      Pawlik TM, Gleisner AL, Bauer TW, et al. Liver-directed surgery for metastatic squamous cell carcinoma to the liver: results of a multi-center analysis. Ann Surg Oncol 2007; 14:2807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/120\">",
"      Hodges JC, Das P, Eng C, et al. Intensity-modulated radiation therapy for the treatment of squamous cell anal cancer with para-aortic nodal involvement. Int J Radiat Oncol Biol Phys 2009; 75:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/121\">",
"      Basik M, Rodriguez-Bigas MA, Penetrante R, Petrelli NJ. Prognosis and recurrence patterns of anal adenocarcinoma. Am J Surg 1995; 169:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/122\">",
"      Belkac&eacute;mi Y, Berger C, Poortmans P, et al. Management of primary anal canal adenocarcinoma: a large retrospective study from the Rare Cancer Network. Int J Radiat Oncol Biol Phys 2003; 56:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/123\">",
"      Beal KP, Wong D, Guillem JG, et al. Primary adenocarcinoma of the anus treated with combined modality therapy. Dis Colon Rectum 2003; 46:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/124\">",
"      Kounalakis N, Artinyan A, Smith D, et al. Abdominal perineal resection improves survival for nonmetastatic adenocarcinoma of the anal canal. Ann Surg Oncol 2009; 16:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/125\">",
"      Papagikos M, Crane CH, Skibber J, et al. Chemoradiation for adenocarcinoma of the anus. Int J Radiat Oncol Biol Phys 2003; 55:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/126\">",
"      de Jong JS, Beukema JC, van Dam GM, et al. Limited Value of Staging Squamous Cell Carcinoma of the Anal Margin and Canal Using the Sentinel Lymph Node Procedure: A Prospective Study with Long-Term Follow-Up. Ann Surg Oncol 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/127\">",
"      Mistrangelo DM, Bell&ograve; M, Cassoni P, et al. Value of staging squamous cell carcinoma of the anal margin and canal using the sentinel lymph node procedure: an update of the series and a review of the literature. Br J Cancer 2013; 108:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/128\">",
"      Balamucki CJ, Zlotecki RA, Rout WR, et al. Squamous cell carcinoma of the anal margin: the university of Florida experience. Am J Clin Oncol 2011; 34:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/54/38762/abstract/129\">",
"      Bieri S, Allal AS, Kurtz JM. Sphincter-conserving treatment of carcinomas of the anal margin. Acta Oncol 2001; 40:29.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2469 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-F6FDDAB425-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_54_38762=[""].join("\n");
var outline_f37_54_38762=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Anal canal versus perianal skin cancers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      STAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Perianal skin cancers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Sites of lymphatic drainage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Staging evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - PET scan",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT OF LOCALIZED SCC OF THE ANAL CANAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Combined modality therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Versus RT alone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Role of mitomycin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Replacement of mitomycin by cisplatin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Capecitabine as an alternative to infusional 5-FU",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H594205038\">",
"      - Can chemotherapy be eliminated for early stage tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - RT dose and schedule",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - 3D-CRT and IMRT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Assessing the response to primary chemoradiotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - HIV-positive men",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8331342\">",
"      Colostomy rates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Quality of life issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Treatment of locally advanced disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Surgical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Recurrent disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Persistent disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H441718822\">",
"      Posttreatment surveillance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Treatment of metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Systemic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Role of regional therapy for liver metastases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Paraaortic nodal involvement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      TREATMENT OF LOCALIZED ADENOCARCINOMA OF THE ANAL CANAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H594204919\">",
"      TREATMENT OF PERIANAL SKIN CANCERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Squamous cell anal canal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Adenocarcinoma of the anal canal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H594205186\">",
"      Treatment of perianal skin cancers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2469\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2469|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/30/14819\" title=\"figure 1\">",
"      Anatomy of the anus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2469|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/60/16333\" title=\"table 1\">",
"      Anal cancer TNM stage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/0/5134\" title=\"table 2\">",
"      TNM stage cutaneous SCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/31/27131\" title=\"table 3\">",
"      Anal outcome hist AJCC",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/51/4922?source=related_link\">",
"      Adjuvant therapy for resected rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/33/1562?source=related_link\">",
"      Anal intraepithelial neoplasia: Diagnosis, screening, prevention, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36826?source=related_link\">",
"      Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/29/12761?source=related_link\">",
"      Classification and epidemiology of anal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32630?source=related_link\">",
"      Intensity-modulated radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41850?source=related_link\">",
"      Management of potentially resectable colorectal cancer liver metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/32/6665?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/46/33513?source=related_link\">",
"      Mitomycin-C pulmonary toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/22/42346?source=related_link\">",
"      Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/32/22018?source=related_link\">",
"      Patient information: Anal cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6041?source=related_link\">",
"      Pretreatment local staging evaluation for rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=related_link\">",
"      Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26455?source=related_link\">",
"      Virology of human papillomavirus infections and the link to cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_54_38763="Carcinoid symptoms";
var content_f37_54_38763=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F63079&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F63079&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Carcinoid symptoms and their putative mediators",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Organ",
"       </td>",
"       <td class=\"subtitle1\">",
"        Symptom",
"       </td>",
"       <td class=\"subtitle1\">",
"        Frequency (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Putative mediator",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Skin",
"       </td>",
"       <td>",
"        Flushing",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        Kinins, histamine, kallikreins, other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Telangiectasia",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyanosis",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pellagra",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        Excess tryptophan metabolism",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Gastrointestinal tract",
"       </td>",
"       <td>",
"        Diarrhea and cramping",
"       </td>",
"       <td>",
"        75 to 85",
"       </td>",
"       <td>",
"        Serotonin",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist1_start\" rowspan=\"3\">",
"        Heart",
"       </td>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        Valvular lesions",
"       </td>",
"       <td class=\"sublist1_start\" rowspan=\"3\">",
"        Serotonin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Right heart",
"       </td>",
"       <td class=\"sublist_other\">",
"        40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Left heart",
"       </td>",
"       <td class=\"sublist_other\">",
"        13",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Respiratory tract",
"       </td>",
"       <td>",
"        Bronchoconstriction",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_54_38763=[""].join("\n");
var outline_f37_54_38763=null;
var title_f37_54_38764="Osmotic cervical dilators";
var content_f37_54_38764=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69543&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69543&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Osmotic cervical dilators",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Name",
"      </td>",
"      <td class=\"subtitle1\">",
"       Material",
"      </td>",
"      <td class=\"subtitle1\">",
"       Size (dry diameter x length) (mm)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Dilation",
"      </td>",
"      <td class=\"subtitle1\">",
"       Comments",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"5\">",
"       Natural",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Laminaria (Laminaria japonica, Laminaria digitata)",
"      </td>",
"      <td>",
"       Dried compressed seaweed stalk",
"      </td>",
"      <td>",
"       <p>",
"        2 to 10 x",
"       </p>",
"       <p>",
"        60 to 85",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        4 hours: 25 percent increase in diameter",
"       </p>",
"       <p>",
"        Overnight: 90 percent increase in diameter",
"        <sup>",
"         [1]",
"        </sup>",
"       </p>",
"      </td>",
"      <td>",
"       Multiple laminaria are generally used.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"5\">",
"       Synthetic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" rowspan=\"4\">",
"       Dilapan-S&reg;",
"      </td>",
"      <td rowspan=\"4\">",
"       Polyacrylate-based hydrogel rod",
"      </td>",
"      <td rowspan=\"4\">",
"       <p>",
"        3 x 55",
"       </p>",
"       <p>",
"        4 x 55",
"       </p>",
"       <p>",
"        4 x 65",
"       </p>",
"      </td>",
"      <td class=\"sublist1_start\">",
"       4 hours:",
"      </td>",
"      <td rowspan=\"4\">",
"       A previous version, Dilapan&reg;, had a tendency to break under high mechanical force; there have been no reports of breakage with Dilapan-S&reg;.",
"       <sup>",
"        [3]",
"       </sup>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       <p>",
"        3 mm size: dilates to 8 mm",
"       </p>",
"       <p>",
"        4 mm size: dilates to 8.5 mm",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       16 to 20 hours:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       <p>",
"        3 mm size: dilates to 10 mm",
"       </p>",
"       <p>",
"        4 mm size: dilates to 11.3 mm",
"        <sup>",
"         [2]",
"        </sup>",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Lamicel&reg;",
"      </td>",
"      <td>",
"       Polyvinyl alcohol polymer sponge; soaked in 500 mg magnesium sulfate",
"      </td>",
"      <td>",
"       <p>",
"        3 x 75",
"       </p>",
"       <p>",
"        5 x 75",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        4 hours (3 mm size): dilates to 8.3 mm",
"       </p>",
"       <p>",
"        16 hours: dilates to 7.8 mm",
"        <sup>",
"         [4]",
"        </sup>",
"       </p>",
"      </td>",
"      <td>",
"       Reduction in cervical resistance occurs mainly in the first 2 hours after insertion.",
"       <sup>",
"        [5]",
"       </sup>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      1. Krammer, J, O'Brien WF. Mechanical methods of cervical ripening. Clin Obstet Gynecol 1995; 38:280.",
"      <br>",
"       2. Bokstrom, H, Wiqvist, N. Preoperative dilatation of the cervix at legal abortion with a synthetic, fast-swelling hygroscopic tent. Acta Obstet Gynecol Scand 1989; 68:313.",
"       <br>",
"        3. Allen, RH, Goldberg, AB. Cervical dilation before first-trimester surgical abortion (&lt;14 weeks' gestation). SFP Guideline 20071. Contraception 2007; 76:139.",
"        <br>",
"         4. Nicolaides, KH, Welch, CC, Koullapis, EN, Filshie, GM. Cervical dilatation by Lamicel-studies on the mechanism of action. Br J Obstet and Gynaecol 1983; 90:1060.",
"         <br>",
"          5. Nicolaides, KH, Welch, MacPherson MB, Johnson, IR, et al. Br J Obstet Gynaecol 1983; 90:475.",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_54_38764=[""].join("\n");
var outline_f37_54_38764=null;
var title_f37_54_38765="Redistribution of thallium";
var content_f37_54_38765=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F62113&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F62113&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Redistribution of thallium",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 249px; background-image: url(data:image/gif;base64,R0lGODlhgQH5ANUAAP///4CAgAAAAICZ//+AgEBAQMDAwEBm/3BwcMDN/9DQ0DAwMBAQEP9AQAAz///AwKCgoP8AACAgIODg4FBQULCwsPDw8GBgYJCQkODm/2CA//8QEBBA//8gICBN///w8P8wMP/Q0P9wcPDz//+wsP9gYFBz//+goKCz//9QUHCN/zBZ//+QkICA95Cm///g4NDZ/7DA/0BN9sDA+4CM+1Bm+gAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAACBAfkAAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7i5uru8UwYGvcHCRQEBSQ8EycrLD8POqcXHyw0NzM/XpdFNydjdptpM3N7joeBL4uTpnOZK6Orvl+xJ7vD1kvJI9Pb7jfhH+vwCIvJnRIQIgQgVESTyYcOGEAkjFlo4pMEGEA8lagREEQCLDiIInMi4saQeiiE2ICMAQESHDyZj2qEIgqW4EiBgyox5IcCE/zcLCYAQgg6nzp0bCwgQQAFCFQMKiFQIgOGnkKlVjxB8QNIdNQArlylrhrRehQsMBDBAYNWJggACCgxBIGABAwY/6drFa8Tfhw4shrj7AKJEWGrWysI7u3Sp3CdK4wqxoBYABgEIKDOwjLmvsSMlGhChR7iEYJaK90VeAGECBARRDEgGIFtu7dq0ZxsoFqDA5yIkNhwFoO/vQeKoU9e7wNYK7ty24+J+vruY7yMkSBQBmPIEcuX2IAADUKGCr9kK6pJnmn7BegqenQAE0H0++G7XASB4TMR1sQoWGKHAZQsYEKAEAlRAgQBOIaggg/EhERYBiI1FREqFQfTGhGIRQP/WfYvI1thS8A1hwQUjqvWbEJEtBYwCC6gFGwAwyqjVikVwKNaHQpwAQgcdRLBBAyUQQAKPZUxYYTJIgniIAgUwIEEBBVAQ1RB3BXClAiiWyEVHT4gTwgMsUAhCBBE0kIJIDwwnhn1OJiIeEgsEWIQCXm4BpnzJGfHCAycQkEIDaCLGwgMvfAFnnBP5x5tTJiJh55c4WrFoER8ASkBoG0QAQgMhPaChpX0yqogABrQ4mxC/tPrLlV7sKU0yS3o4xQMkECBCA0F2AKqRTZ5TqqmIGKiAq7ACkKJjYMgqYYcWZjGmrg2cOWSRJ7Q5z7DEIoKBeTfyVgyksVbax59lUlP/6JrZJvpdt4woJUFzbDirR6aBDormjw0cOmopOiYmjAIIxCjABUZAkBazX9gbyAOhcRqBryEd+S8nSlYT7TAWQKAUf0NIgGCUCDdsLiPuTEshr4USScCh2mpyqS50kTgeEQkKoF/J5U5yaaZkbqqukBVme3EjM+dSAGuTFoHqAgFQADKlPnP7xJi5Csqypy57GLMhSePS9BEL9LTUjD1LEnYUDwS9K6FEa5xtsHisTYtPEIhLrhEYYBCGw4HYjcWfWQ8aJNdreu3uHILLgqqqUwtx7KvNnrxI42C0HejbnQ7569xsYA6LscgasWBjkWsBOCCin/HnSoOeiXgyRy6u/6jVwSAAKQaV1vVo5VUbojm1FrUcEsxZtO6KBQaU/YvURhSA9t+WF5KxwIcAnUxosvuaeO1h4r6LiCPyPIQBDFApPfCNBLxxJGMGunKnaboMs5vKtzJBAFMWg8HYAFgYw9IGryRoT2hw81U1quGNCjiFeQBcCxlWV0CsCWViJSCBm3qxAPhYQALmE8J+WpUsqhXwCskIAYU8ZatgoEoIvYneiFJ3hKn4ZAhYaQsRKHhCoiTnAyRwyQZSwIKjXcF9TJIEA/wGAArkSQh5+x0TUGSXF+rlLjqEYfV6GA5uveAEKdhAB0pwgg3eahoaS2IkqBijvUmuhExYigXgEgDNcP9melrkYhUWFQIWEAoEIqDbFPL3hxPZKHo0TAKKJLCAOk1nVUPgYQ/DFsQzEdGIUCCkIirgHigQSC3HksxzdrhFPW5LCl8sgUPIaLvwXQJP6sMjACDHhPTI5TIFaM97ImTKKLSujynwlAi040pLGGyAc1Hf+pYwAbUwBmEOWpAbASDJE2ryASI4U78wORrxNYJBOutJFiCAIAZcIEA1kiAve1nMLXzgBCXowBBP0MrTXAJVEjDAfo6AgSqBy2Ts9KU3rQBMMQ5zOPZpG0wyVU8s7OoMEggAiphihJot5Z9dqGYBNbkEZGiTABCxD5pSAJYIDFQKhDqDAhRgAScCUAD/xmhpIq+gUXhxtAlAjKcYcYemCLTNpELwYwqIKRIVAiBQJADVB0KjobeVACIplUOCRDhTK9S0WzeFwgvWlARPiZEEQBVBBEQQTO0ICU0AIBSQiDYxIXRAV2JMawTmsKClCYCJBAzos5RRK0HerqsNOEGagHoRAHwgAiT1VEXm+gCgRhWbxZPrHFp6SIDqdVbQaqEZRCoauLEkTUIALWiFkNLGsiSlYB3qmSSLiate9k08FU1jgVpWAkQgMKOVrGkla1sjBYm1Y4hhJCOnMNSx77V64KwQSgDUDwRzA8fJbWkdO1fCTOy3UQ1u+tQ3JSOkJZbHRW7dTjqQZUVOnWJw/614vZBVPASgQK26QOQQEELLrvcO7b2DAfa2Xxka1773hcP13scIuDBhP+AFcIDdgETN9kNncVDvgmEBF2UuUw0SnrAr4JKiqlJPw++Ai6ugUq9SgjgYBo6wiU/Mi90oYVmQNCGLBWJhKslSdSuecQEzrOMlJGAAQA6ykBPgieIicwk2tEoOb9TjNPw4yAc4wJA9IbK4mLMJFohRI4FxRb4QI8dN9gKQNyFcnFVAZ/RtAorwasfLyJLHYWbCmClRHd5QyQhPi5qHAxiXukzgkZGDc5yVMOdJcHiGRigbh2+MZ1Sh6AKAXuegzVBoSUxAZHZOZN+ckBbo6PLMT6QmmP8nnYVKEyEDCUg1kZlwABVYQQUHSC9/ymwFFEkUpgCIJoS+rOEnC3nKZzD1EAbggGI7oAkOiHUVUDCANjwO0UygbGdoFCP0krLXQo4ysCndbCQkINlCGAGspSwEFJig1SNItgsOoIERlDvKLhDCAJh9ABTAwAQmcDezhZABWJsgBmbIJYJtHF4QCzvY3T7Ct5XtAQ4MQAUeAACxTTAAD3zbASvwgAM0AAAVOEAFJnBAvIu9Ag44wAMr2DgADnDsEXDA4RpQdhb4t5SIHkEBVsF5wTV8cDKgmtzeBjcAXq6BAWRg6BEHwAjSHWumIx3I4AY3sYkMbpYDwAUOQAG/tXD/mRThdQj5obWMT9zzLqB6ADEv9gE8kHAjLFwI99Y4BzIgdCEIPepsB7LWpe4Aqsfa6lPvQpWsMgHoDQFKUqJS+nY+4bJb4expT3bRE3B0ibf91FhfAZHrnQCW31vkCTDB2wEA7pAPIAH75rvfV35sGGAc9SbQwuCFUHiQkW8pDMDo2A1+eSpAnuWSP33ljdBzYhsbACE/udZHoAGTe4DuygY3803ucNLHOvBVPzYAYpByB/SeCl0f0ddFOM288n4Kv1f75Ie/BMcXGEECsHmJdex+fv848uwWPhXqX4ln/9f8PPd96Rd8lKcF/JcIvVFHswQyAqdMjIYFggYeYzaA//lXgF9wgIdwaHVyZ2sQgUiRavSmcQTIfmKAgYYQJVPBAAvAgURgZDGmJ6MGIqiWAC7wcFEmgitwABTHbiQoBr42ANoWZKvmCByYHi/4XQSnYHECAwkQA0AWc8CXbPl3egkAA8T3fWHwg792epCAAAxgJxBwhA8Ig8oBgkAWZd3nAVGmAgPgAqnmbk9ggrQAQUMAAdOUZsEVg90wg0A2biaHcToIZDGQalsgh85AS0qoCFq4bW/AhE44AOcGfBwQZUVHhT14gVioDgN3YRmlh33ga0EIZENIBiNghkC4dsWmhlLWhm/4BoboJB4IB6/4BHyIdlH2h1FGcQMwiFaYB/+zyAt4ozeM1wi/OASp9ojn1n2T2GqiaIGCUIy64H9HRoaTwH+lSINniIqAuIoo0IrEmIm7AGO2ZwGTQzmJ+I1DwIRPBoXGRomCWIWZAI2tUGOciAaxuAZnNwAZp4xryIrOuAk/GIpcaEr36HP3x3KTWHTsNoqlsIiM2AsuuGfnyAcw4IRpN4kq4IZwKG/gSGphUGUkIyA5l0VK8GewsmSSJgUOKYpcUJGQmHIYqZGE1pEe+QU5szPR8xlilwRZNhtdRpKSBIqryJJV0IQveXJS1o1RII81GQV5ZniSEyVTEiUSWTNy0WbTdm0GSJNJgHpAqHFqOG8M6QRC+ZBN6QX/inY2RHB7ztQEslFh0BGXvLaVT+CVqLgCFDeIWbCSA3mWY7BpFVV+PDkvkTZKkeSJR9BzpegCsGZyeLmLveiXlWABvDMuTMCWuaQeoJaSVTBni9mYwRcDkSmZiyCNL4iISsA8BkAgUaFr03RVFXcAJleBl0ia8UIwDohn8EViTvAc6XRjNZUBk/iPtikKUDNBiEkEI1ByXFmc8VJjsoQAEWWZEykEfDmQMceUzvkH4uhf04hjPpZtQ8mFKMABI6Cd2/kH+SQE4nQnpVOdV1gECcABOzieY5me38RE+2QEU7E/cASecdh2I+ABlbiF94mfi/AxMVJfNWMAFFBfAOoE/5WGbwi6CdJGARF0AQWykxHaBIXmAh6wkRX6Sv85BI9jAPI1jEgwZ/M5miNqCSx4BEsjAQsyftQooc3mclr3opnASUqgAAtTJyqamM3GbjyqCahZBLw5pFeoAisgokdaCZsoSxTgHhPAAMmpBM6ij3MXpaUwVfohkVKwpVnnpZkAS0loZlTFpEUAa2aaCcf0ghSwFnRhox26BC7XnG96KmEIAO1JBAoAf0IKn0TgcXq6p4iAT/oUOSu1pITKbxt3qIhqCBE1UaEWo2wqBCbAhpI6qYSwUi2FofzZSellYvN5np3qqYIQNQAwAQWge7MEbQB4BOSGnqqKBwwAKSlaBP9TyqYokHS2eqt28ELUJKadyAQesKPBKqx00EjlYW2SEyMGIAF2OnNbBITDlqrM2gdnhnskuReLimVR1BYoOZcryQE10ALqKgMyoK7qOgPbugj7kxV4VgEFsBt7dmh88ZMRUpaxSQPuGrDvGq8hUqJL9Kog5JY/sSB1VBlulpIT6AC1SbCLAKRLMag7NCI3o2YMEmlzSQRjtqkUOwmY5oUQ2k8UAKs/qh4eq5Uge3rmObKSQKw76ahOoDBC+mkU9bHZCnQyCwk0agCcZD49+YJKcBlrEQANkiDSBLEekHQ/CwlhiHvJEoaNtGtNQEu/yWRFAIQAF7WR8Bb0GkmddJz/H9a12gq2fYABG7tD09k/ggmBlbKsaisH8jK2MGReO0e3dQsHBAN/KXs+4kKdaeOvRNm3iNAxAhRqyGmdWyiEiIsIFnUBELCrghm3VVCQkdsGSwMBL6WAQ1B7s7q5jABAkaQWFFAMC5J7o0u6xTK4SlsEE3ABggq6x+q6jnBo/5cGmou7ZtB1vkG4vJulvqtfi1StZtC7xVsGlLkUbqC8yxsGE+CF5lSiyUu80SsHHLaCaTq82YuAetuB2Pu9owC95AsJ5nu+uTu+6vsJ6du+i/C+8IuA7Du/ZFa/9lu6eeO5SCC/+YsHMaIUpMqz/xsKm7kgKuu/BUwHdERNuNYX/8ELuxI8wRRcwRZ8wRicwRq8wRzcwR78wSAcwiI8wsXQtgqBaw1sBHVGwizcwi78wjAcwzI8wyxswonwsHW6wKzQTPmEICSpw6ZATvGHuUBcxH27pCOGBR2jDUvMv+IaAP/UxKbLCRPAO/8DqAZArlTxw1QwIEo7KUv8G+UaEG+xKilyBRZbABIgBAGsHtGmZdPWxgP8CS1Cqhb7GfyaBdCWxmusH3WBReNQAdYbq2aMKr9wBQhykhSFwEzwsD58wGAKCgDyQcRqMDHlsFl5BU7RTBCWyCaCyWPYCwiwRaPkGBRgw0+QHlUGHw2cwlraGUqxGyj8wKPgw9S0FrjWsv9YoE+4psoIAh+6fA0ruASjlLoo4mXnUSBt1Mq0nAScHCWowsz4ewgPmx5TkcuiZLRU4DGdIRvK3LHZbKy2wMnEfJrEOgW25MBU0Rk5XEtKiyB35MfIqwl0UTK6C1M6y7hWEMvpTEf57A1Tq7KSQyAG0jy39oVW4CDSysPTKgBcXATisSCwwdC2HAoLMp1Z/AuP9hOumQUGXTMcnSDSmmtMi7XXMFEPqCpZbDALMMhNkE6QIsQSQMQmGn+/IdM0fU8j8hspvLVZMAEGIwHgAtPRWlnYIKhGrApGuBQPndSfEH4m7dSjcDpLAaFS/QkCFH9XfQoKvNV30NVeXQdgHdb/czDWZK1iZ00KZp3WzzvNbE0IE9DUbz3XdF3Xdn3XvdQbBeAxLo3XixCGqStijVCOr8LXNJVLSwAlOY3O+TFo+yO0myxfF4BzSgFpgm0B+zHZAJA3ARK7b4HKdKAq0nFDT9HMSPDYTyDYTnAZoH1isvFdVwo1dxGodZE3L2QX74UXl1EBzbQZdNHXfouiBwMVu/ETeWOvmSFfV+Kg0jM2alyHUNzcyt2qAQAMSttP57TZn5E3rnowkV0Amm0ZNmYV3TVosjEjl9ETsSzYIpYesHFmVYEZGCCtC9DHfZDCgi0v5SQv70EXeUIZv6HfasHfb6ksdYEgCKMULCIAtL0A/2yhggFwF36KGe81HnAxxa79wHDRE8WwPy8kYgVe4IwkPWWTyXuA3y+k4AWu4AxLc2t5ziqOazFuDJJBGXKh4LHqwMCQ3r2BKguSujcjG62tYQVOI3VRAfpUxtb9QlLioAzuxwzOYQL91Rqe4jqz4jqjFOLy4jcz4zle4LMhGTiu4Ox9MLwxASdiMOAi5OZNy5x0sR6+5C8SIzMtOZWRHpvxBygODF6u4JdxymfRH3cFdlcu44VO448hGT/uhTpDR1Bx5El+AWzbzpch13W9519u6DAEuEVQ3pluDF4e5nJB21WqM5dGUW/uZxFeWc/t12UQhlN+BrKx2K6OBVEC3CZhAKTiXOu83uu+/uvAHuzCPuzEXuzGfuzInuzKvuzM3uzOfmJBAAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Myocardial thallium-201 activity in normal and ischemic dog myocardium. Serial determination of myocardial thallium-201 activity (expressed as percent of initial normal activity) in 27 dogs is measured after 20 minutes of coronary artery occlusion and before reflow. Near equalization of thallium-201 activity in normal and previously ischemic myocardial regions appears by four hours after reperfusion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn with permission from Beller, GA, Watson, DD, Ackell, P, et al. Time course of thallium-201 redistribution after transient myocardial ischemia. Circulation 1980; 61:791. Copyright 1980 American Heart Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_54_38765=[""].join("\n");
var outline_f37_54_38765=null;
var title_f37_54_38766="AIM 60_6";
var content_f37_54_38766=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F56240&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F56240&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Doxorubicin (Adriamycin), ifosfamide, and mesna (AIM 60/6) for advanced soft tissue sarcoma",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        Cycle duration: 21 days.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Doxorubicin",
"        </strong>",
"       </td>",
"       <td>",
"        20 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        per day IV",
"       </td>",
"       <td>",
"        Dilute with 1000 mL normal saline (NS) and administer as a continuous IV infusion over 24 hours daily.",
"       </td>",
"       <td>",
"        1 through 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Ifosfamide",
"        </strong>",
"       </td>",
"       <td>",
"        1500 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        per day IV",
"       </td>",
"       <td>",
"        Dilute with 500 mL NS to a final concentration of 0.6 to 20 mg/mL and administer over two hours daily.",
"       </td>",
"       <td>",
"        1 through 4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Mesna",
"        </strong>",
"        *",
"       </td>",
"       <td>",
"        Total daily dose 900 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Administer 300 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        in NS or 5 percent dextrose (D5W) in water over one hour prior to each daily dose of ifosfamide. Total concentration of mesna should not exceed 20 mg/mL. Repeat at four and eight hours after the initiation of each dose of ifosfamide daily.",
"       </td>",
"       <td>",
"        1 through 4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Hydration:",
"        </strong>",
"        Adequate hydration (at least two liters of oral or IV fluids per day) should be maintained with ifosfamide to reduce the risk of bladder toxicity",
"        <sup>",
"         [2]",
"        </sup>",
"        . Refer to UpToDate topic on \"Cystitis in patients with cancer\". The choice of hydration fluid is empiric and may vary by institution and protocol. The original protocol administered 500 mL of D5W containing electrolytes (sodium acetate 120 mEq/L [equal to 120 mmol/L], magnesium sulfate 500 mg/L [equal to 2.03 mmol/L], and potassium acetate 40 mEq/L [equal to 40 mmol/L]) over one hour before the start of each dose of ifosfamide, and maintenance hydration of the same hydration fluid over one hour at the completion of each ifosfamide dose; IV fluid was discontinued after completion of the eight-hour dose of mesna on each treatment day",
"        <sup>",
"         [1]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        HIGH (&gt;90 percent risk of emesis). Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\". Concomitant administration of aprepitant may increase the risk of ifosfamide neurotoxicity",
"        <sup>",
"         [3-5]",
"        </sup>",
"        ; its use is avoided at some institutions. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        There is no standard premedication regimen. Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Vesicant/irritant properties:",
"        </strong>",
"        Doxorubicin is a vesicant; avoid extravasation. Infusional regimens should be administered through a central venous line. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-neoplastic vesicants\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        This regimen was designed to include primary prophylaxis with a granulocyte colony stimulating factor in all cycles",
"        <sup>",
"         [1]",
"        </sup>",
"        . Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        A lower initial ifosfamide dose may be needed for patients with preexisting renal or liver impairment",
"        <sup>",
"         [2]",
"        </sup>",
"        . A lower starting dose of doxorubicin may be needed for patients with preexisting liver impairment",
"        <sup>",
"         [6]",
"        </sup>",
"        . Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Cardiac issues:",
"        </strong>",
"        Doxorubicin is associated with cardiomyopathy, the incidence of which is related to the cumulative dose. Assess baseline LVEF prior to administration. Doxorubicin is contraindicated for patients with recent myocardial infarction, severe myocardial dysfunction, severe arrhythmia, or previous therapy with high cumulative doses of doxorubicin or any other anthracyclines",
"        <sup>",
"         [6]",
"        </sup>",
"        . Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; CBC with differential and platelet count weekly during treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Ifosfamide is associated with cumulative nephrotoxicity, mostly at a total dose above 60 grams/m",
"        <sup>",
"         2",
"        </sup>",
"        . Clinical manifestations may include hypophosphatemia, renal potassium wasting, metabolic acidosis with a normal ion gap, and rarely, polyuria due to nephrogenic diabetes insipidus. Assess creatinine and electrolytes, including potassium and phosphate, daily during treatment and prior to each subsequent treatment cycle. Refer to UpToDate topic on \"Ifosfamide nephrotoxicity\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Mesna does not prevent hemorrhagic cystitis in all patients",
"        <sup>",
"         [7]",
"        </sup>",
"        . Monitor a morning specimen of urine for hematuria daily, on days 1 through 4. Refer to UpToDate topic on \"Cystitis in patients with cancer\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor for ifosfamide neurotoxicity (confusion, coma, rarely seizures, weakness, neuropathy, ataxia, cranial nerve dysfunction) daily on days 1 through 4. Central nervous system side effects may be especially problematic in those over age 60. Refer to UpToDate topic on \"Neurologic complications of non-platinum cancer chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assay liver function tests prior to each treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor cumulative doxorubicin dose. Reassess LVEF periodically during therapy as clinically indicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        Delay treatment cycle until the absolute neutrophil count is &ge;1500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        and platelet count is &ge;100,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        <sup>",
"         [1]",
"        </sup>",
"        . Discontinue for &gt;2 week delay in recovery. Reduce doses of doxorubicin and ifosfamide by 10 percent for febrile neutropenia despite the use of hematopoietic growth factors.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Neurologic toxicity:",
"        </strong>",
"        Although formal guidelines are not provided by the manufacturer, reduce the ifosfamide dose or administer the same dose over a greater number of days for reversible grade 2 central nervous system toxicity. Discontinue for &ge;grade 3 toxicity. Refer to UpToDate topic on \"Neurologic complications of non-platinum cancer chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Renal toxicity:",
"        </strong>",
"        In the original protocol, a 50 percent dose reduction for ifosfamide was recommended for creatinine rise to 1.5 times ULN during therapy; treatment was discontinued or rise of &gt;1.5 times ULN",
"        <sup>",
"         [1]",
"        </sup>",
"        . In addition, among patients with a normal baseline serum creatinine level, we suggest ifosfamide dose reduction for a day 1 serum creatinine of 1.8 mg/dL or greater.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Bladder toxicity:",
"        </strong>",
"        For microscopic hematuria (greater than 10 RBC per high power field) despite mesna, withhold ifosfamide until complete resolution. Although formal guidelines are not available from the US FDA, reduce ifosfamide dose for grade 3 hemorrhagic cystitis not responding to an increase in IV fluids and mesna.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, doses should be recalculated.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; LVEF: left ventricular ejection fraction; CBC: complete blood count; ULN: upper limit of normal; RBC: red blood cells.",
"     <br/>",
"     * This regimen was designed to be used in the outpatient setting. If necessary, oral mesna may be used; however, oral mesna is not recommended for the initial dose",
"     <sup>",
"      [8]",
"     </sup>",
"     . If the oral route is chosen, patients should receive an initial IV dose of mesna (300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     [20 percent of the total daily ifosfamide dose]) prior to each day's ifosfamide administration, followed by oral mesna tablets at 40 percent of the daily ifosfamide dose (600 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     per dose), administered at two and six hours after the initiation of each dose of ifosfamide",
"     <sup>",
"      [8]",
"     </sup>",
"     . This same dosing schedule is repeated on each day that ifosfamide is administered. The total daily mesna dose is 100 percent of the ifosfamide dose when the oral route is used",
"     <sup>",
"      [9]",
"     </sup>",
"     . If patients vomit within two hours of taking a dose of mesna, they should repeat the dose or receive an IV dose of mesna",
"     <sup>",
"      [9]",
"     </sup>",
"     .",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Worden FP, et al. J Clin Oncol 2005; 23:105.",
"      </li>",
"      <li>",
"       Ifex (ifosfamide) injection. US FDA-approved package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed January 3, 2012).",
"      </li>",
"      <li>",
"       Durand JP, et al. Ann Oncol 2007; 18:808.",
"      </li>",
"      <li>",
"       Jarkowski A. Am J Health-Syst Pharm 2008; 65:2229.",
"      </li>",
"      <li>",
"       Howell JE, et al. J Oncol Pharm Practice 2008; 14:157.",
"      </li>",
"      <li>",
"       Adriamycin (doxorubicin hydrochloride) injection. US FDA-approved package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed January 3, 2012).",
"      </li>",
"      <li>",
"       MESNA injection. US FDA-approved package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed January 3, 2012).",
"      </li>",
"      <li>",
"       Hensley ML, et al. J Clin Oncol 2009; 27:127.",
"      </li>",
"      <li>",
"       MESNEX (mesna) tablets. US FDA-approved package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed January 3, 2012).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_54_38766=[""].join("\n");
var outline_f37_54_38766=null;
var title_f37_54_38767="HALO90 ablation catheter";
var content_f37_54_38767=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F72263&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F72263&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    HALO90 ablation catheter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 335px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    HALO90 ablation catheter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: B&Acirc;RRX Medical Inc. Copyright &copy; 2011. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_54_38767=[""].join("\n");
var outline_f37_54_38767=null;
